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ABSTRACT 
 
Introduction:  
The cardioprotective actions of the hormone melatonin against myocardial ischaemia-
reperfusion injury (IRI) are well-established. It has recently been shown to prevent the harmful 
effects of hyperphagia-induced obesity on the susceptibility of the heart to IRI as well as many 
of the harmful effects of obesity and insulin resistance. However, the exact mechanism 
whereby it exerts its beneficial action is still unknown. 
The aims of this study were to determine the effects of relatively short-term melatonin 
treatment in a rat model of diet-induced obesity on: (i) biometric and metabolic parameters, 
lipid peroxidation, myocardial IRI and intracellular signalling (ii) mitochondrial oxidative 
phosphorylation function (iii) cardiomyocyte glucose uptake and intracellular signalling. In 
addition, the effects of acute melatonin treatment of cardiac microvascular endothelial cells 
(CMEC) were determined on cell viability, nitric oxide production (NO), TNF-α-induced 
dysfunction and intracellular signalling.  
Material and Methods:  
Male Wistar rats were randomly allocated to two groups for 20 weeks feeding with either 
standard rat chow or a high calorie diet. Each group was subdivided into 3 groups receiving 
either water throughout or melatonin (4mg/kg/day, in the drinking water) for the last 6 or 3 
weeks of the experimental programme. Hearts, perfused in the working mode, were subjected 
to ischaemia/reperfusion and infarct size determined. Mitochondria and cardiomyocytes were 
isolated according to standard techniques and oxidative function and glucose uptake 
respectively determined. CMEC NO production and cell viability were quantified by FACS 
analysis of the fluorescent probes, DAF-2/DA and propidium iodide/Annexin V respectively. 
Intracellular signalling was evaluated using Western blot and appropriate antibodies. 
Results:  
The high-calorie diet caused significant increases in body weight gain, visceral adiposity, 
fasting blood glucose, serum insulin, triglycerides, HOMA-IR index and a concomitant 
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reduction in serum adiponectin levels as well as larger myocardial infarct sizes after exposure 
to IRI compared to the control, indicating increased susceptibility to damage. Three as well as 
six weeks of melatonin administration to obese and insulin resistant rats reduced serum insulin 
levels and the HOMA-IR index. Myocardial infarct size was reduced in both control and diet 
groups. These effects were associated with increased activation of baseline myocardial STAT-
3 and the RISK pathway during reperfusion.  
The diet had no effect on the oxidative phosphorylation capacity of mitochondria, isolated from 
non-perfused hearts (baseline), but melatonin administration for 6 weeks induced a reduction 
in state 3 respiration rate; mitochondria isolated from diet hearts subjected to global ischaemia, 
exhibited an attenuated oxidative phosphorylation process which was improved by melatonin 
treatment.  
Melatonin in vitro enhanced cardiomycyte insulin stimulated glucose uptake of normal young 
rats but not of insulin resistant rats.  In vivo melatonin treatment for 6 weeks increased basal 
(in diet group) and insulin stimulated glucose uptake in both control and diet groups. 
Melatonin (1nM) in vitro caused a significant reduction in necrosis and apoptosis of cultured 
CMEC, associated with a decrease in nitric oxide availability and eNOS activation and a 
concomitant increase in PKB/Akt, p38MAPK and AMPK activation. The harmful effects of TNF-
α treatment on signalling in CMEC could be prevented by co-treatment with melatonin.  
Conclusions: 
The results suggest that short-term melatonin treatment was able to significantly attenuate the 
diet-induced increased myocardial susceptibility to ischaemia/reperfusion damage. It may also 
improve cardiac glucose homeostasis and mitochondrial oxidative phosphorylation in an insulin 
resistant state.  Melatonin in vitro protects CMEC against apoptosis and necrosis and reduces 
nitric oxide availability. These beneficial effects of melatonin may ultimately be due to its anti-
oxidant capacity or receptor-mediated actions, but this remains to be established. 
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ABSTRAK 
 
Inleiding:  
Die vermoë van die hormoon, melatonien, om die hart teen iskemie/ herperfusiebesering (IHB) 
te beskerm, is welbekend. Onlangs is ook getoon dat melatonien IHB en verskeie van die 
nadelige effekte van vetsug en insulienweerstandigheid in hiperfagiegeïnduseerde vetsug kan 
voorkom. Die meganisme(s) betrokke by hierdie voordelige prosesse is egter grootliks 
onbekend.  
Die doel van hierdie studie was om die gevolge van korttermyn melatonienbehandeling in ‘n 
model van hiperfagiegeïnduseerde vetsug te ondersoek op (i) biometriese en metaboliese 
parameters, lipiedperoksidasie, miokardiale IHB en intrasellulêre seintransduksie, (ii) 
mitochondriale oksidatiewe fosforilasie, (iii) glukoseopname en intrasellulêre seintransduksie in 
kardiomiosiete en aanvullend, (iv) die invloed van akute melatonienbehandeling van kardiale 
mikrovaskulêre endoteelselle op sellulêre oorlewing, stikstofoksiedproduksie, TNF-α-
geïnduseerde disfunksie en seintransduksie. 
Metodiek:  
Manlike Wistarrotte is ewekansig in twee groep verdeel en vir 20 weke met standaard-rotkos of 
‘n hoëkaloriedieet gevoer.  Elke groep is in 3 subgroepe verdeel, wat deurgaans water of 
melatonien (4mg/kg/dag in die drinkwater) vir 3 of 6 weke voor die beëindiging van die 
eksperiment ontvang het. Harte is geperfuseer volgens die werkharttegniek, blootgestel aan 
iskemie/herperfusie en die infarktgrootte bepaal. Mitochondria en kardiomiosiete is volgens 
standaardtegnieke geïsoleer vir bepaling van oksidatiewe funksie en glukoseopname 
respektiewelik. NO produksie en sellewensvatbaarheid was gekwantifiseer deur 
vloeisitometriese analises (FACS) van die fluoresserende agense, DAF-2/DA en propidium 
jodied/Annexin V onderskeidelik. Intrasellulêre seintransduksie is evalueer met behulp van die 
Western kladtegniek en geskikte antiliggame. 
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Resultate:  
Die hoëkaloriedieet het ‘n beduidende toename in liggaamsgewig, visserale vet, vastende 
bloedglukose, seruminsulienvlakke, trigliseriede, HOMA-IR-indeks en ‘n gepaardgaande 
verlaging in serumadiponektienvlakke tot gevolg gehad, sowel as groter miokardiale infarkte 
na iskemie/herperfusie. Laasgenoemde dui op ‘n groter vatbaarheid vir iskemiese beskadiging 
in harte van vetsugtige diere. 
Drie sowel as ses weke van melatonienbehandeling het die seruminsulienvlakke en HOMA-
indeks in vetsugtige diere beduidend verlaag, vergeleke met die kontroles. Miokardiale 
infarktgroottes was verminder in beide kontrole- en vetsuggroepe. Hierdie effekte het met ‘n 
verhoogde aktivering van basislyn STAT-3 en PKB/Akt en ERKp44/p42 tydens herperfusie 
gepaard gegaan.  
Die dieet het geen invloed op die oksidatiewe fosforilasiekapasiteit van mitochondria, geïsoleer 
uit harte van ongeperfuseerde harte, gehad nie (basislyn), maar melatonienbehandeling vir 6 
weke het Staat 3 respirasie verlaag.  Mitochondria, geïsoleer uit harte van vetsugtige rotte wat 
aan globale iskemie onderwerp was, het ‘n onderdrukte oksidatiewe fosforilasieproses gehad, 
wat egter deur melatonienbehandeling verbeter is. 
Melatonien in vitro het insuliengestimuleerde glukoseopname deur kardiomiosiete van jong, 
maar nie vetsugtige rotte nie, verhoog. In vivo melatonientoediening vir 6 weke het egter 
basale (in die dieetgroep) en insuliengestimuleerde glukoseopname in beide kontrole- en 
vetsuggroepe verhoog. 
Toediening van melatonien in vitro aan mikrovaskulêre endoteelselkulture het ‘n beduidende 
afname in nekrose, apoptose, stikstofoksied- beskikbaarheid en eNOS aktivering 
teweeggebring,  tesame met ‘n verhoogde aktivering van PKB/Akt, p38MAPK en AMPK. Die 
nadelige effekte van TNF-α toediening op seintransduksie in die mikrovaskulêre endoteelselle 
is deur melatonien voorkom. 
Gevogtrekkings:  
Die resultate toon dat melatonien ‘n merkwaardige beskermende effek op die toename in 
vatbaarheid vir iskemiese beskadiging in vetsugtige rotte gehad het.  Dit mag ook miokardiale 
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glukose-homeostase en mitochondriale oksidatiewe funksie in insulienweerstandigheid 
verbeter.  Melatonien in vitro beskerm mikrovaskulêre endoteelselle teen nekrose asook 
apoptose en verminder die beskikbaarheid van stikstofoksied. Hierdie voordelige effekte van 
melatonien mag aan sy anti-oksidantvermoëns of stimulasie van die melatonienreseptor 
toegeskryf word, maar bewyse daarvoor ontbreek nog. 
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CHAPTER ONE 
GENERAL INTRODUCTION 
 
Globally, cardiovascular disease (CVD) especially ischaemic heart disease, is the leading 
cause of death in the world (Lozano et al., 2013) and contributes to 29% of all deaths each 
year (Barry et al., 2008). Previously recognized in developed countries only, CVD has invaded 
developing countries including South Africa, where ischaemic heart disease is the fifth highest 
cause of mortality (Wyk et al., 2013) and the leading cause of mortality in the Western Cape 
Province (Bradshaw et al., 2004). 
 Although multiple causes may contribute to the prevalence of CVD, modern life style 
associated with excessive food intake and reduced physical activity as well as night shift work 
have led to increased risk factors for this condition (Murphy et al., 2006; Grundy, 2008; 
Pothiwala et al., 2009; Danaei et al., 2011), including obesity, insulin resistance, raised blood 
pressure, atherogenic dyslipidaemia, glucose intolerance and a pro-inflammatory state (Alberti 
et al., 2009). Among these factors, insulin resistance is a fundamental feature in the 
development of type 2 diabetes (T2D) and a common pathological link between obesity and 
CVD  in general, and ischaemic heart disease in particular (Reaven, 2011; Abel et al., 2012).  
Convincing epidemiological and experimental studies have shown a strong association 
between obesity/insulin resistance and cardiac diseases including coronary artery disease, 
atrial fibrillation and congestive heart failure (Yusuf et al., 2005; Poirier et al., 2006; Banerjee 
and Peterson, 2007; Reaven, 2012; Shah et al., 2013; Wensley et al., 2013).  Obesity and 
insulin resistance have many effects on cardiac structure and function (Lee et al., 2010; Gray 
and Kim, 2011; Abel et al., 2012; Narumi et al., 2012; Wensley et al., 2013), correlating 
significantly with dysfunction of the heart (Ingelsson et al., 2005; Banerjee et al., 2013). 
Importantly, high fasting insulin levels are positively associated with adverse 
echocardiographic features and risk of subsequent heart failure (Banerjee et al., 2013).  
The mechanism of the development of cardiac disease in obesity and insulin resistance is 
complex and not well understood. Various metabolic abnormalities occuring  in the insulin 
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resistant state have been implicated as risk factors for cardiac diseases (Reaven,1988; 
Reaven , 2004).  Visceral adipose tissue dysfunction and its associated oxidative stress have 
also been linked to increased cardiac disorders (Despres, 2006). Importantly, impairment of 
myocardial glucose uptake and  metabolism may contribute to the mechanical dysfunction 
observed in T2D and obese patients (Chess and Stanley, 2008) and increase their 
susceptibility to ischaemic heart disease (Cubbon et al., 2013) 
The concept of cardioprotection refers broadly to all strategies aimed at the reduction of infarct 
size and full restoration of myocardial function (Heusch, 2013). The most effective therapeutic 
intervention for reducing acute myocardial ischaemic injury and limiting infarct size is timely 
and effective myocardial reperfusion but this also is damaging (Heusch, 2013). Although 
numerous in vivo and in vitro animal investigations reported potential beneficial effects (Vander 
Heide and Steenbergen, 2013), most previous clinical trials have been disappointing (Heusch, 
2013; Vander Heide and Steenbergen, 2013).  Many experimental myocardial infarction (MI) 
models fail to represent the clinical setting in terms of comorbidities (such as obesity, diabetes, 
dyslipidaemia, age and hypertension), the presence of which may interfere with the therapeutic 
cardioprotective intervention (Ghaboura et al., 2011; Sack and Murphy, 2011; Whittington et 
al., 2013). Thus omission to consider these comorbidities has been one of the pitfalls of recent 
promising cardioprotective strategies when translated to the clinic (Vander Heide and 
Steenbergen, 2013). 
In view of the lack of effective therapy, cardioprotection is still an active research area. 
However, with the rising prevalence of obesity and its multiple comorbidities, an ideal 
therapeutic strategy must retain its efficacy under pathological conditions, not only in lean 
subjects, but also in obese and insulin resistant conditions.  
Melatonin or 5-methoxy-N-acetyltryptamine is the neurohormone produced mainly by the 
pineal gland upon the activation of the suprachiasmatic nucleus (SNC) of the hypothalamus 
during the night (Zawilska et al., 2009). It is a highly conserved indolamine found in most 
organisms, including mammals (Hardeland and Fuhrberg, 1996). Its chemical structure is 
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represented by the figure 1.1. Melatonin is a small molecule able to enter all cells (due to its 
lipophilic nature) and confer its pleiotropic effects including, amongst others, 
immunomodulatory, anti-inflammatory, oncostatic and vasomotor properties (Hardeland et al., 
2006; Pandi-Perumal et al., 2006; Hardeland et al., 2011).  In this regard, its classical role as a 
chronobiotic or endogenous synchronizer in the regulation of seasonal as well as circadian 
rhythms along with its sleep inducing effects is well-established (Zawilska et al., 2009). 
Importantly, acute myocardial infarction has been associated with reduced nocturnal serum 
melatonin levels (Dominguez-Rodriguez et al., 2002; Dominguez-Rodriguez et al., 2012).  
Cardioprotective properties of melatonin have been demonstrated in lean animals where 
melatonin (at either physiological or pharmacological doses), given before or after the 
ischaemic insult protected the heart against myocardial ischaemia/reperfusion damage 
(Lochner et al., 2013).   
 
Figure 1.1 Chemical structure of melatonin 
The role of melatonin in obesity has only recently become a subject of investigations. Its 
potential as a tool for effective therapy in obesity-induced metabolic abnormalities was recently 
reviewed (Nduhirabandi et al., 2012; Srinivasan et al., 2013), indicating a growing interest for a 
role for the hormone in obesity. Convincing evidence supports the role for melatonin in 
metabolic regulation (Prunet-Marcassus et al., 2003; Barrenetxe et al., 2004; Hussein et al., 
2007; She et al., 2009; Shieh et al., 2009; Ríos-Lugo et al., 2010; Agil et al., 2011; 
Nduhirabandi et al., 2011) and in glucose homeostasis (Nishida, 2005; Peschke, 2008; 
Peschke and Muhlbauer, 2010). We previously showed that melatonin consumption starting 
before the establishment of obesity, prevented obesity-related abnormalities and protected the 
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isolated hearts subjected to ischaemia-reperfusion injury (Nduhirabandi et al., 2011). However 
the effects of melatonin in obesity are still not yet established, especially on the heart.  
Several mechanisms, including antioxidant activities, anti-adrenergic, anti-inflammatory and 
anti-excitatory effects have been demonstrated (Genade et al., 2008; Dominguez-Rodriguez et 
al., 2009; Patel et al., 2010). Additionally, inhibition of mitochondrial permeability transition 
pore (MPTP) opening (Petrosillo et al., 2009) as an end-effector in cardioprotection has also 
been indicated. However, how melatonin affects these parameters has not been investigated 
in the context of obesity and insulin resistance. Furthermore, the effect of melatonin on 
microvascular endothelial function, which may play a crucial role in ischaemic damage, has not 
been investigated either. Moreover, the effect of melatonin treatment on the heart in 
established obesity remains unknown.  
In view of the many outstanding issues regarding melatonin’s effects, the present dissertation 
focussed on the role of melatonin in cardioprotection in obesity and insulin resistance.  
To better understand the mechanisms of cardioprotection in obesity and insulin resistance, the 
current literature on insulin resistance and obesity and potential mechanisms linking these 
conditions to CVD (metabolic syndrome, adipose tissue dysfunction and oxidative stress) as 
well as  their related cardiac alterations in normoxia and ischaemia-reperfusion injury are 
reviewed in  the following chapter.  Additionally, before the discussion on the role of melatonin 
and the heart, and the effects of melatonin in obesity and insulin resistance, cardioprotection in 
obesity is addressed.  
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            CHAPTER TWO 
2 LITERATURE REVIEW 
 
2.1 OBESITY  AND INSULIN RESISTANCE: A FOCUS ON THE HEART   
2.1.1 INTRODUCTION  
Excessive food intake and reduced physical activity associated with modern life style have led 
to the current dramatic increase in the prevalence of obesity (James, 2008a; de Onis et al., 
2010; Finucane et al., 2011; Swinburn et al., 2011) which is paralleled by an elevated 
incidence of metabolic disorders, including, among others, metabolic syndrome (MetS), type 2 
diabetes (T2D) and cardiovascular diseases (CVD) (Murphy et al., 2006; Grundy, 2008; 
Pothiwala et al., 2009; Danaei et al., 2011). The association of these disorders with obesity 
has been recognized for decades (Haslam, 2007); however it is only in recent years that 
obesity and its related disorders have attracted attention as a serious public health concern 
(James, 2008b). Indeed, apart from an increased risk for T2D and CVD, numerous other 
disorders including obstructive sleep apnoea syndrome (Wolk and Somers, 2007), chronic 
kidney disease (Ruan and Guan, 2009) and some cancers (Pothiwala et al., 2009) have been 
associated with obesity. A major basis for this association is the ability of obesity to induce 
insulin resistance (Johnson and Olefsky, 2013). This is a fundamental aspect in the 
development of T2D (Taylor, 2012) and a common pathological link between obesity and heart 
disease (Reaven, 2011a; Abel et al., 2012), the top leading cause of death in the world 
(Lozano et al., 2013).  
 In this section, insulin resistance and obesity and their specific related metabolic abnormalities 
are described to better understand how obesity and/or insulin resistance affect cardiac 
structure and function. In this regard, the roles of adipose tissue dysfunction and obesity-
associated oxidative stress are discussed. Current literature on the morphology, metabolism 
and function of the heart in the insulin resistant state is also summarized. In the present 
dissertation the concept of “insulin resistant state” refers to any condition or disorder 
associated with impaired insulin action. 
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2.1.2 INSULIN RESISTANCE 
2.1.2.1 Overview: definition, concepts and assessment  
Insulin is a small peptide hormone produced by β-cells of the pancreatic islets and released 
into the circulation following an increase in blood glucose or amino acids. After its discovery 
and its first clinical use around 1920 by Banting and coworkers, when diabetes was a 
devastating disorder without any effective intervention, insulin has been welcomed as anti-
diabetic treatment [for a review, see (Polonsky, 2012)]. In this regard, insulin’s actions have 
since attracted the interest of several investigators (Polonsky, 2012). Indeed, insulin has been 
shown to play a crucial role in the regulation of carbohydrate and lipid metabolism in the body 
and as well as in appropriate tissue development and growth (Sesti, 2006). Moreover, it is 
involved in multiple other cellular processes in various tissues of the body such as the brain 
(Derakhshan and Toth, 2013), pancreatic β-cells (Leibiger et al., 2008), kidneys (Hale and 
Coward, 2013), and the heart and vascular endothelium (Muniyappa et al., 2007; Beale, 2013). 
Therefore, in view of these pleiotropic activities, defects in insulin actions could give rise to 
multiple disorders.  
The concept of insulin resistance was proposed more than seven decades ago when it was 
noted that some insulin-treated diabetic patients required higher doses of insulin than usual 
(Himsworth, 1936).  Classically, insulin resistance refers to the condition in which the body 
produces insulin but does not utilize it properly because of a decreased cellular sensitivity to its 
effects on glucose uptake, metabolism and storage (Formiguera and Canton, 2004).  In this 
condition, normal insulin concentrations become inadequate to produce a normal insulin 
response in target tissues (Cefalu, 2001; Hardy et al., 2012).  Insulin resistance can be 
measured as a reduced glucose disposal rate in rodents and humans in response to defined 
concentrations of insulin (Hardy et al., 2012, Reaven, 1988, Muniyappa et al., 2008). In 
addition to insulin resistance, other concepts such as insulin sensitivity and glucose tolerance 
(or glucose intolerance)  have been introduced in the assessment of insulin action or 
resistance to indicate the concentration of insulin required for a half maximal response and the 
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measurement of how quickly glucose infusion is cleared from the blood, respectively 
(Muniyappa et al., 2008).  
To assess insulin action and resistance various techniques are being used [for details, see 
(Muniyappa et al., 2008; Dube et al., 2013)].  Among the available techniques, although it is 
more laborious and complex, the glucose clamp method is regarded as the gold standard. The 
simple and more convenient technique to assess insulin resistance is the homeostasis model 
assessment-estimated insulin resistance (HOMA-IR) index. This is expressed as the product of 
fasting plasma insulin and fasting plasma glucose divided by 22.5 (Dube et al., 2013). 
2.1.2.2 Insulin signalling and action: tissue-specific  
Insulin signalling has been shown to be tissue-specific and varies depending on the type and 
function of the organ/tissue target (Benito, 2011; Rask-Madsen and Kahn, 2012). Accordingly, 
the actions of insulin manifest also differently in various organs such as in the liver, adipose 
tissue, skeletal muscle, heart and vessels (Benito, 2011; Rask-Madsen and Kahn, 2012). 
Insulin signalling pathways have been intensively reviewed (Saltiel and Kahn, 2001; Sesti, 
2006; Mlinar et al., 2007; Bertrand et al., 2008; Benito, 2011; Rask-Madsen and Kahn, 2012). 
In this section, a brief summary of insulin signalling and actions in insulin sensitive and 
resistant tissues is given. Additionally, a simplified representation of insulin signalling and its 
actions is supplied in figure 2.1. 
2.1.2.2.1 Insulin signalling in insulin-sensitive tissues 
In insulin-sensitive tissues, insulin binds to its receptor and initiates a complex spectrum of 
biological effects including insulin receptor autophosphorylation creating docking sites for 
downstream interacting proteins  such as insulin receptor substrate 1 to 4 (IRS1-4).  After IRS 
interaction, three potential signal transduction pathways take place including: the 
phosphatidylinositol 3-kinase (PI3-K)/Akt, the Ras-mitogen-activated protein kinase (MAPK) 
and  the CAP/Cbl/TC10 pathways (Saltiel and Kahn, 2001).  
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• PI3-K/Akt pathway  
The PI3-K/Akt dependent pathway is responsible for most of the metabolic actions of insulin. It  
is initiated by tyrosine phoshorylation of the insulin receptor substrate (IRS-1-4) which, when 
phosphorylated, associates with p85, a subunit of PI3-K  enabling formation and activation of 
the holo-enzyme to produce phosphatidylinositol-3,-4,-5-phosphate (PIP3).  Increased PIP3 
results in activation of protein kinase B (PKB/Akt) via activation of phosphoinositide-dependent 
kinase 1 (PDK1) and other down stream effector molecules, which mediate the metabolic 
effects of insulin, including translocation of the glucose transporter 4 (GLUT-4) to the 
membrane, and glycogen synthesis via PKB/Akt mediated inhibitory phosphorylation of 
glycogen synthase kinase 3 (GSK-3). Other actions such as lipid synthesis, protein synthesis 
as well as nitric oxide (NO) production are also mediated by this PKB/Akt pathway (see figure  
2.1).  In parallel with PKB/Akt, PDK1 is also able to activate atypical protein kinase C (PKC) ζ 
and λ. The role of PKC ζ and λ in insulin-induced activation of GLUT-4 translocation and long-
chain fatty acid uptake has recently been demonstrated in cardiomyocytes (Luiken et al., 2009; 
Habets et al., 2012).  
• Ras- MAPK pathway  
The Ras-MAPK-dependent pathway cooperates with the PI3-K/Akt pathway to control cell 
proliferation. It is initiated by the successive activation of Shc, Grb2, mSOS, and Ras.  Ras 
activation triggers the cascade of Raf to MEK1 to extracellular regulated kinase (ERK) 42/44.  
ERK 42/44 are MAPK subtypes that mediate the mitogenic and the pro-inflammatory effects of 
insulin (Sasaoka et al., 1994).  
• CAP/Cbl pathway 
The CAP/Cbl pathway has been suggested as an additional pathway for glucose uptake in 
order to be fully manifested (Saltiel and Kahn, 2001). In this pathway, after the phosphorylation 
of insulin receptor substrate (IRS), the adapter protein CAP recruits proto-oncogen Cbl to the 
phosphorylated IRS and the activation of Cbl results in a cascade reinforcing GLUT-4 
translocation (Gupte and Mora, 2006). This translocation is also stimulated by the PI3-K 
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pathway and has recently been demonstrated in the cardiomyocytes (Contreras-Ferrat et al., 
2010).  
All of these insulin signalling pathways act in a concerted fashion to coordinate the regulation 
of GLUT-4 vesicle trafficking, protein synthesis, enzyme activation and inactivation, and gene 
expression, which result in the regulation of glucose, lipid and protein metabolism and cell 
survival (Sesti, 2006).  
 
Figure 2.1 Insulin signalling and actions (simplified). Binding of insulin to the IR activates three 
different signal transductions: 1) PI3-K/PKB/Akt dependent pathway for metabolism (lipid 
synthesis, glucose catabolism, glycogen synthesis, and protein synthesis as well as nitric oxide 
(NO) production), 2) CAP/Cbl pathway (additional pathways required for glucose transporter-4 
(GLUT4) translocation), and 3) the mitogen-activated protein kinase (MAPK) pathway (for gene 
expression, proliferation, differentiation).  IRS: insulin receptor substrate; PI3-K: phospho 
inositide-3-kinase; PDK-1: phosphoinositide-dependent kinase 1; PKB/Akt: protein kinase B; 
aPKC: atypical protein kinases C; mTOR: mammalian target of rapamycin; p70S6K: p70 
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ribosomal S6 kinase; PEPCK: phosphoenol pyruvate carboxykinase; GSK-3: glycogen 
synthase kinase 3 (adapted from Saltiel and Kahn, 2001; Sesti, 2006; Mlinar et al., 2007). 
2.1.2.2.2 Compromised insulin signalling/action 
Impaired insulin signalling/action may result from defects at several levels: 1) prereceptor 
(abnormal insulin), 2) receptor (reduced receptor number or affinity), 3) post-receptor such as 
abnormal signal transduction and phosphorylation [e.g., phosphorylation of IRS-1 at serine/ 
threonine (Ser/Thr)] as well as defects in glucose transporters (e.g., decreased GLUT-4 
expression or translocation) [for review, see (Sesti, 2006; Benito, 2011; Beale, 2013)]. 
Amongst these defects, post-receptor insulin signalling abnormalities have been indicated to 
contribute significantly to insulin resistance and are associated with various clinical disorders 
including, amongst others, hyperglycaemia-induced tissue damage, dyslipidaemia, 
inflammation, hypertension, and MetS (Griffin et al., 1999; Sesti, 2006; Mlinar et al., 2007; 
Chess and Stanley, 2008). This is discussed further below in the section on the mechanism of 
obesity-induced insulin resistance (section 2.1.4). 
2.1.2.2.3 Manifestation of insulin resistance 
In obesity and T2D, the manifestation of impaired insulin actions and signalling have been 
shown to be time-dependent and tissue-specific (Benito, 2011; Rask-Madsen and Kahn, 2012).  
For example, in the study conducted by Kleemann et al. (2010) on mice fed a high fat diet, 
peripheral tissues implicated in body metabolism were differently affected by insulin resistance.  
With time, mice fed a high fat diet became increasingly obese and showed a gradual increase 
in glucose intolerance (Kleemann et al., 2010).  At a cellular level, impaired insulin action first 
manifested in the liver (week 6) and then in white adipose tissue (week 12), while skeletal 
muscle remained insulin-sensitive (Kleemann et al., 2010). Additionally, the development of 
insulin resistance was paralleled by tissue-specific gene expression changes, metabolic 
adjustments, changes in lipid composition and inflammatory responses (Kleemann et al., 2010) 
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In skeletal muscle, impaired insulin action is manifested by a decrease in glucose transport and 
a decline in muscle glycogen synthesis in response to normal circulating insulin (Hardy et al. 
2012). In the liver, it refers to the inability of insulin to suppress gluconeogenesis while 
continuing to stimulate fatty acid synthesis (Hardy et al. 2012). This is believed to be the cause 
of enhanced fasting hyperglycaemia and hypertriglyceridaemia or lipoproteinaemia in MetS or 
T2D (Benito, 2011, Hardy et al. 2012, Rask-Madsen and Kahn, 2012). In adipose tissue, 
impaired insulin action is manifested as reduced insulin-stimulated glucose transport, as well 
as attenuated inhibition of lipolysis (Hardy et al. 2012). As described further below in the 
section on adipose tissue dysfunction (section 2.1.4.1), this is believed to promote lipolysis in 
adipocytes and secretion of pro-inflammatory cytokines by macrophages (Rask-Madsen and 
Kahn, 2012, Hardy et al. 2012).   
Impaired insulin action is a prerequisite precursor for the development of T2DM and a feature 
of a number of clinical disorders such as hypertension, dyslipidaemia and MetS (DeFronzo and 
Ferrannini, 1991; Reaven, 1988). However, it can also be observed in non-clinical states such 
as human pregnancy (Beale, 2013).  The present dissertation will focus exclusively on obesity. 
Not only this is the most prevalent insulin resistant state, but also many of the metabolic 
abnormalities associated with insulin resistance are closely related to obesity (Cornier et al., 
2008). Accordingly, the following section focuses on obesity and its related metabolic 
alterations as well as the mechanism of obesity-induced insulin resistance. 
2.1.3 OBESITY  
2.1.3.1 Obesity: definition, cause and prevalence 
Obesity is a chronic metabolic disorder characterized by  increased body fat accumulation to 
the extent that adverse health consequences may occur.  It is geneally defined by a body 
mass index (BMI) of ≥30kg/m2.  BMI (ratio of weight divided by height squared) is a simple 
screening  tool to estimate total body fat (Stegger et al., 2011). Because of its poor sensitivity 
and specificity, other  measurements such as waist circumference, waist-to-hip ratio, skinfold 
thickness, and bioelectrical impedance are commonly used additionally to assess the body fat 
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distribution and composition (Lau and Obesity Canada Clinical Practice Guidelines Steering 
Committee and Expert Panel, 2007; Stegger et al., 2011; Canoy et al., 2013; De Schutter et 
al., 2013). The causes of obesity are complex and multifactorial.  Apart from  the involvement 
of genetic susceptibility, gender and ethnicity factors, obesity results from imbalance between 
energy consumption and expenditure and it is closely associated with reduced physical activity 
(Haslam and James, 2005; Swinburn et al., 2009; Swinburn et al., 2011; Malik et al., 2012).  
Previously only recognized in developed countries, recent observations show also an increase 
in obesity prevalence in developing countries including South Africa (Malik et al., 2012). A 
recent systematic review of health examination surveys and epidemiological studies has 
shown that the prevalence of global obesity increased from 4.8% in 1980 to 9.8% in 2008 for 
men, and from 7.9% in 1980 to 13.8% in 2008 for women, representing 205 million men and 
297 million women with obesity and 1.46 billion people with overweight in 2008 (Finucane et 
al., 2011).  If the current trend continues it is predicted that by 2030 up to 58% of the worldwide 
adult population (3.3 billion) could be either overweight or obese (Kelly et al., 2008).  This 
alarming prevalence is not only a concern among adults, but overweight and obesity 
prevalence is also dramatically increasing in children. In 2010, 43 million children (35 million in 
developing countries) were estimated to be overweight and obese while 92 million were at risk 
of overweight (de Onis et al., 2010). Factors including excessive food intake and reduced 
physical activity associated with modern life style due to the current socio-economic and 
nutrition transition have been blamed for this phenomenon in developing countries (James, 
2008a; Malik et al., 2012; Popkin et al., 2012). 
2.1.3.2 Obesity and insulin resistance  
Obesity is associated with defects in insulin action and signalling (Kahn and Flier, 2000). In 
addition, convincing evidence exists that increased body fat accumulation, particularly visceral 
obesity, is involved in the development of the insulin resistant state (Tchernof and Despres, 
2013).  It was established that lean individuals with no previous family history of obesity or 
diabetes became insulin resistant following experimental overnutrition (DeFronzo and 
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Ferrannini, 1991).  In animal models of obesity, insulin resistance/hyperinsulinaemia induced 
by a high fat/calorie feeding was accompanied with (Lima-Leopoldo et al., 2008) or without (du 
Toit et al., 2008) glucose intolerance.  Insulin resistance was also shown to be associated with 
obesity related metabolic abnormalities such as dyslipidaemia, endothelial dysfunction and 
hypertension as well as other features of the MetS (Cornier et al 2008; Beale, 2013, Reaven, 
2004). However, apart from this evident association, the link between insulin resistance and 
obesity/overweight has been shown to be more complex (McLaughlin et al., 2004; McLaughlin 
et al., 2007; Hardy et al., 2012; Bradshaw et al., 2013; Tchernof and Despres, 2013). 
Epidemiological investigations have shown that not all overweight/obese persons are insulin 
resistant or metabolically unhealthy (McLaughlin et al., 2004; Vikram et al., 2006; McLaughlin 
et al., 2007).  Additionally, it has also been shown that not all people with a normal body weight 
or without insulin resistance are necessarily metabolically healthly (Vikram et al., 2006). This 
heterogeneity in the relationship between insulin resistance and obesity has attracted more 
recent investigations to better understand the mechanism of development of insulin resistance 
as well as MetS (Hardy et al., 2012; Bradshaw et al., 2013; Tchernof and Despres, 2013).  A 
study conducted by McLaughlin et al. (2004) showed that among people who developed insulin 
resistance, 36% were obese (BMI ≥ 30.0 kg/m2) and approximately 16% were of normal weight 
(BMI ≤25kg/m2) while 30% of insulin sensitive individuals were overweight or obese (BMI ≥ 
25kg/m2).  Another epidemiological study reported that 28.8% of Asian Indian adolescents with 
normal BMI and waist circumference presented with fasting hyperinsulinaemia (Vikram et al., 
2006).   
These heterogeneous phenotypes in insulin resistant and obese people could be explained by 
genetic predisposition or previous family history and ethnicity as well as environmental factors 
(Wang et al., 2009; Norris and Rich, 2012).  Interestingly, genetic predisposition can also be 
modified by environmental factors such as physical exercise and dietary habits (Naukkarinen et 
al., 2011), supporting the actual association between an “obesogenic environment” and 
increased prevalence of insulin resistance and its related disorders (Ginter and Simko, 2012).  
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Furthermore, the crucial role of obesity in the actual rise in insulin resistance prevalence has 
strongly been supported by the observation that an increase in BMI is more prevalent in insulin 
resistant individuals (Stefan et al., 2008). More interestingly, although some overweight/obese 
individuals were found to have normal insulin sensitivity, it was recently observed that these 
obese metabolically healthy subjects were more susceptible to develop metabolic 
abnormalities at a later stage compared to normal weight individuals (Bradshaw et al., 2013). 
To better understand the mechanism of obesity-induced insulin resistance, its associated 
metabolic abnormalities are described in the section below, focusing on MetS .  
2.1.3.3 Obesity-associated metabolic abnormalities 
2.1.3.3.1 MetS 
• Concept and importance 
The concept of MetS defined as cluster of metabolic abnormalities associated with increased 
CVD was proposed and published by the WHO and other medical groups including the 
National Cholesterol Education Program’s Adult Treatment Panel III (NCEP ATPIII) for an easy 
clinical diagnosis and treatment of an increased cardiometabolic risks (Cornier et al., 2008).  
The most accepted components of MetS include abdominal obesity, insulin resistance, raised 
blood pressure, atherogenic dyslipidaemia (raised triglycerides and lowered high-density 
lipoprotein cholesterol), glucose intolerance, and a pro-inflammatory state (Alberti et al., 2009). 
 Historically, the MetS concept has evolved from the concept of the “Syndrome X” introduced in 
1988 by Reaven, to describe an aggregation of independent coronary heart disease risk 
factors in the same individual (Reaven, 1988). Concordantly, additional risk factors or 
biomarkers have been identified in patients with MetS (Khoshdel et al., 2012).  As a 
consequence, many other terms including the “deadly quartet”, the “cardiometabolic 
syndrome”, and the “insulin resistance syndrome” and recently the “circulatory syndrome” have 
been introduced in the medical literature to describe the syndrome (Khoshdel et al., 2012).  
Despite ongoing debate and considerable controversies over its specific definition and related 
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clinical utility (Kahn et al., 2005; Woodward and Tunstall-Pedoe, 2009; Reaven, 2011b; Rachas 
et al., 2012; Ma and Zhu, 2013), MetS is widely recognised. 
Although differing definitions might have affected its estimated prevalence, there is a 
continuing rise in MetS in most developed and developing countries with 20% to 30% of the 
adult population being characterized as having this condition (Grundy, 2008). Furthermore, to 
worsen the situation, apart from the increased risk for CVD and T2D, additional numerous co-
morbidities have been observed in patients with MetS including non-alcoholic fatty liver disease 
(Uchil et al., 2009), reproductive disorders (Michalakis et al., 2013), obstructive sleep apnoea 
syndrome (Wolk and Somers, 2007), chronic kidney disease (Ruan and Guan, 2009), 
osteoarthritis (Katz et al., 2010), periodontal diseases (Pietropaoli et al., 2012), some cancers 
(Pothiwala et al., 2009), sleep/wake disturbances as well as other circadian alterations 
(Gomez-Abellan et al., 2012; Reiter et al., 2012).  Moreover, patients with MetS were recently 
indicated to be at high risk for neurological disorders such as depression and Alzheimer's 
disease (Farooqui et al., 2012). 
• Pathophysiology of MetS: role of obesity and insulin resistance 
The pathological processes underlying the development of MetS in obesity are still complex 
and not well understood. In this regard, epidemiological evidence has suggested obesity to be 
the driving force behind MetS prevalence, while insulin resistance is regarded a key 
pathological mechanism (Eckel et al., 2010).  In subjects with a first-degree relative with T2D, 
insulin resistance has been shown to be the best predictor of MetS as opposed to BMI and 
waist circumference (Utzschneider et al., 2010).  However, not all MetS patients exhibit insulin 
resistance. As previously emphasized, this can be explained by the heterogeneity of insulin 
resistance and/or obesity phenotype(s), where some non-obese and obese people are found to 
be insulin resistant and insulin sensitive, respectively. 
Insulin resistance frequently clusters with abnormal circulating lipids, glucose intolerance and 
high blood pressure in obese MetS patients (Steinberger et al., 2009). Since these 
abnormalities are strongly associated with an increase in visceral fat and/or ectopic lipid 
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deposition, mechanistically the hypothesis of adipose tissue dysfunction (see section 2.1.4.1) 
could explain the development of MetS and serves as key explanation for the actual increase 
in other metabolic disorders.  As recently indicated, this entails the most accepted view of the 
MetS concept as an useful tool to identify the centrally obese patient with increased risk for 
CVD and T2D (Eckel et al., 2010).  Although not all obese people present with MetS, obesity 
has been observed to be more prevalent in MetS patients (Grundy, 2008; Grundy, 2012).  The 
pathological pathways of obesity-induced MetS are represented in figure 2.2. 
Although many hypotheses have been suggested for the development of insulin resistance and 
MetS in obesity, the role of adipose tissue has recently attracted more attention. This is 
described in the following section. 
  
Figure 2.2 Simplified mechanisms of obesity-induced MetS. An increase in adipose tissue 
causes elevations of circulating free fatty acids (FFA) and altered adipose tissue derived 
substances which contribute to a proinflammatory state and a prothrombotic state. An increase 
in FFA induces insulin resistance (IR) (in muscle) which contributes to an elevation of plasma 
glucose. Over time, a high FFA may impair beta-cell function through “lipotoxicity”; this also 
contributes to elevated blood glucose levels. Elevated FFA probably contributes additionally to 
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an increase in hepatic glucose output (HGO) and worsening of  hyperglycaemia. Futhermore, 
elevated circulating FFA underlies an increase in plasma triglycerides (TG), which in turn 
lowers high-density lipoprotein (HDL) cholesterol levels. Finally, although the mechanisms for 
increased in blood pressure (BP) in obesity remain unkown, many investigators also believe 
that a proinflammatory state predisposes to CVD, as does a prothrombotic state (adapted from 
Grundy, 2012).  
2.1.4 MECHANISM OF OBESITY- INDUCED INSULIN RESISTANCE 
The mechanism underlying the development of insulin resistance in obesity and its related 
disorders is still not well-elucidated.  Several pathophysiological mechanisms from increased 
fat accumulation to a low-grade inflammatory state have been proposed to explain the 
mechanisms of insulin resistance (Boden, 2011; Ye, 2013). They include essentially: 1) 
adipose tissue dysfunction (adipose tissue-derived hormone abnormalities), 2) generation of 
lipid metabolites, 3) lipotoxicity, 4) cellular stress (oxidative and endoplasmic reticulum stress) 
and 5) hypoxia [for review, see (Otani 2011; Boden, 2011; Qatanani et al 2007; Ye, 2013;  
Samuel and Shulman, 2012)].  Mitochondrial dysfunction, though controversial in being a 
consequence of insulin resistance, was also included as a cause due to its potential 
involvement in adipose tissue dysfunction (Ye, 2013).  Similarly, some studies suggested that 
hyperinsulinaemia may lead to insulin resistance, especially in the presence of fatty acids (Ye, 
2013).   
The mechanism of insulin resistance has been recently reviewed  focussing on ectopic lipid 
accumulation, the role of endoplasmic reticulum stress and activation of the unfolded protein 
response, and the contribution of systemic inflammation (Samuel and Shulman, 2012).  All 
these factors taken together, it appears that the insulin resistant condition is a complex and 
multifactorial disorder resulting from an interaction of various factors including genetic 
predisposition, ethnicity as well as environmental factors (Beale, 2013).  
The description of all of these factors involved in obesity-induced insulin resistance, though 
very important for a better understanding of the impact of obesity and insulin resistance on the 
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heart as well as the potential therapy in these conditions, do not fall within the scope of the 
present dissertation. In the following section, an overview on the role of adipose tissue in the 
development of insulin resistance is given. 
2.1.4.1 Role of adipose tissue in obesity-induced insulin resistance 
2.1.4.1.1 Adipose tissue: structure 
Adipose tissue is traditionally known as the major storage site of surplus energy in the form of  
fat. In addition to adipocytes held together by a framework of collagen fibers, adipose tissue 
also consists of other cells including stromal-vascular cells, endothelial cells, leukocytes, 
macrophages and  pre-adipocytes as well as nerve tissue (Fain et al., 2004; Schuster, 2009; 
Turer et al., 2012).  Mammalian adipose tissue is essentially divided into brown and white 
adipose tissues while a third type “brite or beige fat” has recently been described (Mueller, 
2013). In humans, fat exists mainly as white adipose tissue, brown adipose tissue being 
located mainly around the neck and large blood vessels of the thorax at birth and thereafter 
replaced by white adipose tissue (Sethi and Vidal-Puig, 2007). However, recent evidence 
revealed the presence of “brown adipose tissue-like” fat in adult humans (Virtanen et al., 2009; 
Mueller, 2013).  In the present dissertation (except where it is specifically mentioned), the term 
adipose tissue generally refers to white adipose tissue. 
2.1.4.1.2 Adipose tissue: active endocrine and immune organ 
Adipose tissue plays a crucial role in the regulation of various metabolic and physiological 
processes (Trujillo and Scherer, 2006; Sethi and Vidal-Puig, 2007; Li et al., 2011; Blüher, 
2013). Under normal conditions, adipose tissue stores surplus energy in the form of neutral 
triglycerides and  releases it into circulation in the form of free fatty acids (FFA) during fasting 
or starvation. Unlike  white adipose tissue, brown adipose tissue provides energy from non-
oxidative phosphorylation in the form of heat, largely for cold adaptation (Saely et al., 2010).  In 
addition to this traditional view, adipose tissue is also recognized as a highly dynamic 
endocrine and immune organ releasing a range of bioactive substances collectively called 
“adipokines” (Fain et al., 2004; Leal and Mafra, 2013).  These adipose-tissue secreted 
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substances have both local (autocrine and/or paracrine) and systemic (endocrine) actions, 
playing an important role in the regulation of various metabolic and physiological processes 
including, amonst others, adipocyte differentiation, local and systemic inflammation, overall 
energy balance, glucose and lipid metabolism as well as blood pressure in normal and 
pathological conditions (Trujillo and Scherer, 2006; Sethi and Vidal-Puig, 2007; Li et al., 2011; 
Blüher, 2013)(see table 2.1).  
The number of adipokines continues to grow day by day to such extent that actually there are 
more than 600 bioactive factors (Bluher et al., 2013), for example, leptin, adiponectin, resistin, 
zinc-α2-glycoprotein (ZAG), apelin, visfatin, vaspin, retinol binding protein-4 (RPB-4), omentin, 
chemerin and endotrophin (Turer et al., 2012; Leal and Mafra, 2013). Adipokines  that are also 
secreted by other tissues include tumor necrosis factor α (TNF-α), interleukin 6 (IL–6), 
monocyte chemo-attractant protein 1 (MCP-1), plasminogen activator inhibitor 1 (PAI-1), serum 
amyloid A (SAA), angiotensinogen (AT) and lipoprotein lipase (Vazquez-Vela et al., 2008; Leal 
and Mafra, 2013).  In view of the role of these various adipokines, adipose tissue may indeed 
play an important role in the development of metabolic alterations in obesity (Vazquez-Vela et 
al., 2008; Blüher, 2013; Leal and Mafra, 2013; Xu et al., 2013).   
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Table 2.1 Adipokines in obesity 
ADIPOKINE       MAIN FUNCTION LEVELS  IN OBESITY 
ENERGY HOMEOSTASIS 
Leptin Beneficial: ↑ Energy expenditure and ↓ Energy 
consumption 
↑ (but neuronal 
resistance to its action 
GLUCOSE HOMEOSTASIS 
Adiponectin Beneficial: ↑insulin sensitivity, ↑AMPK and ↓ gluconeogenesis ↓ 
Omentin Beneficial: ↑ adipocytes glucose uptake ↓ 
Leptin Harmful: ↑ SOCS-3 expression ↑ 
Resistin Harmful: ↑ gluconeogenesis and ↓AMPK and IRS-2 ↑ 
RBP-4 Harmful: ↑ hepatic gluconeogenesis and ↓ muscle insulin signalling ↑ 
TNF-α Harmful: ↓ insulin signalling ↑ 
IL-6 Harmful: ↓ Insulin signalling ↑ 
CARDIOVASCULAR SYSTEM 
Adiponectin Beneficial: ↓ adhesion molecules expression, 
↑cardioprotection ↓ 
Apelin Beneficial: ↑ cardiac contractility and ↓ blood pressure ↑ 
AT Harmful: ↑ blood pressure ↑ 
PAI-1 Harmful: ↓ fibrinolysis ↑ 
TNF-α Harmful: ↑ adhesion molecules ↑ 
IL-6 Harmful: ↑VLDL and CRP ↑ 
INFLAMMATION 
Adiponectin Beneficial: inhibition of  TNF-α, NF-κB activation ↓ 
Omentin Beneficial: NF-κB inhibition ↓ 
Leptin Harmful: cytokine-like structure ↑ 
TNF-α Harmful: NF-κB activation ↑ 
IL-6 Harmful: pro-inflammatory factor ↑ 
 
Only some adipokines have been included in the table. AMPK: AMP-activated protein kinase; 
SOCS: suppressor of cytokine signalling; RBP-4: retinol-binding protein-4: TNF-α: tumor 
necrosis factor-alpha; IL-6: interleukin-6; AT: angiotensinogen; PAI-1: plasminogen activator 
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inhibitor-1; VLDL, very low density lipoprotein; CRP, C-reactive protein; NF-κB: nuclear factor 
kappa-B (adapted from Leal and Mafra, 2013). 
2.1.4.1.3 Adipose tissue dysfunction-induced inflammation 
Obesity is associated with low-grade inflammation (Lionetti et al., 2009; Bluher et al., 2013). In 
fact, in genetically and environmentally susceptible individuals, chronic overnutrition with an 
excessive energy intake and low energy expenditure results in adipocyte hypertrophy and 
visceral fat accumulation, due to saturation of the expansion capacity or inability of 
subcutaneous adipose tissue to expand (Lionetti et al., 2009; Bluher et al., 2013). This is 
accompanied by macrophage recruitment, hypoxia as well as oxidative stress, all leading to 
adipose tissue dysfunction (Lionetti et al., 2009, de Luca and Olefsky, 2008, Furukawa et al 
2004) (see figure 2.3).  As a consequence, circulating FFA increase and excessive fats 
accumulate inappropriately in non-adipose tissues such as liver, pancreas, kidneys and 
muscles as well as the heart (or around them) and negatively affect their normal metabolism 
and function (Christoffersen et al., 2003; Vazquez-Vela et al., 2008; Shimabukuro, 2009). This 
ectopic fat deposition in undesired sites leads to a lipotoxic state inducing local and systemic 
low-grade inflammation that gives rise to insulin resistance (Lionetti et al., 2009).   
Dysfunctional and inflamed adipose tissue is accompanied by dramatic alterations in the 
release of adipokinescollectively termed adipokines dysregulation (Leal and Mafra, 2013). For 
example, compared to normal subjects, circulating leptin levels are elevated in obesity (Lin et 
al., 2000) while suprisingly, circulating adiponectin levels are reduced in obese subjects 
despite being produced by adipose tissue (Arita et al., 1999).  However, similar to leptin, 
resistin, chemerin, apelin, angiotensin, TNF-α and IL-6 are elevated in obesity while omentin, 
similar to adiponectin, is reduced in overweight or obese subjects  compared to lean individuals 
(Leal and Mafra, 2013). Adipokine dysregulation may play a crucial role in the development of 
obesity-induced metabolic abnormalities, endothelial cell dysfunction and cardiovascular 
diseases (Turer et al., 2012; Blüher, 2013). 
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Figure 2.3 Simplified mechanisms for adipose tissue-induced inflammation and insulin 
resistance in obesity. Obesity-induced changes in skeletal muscle, adipose tissue and the liver 
result in localized inflammation and insulin resistance (IR) through autocrine and paracrine 
signalling. Endocrine-mediated cross-talk between insulin target tissues contributes to insulin 
resistance in distant tissues. Systemic inflammation and insulin resistance are the net effect of 
these changes. : endocrine crosstalk, FFA: free fatty acids, ER: endoplasmic reticulum 
[adapted from de Luca and Olefsky (2008)]. 
In general, adipokines have been shown to affect central and peripheral organs implicated in 
metabolism (brain, liver, pancreas, muscle, adipose tissue) as well as the reproductive tract [for 
review, see (Trujillo and Scherer, 2006)]. Specifically, adipokines are actively implicated in 
various processes such as the regulation of energy homeostasis (e.g., leptin), insulin sensitivity 
(glucose homeostasis) and inflammation (e.g., TNF-α, IL-6, resistin, visfatin, adiponectin) as 
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well as  cardiovascular function (e.g., adiponectin, AT, PAI-1, RPB-4) (Leal and Mafra, 2013). 
Some functions of adipokines are summarized in table 2.1. 
In obesity, as well as in other related metabolic disorders, adipokines may induce insulin 
resistance either directly by affecting the insulin signalling pathway or indirectly via stimulation 
of inflammatory pathways (Piya et al., 2013). In this context, it has been shown that pro-
inflammatory adipokines (e.g., TNF-α, leptin, IL-6, resistin, visfatin) may directly induce serine 
phosphorylation of insulin receptor substrate 1 and 2 (IRS-1,2) or  indirectly  disrupt the insulin 
signalling via inflammatory pathways including the c-Jun N-terminal kinases (JNK) and I-Kappa 
B kinase β (IKKβ)/NF-κB through a series of transcriptional events (de Luca and Olefsky, 2008)  
(see figure 2.4). 
 
Figure 2.4 Interactions between insulin signalling and inflammatory pathways. The insulin 
signalling cascade branches into two main pathways. The PI3-K-PKB/Akt pathway mediates 
insulin action on nutrient metabolism including glucose uptake. The Ras/MAPK pathway 
mediates insulin’s effect on gene expression, but also interacts with the PI3-K-PKB/Akt 
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pathway to control cell growth and differentiation. Activation of the insulin receptor leads to 
tyrosine phosphorylation of IRS-1 thereby initiating signal transduction. Stimulation of the 
NFκB and AP-1 Fos/Jun inflammatory pathways results in the activation of the serine kinases, 
IKKβ and JNK1, which reduce the signalling ability of IRS-1. Additional inflammation-related 
negative regulators of IRS proteins include the suppressors of cytokine signalling (SOCS) 
proteins and nitric oxide (NO), which are induced in inflammation, and promote IRS 
degradation. NO also reduces PI3-K/Akt activity by s-nitrosylation of PKB/Akt (de Luca and 
Olefsky, 2008). 
2.1.4.1.4 The role of adipose dysfunction in insulin resistance 
While adipose tissue volume or distribution has been traditionally considered as crucial in the 
development of metabolic disorders, mounting evidence also supports the role of adipose 
tissue dysfunction in the development of metabolic complications independent of adipose 
tissue volume or distribution [for review see (Patel and Abate, 2013)].  As described above, 
obesity-induced insulin resistance may result from complex cross-talks between the skeletal 
muscles; liver and adipose tissue (see figure 2.3). Therefore, a decreased capacity for 
adipocyte differentiation and angiogenesis along with adipocyte hypertrophy can trigger a 
vicious cycle of inflammation leading to subcutaneous adipose tissue dysfunction as indicated 
by increased visceral fat accumation and ectopic fat deposition, all leading to systemic insulin 
resistance (Goossens, 2008; Lionetti et al., 2009).    
In skeletal muscle, elevated FFA and pro-inflammatory cytokines (TNF-α, Il-6) inhibit insulin-
mediated glucose uptake pathways which result in a reduced insulin sensitivity contributing to 
hyperglycaemia, which is associated with increased oxidative stress (Furukawa et al., 2004; 
Vincent and Taylor, 2006; Galili et al., 2007; Singh et al., 2011). 
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2.1.4.2 Role of oxidative stress in obesity and insulin resistance 
2.1.4.2.1 An overview: concept and assessment  
Except organisms specifically adapted to life under anaerobic conditions, all animals and 
plants on earth require oxygen for efficient production of energy.  At cellular level, this occurs 
via various metabolic pathways localized in different cellular compartments and leads to the 
production of “free radical species” and normal molecules.  Free radicals are defined as any 
chemical species capable of independent existence that contains one or more unpaired 
electrons.  The concept of reactive oxygen species (ROS) refers to chemical species (free 
radicals or non-radicals) associated with the oxygen atom and having a higher reactivity with 
other molecules than molecular oxygen (O2). ROS include the superoxide anion (O2−), 
hydrogen peroxide (H2O2), hydroxyl radical (•OH), and singlet oxygen (1O2), but there are also 
other species which are particularly associated with oxidation of membrane lipids (“reactive 
lipid species”) such as lipid peroxyl radical (•ROO), lipid alkoxyl radical (•RO) and lipid 
hydroperoxide (ROOH) (Toyokuni, 1999).  Reactive nitrogen species (RNS) refers to the 
chemical species derived from nitric oxide (NO). They include nitric oxide (NO) and its 
derivatives such as nitrogen dioxide radical (•NO2) and other non-radicals like peroxynitrite 
(ONOO−) and its protonated form (peroxynitrous acid, ONOOH), alkylperoxynitrite (ROONO), 
nitrosil (NO+), nitronium cation (NO2+), and dinitrogen trioxide (N2O3). Other reactive species 
include carbonyl radical (•RC3), thiyl radical (RS•) and hypochlorous acid (HOCl) as well as 
ozone (O3).  For more details on reactive species, see Pourova et al. (2010) and Valko et al. 
(2007). 
 Cells regulate the ROS/RNS levels by a common scavenging system composed of various 
antioxidants and the equilibrium between oxidative agents and the antioxidant defense is of 
crucial importance for homeostasis (Cadenas, 1997; Valko et al., 2007).  Cellular antioxidant 
defense mechanisms include, amongst others, enzymatic antioxidants such as superoxide 
dismutase (SOD) [with cytosolic (Cu-ZnSOD) and mitochondrial (Mn-SOD) forms], glutathione 
peroxidase (GPx), catalase (CAT) and non-enzymatic antioxidants such as ascorbic acid 
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(Vitamin C), α-tocopherol (Vitamin E), glutathione (GSH), carotenoids, flavonoids, α-lipoic acid, 
and trace minerals (zinc, selenium, and magnesium), melatonin and  other antioxidants (Valko 
et al., 2007).  
Under well controlled conditions, ROS/RNS play a role in the regulation of cell function and 
they may also act as signalling molecules [for review see (Valko et al., 2007; Pourova et al., 
2010)].  On the other hand, if imbalanced, ROS/RNS can contribute to the progression of 
various human diseases. This condition is referred to as “oxidative stress” and is  
characterized by an elevated ROS/RNS production and insufficient antioxidant capacity 
causing  accumulation of these species and eventual cell damage (DNA damage, lipid 
peroxidation and oxidized protein) (Singal et al., 1998; Hansel et al., 2004; Grattagliano et al., 
2008) as well as disruption of redox balance and signalling (Jones, 2006).   
Oxidative stress levels can be assessed in biological fluids or specific tissues using 
appropriate biomarkers including measurement of the levels of endogenous and dietary 
antioxidants, ROS or RNS (Tarpey and Fridovich, 2001; Gomes et al., 2005), lipid peroxidation 
products [thiobarbituric reactive acid substances (TBARS), malondialdehyde (MDA), lipid 
hydroperoxides (PEROX), F2-isoprostanes (e.g., 8-epiPGF2α) and conjugated dienes (CD)], 
derivatives of reactive oxidative metabolites (DROM) as well as the ratio of oxidized to reduced 
glutathione (Eh-GSH) and cysteine (Eh-CySH) (Neuman et al., 2007).  
2.1.4.2.2 Evidence for obesity- associated oxidative stress 
Increased body fat accumulation and its related abnormalities have been associated with 
increased systemic and tissue oxidative stress (Furukawa et al., 2004; Vincent and Taylor, 
2006; Galili et al., 2007; Singh et al., 2011).   It is now generally accepted that obesity may be 
a state of chronic oxidative stress (Vincent et al., 2007; Codoner-Franch et al., 2009; Wu et al., 
2009).  For instance, in a meta-analysis of data published between 1975 and 2006 (Vincent et 
al., 2007), it was found that obesity elevates oxidative stress in young and old clinical 
populations as shown by elevation in lipid peroxidation or protein oxidation, associated with 
low systemic anti-oxidant defense.  In a study evaluating the metabolic profile of 148 clinically 
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healthy middle-aged women, anthropometric measurements, leptin, high-sensitivity C-reactive 
protein (hs-CRP) and plasminogen activator inhibitor-1 (PAI-1) were higher in the overweight 
group compared to normal weight women (Wu et al., 2009). In addition, these parameters 
were positively associated with oxidative stress as measured by urinary excretion of 8-epi-
PGF2α) (Wu et al., 2009). Similar observations have also been made in obese men with or 
without diabetes, supporting the role of increased adiposity in the development oxidative stress 
(D'Archivio et al., 2011). It has also been reported in animal studies that chronic consumption 
of high fat/high refined sugar diets results in elevation of oxidative stress (Roberts et al., 2006).  
Importantly, obesity is associated with coronary endothelial dysfunction (Galili et al., 2007), 
increased oxidative stress (Vincent et al., 1999) as well as apoptosis (Li et al., 2005) in the 
heart. 
2.1.4.2.3 Oxidative stress in obesity and insulin resistance 
The potential causes of increased oxidative stress in obesity include hyperglycaemia, 
increased muscle activity to carry excessive weight, increased tissue lipid levels, inadequate 
antioxidant defenses, chronic inflammation, endothelial ROS production and hyperleptinaemia 
[for reviews see (Vincent et al., 1999; Vincent and Taylor, 2006; de Ferranti and Mozaffarian, 
2008)].  Briefly, at cellular and molecular levels, these free-radical generating conditions have 
been shown to be associated with elevated free fatty acids, cortisol, angiotensin II, 
deregulation of adipokines and increased inflammatory cytokines (Lastra and Manrique, 2007; 
Qatanani and Lazar, 2007; Monteiro and Azevedo, 2010). It has also been suggested that 
many stress signals that originate in adipose tissue result in increased ROS and RNS levels, 
alter the function of mitochondria and endoplasmic reticulum, and converge on common 
pathways, which in turn regulate one another (Codoñer-Franch et al., 2011).   
A study performed on a mouse model of diet-induced insulin-resistance demonstrated that 
excessive ROS production in skeletal muscle and its subsequent mitochondrial dysfunction 
development resulted from hyperglycaemia and hyperlipidaemia, and normalization of 
glycaemia or antioxidant treatment decreased muscle ROS production and restored 
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mitochondrial integrity (Bonnard et al., 2008). Additionally, as described below, the coordinated 
regulation of the pathways affected by ROS and RNS appears to be a central feature of 
obesity and may result in the perpetuation of inflammation and oxidative stress (Codoñer-
Franch et al., 2011).    
However, the mechanisms linking obesity and its associated insulin resistance and 
overproduction of ROS/RNS are still to be clarified. In addition, the question of whether 
excessive formation of ROS/RNS is a primary cause or a downstream consequence of insulin 
resistance remains under debate. It was suggested that in response to energy substrate over-
supply in obesity, in addition to an inflammatory state, increased oxidative stress in adipose 
tissue and then in remote tissues [via increased nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase activity], and a concomitant reduction in antioxidant enzymes are the early 
triggers of insulin resistance and associated cardiovascular complications (e.g., endothelial 
dysfunction) (Furukawa et al., 2004; Grattagliano et al., 2008; Otani, 2011).  
In the pre-diabetic state, insulin resistance-induced hyperglycaemia is also known to contribute 
to increased ROS production exacerbating the insulin resistant state via glycation pathways 
(Grattagliano et al., 2008). In this regard, it is well established that elevated ROS levels 
negatively affect insulin signalling (PI3-K/Akt) via stress-activated kinases (e.g., p38MAPK, 
JNK, GSK-3β, IKKβ) (Houstis et al., 2006; Henriksen et al., 2011; Rains and Jain, 2011; Zhai 
et al., 2011) (see figure 2.5).  However, it was shown that mice lacking one of the key enzymes 
involved in the elimination of physiological ROS, glutathione peroxidase 1 (GPx1), were 
protected from high-fat diet-induced insulin resistance confirming the causal evidence for the 
enhancement of insulin signalling by ROS in vivo (Loh et al., 2009).  These controversial 
results clearly indicate that more studies are required to solve this problem. 
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Figure 2.5 Schematic representation of the overproduction of oxidants from NADPH oxidase 
and mitochondrial sources in mammalian skeletal muscle, with subsequent enhanced 
engagement of p38 MAPK and other stress-activated kinases, including JNK, GSK-3, IKKβ, 
and others, associated with diminished insulin signalling and reduced glucose transport 
activity. GLUT-4: glucose transport 4, ANG II: angiotensin II, AT1R: angiotensin type 1 
receptor [adapted from Henriksen et al. (2011)].  
2.1.4.2.4 Clinical use of antioxidants in obesity and insulin resistance 
In view of the above mentioned evidence for increased oxidative stress in obesity, the question 
arises whether antioxidant supplementation could reverse its detrimental actions.  Antioxidant 
supplementation in obesity, the MetS, diabetes and CVD unfortunately yielded disappointing 
findings in large scale human studies with a number of reports even showing detrimental 
effects (Blot et al., 1993; Skrha et al., 1999; Yusuf et al., 2000; Kris-Etherton et al., 2004).  
These failures have been recently reviewed (Steinhubl, 2008; Sheikh-Ali et al., 2011). The type 
and dose of antioxidants used, patient cohorts included in the trials as well as  the trial design 
itself have been pointed out as the main causes of the disappointment (Steinhubl, 2008; 
Sheikh-Ali et al., 2011). Additionally, a mechanistic explanation involving endoplasmic 
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reticulum stress as the cause of the failure has been suggested (Mooradian and Haas, 2011). 
However, the overall clinical relevance of conventional antioxidants in metabolic diseases is 
still a challenging field.  Some authors even suggest that there is no clear evidence that a 
reduction in free radical generation will correct the imbalance causing obesity and insulin 
resistance (Tiganis, 2011).  In fact, there are still divergences around the role of ROS and 
antioxidants (promoting and decreasing insulin sensitivity) (Tiganis, 2011). These findings led 
some authors to suggest that more caution should be exercised in the clinical use of 
antioxidants in insulin resistant conditions (Tiganis, 2011). Indeed, as argued in a recent 
review the point where ROS/RNS levels go from “good” to “bad” has not yet been delineated 
(Tiganis, 2011). 
Nevertheless, surprisingly, small clinical studies using antioxidants did report beneficial effects 
(Vincent et al., 2006; Sutherland et al., 2007).  A study by Vincent et al. (2009) showed that 8 
weeks of antioxidants (combination of vitamin E, vitamin C, and β-carotene) supplementation 
to overweight young adults, moderately improved insulin sensitivity. This was associated with 
an increase in adiponectin levels and a reduction in plasma lipid hydroperoxide and endothelial 
adhesion molecules (Vincent et al., 2009). Here, additional long term and large scale studies 
are urgently required to validate these promising results. Furthermore, a meta-analysis of 50 
studies and 534,906 individuals indicated that the non-classical antioxidant (Mediterranean 
diet) has exhaustively reduced abdominal obesity and other MetS components (Kastorini et al., 
2011). The antioxidant melatonin, which is also present in some of the common ingredients of 
the traditional Mediterranean diet (Iriti et al., 2010), is reported to be more effective compared 
to other classical antioxidants (vitamins C and E) (Martin et al., 2000; Montilla-Lopez et al., 
2002) and it does not have pro-oxidant actions (Korkmaz et al., 2009a). We have recently 
indicated its potential therapeutic use in obesity-related abnormalities (Nduhirabandi et al., 
2012). This is described further in the section on melatonin and obesity (section 2.4). 
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2.1.5 SUMMARY 
The association of obesity and insulin resistance is an area of much interest and enormous 
public health impact: more than 27068 articles are found in Pubmed with more than a half of 
them being published in the last 5 years (searched on 20/08/2013).  The increased prevalence 
of obesity in insulin resistant patients is evident.  However, insulin resistance per se has been 
viewed as an adaptative mechanism (to protect cells against acute lipid overload and overflow 
and inflammation) which becomes ineffective and leads to multiple metabolic abnormalities in 
the chronic state (Tsatsoulis et al., 2013).  Althought many of these abnormalities can also 
occur in non-insulin resistant subjects (Reaven, 2004), they are closely related to obesity 
(Cornier et al., 2008) and are strongly associated with increased risk for cardiac diseases 
(Reaven,1988).  
2.1.6 CARDIAC ALTERATIONS IN OBESITY AND INSULIN RESISTANCE 
Convincing epidemiological and experimental studies have shown a strong association 
between obesity/insulin resistance and cardiac diseases, including coronary artery disease, 
atrial fibrillation, and congestive heart failure (Yusuf et al., 2005; Poirier et al., 2006; Banerjee 
and Peterson, 2007; Reaven, 2012; Shah et al., 2013; Wensley et al., 2013). Globally, the 
oversupply of substrates has been suggested to lead first to adaptive changes which over time 
become maladapted, causing contractile dysfunction of the heart (Harmancey et al., 2008).  
This section focuses on the impact of obesity and insulin resistance on cardiac structure, 
metabolism and function in normoxia and ischaemia-reperfusion injury. Vascular endothelial 
dysfunction in obesity and insulin resistance is also summarized to better understand the 
contribution of vascular dysfunction in cardiac events. The description of hypertension as well 
as other related vascular abnormalities and their specific role in cardiac alterations associated 
with obesity and insulin resistance (Alpert, 2001), is unfortunately beyond the scope of the 
present dissertation.  
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2.1.6.1 Endothelial dysfunction in obesity and insulin resistance  
2.1.6.1.1 Endothelial dysfunction: concept and assessment 
The endothelium is the thin layer of cells that lines the interior of blood vessels. It acts as an 
endocrine organ, able to produce and release various metabolically active substances, playing 
a vital role in maintaining circulatory homeostasis (Davel et al., 2011). The endothelium 
mediates blood vessel tone, haemostasis, neutrophil recruitment, hormone trafficking, and fluid 
filtration (Hirase and Node, 2012).  Vascular endothelial dysfunction is a pathological condition 
characterized by an imbalance between endothelium-derived relaxing (EDRFs) (e.g., nitric 
oxide (NO), prostacyclin) and contractile (EDCFs) (e.g., thromboxane A2 or endothelin) factors 
(Davel et al., 2011).  The definition of endothelial dysfunction has also been extended to 
include imbalance between growth promoting and inhibiting factors, pro-atherogenic and anti-
atherogenic factors, and pro-coagulant and anti-coagulant factors (Caballero, 2003; 
Muniyappa and Sowers, 2013).  Endothelial dysfunction can result from and/or contribute to a 
variety of disease states, including diabetes mellitus, coronary artery disease, hypertension, 
and hypercholesterolaemia (Davel et al., 2011). To date, endothelial dysfunction is the most 
clearly defined and well understood early precursor of atherosclerosis [for review see (Mudau 
et al., 2012)]. Various methods to determine endothelial function and dysfunction have been 
used in epidemiological and experimental studies. As recently reviewed, these include use of 
biochemical markers, circulating endothelial cells and endothelial microparticles, molecular 
genetic tests and invasive and non-invasive tools with and without pharmacological and 
physiological stimuli (e.g., peripheral arterial tonometry, flow-mediated dilation, forearm 
plethysmography, finger-pulse plethysmography, pulse curve analysis and quantitative 
coronary angiography) (Schnabel et al., 2011; Mudau et al., 2012; Bruyndonckx et al., 2013). 
2.1.6.1.2 Endothelial dysfunction in obesity and insulin resistance 
Obesity is associated with impaired systemic and coronary endothelial function (Galili et al., 
2007). In this regard, the factors that could adversely affect endothelium function include 
changes in blood pressure (BP), glucose levels, lipid metabolism, systemic inflammation and 
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oxidative stress, sympathetic hyperactivity, adipokines and physical (in)activity (Kobayasi et 
al., 2010; Davel et al., 2011).  Several studies have shown that endothelial dysfunction results 
from reduced NO bioavailability, increased oxidative stress, elevated expression of pro-
inflammatory and pro-thrombotic factors, and leads to abnormal vasoreactivity (Muniyappa and 
Sowers, 2013). The role of endothelial dysfunction in obesity has been studied in several 
experimental studies. For example, Kobayasi et al. (2010) using obese mice fed a high-fat diet 
have shown that the expression of endothelial nitric oxide synthase (eNOS) and Cu/Zn-SOD 
was significantly decreased in the aortas from obese mice.  Although total p65 NF-κB subunit 
expression was not affected by obesity, the expression of the NF-κB inhibitor IκB-α was 
reduced with a concomitant impaired endothelium-dependent relaxation in aortas from obese 
mice (Kobayasi et al., 2010). In addition, the expression of TNF-α was increased in aortas from 
obese mice compared to the control group (Kobayasi et al., 2010).  In the same study, the 
high-fat diet feeding was associated with an increase in body weight, fat mass, glucose blood 
levels and blood pressure, and increased lipid accumulation into macrovesicular droplets in 
hepatocytes, a feature of hepatic steatosis (Kobayasi et al., 2010). The obesity-induced 
impaired endothelial function was also demonstrated in other animal models of obesity 
(Villalba et al., 2009; Costa et al., 2011) as well as in humans (Jonk et al., 2011; Bagi et al., 
2012).  A study using venous occlusive plethysmography, reported a significant correlation 
between impaired endothelium-dependent vasodilatation and insulin resistance in subjects 
with uncomplicated obesity (Pasimeni et al., 2006).  
Endothelial dysfunction may also contribute to insulin resistance (Caballero, 2003).  In this 
regard, impaired endothelium function has been shown to alter the transcapillary passage of 
insulin to target tissues and reduce the insulin availability to metabolically active tissues (such 
as skeletal muscle, liver, heart) and subsequent impairment of insulin-stimulated glucose and 
lipid metabolism (Cersosimo and DeFronzo, 2006). For example, in obese pigs, coronary 
endothelium-dependent vasorelaxation was reduced in association with increased myocardial 
microvascular permeability compared to normal pigs (Galili et al., 2007).  Interestingly, in this 
obesity model, endothelial dysfunction was associated with increased vascular oxidative stress 
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in association with increased levels of leptin and preceded the development of insulin 
resistance and systemic oxidative stress (Galili et al., 2007). Importantly, this study has 
demonstrated the potential contribution of endothelial dysfunction to impaired insulin action as 
previously suggested (Cersosimo and DeFronzo, 2006). In a rat model of diet-induced obesity, 
defective endothelium function was also identified in the absence of insulin resistance 
(Naderali et al., 2001).  
However, the causal relationship between insulin resistance and endothelial dysfunction is 
more complex (see figure 2.6). Both disorders share causal factors such as dyslipidaemia, 
glucotoxicity, lipotoxicity, inflammation and impaired PI3-K-dependent insulin signalling 
pathways, leading to reciprocal relationships between insulin resistance and endothelial 
dysfunction (Muniyappa and Quon, 2007) (see figure 2.6). It has been suggested that during 
insulin-resistant conditions, pathway-specific impairment in PI3-K-dependent signalling may 
cause an imbalance between NO production (PI3-K/Akt-eNOS pathway) and secretion of 
endothelin-1 (MAPK pathway), leading to endothelial dysfunction (Muniyappa and Sowers, 
2013). However, a preserved coronary endothelial function has been reported in insulin 
resistant animals (Sánchez et al., 2010; Contreras et al., 2011). This phenomenon could be 
explained by an association with other early adaptive mechanisms which, over time, may 
become maladaptative (Sánchez et al., 2010).  
2.1.6.1.3 Endothelial dysfunction and adipose tissue  
As presented in figure 2.6, visceral adiposity may also affect endothelial function (Bagi et al., 
2012).  For example, in a randomized controlled longitudinal study of normal-weight healthy 
young subjects, modest fat gain resulted in impaired endothelial function, even in the absence 
of changes in blood pressure; interestingly, this endothelial dysfunction recovered after weight 
loss (Romero-Corral et al., 2010).  The role of visceral fat mass in endothelial dysfunction was 
also confirmed in an uncontrolled, cross-sectional study of severely obese subjects where the 
severity of endothelial dysfunction was shown to correlate with the degree of visceral adiposity 
independently of traditional risk factors or the degree of liver steatosis and plasma adiponectin 
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(Sturm et al., 2009).  Although the mechanisms linking visceral adiposity to endothelial 
dysfunction are complex and still not yet clear, adipose tissue dysfunction and increased 
circulating fatty acids as well as deregulation of adipokines secretion (endocrine action) may 
play a crucial role in development of endothelial dysfunction in obesity (Caballero, 2003; 
Cersosimo and DeFronzo, 2006; Rega-Kaun et al., 2013).  
 In addition to visceral adiposity, increased pericardial adipose tissue in obese individuals may 
also contribute to endothelial dysfunction (Bagi et al., 2012; Gaborit et al., 2012; Payne et al., 
2012).  In this regard, a study by Gaborit et al. (2012) on 30 healthy volunteers with normal left 
ventricular function, has found a significant negative correlation between epicardial fat volume 
and myocardial blood flow which was also associated with reduced adiponectin levels, but not 
with obesity (BMI, waist circumference), C-reactive protein, lipid or glycemic parameters. 
Interestingly, while adiponectin levels and epicardial fat volume remained independently 
associated with myocardial blood flow, a high epicardial fat content was associated with a 
lower coronary microvascular response (Gaborit et al., 2012), suggesting that epicardial fat 
could influence endothelial function via its secreted adipokines (Gollasch, 2012; Payne et al., 
2012).  Recent evidence has shown that epicardial fat volume is an independent predictor of 
impaired diastolic function in apparently healthy overweight patients even after accounting for 
associated co-morbidities such as MetS, hypertension, and subclinical cardiac artery disease 
(Cavalcante et al., 2012). 
Since it is important to maintain a balance between coronary blood flow and myocardial 
metabolism for normal cardiac function, an impairment in coronary blood flow due to 
endothelial dysfunction and its associated microvascular dysfunction, as demonstrated above, 
has been shown to play a crucial pathophysiological role in cardiac dysfunction in obesity and 
insulin resistance (Poirier et al., 2006).  Importantly, a high prevalence of co-morbidities such 
as overweight/obesity, diabetes and chronic obstructive pulmonary disease drives myocardial 
dysfunction and remodelling via coronary microvascular endothelial inflammation, causing 
heart failure with preserved ejection fraction (Paulus and Tschöpe, 2013).  Myocardial 
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remodelling in obesity and insulin resistance is described in the next section. It involves 
changes in myocardial metabolism, structure and function (Abel et al., 2008). 
  
 Figure 2.6 Relationships between insulin resistance, visceral adiposity and endothelial 
dysfunction.  Insulin resistance can cause endothelial dysfunction through altered PI3-K-
PKB/Akt signalling. Endothelial dysfunction, in turn, can cause insulin resistance owing to 
diminished blood flow and capillary recruitment, leading to decreased substrate and insulin 
delivery. Endothelial dysfunction can lead to insulin resistance, as well as visceral adiposity by 
impaired mitochondrial biogenesis. Visceral adipose tissue can secrete adipokines and FFAs, 
which can cause endothelial dysfunction and peripheral insulin resistance. Finally, insulin 
resistance can lead to atherogenic dyslipidaemia, which can contribute to visceral obesity 
(Huang, 2009).  
2.1.6.2 Myocardial metabolism in obesity and insulin resistance 
Obesity and insulin resistance are associated with changes in myocardial metabolism (Abel et 
al., 2008; Harmancey et al., 2008). These changes have been observed in humans and in 
several animal models of diet-induced obesity and insulin resistance (Abel et al., 2008; Chess 
and Stanley, 2008). A reduced cardiac efficiency and altered substrate metabolism have been 
reported to precede the onset of hyperglycaemia and contractile dysfunction in obesity, insulin 
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resistance and diabetes (Buchanan et al., 2005). In this regard, the development of cardiac 
insulin resistance and decreased mitochondrial oxidative metabolism have been found to be 
the early metabolic changes in the development of cardiac hypertrophy, which create an 
energy deficit that may contribute to the progression from hypertrophy to heart failure (Zhang et 
al., 2013). Apart from an altered fuel (glucose and lipid) availability, various other mechanisms 
such as adipokine signalling and altered insulin signalling may also influence myocardial 
metabolism in obesity (Lopaschuk et al., 2007; Harmancey et al., 2008).   
2.1.6.2.1 Myocardial metabolism under normoxic conditions 
A normal healthy heart is able to display great flexibility in its choice of substrates, depending 
on their availability in the circulation, myocardial workload and relative oxygen supply 
(Taegtmeyer et al., 2004).  Normally,  a switch in cardiac fuel prefence  from  glucose  to fatty 
acids occurs just after birth, when oxygen availability and dietary fat content increase, 
rendering fatty acids the preferable substrate for the heart (Girard et al., 1992; Rider et al., 
2013). This is related to substrate selection via the Randle cycle (inhibition of glucose uptake 
and catabolism by FFA oxidation) (Randle et al., 1963; Bertrand et al., 2008).  Substrate 
uptake and metabolism in the normal heart is a highly regulated process. Several recent 
reviews have been published (Stanley et al., 2005; Coort et al., 2007; Lopaschuk et al., 2010; 
Rider et al., 2013) and only a short  summary on FFA and glucose metabolism will be given 
below.  
 Under physiological conditions, cardiomyocytes oxidize predominantly long chain fatty acids 
(LCFA) (60-70%) while glucose (20%) and lactate (10%) are metabolized to lesser extent 
(Coort et al., 2007). Smaller contributions from other oxidizable substrates such as ketones 
and amino acids have also been indicated (Stanley et al., 2005).   LCFA enter the sarcolemma 
by passive diffusion and a protein-mediated transport system (fatty acid transport protein 
(FATP)) or a plasma membrane fatty acid binding protein (FABPpm) (Coort et al., 2007).  Once 
in the cytosol, the non-esterified FFAs bind to FABP and are then activated by esterification to 
fatty acyl-CoA.  Fatty acid β-oxidation occurs primarily in the mitochondria and to a small extent 
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in peroxisomes (Stanley et al., 2005).  Approximately  80% of the cytosolic long  chain fatty 
acyl-CoA are transported across the inner mitochondrial membrane for further β-oxidation and 
eventual ATP generation, while the remaining (20%) is esterified into TG to constitute the 
intracardiac TG pool (Chess and Stanley, 2008).   
Besides FFA β-oxidation, cardiomyocytes oxidize pyruvate derived in approximately equal 
amounts from glycolysis and lactate oxidation. Pyruvate can be converted to lactate in the 
cytosol or enter the mitochondria for either decarboxylation to acetyl-CoA by pyruvate 
dehydrogenase (PDH) or carboxylation to oxaloacetate or malate (in the citric acid cycle) 
(Sundqvist et al., 1989; Stanley et al., 2005). Glucose entry into the cardiomyocytes is 
passively regulated by the transmembrane glucose gradient and glucose transporters in the 
sarcolemma (mainly GLUT-4, and to a lesser extent GLUT-1) (Stanley et al., 2005). In 
response to insulin stimulation, glucose transporters translocate from intracellular vesicles to 
the sarcolemmal membrane which increases the membrane capacitance for glucose transport 
and the rate of glucose uptake. GLUT-4 translocation can  also be stimulated by the activation 
of AMP-activated protein kinase (AMPK) following  a cellular stress such as increased work 
demand or injury (Sambandam and Lopaschuk, 2003; Russell et al., 2004).  It is well 
established that in the well-perfused heart, approximately 60–90% of the acetyl-CoA is derived 
from β-oxidation of fatty acids, with 10–40% produced by the oxidation of pyruvate (Stanley et 
al., 2005). However, a shift towards glucose, lactate and endogenous glycogen utilization 
assumes greater importance in conditions such as ischaemia, increased workload and 
pressure overload (Sambandam et al., 2002; Stanley and Chandler, 2002; Grossman et al., 
2013).   
2.1.6.2.2 Myocardial metabolism: contribution of obesity and insulin resistant  
conditions 
Obesity results in elevated blood FFA levels and increased supply of FFA to the heart. This 
leads to an increase in FFA oxidation and a decrease in glucose utilization. With time, 
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continuous excessive FFA uptake overwhelms the FFA accumulation capacity of the heart 
causing contractile dysfunction (Young et al., 2002).   
The role of elevated FFA in the development of myocardial insulin resistance and cardiac 
dysfunction involves  various pathways related to excessive FFAs β-oxidation and excessive 
lipid accumulation (Lopaschuk et al., 2010).  
Increased FFA β-oxidation is associated with increased oxygen consumption in animals and 
humans (Peterson et al., 2004; Banerjee and Peterson, 2007). This, initially adaptative, can 
over time cause an increased production of ROS and contribute to development of myocardial 
oxidative stress, ER stress, cell death and/or Ca2+ handling abnormalities (Mittendorfer and 
Peterson, 2008), which in turn may lead to heart failure (Chess & Stanley, 2008).  Recently, in 
obese insulin resistant  rats, myocardial dysfunction caused by obesity has been shown to be 
associated with reduced gene expression of proteins related to Ca2+ transport, impaired L-type 
Ca2+ channel activity without affecting SERCA2a expression and function as well as L-type 
Ca2+ protein levels (Lima-Leopoldo et al., 2008).  Although the mechanism responsible for the 
alteration in genes responsible for myocardial Ca2+ handling is still unknown, it could reflect a 
compensatory mechanism to the impaired myocardial Ca2+ handling observed in obesity 
(Mittendorfer and Peterson, 2008). However, in another model of diet-induced obesity, a 
significant reduction of myocardial  SERCA2a expression has been observed (Huisamen et al., 
2012). 
In addition to increased FFA β-oxidation, a continous lipid supply may lead to excessive lipid 
storage associated with eventual intramyocellular FFA accumulation (steatosis) and lipotoxicity 
(Granér et al., 2013; Wang et al., 2013). Here, the excess FFA in the cardiomyocytes may 
contribute to lipotoxicity via increased diacylglycerol and ceramide pathways (Mittendorfer and 
Peterson, 2008; Zhang et al., 2011). This has been associated with mitochondrial dysfunction 
and impaired insulin-stimulated glucose oxidation (Zhang et al., 2011) and may lead to cell 
death and eventual cardiac dysfunction (Chess and Stanley, 2008; Mittendorfer and Peterson, 
2008) (see figure 2.7).   
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Apart from the contribution of an excess supply of FFA, as above indicated, adipokine 
signalling may also affect the myocardial metabolism in obesity. For example, in patients with 
acute myocardial infarction as well as in animal models, obesity has been associated with a 
reduction in serum adiponectin levels (Piestrzeniewicz et al., 2007; Lee et al., 2010), which 
were associated with an atherogenic lipid profile and higher levels of inflammatory markers 
(Piestrzeniewicz et al., 2007).  Additional important mechanisms which may directly contribute 
to the pathophysiology of cardiac insulin resistance and its complications include changes in 
AMP-activated protein kinase (AMPK) signalling, oxidative stress, inflammation, advanced 
glycation end products (AGE), endoplasmic reticulum stress and autophagy [for review, see 
(Abel et al., 2012; Mellor et al., 2013)]. 
 
Figure 2.7 Myocardial metabolism under conditions of elevated fatty acids (details in the text). 
FATP: fatty acid transport proteins; FFAs: free fatty acids; DAG: diacylglycerol; PKC: protein 
kinase C; PPAR: Peroxisome proliferator-activated receptor; PDH: pyruvate dehydrogenase; 
RXR: retinoid X receptor; PGC: peroxisome proliferator-activated receptor-gamma coactivator. 
IR: insulin receptor; IRS: insulin receptor substrate [adapted from Chess and Stanley (2008)]. 
Stellenbosch University  http://scholar.sun.ac.za
 41 
 
2.1.6.2.3 Myocardial metabolism in obesity: contribution of impaired insulin action 
As previously indicated, under physiological circumstances, insulin regulates substrate 
utilization in multiple tissues including the heart, skeletal muscle, liver and adipose tissue 
(Benito, 2011; Rask-Madsen and Kahn, 2012). In an in vivo setting, insulin by  its antilipolytic 
effect reduces circulating FFA (Mazumder et al., 2004; Grossman et al., 2013), hence 
regulating FFA availability to the heart. In the perfused heart, insulin stimulates glucose uptake 
and oxidation as well as LCFA uptake but not LCFA oxidation, which may lead to an increased 
intracardiac TG pool (Dyck et al., 2001). Hence, due to the high and tightly regulated energy 
demands in the heart, changes in systemic insulin sensitivity or changes in myocardial insulin 
action can significantly impact on cardiac metabolism and function (Abel et al., 2012).  
In insulin resistant states, because of the combined effects of elevated circulating FFA and 
insulin resistance, the myocardium uses fatty acids most exclusively to support its energy 
supply (Lopaschuk et al., 2010).  In this regard, several studies have consistently reported  a 
strong association between  excess FFA accumulation in the myocardium and impaired insulin 
signalling and reduced glucose uptake (Lopaschuk et al., 2007; Martins et al., 2008). During 
the development of obesity and T2D, alterations in cardiac lipid homeostasis was found to 
precede and influence alterations in glucose homeostasis (Coort et al., 2007). For example, 
continuous exposure of cardiac myocytes to FFA was shown to reduce both insulin-and stress-
stimulated glucose transport (Asrih et al., 2012).  
Impairment of insulin-stimulated glucose transport has been considered as the most consistent 
change that develops early in the hearts in animal models in the evolution of insulin resistance 
(Wright et al., 2009).  As recently demonstrated by Cook et al. (2010), this change manifests 
before or without any defect in  insulin–stimulated increase in PI3-K and PKB/Akt signalling 
and occurs as a consequence of both reduced GLUT-4 protein and impaired GLUT-4 
translocation (Cook et al., 2010; Abel et al., 2012). In a rat model of hyperphagia-induced 
obesity, early myocardial changes were characterized by elevated basal phosphorylation of 
PKB/Akt and severe downregulation of IRS-1 and SERCA2a expression (Huisamen et al., 
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2012). These latter changes were also reported in rats fed a high fat diet (Ouwens et al., 2005).  
However, as expected over  time, these rats exhibited impaired myocardial insulin signalling by 
reducing phosphorylation of PKB/Akt and associated PI3-K activity with a concomitant 
hypophosphorylation of phospholamban (Ouwens et al., 2005) and a reduced myocardial 
acetyl-CoA carboxylase (ACC) phoshorylation (Ouwens et al., 2007).   
Convincing evidence in animal models of obesity and insulin resistance, including chronic high-
fat feeding, db/db mice, and ob/ob mice, indicates that increased myocardial fatty acid 
oxidation rates are associated with depressed rates of glucose oxidation (Buchanan et al., 
2005; Lopaschuk et al., 2007; Ussher and Lopaschuk, 2013). For example, high fat-induced 
obese mice had markedly reduced insulin-stimulated glucose oxidation compared with low fat–
fed WT mice (Ussher et al., 2009). Concordantly, rats with heart failure fed a high-saturated fat 
diet exhibited peripheral and myocardial insulin resistance, decreased myocardial glucose 
utilization rates, alterations in cardiac insulin signalling (Christopher et al., 2010) and poor 
cardiac effiency (Buchanan et al., 2005; Lopaschuk et al., 2007). As expected, the clinical 
relevance of these findings was confirmed in obese and insulin-resistant women, where 
elevated myocardial fatty acid oxidation rates were accompanied by a significant decrease in 
cardiac efficiency  (Peterson et al., 2004).  
However, suprisingly, despite impaired myocardial insulin responsiveness and profound 
metabolic changes associated with reduced rates of glucose uptake, hearts isolated from rats 
fed a high-sucrose diet exhibited increased rates of both glucose and oleate oxidation 
(Harmancey et al., 2012). This was associated with improved cardiac efficiency, indicating the 
initial role of insulin resistance as an adaptative mechanism to protect against  fuel toxicity in 
the stressed heart of these rats (Harmancey et al., 2012). Recently an in vivo study in young 
and middle aged mice with a high-fat diet-induced hyperinsulinaemia reported an increased 
cardiac glucose uptake and mitochondrial function despite peripheral insulin resistance (Gupte 
et al., 2013). These findings were associated with elevation of myocardial fatty acid oxidation 
rates which can be considered as adaptive mechanism against the accumulation of lipid 
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intermediates in the heart (Gupte et al., 2013).  In addition to this controversial metabolic effect 
(probably due to difference in animal models and expermiental design), the role of myocardial 
insulin resistance on contractile function is also not consistent with  studies reporting a 
depressed (Ouwens et al., 2005; Ouwens et al., 2007; Mellor et al., 2013) or preserved 
contractile function (Christopher et al., 2010). These controversial observations have also been 
reflected in the setting of myocardial ischaemia-reperfusion damage. This is discussed furher 
below (see section 2.1.6.5).  
2.1.6.3 Myocardial morphology in obesity and insulin resistance 
2.1.6.3.1 Concepts 
The morphology of the heart in obesity and insulin resistance has been intensively investigated 
(Alpert, 2001; Abel et al., 2008; Lavie et al., 2009; Aurigemma et al., 2013).  Obesity, 
particularly morbid obesity, and insulin resistance have been strongly associated with cardiac 
remodelling including ventricular dilatation and hypertrophy which may result in heart failure 
(Luaces et al., 2012; Aurigemma et al., 2013).  Myocardial remodelling is classically defined as 
genomic expression, molecular, cellular and interstitial changes that manifest clinically as 
changes in size (dimensions and mass), shape and function of the myocardium after cardiac 
injury, pressure or volume overload (Cohn et al., 2000).   Cardiac hypertrophy is referred to as 
an increase in the size of the entire heart, but more commonly, alterations occur in specific 
cardiac chambers relative to body size (Rider et al., 2011). Two types of hypertrophy, namely 
concentric and eccentric hypertrophy, have been observed in obesity and insulin resistance 
(Sundström et al., 2000; Velagaleti et al., 2010; Ashrafian et al., 2011). Concentric hypertrophy 
indicates an increase in wall thickness relative to chamber size while eccentric hypertrophy is 
characterized by chamber enlargement that is more prominent than the increase in wall 
thickness (Abel et al., 2008).   
The concept of “obesity cardiomyopathy” has been used to indicate cardiac functional and 
structural changes associated with obesity or adiposity, independently of other known cardiac 
disease such as hypertension and coronary artery disease (Alpert, 2001; Wong and Marwick, 
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2007). Although the existence of “obesity cardiomyopathy” has been questioned (Owan and 
Litwin, 2007), it has undoubtedly been proved in human and animal studies (Wong and 
Marwick, 2007).  In diabetic conditions, this concept refers to the structural and functional 
abnormalities of the myocardium in diabetic patients without coronary artery disease or 
hypertension (Boudina and Abel, 2010; Miki et al., 2013).  It is, however, difficult to separately 
assess the contribution of diabetic or obesity-related cardiomyopathy to the overall cardiac or 
ventricular dysfunction (Abel et al., 2008). Therefore, it appears that there is no single 
pathophysiologic mechanism which can account for the host of clinical expressions of obesity-
related cardiomyopathies (Wong and Marwick, 2007).  Metabolic as well as hemodymanic 
factors have been implicated in the development of obesity-related cardiac alterations 
(Ashrafian et al., 2011). 
2.1.6.3.2 Evidence in humans 
The adverse effect of obesity on cardiac morphology has been widely investigated in humans. 
Early post-mortem studies have focussed on the excessive epicardial fat accompanying the 
hypertrophied heart in severely obese subjects (Alpert and Chan, 2012).  Echocardiographic 
and postmortem studies between 1980 and 1990 [for review see Alpert (2001)] have 
collectively reported that morbid obese patients had LV enlargement, increased LV wall 
thickness, increased LV radius to thickness ratio, increased LV mass, left atrial enlargement, 
right ventricular enlargement and hypertrophy (Alpert and Chan, 2012).   From these studies it 
was concluded that an eccentric LV hypertrophy is commonly present in  patients with severe 
obesity (Poirier et al, 2006). A recent study by Luaces et al. (2012) in morbid obese patients 
(average age of 40 years, 82.9% being female), has shown that the morbid obesity phenotype 
was not homogeneous: 29.3% of patients had normal LV geometric patterns, the remaining 
70.7% had some form of ventricular remodelling, the most frequent being eccentric 
hypertrophy (which was present in 34.1% of patients) and concentric hypertrophy (in 19.5% of 
cases.  These variations could be linked to the presence of other associated comorbidities 
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(87.8% of patients). Importantly, only patients with an eccentric hypertrophy pattern were found 
to have a lower LV ejection fraction (Luaces et al., 2012).   
In contrast to the traditional concept that the hypertrophy associated with obesity is eccentric, 
most other recent studies (echocardiographic and cardiac magnetic resonance) reported a 
greater prevalence of concentric patterns (Woodiwiss et al., 2008; Turkbey et al., 2010; Rider 
et al., 2011; Shah et al., 2013).  In a cohort of healthy female subjects with a wide BMI range, 
ventricular hypertrophy occurred without associated cavity dilatation in overweight individuals, 
while in obesity both cavity dilatation and ventricular hypertrophy were observed (Rider et al., 
2011). 
2.1.6.3.3 Animal evidence 
 Cardiac remodelling has also been demonstrated in animal models of obesity [for review, see 
(Abel et al., 2008)].  In spontaneously hypertensive rats, dietary-induced obesity has been 
shown to accelerate the progression from concentric cardiac hypertrophy to pump dysfunction, 
independent of blood pressure changes or alterations in glycaemia (Majane et al. 2009).  
Compared to controls, hearts isolated from diet-induced obese rats were hypertrophied as 
indicated by increased heart weight to body weight ratios (Du Toit et al., 2005; Nduhirabandi et 
al. 2011) and LV weight to tibial length ratios (du Toit et al., 2008).  An echocardiographic study 
in obese dogs has reported asymmetric concentric hypertrophy without chamber dilatation 
(Mehlman et al., 2013).  
2.1.6.3.4 Mechanism of myocardial hypertrophy/remodelling 
The traditionally accepted mechanism underlying ventricular adaptation to obesity suggests 
that cavity dilatation in response to increased blood volume and elevated filling pressure 
results in ventricular hypertrophy as a compensatory mechanism (Rider et al., 2011, Alpert 
2012).  This has been supported by early studies in 1980s to 1990s and was associated with 
eccentric hypertrophy (Alpert 2012). It appears that obesity may influence cardiac structure 
both directly and via its closely associated comorbidities such as hypertension, diabetes, 
sleep-disordered breathing, kidney dysfunction, atherosclerosis, and endothelial dysfunction 
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(Abel et al., 2008; Aurigemma et al., 2013).  Additional mechanisms other than haemodynamic 
adaptations may also play a crucial role in cardiac remodelling in obesity and insulin resistance 
(Abel et al., 2008; Ashrafian et al., 2011). These are represented in the figure 2.8 and include 
metabolic factors (fuel availability) as well as humoral factors (such as oxidative stress, 
adipokines and inflammation) (Abel et al., 2008).  In this regard, visceral obesity was shown to 
correlate with LV mean wall thickness, concentric LV hypertrophy and remodelling, but not with 
LV end-diastolic diameter or eccentric LV hypertrophy (Woodiwiss et al., 2008).  From these 
findings it was concluded that obesity may promote left ventricular concentric rather than 
eccentric geometric remodelling and hypertrophy independently of blood pressure (Woodiwiss 
et al., 2008). This effect may be mediated through leptin resistance and obesity-induced 
hypertrophy (Majane et al., 2009; Rider et al., 2012). Hyperglycaemia as well as insulin 
resistance may promote LV concentric remodelling (Sundström et al., 2000; Velagaleti et al., 
2010). 
2.1.6.4 Myocardial function in obesity and insulin resistance 
Obesity and insulin resistance affect cardiac function in many ways (Gray and Kim, 2011; Abel 
et al., 2012; Narumi et al., 2012). Here, only studies under normoxic conditions are considered. 
Globally, studies have shown that in obese (BMI ≥30) subjects the degree of impairment of the 
heart function was parallel to the degree of obesity (de Divitiis et al., 1981; Sokmen et al., 
2013).  In addition, not only morbidly obese subjects develop obesity-related cardiac 
dysfunction (Luaces et al., 2012), but also overweight people (BMI>25) were found to have 
impaired cardiac function (Marinou et al., 2010), independent of their age. 
In humans, most of the studies performed on obesity and insulin resistant conditions have 
reported an association of LV hypertrophy with LV diastolic dysfunction, and occasionally LV 
systolic dysfunction in long standing obesity (Aurigemma et al., 2013).  In addition, subclinical 
myocardial alterations were also observed in obese adults especially hypertension and 
hypertrophy, reflecting impaired regional LV relaxation, segmental atrial, and systolic 
dysfunction (Santos et al., 2011).  In an elderly randomly-derived community cohort study, 
Stellenbosch University  http://scholar.sun.ac.za
 47 
 
overweight and obesity were both associated with an impairment of LV diastolic function 
independently of LV mass and obesity-associated risk factors such as hypertension, diabetes 
(Russo et al., 2011), indicating an additive effect of ageing.   
Subclinical LV diastolic dysfunction was present in all grades of isolated obesity (i.e., without 
other pathological conditions such as hypertension) and correlated with increased systolic 
function in the early stages of obesity (Pascual et al., 2003).  A strong positive correlation 
between insulin resistance (HOMA-IR) and indices of LV function in all grades of obesity at a 
preclinical stage was also reported (Zeybek et al., 2010; Kibar et al., 2013), confirming the 
implication of metabolic factors in myocardial dysfunction as previously indicated. However, 
similar to the metabolic and morphological changes in the heart of obese and insulin resistant 
subjects, the mechanisms leading to cardiac dysfunction are complex and still not fully 
understood.  
Adaptative and maladaptative mechanisms associated with increased adiposity may be 
implicated in the development of LV dysfunction in obesity (Harmancey et al., 2008; Luaces et 
al., 2012; Aurigemma et al., 2013; Khan and Movahed, 2013; Lavie et al., 2013). This is linked 
to cardiac remodelling as discussed above.  Conventionally, the total blood volume and cardiac 
output correlate positively and proportionately with the degree of excess body weight (Chan 
and Alpert, 2012).  Therefore, to meet the increased metabolic (oxygen) demand associated 
with excess adipose tissue in obese patients a compensatory increase in cardiac output is 
required (Poirier et al., 2006). This is accomplished by increasing stroke volume and as 
consequence, the left ventricular chamber dilates to accommodate the increased venous return 
and LV hypertrophy may ensue (Vasan, 2003; Abel et al., 2008; Ashrafian et al., 2011). This is 
an adaptative mechanism for normalizing LV wall stress. Should normalization fail, it 
predisposes to an impaired LV diastolic relaxation (Alpert and Chan, 2012).  If the wall stress 
remains high, a subsequent LV systolic dysfunction may develop (Alpert, 2001). However, as 
previously indicated in the section of cardiac morphology, this traditional haemodynamic 
hypothesis to explain the development of obesity-induced cardiac abnormalities, though 
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attractive, is under debate as it is not fully supported by many of the recent findings (Litwin, 
2010; Ashrafian et al., 2011).  
Similar to the LV, obesity may affect right ventricular (RV) function through increased cardiac 
output. The coexistence of high cardiac output, LV hypertrophy, and LV diastolic dysfunction 
(and in some cases systolic dysfunction) may lead to left heart failure with subsequent 
pulmonary venous hypertension, pulmonary arterial hypertension and right heart failure as 
obesity-related obstructive sleep complications (Alpert and Chan, 2012).  A recent study in 
young normotensive healthy adults has found that isolated obesity was associated with 
subclinical impairment in RV diastolic and systolic function and subsequent dilatation of right 
cardiac chambers (Sokmen et al., 2013).  
In animal models of diet-induced obesity, these alterations in cardiac function were also 
demonstrated in vivo and in isolated hearts as well as in cardiomyocytes (Abel et al., 2008). 
Increased body weight was associated with a reduced cardiac performance/efficiency in rats 
(du Toit et al., 2005; Akki and Seymour, 2009; Majane et al., 2009), mice (Christoffersen et al., 
2003; Buchanan et al., 2005) and rabbits (Carroll et al., 1997; Carroll et al., 1999) as well as in 
dogs (Mehlman et al., 2013).  After 16 weeks of feeding rats a high calorie diet, basal function 
of the isolated hearts from obese rats was significantly depressed compared to age-matched 
controls (du Toit et al., 2008; Nduhirabandi et al., 2011).  Similarly, Akki and Seymour (2009) 
observed that isolated hearts from rats fed with a western diet for  9 weeks showed a decline 
in myocardial function and a concomitant increase in myocardial oxygen consumption. 
Conversely, obesity had no effect  on in vivo basal cardiac function  of obese rats (Wensley et 
al., 2013) and mice (Calligaris et al., 2013), fed an obesity-inducing diet  for 30 weeks.  
However, the pathophysiological mechanisms underlying the development of myocardial 
dysfunction in obesity are not well understood. The potential mechanisms involved in the 
development of cardiac dysfunction in obesity and insulin resistance are represented in figure 
2.8.  Briefly, obesity may affect the heart as follows:  1) volume overload leads to increased 
cardiac output and hypertension (haemodynamic factors). 2) Increased sympathetic and renin-
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angiotensin-aldosterone activation causes hypertension. 3) Insulin resistance associated 
hyperinsulinaemia increases advanced glycation end-products and IGF-1 production and 
facilitates fatty acid uptake, leading to lipotoxicity and cell damage. 4) Visceral adipose tissue 
increases oxidative stress which causes adipokines dysregulation (leptin resistance and 
hypoadiponectaemia). These alterations lead to cellular changes and metabolic alterations. 5) 
Cellular alterations are due to neurohormonal and metabolic factors, oxidative stress and 
adipokines.  
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Figure 2.8 Potential mechanisms of the structural and functional changes of the heart in obesity (description in the text). OSA: obstructive sleep 
apnea, AGE: advanced glycation end-products, IGF-1: insulin-like growth factor-1, TG: triglyceride, RAS: renin angiotensin system [adapted from 
Ashrafian et al.(2008); Sung and Kim (2010)]. 
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2.1.6.5 Myocardial ischaemia-reperfusion injury in obesity and insulin resistance 
2.1.6.5.1 Myocardial ischaemia-reperfusion injury (IRI): concepts  
Myocardial ischaemia refers to the condition in which the coronary blood supply to the heart 
muscle is diminished and thus the supply of oxygen and nutrients is inadequate or insufficient 
to maintain normal oxidative metabolism (Jennings and Yellon, 1992; Opie, 2004).  Myocardial 
infarction (MI) is defined as a pathological condition characterized by cell death due to 
prolonged ischaemia (Thygesen et al., 2012).  Clinically, myocardial ischaemia or ischaemic 
heart disease (IHD) generally results from the formation of atherosclerotic lesions in the 
coronary arteries and when this situation is not rectified, it leads to MI or cell death (Opie, 
2004; Thygesen et al., 2012).  The ischaemic myocardium can be salvaged by reperfusion 
even hours after the onset of the coronary occlusion (Skyschally et al., 2008). However, 
reperfusion itself induces severe and irreversible damage to the myocardium and coronary 
arteries, collectively called “reperfusion injury”. Therefore, the concept of myocardial IRI refers 
to myocardial damage induced by both sustained ischaemia and reperfusion (Skyschally et al., 
2008).  
The pathophysiology of myocardial IRI has been reviewed in great detail (Opie, 2004; Yellon 
and Hausenloy, 2007; Perrelli et al., 2011; Hausenloy and Yellon, 2013; Jennings, 2013) and is 
summarized in the section on obesity and cardioprotection (see section 2.2). The following  
section focuses on available evidence for myocardial infarction in human and animal studies. 
The so-called “obesity paradox” is also included. 
2.1.6.5.2 Epidemiological evidence 
Obesity, particularly visceral obesity, is widely recognised as a major risk factor for coronary 
artery disease (CAD) (Jensen et al., 2008) and MI (Yusuf et al., 2005; Zeller et al., 2008).  For 
example, in a large prospective study of >54 500 Danish men and women aged 50 to 64 years 
at baseline (1993 to 1997) and free of coronary artery disease, overweight (BMI≥25 and ≤ 29.9 
kg/m2) and obese (BMI ≥30 kg/m2), were independently associated with a higher risk of acute 
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coronary syndrome (Jensen et al., 2008).  In a cohort of 16 657 patients with MI recruited in 
444 Polish cities, 42.8% of subjects were classified as overweight, 31.7% as obese and 39.8% 
had visceral obesity, indicating that obesity and overweight had a high prevalence in CAD 
patients, with women the most affected (Kaess et al., 2010). A similar association was also 
reported by Zeller et al. (2008) in a French population-based cohort of patients with acute MI 
where 75% were overweight or obese with 50% having visceral obesity and 15% being obese 
(BMI≥30 kg/m2). Using the concentration of total creatine phosphokinase (CPK) and CPK-MB 
isoenzyme as an estimate of myocardial infarct size,  a strong association between visceral 
obesity and  acute MI was  confirmed in a cross sectional study of 40 men with acute MI 
(Iglesias et al., 2009). Importantly, compared with normal weight, overweight and obesity were 
associated with premature occurrence of acute MI (Suwaidi et al., 2001). In addition, the 
association of visceral adiposity with acute MI was reported to be independent of other risk 
factors like HDL-c, IL-6 levels, hypertension, and diabetes (Nicklas et al., 2004).  Obese 
women have been reported to have a higher risk for CAD than men (Nicklas et al., 2004; 
Kaess et al., 2010), indicating the impact of the gender on the incidence of MI.   
Apart from the gender influence, other factors such as obesity-related comorbidities may also 
affect the risk for acute MI in obese patients. Studies have consistently shown that  insulin 
resistance and other components of the MetS such as dyslipidaemia, fasting hyperglycaemia 
and elevated blood pressure were associated with an increased incidence of CAD (Ranjith et 
al., 2007; Fedorowski et al., 2009; Prasad et al., 2010). A recent study by Karrowni et al. 
(2013) in nondiabetic post-MI patients found that  insulin resistance, as measured by HOMA-
IR, was strongly associated with multivessel CAD.  As expected, the incidence of MetS was 
elevated in patients with MI (54%) with obesity as the essential feature (Prasad et al., 2010). 
This association has also been confirmed in other studies (Ranjith et al., 2009; Al-Aqeedi et al., 
2013). In these studies, the most common abnormalities were reduced HDL-cholesterol, 
elevated fasting blood glucose, hypercholesterolaemia, raised non-HDL-cholesterol, and 
elevated TG, followed by increased waist circumference and raised blood pressure (Ranjith et 
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al., 2009; Al-Aqeedi et al., 2013). As a consequence, it has been suggested that the 
combination of established risk factors and additional metabolic derangements associated with 
excess adiposity may predispose to early plaque rupture and MI  in obese patients (Madala et 
al., 2008).  
• Obesity paradox and MI  
Despite the above evidence for a higher prevalence of obesity in MI patients, obesity has been 
consistently reported to have an unexpected ‘protective effect’ on the outcome of percutaneous 
coronary intervention (PCI), referred to as the obesity paradox (Diercks et al., 2006; Romero-
Corral et al., 2006). This was described  with  a U-shape relationship where overweight and 
moderate obesity were beneficial while underweight and severely obese patients showed an 
increased mortality (Azimi et al., 2013).  The mechanism underlying  the obesity paradox is 
complex and remains unclear. Importantly, additional studies have also reported that in the 
long term the obesity paradox is no longer significant and the adverse health effects of obesity 
may predominate (Das et al., 2011; Kadakia et al., 2011).  
In this regard, it is indicated that excess weight at time of presentation of myocardial infarction 
is associated with lower initial mortality risks but with higher long-term risks including recurrent 
re-infarction and cardiac death (Nigam et al., 2006). In these patients, the obesity paradox 
could be affected by a later occurrence of type 2 diabetes (Adamopoulos et al., 2011) or by 
age (Maggioni et al., 1993; Shih et al., 2011). It has been reported that hyperinsulinaemia, age 
and estimates of left ventricular systolic function were independently associated with 7-year all-
cause of mortality following acute MI in non-diabetic subjects (Kragelund et al., 2004). 
2.1.6.5.3 Animal evidence 
Despite the evidence of an association between obesity and ischaemic heart disease (Ranjith 
et al., 2007; Fedorowski et al., 2009; Prasad et al., 2010) and a high sensitivity of the diabetic 
heart to myocardial IRI in humans (Cubbon et al., 2013), experimental data on the impact of 
obesity and insulin resistance on myocardial IRI are still controversial (Miki et al., 2012; 
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Whittington et al., 2012).  In this regard, several investigations using diet-induced obesity and 
insulin resistance as well as obese or non-obese diabetic models have been conducted (Miki et 
al., 2012; Whittington et al., 2012), however, only a few studies will be referred to in this 
section. Compared to non-obese animals, myocardial infarct size in animal models of obesity 
and insulin resistance was larger or smaller or similar (Miki et al., 2012; Whittington et al., 
2012). The reason for this inconsistency remains unclear.   
A number of studies have reported that diet-induced obesity and insulin resistance decreased 
myocardial tolerance to ischaemia-reperfusion damage. For example, in vivo (Clark et al., 
2011; Wensley et al., 2013) and  in vitro (du Toit et al., 2008; Essop et al., 2009; Huisamen et 
al., 2011; Nduhirabandi et al., 2011) studies using obese and insulin resistant male rats 
reported increased susceptibility to IRI  in the obese hearts compared with their control 
counterparts.  Similar findings were reported in other studies using mice fed a high-fat diet 
(Thakker et al., 2008), ob/ob mice (in vivo) (Bouhidel et al., 2008), db/db mice (in vivo) (Jones 
et al., 1999; Lefer et al., 2001), Zucker obese (ZO) rats (in vitro) (Katakam et al., 2007), Zucker 
diabetic fatty (ZDF) rats (Sidell et al., 2002) as well as type 2 diabetic BBZ rats (in vivo) (Li et 
al., 2008).  Collectivelly, these studies have shown increased infarct size associated with 
concomitant poor functional recovery in obese hearts compared to the controls.  Interestingly, 
the changes in obese rat hearts have been associated with a reduction in PKB/Akt and GSK-
3β expression and phosphorylation as well as  eNOS expression (Wensley et al., 2013). 
A recent study in a porcine dietary model of MetS showed  profound contractile dysfunction 
and reduced mechanical/metabolic efficiency after relatively brief low-flow ischaemia compared 
to their lean controls (Huang et al., 2013).  With a similar protocol (global low-flow ischaemia), 
hearts from obese male Sprague Dawley (SD) rats rats fed a high-fat/low-carbohydrate diet 
also had impaired post-ischaemic LV functional recovery associated with increased lactate 
dehydrogenase release (Liu and Lloyd, 2013) and reduced insulin signalling as assessed by 
PKB/Akt phosphorylation (Wang et al., 2008). Impaired cardiac functional recovery was also 
Stellenbosch University  http://scholar.sun.ac.za
  
55 
 
observed in male SD rats fed a high sucrose diet (total global ischaemia) (Harmancey et al., 
2013) and C57BL/6J mice fed a high-fat diet (Aasum et al., 2008).  
Paradoxically, in other studies (both in vivo and in vitro), diet-induced obesity and insulin 
resistance (Donner et al., 2013) and NaCl-induced hypertensive-glucose intolerant (HGI) rats 
(Mozaffari and Schaffer, 2003; Mozaffari and Schaffer, 2008) have shown to improve 
myocardial ischaemic tolerance.  For example, Donner et al. (2013) after feeding rats a high 
carbohydrate obesogenic diet for 32-weeks found that in vivo (45 min left anterior descending 
artery occlusion and 120 min reperfusion) or ex vivo (25 min ischaemia and 60 min 
reperfusion) hearts from obese rats had small myocardial infarct size and a concomitant 
increase in functional recovery. These hearts also exhibited post-ischaemic increases in 
PKB/Akt expression and phosphorylation of eNOS, GSK3β and ERK42/44 (Donner et al., 
2013).  Interestingly, isolated hearts from young rats (fed a high-calorie diet for 8 weeks) 
exhibited smaller infarct size despite their poor post-ischaemic recovery (Huisamen et al., 
2012). This “cardioprotective” feature of obesity and insulin resistance has previously been 
reported in male Goto Kakizaki (GK) rats and ZDF rats compared to their controls (in vitro) 
(Kristiansen et al., 2004; Wang and Chatham, 2004; Kristiansen et al., 2011). 
To complicate matters further, a high caloric diet  (Lacerda et al., 2012) or a high fat diet 
(induced MetS) (Thim et al., 2006; Mozaffari and Schaffer, 2008) had no effect on myocardial 
infarct size. Similar findings were also reported in in vitro studies using hearts from ob/ob mice 
(Przyklenk et al., 2011) and in vivo GK rats (Matsumoto et al., 2009). 
2.1.6.5.4 Why are different responses to IRI observed? 
The differences in responses to IRI observed in obese, insulin resistant animals are difficult to 
explain. In studies demonstrating obesity-induced exacerbation of  myocardial IRI, various 
reasons have been proposed such as: (1) increased inflammation (Thakker et al., 2008), (2) 
increased oxidative stress (Katakam et al., 2007; Ansley and Wang, 2013) and (3) a cascade 
of maladaptative metabolic changes in FFA metabolism (Harmancey et al., 2013). Indeed, the 
development of microinfarctions associated with an exaggerated inflammatory response was 
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found  in hearts from DIO animals (Thakker et al., 2008). This was accompanied by an 
increase in inflammatory markers such as chemokines (e.g, MIP-1α and β) and cytokines (e.g. 
TNF-α, IL-6, IL-10, TGF-β1) (Thakker et al., 2006), elevated circulating ANG II, TNF-α and FFA 
(du Toit et al., 2005; du Toit et al., 2008; Thakker et al., 2008).  Although it is known that 
moderate ROS production is a crucial factor in cardioprotection (Perrelli et al., 2011; 
Braunersreuther et al., 2012), chronic oxidative stress has been shown to  contribute to 
increased myocardial susceptibility to IRI following  high-fat feeding (Ballal et al., 2010; Ansley 
and Wang, 2013; Liu and Lloyd, 2013).   
Concerning adaptative changes in substrate metabolism in IRI, it was shown that in an early 
pre-diabetic state, the tolerance of the myocardium to ischaemia is reduced by decreasing 
glycolytic flux adaptation (Morel et al., 2005).  Additionally, metabolic alterations in T2D were 
associated with protection against IRI at the onset, but in the late stages progressive 
dysfunction of glucose oxidation occurred (Povlsen et al., 2013). A recent study on rats fed a 
high sucrose diet has suggested that myocardial insulin resistance induced metabolic 
derangements that negatively impact on contractile recovery during reperfusion (Harmancey et 
al., 2013). These metabolic derangements were accompanied by a decreased capacity for 
mitochondrial oxidation of long chain fatty acids, rather than a change in glucose oxidation 
(Harmancey et al., 2013).  
Thus, obesity and insulin resistance induced-cardioprotection (Povlsen et al., 2013) or 
exacerbation of post-ischaemic injury (Harmancey et al., 2013; Povlsen et al., 2013), depends 
on the duration of adaptation and appears to be the overal result of adaptative changes in FFA 
and glucose metabolism (Lopaschuk et al., 2007).  However, as substrate availability, severity 
of ischaemia, and duration of diabetes (hyperglycaemia, hyperinsulinaemia) could not justify 
the improved post-ischaemic recovery (low-flow ischaemia) in the hearts from ZDF rats (Wang 
and Chatham, 2004), other mechanisms or factors may be implicated.  The susceptibility or 
sensitivity of the diabetic heart to acute IRI may be dependent on the animal models and 
experimental conditions used (Paulson, 1997; Whittington et al., 2012). In this regard,  as 
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pointed out by Whittington et al. (2012), the diabetic heart was shown to be “protective” or  
“less sensitive” to acute IRI in studies which used (1) a short duration of diabetes (<6 weeks); 
(2) glucose as the only substrate; (3) global ischaemia (Paulson, 1997; Whittington et al., 
2012). On the other hand, hearts obtained from rats with more severe and prolonged diabetes, 
perfused with fatty acids as substrates using a low-flow IRI protocol (i.e, a better simulation of 
the clinical scenario), were found to be more susceptible or sensitive to IRI (Paulson, 1997; 
Whittington et al., 2012). 
2.1.6.5.5 The role of mitochondria and myocardial IRI in obesity and insulin resistance 
Mitochondria are the primary subcellular organelles for oxidation of fatty acid and glucose. 
Mitochondrial dysfunction is defined as reduction in mitochondrial number, density or function 
(Ansley and Wang, 2013) and may contribute to myocardial FFA and lipid accumulation 
(Ansley and Wang, 2013). Evidence supports excess ROS generation in parallel with 
mitochondrial dysfunction in the obese or diabetic heart (Boudina et al., 2009). Excessive ROS 
production is proposed to contribute to both functional perturbations and susceptibility to 
ischaemic injury in the obese or diabetic heart (Ansley and Wang, 2013) which display fewer 
and more widely dispersed mitochondria than images from lean hearts (Katakam et al., 2007). 
The increase in myocardial infarct size  in obese rats was associated with diminished 
mitochondrial ADP phosphorylation rates (Essop et al., 2009), but without differences in 
mtDNA levels and the degree of oxidative stress-induced damage (Essop et al., 2009). Thus, it 
was suggested that a decreased mitochondrial bioenergetic capacity in pre-diabetic rat hearts 
may impair the respiratory capacity and thus reduce basal contractile function and tolerance to 
acute oxygen deprivation (Essop et al., 2009).   
Furthermore, mitochondria isolated from ZO hearts exhibit enhanced ROS production and 
morphological features suggestive of metabolic and oxidative stress (Katakam et al., 2007; 
Boudina et al., 2009). Similar observations were made in Zucker diabetic fatty rats, which are 
genetically identical to the ZO rats except that they develop severe hyperglycaemia at an early 
age (Kristiansen et al., 2004).  
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2.2 CARDIOPROTECTION AND OBESITY  
2.2.1 CARDIOPROTECTION: ACTIVE AND CHALLENGING FIELD 
The concept of cardioprotection refers broadly to all strategies aimed at the reduction of infarct 
size and full restoration of myocardial function (Heusch, 2013). The most effective therapeutic 
intervention for reducing acute myocardial-ischaemic injury and limiting infarct size (MI) is 
timely and effective myocardial reperfusion using either thrombolytic therapy or primary 
percutaneous coronary intervention (PPCI) (Heusch, 2013). Since reperfusion induces 
damage, there is a continuous need to prevent or reduce the damage resulting from 
myocardial IRI. This has recently been a subject of focused reviews in Circulation Research 
(Jennings, 2013; Kloner, 2013; Ovize et al., 2013; Vander Heide and Steenbergen, 2013). 
Only a summary is given below. 
Despite a tremendous number of in vivo and in vitro animal investigations reporting potential 
beneficial effects (Vander Heide and Steenbergen, 2013), previous clinical trials have been 
disappointing (Heusch, 2013; Vander Heide and Steenbergen, 2013). Various reasons have 
been suggested. They include among others mainly inappropriate use of experimental animal 
models, the clinical testing of inconclusive therapies, and poor clinical trial design (Heusch, 
2013). Many experimental MI models fail to represent the clinical setting in terms of 
comorbidities (such as age, diabetes, dyslipidaemia, and hypertension) and concomitant 
medication, the presence of which may interfere with the therapeutic cardioprotective 
intervention (Ghaboura et al., 2011; Sack and Murphy, 2011; Whittington et al., 2013).  
Many reviews on the pathophysiology of myocardial IRI have appeared in recent years (Opie, 
2004; Yellon and Hausenloy, 2007; Perrelli et al., 2011; Hausenloy and Yellon, 2013; 
Jennings, 2013). In this section, to better understand the contribution of obesity and insulin 
resistance to the IRI and potential cardioprotective strategies, particularly in the context of 
melatonin’s effects, only events associated with IRI are summarized focusing on the role of 
mitochondria and ROS. 
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2.2.2 ALTERATIONS AND MECHANISM OF ISCHAEMIC INJURY 
The pivotal feature of ischaemia is that oxygen supply to the mitochondria is inadequate to 
support oxidative phosphorylation (Solaini and Harris, 2005).  It is well established that the 
major outcomes of ischaemia are poor oxygen delivery (hypoxia) and poor washout of 
metabolites including lactate and protons associated with a severe cellular acidosis (low pH) 
(Hausenloy and Yellon, 2013; Jennings, 2013; Vander Heide and Steenbergen, 2013). 
Functional changes due to ischaemic injury are associated with metabolic and ultrastructural 
alterations (Jennings, 2013). It is also well established that the gravity (e.g., reversibility or 
irreversibility) of the injury depends on severity of coronary flow reduction, the length of the 
ischaemic insult as well as the location being affected (e.g., possibility of collateral flow) [for 
review see (Skyschally et al., 2008; Jennings, 2013)]. The most likely mechanism causing 
cardiomyocyte death during severe ischaemia is the disruption of the sarcolemma (Jennings, 
2013). 
2.2.3 ALTERATIONS DUE TO REPERFUSION INJURY 
It is technically difficult to clearly identify and distinguish between damage induced by 
ischaemia from that caused by reperfusion (Skyschally et al., 2008). Nevertheless, it is well 
known that despite its beneficial effect in limiting the progression of ischaemic injury, 
reperfusion itself exacerbates the ischaemic alterations as it can be responsible for 40–50% of 
the infarct (Kloner, 1993).  While the myocardium can tolerate 15 to 20 min of ischaemia 
(Skyschally et al., 2008), the restoration of blood flow may result in arrhythmias, contractile 
dysfunction (myocardial stunning), microvascular impairment (endothelial dysfunction) as well 
as irreversible myocardial damage (infarction) within the first minutes of reperfusion (Kloner, 
1993). Thus, the concept of “lethal reperfusion injury” refers to the damage caused by 
reperfusion, resulting in death and loss of cells that were viable or reversibly injured during 
ischaemic episode (Kloner, 1993). Although microvascular impairment/injury is also important 
(Prasad et al., 2009), only the mechanism of lethal reperfusion injury is summarized below 
focusing on the role of mitochondria and ROS.  
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2.2.4 MITOCHONDRIA AND ROS: CRUCIAL  ROLE  IN  REPERFUSION INJURY 
Although reperfusion injury is complex and multifactorial, the mitochondria and ROS have been 
suggested to play a crucial role in this phenomenon (Perrelli et al., 2011; Hausenloy and 
Yellon, 2013). A recent review on the potential mechanisms of reperfusion injury has revealed 
four pathways including  the role of pH,  Ca2+, cell swelling  and oxidative stress as the hub of 
this phenmenon (Vander Heide and Steenbergen, 2013). With regard to oxidative stress, ROS 
are produced by several extracellular and intracellular processes with  the mitochondria 
representing the most relevant site for ROS formation in the cardiomyocytes (Perrelli et al., 
2011), indicating the central role of mitochondria in exacerbation of cardiomyocyte injury 
(Perrelli et al., 2011).   
The role of excessive ROS generation at early reperfusion has consistently attracted much 
attention (Dhalla et al., 2000; Opie, 2004; Misra et al., 2009). The rapid restoration of oxygen 
supply and physiological pH causes excessive ROS generation by xanthine oxidase (mainly 
from endothelial cells), the re-energized mitochondrial electron transport chain (ETC) and by 
NADPH oxidase (mainly from neutrophils) (Dhalla et al., 2000). As described by Opie (2004), 
ROS mediate myocardial injury by: 1) inducing mitochondrial permeability transition pore 
(MPTP) opening, 2) acting as neutrophil chemo-attractants, 3) mediating dysfunction of the 
sarcoplasmic reticulum, 4) contributing to intracellular Ca2+ overload and 5) damaging essential 
molecules (lipid, DNA, protein). Despite the detrimental actions of ROS in acute IRI, 
experimental and clinical studies using antioxidants yielded inconsistent and disappointing 
outcomes probably due to inability of the antioxidants to enter the cell (Hausenloy and Yellon 
2013).  Therefore an effective antioxidant with elevated ability to enter the cell would be 
beneficial in this context. 
 Recent studies have revealed that mitochondrial dysfunction and damage, particularly the 
MPTP opening, may play a critical role in the reperfusion injury (Yellon and Hausenloy, 2007; 
Perrelli et al., 2011; Hausenloy and Yellon, 2013). The MPTP is a non selective large 
conductance pore in the inner mitochondrial membrane connecting the mitochondrial matrix 
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and the cytosol (Halestrap and Pasdois, 2009).  In the setting of acute IRI, the MPTP has been 
shown to remain closed during ischaemia and open at reperfusion only in response to 
mitochondrial Ca2+ and phosphate overload, oxidative stress, relative ATP depletion and rapid 
elevation of  pH (Halestrap and Pasdois, 2009).  Massive MPTP opening results in complete 
mitochondrial depolarisation, uncoupling of oxidative phosphorylation leading to ATP depletion, 
mitochondrial swelling and rupture of external mitochondrial membranes (Halestrap and 
Pasdois, 2009).  
Collectively, at early reperfusion, MPTP opening, mitochondrial damage, the rapid washout of 
lactic acid and metabolites together with the re-energized ETC in the setting of increased 
intracellular Ca2+ lead to cardiomyocyte hypercontracture, apoptosis and necrosis (Hausenloy 
and Yellon, 2013). Thus, a combined cardioprotective strategy correcting and/or preventing 
altered myocardial metabolism and mitochondrial damage would be of great therapeutic 
relevance in the energy-depleted heart (Grossman et al., 2013). However, omission to consider 
the comorbidities has been one of the pitfalls of recent promising cardioprotective strategies 
when translated to the clinic (Vander Heide and Steenbergen, 2013). This is the focus of the 
following section. 
2.2.5 CARDIOPROTECTION IN OBESITY AND INSULIN RESISTANT CONDITIONS: 
UNRESOLVED ISSUE 
Despite the disappointing outcomes of previous clinical trials, the discovery  of the endogenous  
cardioprotective mechanisms  such as ischaemic preconditioning (IPC) and postconditioning 
(IPOC) evoked a new  interest  in the possibity of effective cardioprotection (Heusch, 2013). In 
the laboratory, using animals IPC and IPOC elicit significant cardioprotection by applying short 
periods of ischaemia separated by short reperfusion intervals either before ischaemia or at the 
beginning of reperfusion, respectively (Zhao and Vinten-Johansen, 2006).   
Unfortunately, IPC and IPOC are impaired in experimental obesity and insulin resistance as 
well as in ageing and diabetes (Katakam et al., 2007; Yin et al., 2012).  Katakam and co-
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workers (2007) were the first to show the failure for IPC to confer cardioprotection in ZO rats 
compared with Zucker lean rats. Their study showed that inhibition of mitochondrial KATP 
channels abolished IPC in lean hearts with no effect on ZO hearts (Katakam et al., 2007). They 
further demonstrated a significantly diminished membrane depolarization and ROS generation 
in isolated mitochondria from ZO hearts compared with lean hearts. Similarly, in ZDF rats, IPC 
was also not effective (Kristiansen et al., 2004).   
Furthermore, IPOC was found ineffective in obese ob/ob mice (Bouhidel et al., 2008).  Hearts 
from these obese animals when exposed to IRI, exhibited increased infarct sizes and a 
concomitant reduction in activation of PKB/Akt, ERK42/44 and AMPK during reperfusion 
(Bouhidel et al., 2008).  Figure 2.9 represents the major signalling pathways of IPC- and IPOC-
mediated cardioprotection. It was suggested that obesity and diabetes may inhibit cardio 
protective pathways and exacerbate ischaemia-reperfusion-induced MI (Yin et al., 2012).                               
 
 
 Figure 2.9 Major signalling pathways of IPC- and IPOC-mediated protection against cardiac 
cell death [adapted from Yin et al. (2012)]. Myocardial protection of IPC and IPOC were 
proposed to be mediated by stimulation of the prosurvival signalling pathway PI3-K/Akt 
pathway to inhibit the GSK-3β activation either via PI3-K pathway or JAK2/STAT-3 pathway. 
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Obesity and diabetes can inhibit the activation of STAT-3 or PKB/Akt to consequently activate 
GSK-3β that in turn induces mitochondrial cell death which is the critical cellular event for 
ischemia/reperfusion-induced MI (Yin et al., 2012).  
In view of the current lack of effective therapy as discussed above, cardioprotection is still an 
active research area. However, with the rising prevalence of obesity and its multiple 
comorbidities, an ideal therapeutic strategy must retain its efficacy under pathological 
conditions, not only in lean subjects, but also in obese and insulin resistant conditions. 
 As described in the following section, the pineal gland hormone melatonin is a multifunctional 
molecule having anti-excitatory, antioxidant, immunomodulatory, anti-inflammatory, oncostatic 
and vasomotor properties (Hardeland et al., 2006).  Its potential cardioprotective properties 
have been established in lean animals (Lochner et al., 2013).  Additionally, melatonin has been 
shown to be involved in body weight regulation in seasonal animals.  We previously showed 
that melatonin consumption starting before the establishment of obesity, prevented obesity-
related abnormalities and protected the isolated hearts subjected to IRI (Nduhirabandi et al., 
2011).  The effects of melatonin in leans and obese conditions are summarized in the following 
sections.  
2.3 MELATONIN AND THE HEART 
2.3.1 MELATONIN: A MULTIFUNCTIONAL MOLECULE 
As indicated above, melatonin is the neurohormone mainly produced by the pineal gland upon 
the activation of the suprachiasmatic nucleus (SNC) of the hypothalamus during the night [for 
details on biosynthesis and metabolism of melatonin, see Zawilska et al. (2009)].  It is a highly 
conserved indolamine found in most organisms including bacteria, algae, plants, fungi, insects, 
nematodes and vertebrates including mammals (Hardeland and Fuhrberg, 1996).  In humans, 
the normal circulating melatonin levels vary between 1-10pM and 43-400pM, during the day 
and the night, respectively (Barrenetxe et al., 2004; Bonnefont-Rousselot and Collin, 2010).  
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Viewed as a multifunctional molecule  with very versatile biological signalling properties 
(Hardeland et al., 2011), melatonin is a small compound able to cross all morphological 
barriers and acts within every subcellular compartment due to its highly lipophilic and 
hydrophilic properties (Venegas et al., 2012). Since its isolation by Lerner and co-workers 
(Lerner et al., 1958), melatonin has been shown to play a role in most physiological functions 
in animals and humans (Hardeland et al., 2011; Hardeland, 2012). Indeed, apart from its 
classical role as a chronobiotic or endogenous synchronizer in the regulation of seasonal as 
well as circadian rhythms along with its sleep inducing effects (Zawilska et al., 2009), 
melatonin has anti-excitatory, antioxidant, immunomodulatory, anti-inflammatory, oncostatic 
and vasomotor properties (Hardeland et al., 2006; Pandi-Perumal et al., 2006; Hardeland et 
al., 2011). However, besides its universal availability and, presumably, its presence in our daily 
food consumption (Tan et al., 2012), its effects and underlying mechanisms are vast and not 
fully explored (Hardeland et al., 2012).   
Melatonin has powerful antioxidant properties with strong cytoprotective activities [for review, 
see (Reiter et al., 2008; Korkmaz et al., 2009a)].  It has been proved to be more effective than 
other classical antioxidants (Montilla-Lopez et al., 2002; Sener et al., 2003)  due to its multiple 
free radical scavenger cascades and its ability to stimulate the natural antioxidant capacity 
(Tan et al., 2007a). In addition to this, its metabolites also have free radical scavenging 
activities and, thereby enhancing the actions of melatonin (Tan et al., 2007b; Korkmaz et al., 
2009a). Recently, the efficacy of melatonin to improve oxidative stress-mediated metabolic 
disorders via its gene regulation has been shown to be linked to epigenetic mechanisms 
(Korkmaz et al., 2012). The antioxidant actions of melatonin are summarized in table 2.2. 
Besides its pineal production, melatonin is also secreted by a wide variety of tissues including 
the retina, thymus, spleen, heart, muscle, liver, stomach, intestine, placenta, testis, cerebral 
cortex, and striatum (Stefulj et al., 2001; Sanchez-Hidalgo et al., 2009; Sanchez-Hidalgo et al., 
2009; Venegas et al., 2012). The melatonin content in these tissues varies and decreases with 
age to a similar extent as the pineal melatonin production (Sanchez-Hidalgo et al., 2009; 
Stellenbosch University  http://scholar.sun.ac.za
  
65 
 
Sanchez-Hidalgo et al., 2009). Commonly, nocturnal  melatonin production as shown by its 
circulating levels as well as its primary urinary metabolite, 6-sulfatoxymelatonin (aMT6s), is 
lowered in various pathologies characterized by increased oxidative stress, such as 
neurological disorders, CVD and T2D as well as obstructive sleep apnoea syndrome 
(Hernandez et al., 2007; Hardeland, 2012).  Interestingly, circulating melatonin levels can be 
influenced by the diet (Sae-Teaw et al., 2012; Johns et al., 2013) and the minute amounts of 
melatonin present in red wine have been shown to protect the heart against myocardial 
ischaemia-reperfusion damage (Lamont et al., 2011), indicating its therapeutic potential in 
CVD.   
 This section summarizes the available evidence for the effects of melatonin on the heart, 
focusing on its cardioprotective properties.  
2.3.2 THE LINK BETWEEN THE HEART AND MELATONIN  
The link between the heart and melatonin and the influence of endogenous melatonin on 
cardiovascular function in general are well established (Dominguez-Rodriguez et al., 2010).  
Diurnal variations can be seen in blood pressure, heart rate, cardiac output and endothelial 
dilatory capacity of peripheral and coronary arteries, sympathetic activity, cardiac electrical 
stability and platelet aggregation (Dominguez-Rodriguez et al., 2010; Takeda and Maemura, 
2011). Pathological conditions, for example adverse cardiac  events, including MI (Dominguez-
Rodriguez et al., 2002), sudden cardiac death (Muller et al., 1987) and arrhythmias (Siegel et 
al., 1992)  have also been linked to the circadian rhythm in humans, having a higher incidence 
in the early morning, when circulating melatonin levels are considerably lower (Altun et al., 
2002).  
The most important evidence linking melatonin to cardiac function was the identification of 
membrane MT1 and MT2 receptors along with other intracellular binding sites such as the 
cytosolic quinone reductase 2 enzyme  [also called the putative melatonin receptor 3 
(QR2/MT3) and melatonin nuclear receptors (e.g., retinoic acid subfamily of orphan receptors  
Stellenbosch University  http://scholar.sun.ac.za
  
66 
 
(RORx)] in the heart and arteries (Ekmekcioglu et al., 2003; Peliciari-Garcia et al., 2011; 
Schepelmann et al., 2011). These receptors offer possibilities for melatonin signalling to 
interact with the heart function.  Melatonin may indirectly affect cardiovascular function via MT 
receptors in the SCN which are known to modulate the cardiovascular function via 
multisynaptic autonomic neurons (Scheer et al., 2003).  Melatonin may also influence the 
physiology of the heart via its direct actions on the peripheral intrinsic circadian clocks 
identified in both cardiomyocytes (Durgan and Young, 2010; Peliciari-Garcia et al., 2011)   and 
vessels (Reilly et al., 2007).   Surprisingly, melatonin has also been shown to be secreted 
within the heart (Sanchez-Hidalgo et al., 2009; Sanchez-Hidalgo et al., 2009).  However, the 
exact role for cardiac melatonin remains unknown. 
2.3.3 EFFECTS OF MELATONIN ON THE HEART 
2.3.3.1 Animal studies 
Under normal conditions melatonin treatment has no effect on heart function. Animal studies 
showed that prolonged melatonin consumption under normal conditions affected cardiac 
metabolism, reduced the absolute and relative heart weights (Bojkova et al., 2008; 
Nduhirabandi et al., 2011) and increased its glycogen content (Kassayova et al., 2006) but had 
no effects on heart function in vivo (Patel et al., 2010) or ex vivo (Nduhirabandi et al., 2011).  
Although raising circulating melatonin concentrations by administration of exogenous 
melatonin does not appear to be harmful to the heart, the presence of very low circulating 
concentrations (as occurring during daytime) is essential and pinelalectomy has profound 
effects on the heart.   Surgical removal of pineal gland followed by 2 months of stabilization 
caused an increase in serum cholesterol and cardiac malondialdehyde (MDA) levels as well as 
increased heart weight (Mizrak et al., 2004).  Other morphological changes such as increased 
myocardial fibrosis, myxomatous degeneration of the valves and thickening of left atrial 
endocardium were also observed in the hearts isolated from these pinealectomized rats 
(Mizrak et al., 2004).  Importantly, despite failure to improve morphological alterations 
(presumably due to the short treatment time) melatonin administration (4 mg/kg/day) for 2 days 
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reversed the changes in circulating cholesterol and cardiac MDA levels in these animals 
(Mizrak et al., 2004). 
2.3.3.2 Human studies 
Similar to experimental animals, administration of 3 mg of melatonin in healthy male volunteers 
had no effect on their heart rate (Kitajima et al., 2001). In pathological conditions, patients with 
CAD have impaired nocturnal melatonin secretion (Brugger et al., 1995; Altun et al., 2002) and 
subjects with MI were reported to have reduced circulating melatonin levels (Dominguez-
Rodriguez et al., 2002).  Concordantly, a significant association between single nucleotide 
polymorphisms (SNPs) (rs28383653) of melatonin receptor type 1A (MT1A) and coronary 
artery disease has been demonstrated in a recent case-control study (SamimiFard et al., 
2011). In a cohort of survivors of acute MI, reduction of circulating melatonin was also 
associated with greater adverse remodeling (Dominguez-Rodriguez et al., 2012).  As a 
consequence, reduced serum melatonin concentrations measured at admission are now 
considered as an independent predictor of LV remodeling (Dominguez-Rodriguez et al., 2012). 
Importantly, in a double blind randomized clinical trial, melatonin supplementation was able to 
improve LV ejection fraction in patients with heart failure (Garakyaraghi et al., 2012). Thus, 
melatonin treatment could play a clinically relevant role in the pharmacotherapy of cardiac 
diseases. 
The beneficial effects of exogenous melatonin on the heart have been documented in 
physiological conditions such as ageing (Petrosillo et al., 2010) and in pathophysiological 
conditions such as hyperthyroidism (Ghosh et al., 2007), cadmium-induced oxidative damage 
(Mukherjee et al., 2011) and myocardial hypertrophy (Reiter et al., 2010b). Detailed description 
of these effects, although important, is beyond the scope of the present dissertation.  The 
effect of melatonin on the heart in obesity is discussed in the section on melatonin and obesity 
(see, section 2.4). 
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2.3.4 MELATONIN AND MYOCARDIAL IRI 
The role of oxidative stress and excessive free radical production in the pathogenesis of 
myocardial infarction as well as experimental ischaemia-reperfusion damage is well 
established (Opie, 2004) (see also section 2.2., on cardioprotection in obesity). The ability of 
exogenous melatonin to attenuate ischaemia-reperfusion damage in rodent hearts has been 
demonstrated in isolated hearts (ex vivo)(Tan et al., 1998; Kaneko et al., 2000; Lagneux et al., 
2000; Szarszoi et al., 2001; Lamont et al., 2011), in vitro in isolated cardiomyocytes (Salie et 
al., 2001)  as well as in vivo (Lee et al., 2002; Sahna et al., 2002; Sahna et al., 2005). Table 
2.3 summarizes the effects of melatonin in experimental MI. 
The potential beneficial actions of endogenous melatonin were uncovered by the observation 
that hearts from pinealectomized animals exhibited a larger post-ischaemic MI than those from 
non-pinealectomized rats (Sahna et al., 2002). Melatonin administration was able to attenuate 
ventricular fibrillation and reduce infarct size and mortality rate in these pinealectomized rats 
(Sahna et al., 2002). Investigations in our own laboratory have demonstrated the long-term 
effects of melatonin: hearts perfused after 1 to 7 days after oral melatonin administration (20 or 
40 µg/mL) were found to be protected against IRI damage and this cardioprotection persisted 
for 2-4 days after withdrawal of treatment (Lochner et al., 2006). Importantly, melatonin at 
either physiological or pharmacological doses, given before or after the ischaemic period was 
able to protect the heart against myocardial ischaemia/reperfusion damage (Lochner et al., 
2013). Interestingly, the study done by Lamont and co-workers (2011) also found melatonin in 
the picomolar range to be protective in retrogradely perfused rat hearts.  However, using the 
isolated perfused working rat heart, it was found that melatonin was effective only in the 
micromolar range (Lochner et al., 2006).  Whether melatonin has a biphasic effect in these ex 
vivo perfused hearts (Lochner et al., 2013), remains to be further investigated. 
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2.3.4.1 Mechanisms of melatonin-induced cardioprotection  
The mechanisms underlying the beneficial effects of melatonin on the ischaemic heart has not 
yet been fully elucidated. Several mechanisms including its antioxidant, anti-adrenergic, anti-
inflammatory and anti-excitatory actions have been proposed. Importantly, melatonin receptors 
have been shown to be involved in its myocardial effects (Lochner et al., 2006).  
2.3.4.1.1 Antioxidant mechanisms 
The antioxidant actions of melatonin are well established (Reiter et al., 2008; Korkmaz et al., 
2009a; Bonnefont-Rousselot and Collin, 2010). In the setting of myocardial IRI, several reports 
indicated that melatonin protects the heart directly via its free radical scavenging actions and 
indirectly via its stimulatory effects on antioxidant capacity (Patel et al., 2010; Reiter et al., 
2010a) (see table 2.2). Indeed, melatonin was able to neutralize a number of toxic reactants 
including reactive oxygen species and free radicals induced by myocardial IRI (Reiter and Tan, 
2003; Reiter et al., 2010a). For example, in an in vivo rat model of myocardial IRI, melatonin 
significantly increased glutathione (GSH) levels and reduced the lipid peroxidation (MDA) of 
the heart tissues after reperfusion (Sahna et al., 2005).  Similar findings were observed in 
other in vivo and in vitro studies where it was shown that melatonin also suppressed 
superoxidase (˙O2) production, reduced myeloperoxidase (MPO) activity and increased 
superoxide dismutase (SOD)(Lee et al., 2002; Ceyran et al., 2008; Sahna et al., 2008), 
reduced hydroxyl radical (OH˙) (Kaneko et al., 2000) as well as  total ROS generation (Salie et 
al., 2001).  Interestingly, these antioxidant properties were also confirmed in rat models of 
coronary artery ligation-induced ischaemic heart failure (Sehirli et al., 2013) and isopreterenol-
induced MI (Mukherjee et al., 2010).   
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Table 2.2. Antioxidant effects of melatonin 
ACTIONS TARGET/SITE OF ACTION OUTCOME 
Scavenging 
ROS 
Hydyrogen peroxide ↓ 
Hydroxyl radical ↓ 
Singlet oxygen ↓ 
Superoxide anion ↓ 
RNS 
Nitric oxide ↓ 
Peroxynitrite anion ↓ 
Stimulation Antioxidant 
enzymes 
Superoxide dismutase ↑ 
Catalase ↑ 
Glutathione peroxidise ↑ 
Glutathione reductase ↑ 
Glucose-6-phosphatase dehydrogenase ↑ 
Gamma-glutamylcysteine synthase ↑ 
Inhibition Pro-oxidant 
enzyme 
Nitric oxide synthase ↓ 
Lipo-oxygenase ↓ 
Myeloperoxidase ↓ 
ROS: reactive oxygen species, RNS: reactive nitrogen species,↑: increase, ↓: decrease 
(adapted from Tengattini et al., 2008; Reiter et al., 2003). 
Although the efficacy of the classic antioxidants such as vitamin E, vitamin C and glutathione 
(GSH) is increased when used in combination with melatonin (Gitto et al., 2001), melatonin 
was shown to be more potent than vitamin C in protecting against arrhythmias (Tan et al., 
1998).  In fact, several melatonin metabolites (e.g., N1-acetyl-N2-formyl-5-methoxy kynura- 
mine (AFMK) which are formed when melatonin neutralizes damaging reactants are 
themselves free radical scavengers (Tan et al., 2007a; Reiter et al., 2008). This would increase 
the efficacy of melatonin in pathological conditions associated with increased oxidative stress 
(Korkmaz et al., 2009a; Bonnefont-Rousselot and Collin, 2010). 
Furthermore, melatonin treatment has been shown to protect against mitochondrial 
dysfunction, the major source of reactive oxygen and nitrogen species (ROS/RNS) (Lopez et 
al., 2009; Paradies et al., 2010). Concordantly, the antioxidant properties of melatonin were 
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also associated with a reduction in intracellular Ca2+ (Tan et al., 1998; Salie et al., 2001) and 
apoptosis (Dobsak et al., 2003; Ceyran et al., 2008) as well as increases in SERCA and 
Na+,K+-ATPase activity (Sehirli et al., 2013) in the cardiac tissue.  
2.3.4.1.2 Other mechanisms  
In addition to its antioxidant activities, the anti-adrenergic, anti-inflammatory and anti-excitatory 
effects of melatonin are also involved in cardioprotection (Genade et al., 2008; Dominguez-
Rodriguez et al., 2009; Patel et al., 2010). In this regard, the significance of the MT receptors 
has been consistently demonstrated (Lochner et al., 2006; Sallinen et al., 2007; Genade et al., 
2008).  As mentioned above, the most important link between melatonin and cardiac function 
was the identification of membrane MT1 and MT2 receptors along with other intracellular 
binding sites in the heart (Ekmekcioglu et al., 2003; Peliciari-Garcia et al., 2011; Schepelmann 
et al., 2011).  The role of these receptors in the cardiovascular system has been intensively 
reviewed (Paulis et al., 2012; Slominski et al., 2012; Lochner et al., 2013) and therefore in this 
section only their contribution to cardioprotection is discussed. 
Despite the finding that circulating melatonin levels are reduced in patients with myocardial 
infarction (Dominguez-Rodriguez et al., 2002), experimental myocardial infarction was shown 
to increase circulating melatonin levels, followed by enhancement of MT receptors expression 
(Sallinen et al., 2007). The importance of these receptors in cardioprotection was further 
supported by the observation that luzindole, a melatonin receptor antagonist, was able to 
suppress the cardioprotection induced by melatonin (Lochner et al., 2006). These events may 
eventually affect the probability of the MPTP opening (Petrosillo et al., 2009). Petrosillo and co-
workers (2009) reported that melatonin protected hearts against reperfusion injury by inhibiting 
the opening of the MPTP probably via prevention of mitochondrial cardiolipin peroxidation. 
Melatonin protected against the alterations in the various mitochondrial bioenergetic 
parameters associated with ischaemia-reperfusion (Petrosillo et al., 2006; Petrosillo et al., 
2009). It significantly lowered the degree of mitochondrial lipid peroxidation, counteracted the 
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reduction in state 3 respiration and respiratory control ratio and prevented the loss of complex I 
and complex III activities (Petrosillo et al., 2009).  
Using the rat model of isoproterenol (beta-adrenergic)-induced myocardial infarction, it was 
shown that melatonin pretreatment not only improved the antioxidant profile, but also reduced 
myocardial total cholesterol levels and increased phospholipids (Patel et al., 2010).  Whether 
these effects are maintained in the scenario of ischaemia-reperfusion remains to be 
established.  
Although the involvement of the MT receptor in melatonin-induced cardioprotection is known, 
to the best of our knowledge only one study investigated the effects of a melatonin agonist on 
myocardial IRI in mice (Chen et al., 2003). In this study, unexpectedly, the melatonin receptor 
agonist 8-Methoxy-2-propionamidotetralin which has no antioxidant activity was not found to 
be cardioprotective (Chen et al., 2003).  
To date, cardioprotective actions of melatonin have been associated with downstream 
signalling events including activation of the reperfusion injury salvage kinase (RISK) pathway 
(PI3-K, PKB/Akt, ERK42/44) and the protective survivor activating factor enhancement (SAFE) 
pathway (JAK/STAT-3) [for more details on signalling pathways, see (Lochner et al., 2013)]. 
Lamont and coworkers (2011) showed that hearts pretreated with picomolar quantities of 
melatonin (followed by washout before freeze-clamping) had increased STAT-3 activation 
before the onset of sustained ischaemia and this  was associated with a reduction in infarct 
size during reperfusion. Involvement of TNF-α and STAT-3 in melatonin-induced cardio 
protection was further demonstrated by the fact that hearts from TNF-α receptor 2 knockout 
and cardiac STAT-3-deficient mice could not be protected against IRI by melatonin (Lamont et 
al., 2011). This observation lends a new perspective to the ability of melatonin to protect the 
heart, suggesting that activation of the SAFE pathway before the onset of ischaemia may also 
play a role in subsequent cardioprotection. However, whether this holds true for PKB/Akt and 
ERK42/44 activation before ischaemia is not known.   
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 Table 2.3 The effects of melatonin on  myocardial ischaemia-reperfusion injury  
STUDY TYPE MODEL IR DURATION MELATONIN EFFECTS 
Tan et al.,1998 Ex vivo 
isolated  rat heart   
(Langendorf ) 
10/10 
(min/min) ↓ premature ventricular contraction and fibrillation 
Kaneko et al., 
2000 
Ex vivo 
isolated  rat heart  
(Langendorf ) 
30/30 
(min/min) 
↓ ventricular tachycardia and fibrillation; restored ventricular 
function;↓ lipid peroxidation; lowered OH˙ generation 
Lagneux et al., 
2000 
Ex vivo 
isolated  rat heart  
(Langendorf ) 
5/30 
(min/min) ↓ reperfusion arrythmias;↓ infarct size 
Szarszoi et al., 
2001 
Ex vivo 
isolated  rat heart  
(Langendorf ) 
20/40 
(min/min) 
↓ fibrillation; low concentration had no effect on IR of the 
isolated perfused heart rat 
Salie et al., 2001 Ex vivo 
Cardiomyocyte in culture 
( rats) 12.5 or 27.5/1.5 
↓ morphoplogical damage, lowered oxygen free radical 
generation, ↓ intracellular [Ca²+] 
Dobsak et al., 
2003 
Ex vivo 
isolated and perfused  
working rat heart 
30/45 
(min/min) 
Improved hemodynamic parameters and ↓post-ischemic 
arrhythmias during reperfusion;  ↓ incidence of apoptotic cells 
Genade et al., 
2006 
Ex vivo 
isolated rat  heart / 
working  heart 
20/30 
(min/min) 
Global ischemia (GI): protective  effects during reperfusion, 
abolishes cardioprotection before and during  ischaemia 
preconditioning protocol 
Lochner et al., 
2006 
Ex vivo 
Isolated rat  heart/ 
working heart 
20/30 
(GI) or 
35/30(RI) 
(min/min) 
Before and during reperfusion: improved cardiac output and 
work performance; ↓ infarct size; long term ↓ IFS (RI). 
Luzindole abolishes these effects.  Melatonin receptor 
involved in cardioprotection. 
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STUDY TYPE MODEL IR DURATION MELATONIN EFFECTS 
Petrosillo et al., 
2006 
Ex vivo Langendorff  
30(GI)/120 or 15 
(min/min) 
↑ content of cardiolipin with ↓ peroxidized cardiolipin,  ↓ rates of 
mitochondrial oxygen consumption, complex I and complex III 
activity,  and H2O2 production;  ↑post-ischaemic  LVDp and ↓ 
LVED p 
Genade et al., 
2008 
Ex vivo  
Langendorff and working 
heart 
35 RI/30 or 120 
(min/min) 
Anti β-adrenergic effects: ↓ IFS, 
↓NOS & cAMP; ↑post-ischaemic PKB/Akt, ↓p38 MAPK 
activation. 
Yeung et al., 2008 Ex vivo 
Isolated heart rat 
(Langendorff) 
( chronic hypoxic rats) 
30/120 
min/min 
infarct size reduction, improves Ca2+ handling by preserving 
SERCA expression, ↓MDA levels, ↓LDH 
Petrosillo et al., 
2009 
Ex vivo Langendorff  
30 GI /120 or 15 
(min/min) 
Inhibition of MPTP opening. Before and during reperfusion: ↓ 
IFS, improves function recovery ( ↑ LVDp and ↓ LVED p), 
↓necrosis (↓LDH);  reduction  MPTP opening sensitivity by 
increasing resistance to Ca2+, prevention of NAD+ release and 
mitochondrial cytochrome-c release 
Lamont et al., 
2011 
Ex vivo Langendorff  
30 RI/120 
(min/min) ↓ IFS, ↑ pre-ischaemic STAT3 phosphorylation 
Nduhirabandi et 
al., 2011 
Ex vivo Working heart 40RI/120(min/min) ↓ IFS, ↑ post-ischaemic PKB/Akt, ERK42/44,↓p38MAPK 
activation  
Yang et al., 2013 Ex vivo Langendorff,  45RI/60 (min/min) ↓IFS,↑ STAT-3 activation,↑Bcl2, ↓Bax, improved cardiac function  
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STUDY TYPE MODEL IR DURATION MELATONIN  EFFECTS 
Chen et al., 2009 
In vivo & ex 
vivo 
In situ mice & isolated 
mice heart (Langendorff)  
50min/4 h 
40/45(min/min) ↑LVEDp and ↓ LDH level , ↓IFS ; GPx not involved  
Lee et al., 2002 In  vivo in situ   rat heart 
45/60 
(min/min) 
↓ ventricular  tachycardia and fibrillation; lowered total 
ventricular contractions, suppression of  superoxidase 
production (˙O2) and ↓MPO activity, ↓ IFS, ↓ survival 
Sahna et al., 
2002b 
In  vivo in situ   rat heart 
7/7 
(min/min) ↓ ventricular fibrillation, ↓mortality 
Sahna et al., 
2002a 
In  vivo in situ   rat heart 
3/120 
(min/min) ↓ IFS 
Dave et al., 1998 In  vivo in situ rabbit heart 
30/180 
(min/min) No improvement in cardiac function, no reduction in IFS 
Chen et al.,2003 In vivo In situ mice heart 
60 /4 
(min/h) 
Treatment 30 min before ischemia: ↓  IFS/risk area. 
 Treatment after  ischaemia: no effect  
Sahna et al., 2005 In vivo in situ heart   rat 
30/120 (RI) 
(min/min) ↓ infarct size,↓ MDA values, ↑GSH levels 
Deniz  et al., 2006 In vivo 
in situ heart   rat 
(chronic nitric oxide 
synthase inhibited rats) 
30/120 (RI) 
(min/min)  ↓ IFS & BP 
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STUDY TYPE MODEL IR DURATION MELATONIN EFFECTS 
Bertuglia et al., 
2007 
In vivo 
In situ heart 
cardiomyopathic 
hamsters 
30/30 
(min/min) 
↓ post ischaemic VT and VF, lowed % lethality ;                           
↓ oxidative stress (lipid peroxidation: TBARS) and nitrosative 
stress (nitrite/nitrate), leukocyte adhesion, vascular 
permeability, increased capillary perfusion, reduced MAP. 
Sahna et al., 
2008 
In vivo 
in situ heart   rat 
(chronic nitric oxide 
synthase inhibited rats) 
30/120 (RI) 
(min/min) ↓ IFS & BP; ↓ MDA values, ↓MPO levels 
Ceyran et al., 
2008 
In vivo In situ  heart rat 
20/20 
(min/min) 
↓cardiac troponin (cTn-T), ↓MDA, ↓MPO levels 
↑ SOD levels, ↑Bcl-2 expression 
↓Fas expression,↓ oedema myofibrils, vascularity, 
inflammatory infiltration 
 
Legend: ↓: decrease, ↑: increase, GI: global ischaemia, RI: regional ischaemia, IR: ischaemia-reperfusion, IFS: infarct size, MPTP: mitochondrial 
permeability transition pore, SERCA2a,: sarco-(endo)-plasmic reticulum Ca2+-ATPase2, LDH: lactate dehydrogenase, VT: ventricular tachycardia; 
VF:ventricular  fibrillation, MPO:myeloperoxidase, SOD: superoxide dismutase, MAP: mean arterial pressure, HR: heart rate, BP: blood pressure; 
GSH: reduced glutathione, LVDp:left ventricular developed pressure, LVEDp: left ventricular end-diastolic pressure, TBARS: thiobarbituric acid 
reaction substance, MDA: malondialdehyde. 
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2.4 MELATONIN AND OBESITY 
2.4.1 LINK BETWEEN OBESITY AND MELATONIN: CIRCADIAN RHYTHM 
 “Circadian rhythm” classically refers to any biological process that displays an endogenous 
24-hour cycle (e.g., neurohormone secretion)(Martino and Sole, 2009), while  the term 
“diurnal” refers to conditions in which there are both an endogenously generated circadian 
cycle and one modulated by external cues (zeitgebers) from the environment, predominantly 
light(Martino and Sole, 2009). Light is the main zeitgeber for the master clock, which is located 
in the suprachiasmatic nucleus (SCN) of the hypothalamus (Martino and Sole, 2009).  The 
pineal gland hormone melatonin is secreted during the dark and classically acts as a 
chronobiotic factor or endogenous synchronizer participating in regulation of seasonal as well 
as circadian rhythm (Zawilska et al., 2009).  
There is a strong link between the development of obesity and a disrupted circadian system 
(chronodisruption) (Boer-Martins et al., 2011; Bray and Young, 2012; Gomez-Abellan et al., 
2012; Reiter et al., 2012). Epidemiological and experimental studies have shown that 
alterations in circadian rhythm in obesity [as shown  by the decrease in the amplitude of daily 
pineal melatonin rhythm in shift workers (Lund et al., 2001), T2D patients (Peschke et al., 
2006) as well as in rats fed a high-fat diet (Cano et al., 2008)], is accompanied by changes in 
other circulating metabolic factors including, amongst others, glucose, insulin, leptin, 
corticosterone, thyroid-stimulating hormone, prolactin, luteinizing hormone and testosterone 
(Lund et al., 2001; Cano et al., 2008). Although the causal relationship between 
chronodisruption and obesity can be considered as bidirectional (Bray and Young, 2012), the 
supplementation of melatonin as well as melatonin agonists have been beneficial in resetting 
the circadian rhythm (Zawilska et al., 2009)  and ameliorating the obesity-related abnormalities 
(She et al., 2009; Oxenkrug and Summergrad, 2010; Cardinali et al., 2011b; Hardeland, 2012).   
The following section is limited to the role of melatonin in obesity and insulin resistance 
focusing on recent findings in animal and clinical studies. The potential underlying mechanisms 
are also included. 
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2.4.2 MELATONIN AND OBESITY: ANIMAL STUDIES 
2.4.2.1 Body weight and fat mass regulation: from seasonal to non-seasonal animals  
Melatonin plays an important role in body weight regulation and energy metabolism. The 
involvement of melatonin in the regulation of body fat mass and energy metabolism was first 
observed in seasonal animals (Bartness and Wade, 1985) and attributed to its role as regulator 
of seasonal and circadian rhythms (Arendt, 2006).  In these seasonal animals, any increase in 
circulating melatonin levels due to photoperiodic changes or exogenous melatonin 
administration, depending on the animal species, was eventually associated with a reduction 
or an increase in body fat mass (Bartness and Wade, 1985; Bartness et al., 2002).  
Interestingly, non-seasonal animals like the obese Zucker rats exposed to long photoperiod 
conditions (characterized by a low nocturnal melatonin production) had an increased body 
mass gain compared to those exposed to short photoperiods (Larkin et al., 1991).  In line with 
this, surgical removal of the pineal gland caused a reduction in circulating melatonin levels and 
an increase in body weight after 3 weeks in obese but not in normal rats (Prunet-Marcassus et 
al., 2003).  When the postoperative period was extended to 2 months, the normal rats had also 
increased their body and heart weights (Kurcer et al., 2006). These pinealectomy-induced 
changes could be prevented by melatonin (30 mg/kg/day, i.p. at 1 hour before lights-out) for 3 
weeks (Prunet-Marcassus et al., 2003). The same workers also showed that melatonin 
administered in the same manner, was able to reduce high-fat diet-induced body weight gain 
without affecting the total food intake (Prunet-Marcassus et al., 2003).   In young normal rats a 
decrease in body weight and visceral fat mass was also noticed following 3 or 6 months of 
prolonged melatonin consumption in drinking water (4µg/mL) (Bojkova et al., 2006; Kassayova 
et al., 2006). Similar effects have also been reported in normal middle-aged rats (Rasmussen 
et al., 1999; Rasmussen et al., 2001) without altering food consumption (Wolden-Hanson et 
al., 2000). These metabolic effects were independent of gonadal function (Puchalski et al., 
2003b). 
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2.4.2.2 Melatonin and obesity: effect on diet-induced obesity  
Several animal investigations have consistently demonstrated the efficacy of melatonin to 
prevent the development of obesity or reduce obesity-related metabolic features (Prunet-
Marcassus et al., 2003; Barrenetxe et al., 2004; Hussein et al., 2007; She et al., 2009; Shieh et 
al., 2009; Ríos-Lugo et al., 2010; Agil et al., 2011; Nduhirabandi et al., 2011) and the potential 
therapeutic value of melatonin treatment in obesity and MetS has recently been summarized 
(Nduhirabandi et al., 2012). Collectively, it was shown that long-term melatonin administration 
significantly reduced body weight and visceral fat mass as well as circulating glucose, insulin,  
leptin, TG, free fatty acid (FFA) and total cholesterol levels in young Zucker diabetic fatty rats 
(Agil et al., 2011; Agil et al., 2012b), in middle-aged rats fed a high-fat diet (Puchalski et al., 
2003a; Ríos-Lugo et al., 2010), in young rats on a high-fat/high-sucrose diet (She et al., 2009) 
as well as rats drinking 10% fructose solution (Cardinali et al., 2013).  In these studies, daily 
melatonin was administered in drinking water at 0.2-4µg/mL (Puchalski et al., 2003a), 25µg/mL 
(Ríos-Lugo et al., 2010; Cardinali et al., 2013) or via intraperitoneal injection at 4mg/kg (She et 
al., 2009) for a period of 8 to 12 weeks without affecting the total food intake. A study in rabbits 
fed a high fat diet has, however, reported a reduction in food intake after 4 weeks of melatonin 
treatment (1mg/kg/day subcutaneously) (Hussein et al., 2007).  This weight loss inducing 
effect of melatonin was also confirmed in other animal models of obesity; for example, a rat 
model of ovariectomized-induced obesity (Sanchez-Mateos et al., 2007; Baxi et al., 2012) and 
female rats treated with olanzapine (Raskind et al., 2007).  
2.4.2.3 Effect of melatonin on obesity-induced dyslipidaemia  
Melatonin has been shown to improve obesity-induced dyslipidaemia. This was first 
documented in non-obese hypercholesterolaemic rats (Hoyos et al., 2000; Hussain, 2007) and 
thereafter confirmed in various rat models of obesity (Prunet-Marcassus et al., 2003; Agil et al., 
2011; Nduhirabandi et al., 2011; Nduhirabandi et al., 2012; Zhang et al., 2012).  For example, 
oral melatonin (4-10mg/kg/day for 6 to 12 weeks) raised the high-density-lipoprotein 
cholesterol (HDL-c) in both obese and lean Zucker rats (Agil et al., 2011)  or in high fat/high-
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sucrose diet-induced obese rats (She et al., 2009) . This has also been confirmed in obese 
rabbits (Hussein et al., 2007), associated with a concomitant reduction in circulating TG, FFA, 
low-density-lipoprotein cholesterol (LDL-c) with (Hussein et al., 2007; She et al., 2009) or 
without (Ríos-Lugo et al., 2010; Agil et al., 2011) effect on total cholesterol levels.  Similar 
results were recently confirmed in ApoE-knockout C57BL/6J male mice fed a high-fat diet 
(Zhang et al., 2012) and in rats fed a high-fructose diet for 4 weeks (Kitagawa et al., 2012).  
Although the latter model did not gain weight, two weeks of co-administration of oral melatonin 
(10mg/kg/day) reduced the intra-abdominal fat mass and circulating FFA levels as well as 
hepatic TG and cholesterol contents (Kitagawa et al., 2012). These studies strongly support 
the suggestion that melatonin supplementation may ameliorate overweight and normalize lipid 
metabolism in humans.   
2.4.2.4 Effect of melatonin on obesity-associated oxidative stress and inflammation 
Obesity is associated with elevated oxidative stress and low antioxidant status (Vincent and 
Taylor, 2006; D'Archivio et al., 2011). The antioxidant as well as anti-inflammatory activities of 
melatonin are well established (Korkmaz et al., 2009a; Korkmaz et al., 2012) and a daily 
melatonin administration to obese rabbits (1mg/kg subcutaneously for 4 weeks)(Hussein et al., 
2007) or rats (4mg/kg, i.p for 8 weeks) (She et al., 2009)  increased GSH-Px, SOD activity and 
HDL-c levels and  reduced oxidative stress as indicated by low plasma MDA levels.  
Furthermore, in young obese Zucker rats, chronic oral melatonin administration (10mg/kg/day) 
for 6 weeks attenuated circulating biomarkers of systemic oxidative stress [basal plasma lipid 
peroxidation and Fe2+/H2O2-induced  lipid oxidation) and low-grade inflammation [plasma 
interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP) values] 
without affecting their profile in non-obese animals (Agil et al., 2012a).  It is well established 
that low-grade chronic inflammation contributes to the pathogenesis of insulin resistance and 
diabetes as well as cardiovascular complications (de Rooij et al., 2009). The antioxidant 
properties of melatonin have been reported along with the improvement in the metabolic profile 
in diabetes (Nishida, 2005; Agil et al., 2011; Agil et al., 2012a) and diet-induced obesity 
Stellenbosch University  http://scholar.sun.ac.za
  
81 
 
(Hussein et al., 2007; She et al., 2009).  However, whether the improvement in insulin 
resistance by melatonin precedes or follows its suppressive effects on oxidative stress and 
inflammation is still not yet known. 
2.4.2.5 Effects of melatonin on obesity-related cardiovascular alterations 
Melatonin supplementation is able to improve cardiovascular function in lean or obese animals 
with insulin resistance (Leibowitz et al., 2008; Kozirog et al., 2011). A decrease in melatonin 
secretion was associated with hypertension in fructose fed rats (Leibowitz et al., 2008).  
Administration of melatonin to these fructose-induced MetS rats attenuated the increase in 
blood pressure and other metabolic abnormalities (Leibowitz et al., 2008; Cardinali et al., 
2013).  Similarly, in rabbits receiving a high-fat diet, intake of melatonin was associated with a 
lowering of BP, heart rate and sciatic nerve activity (Hussein et al., 2007). Melatonin prevented 
the appearance of fatty streaks produced by a mass of foam cells covered by the endothelium 
and a thin layer of mononucleated cells in the carotid artery intima of hypercholesterolemic rats 
(Pita et al., 2002). It was also able to prevent deposition of fat in the subintimal layer in the 
blood vessels and heart (Hussein et al., 2007), indicating melatonin’s anti-atherosclerotic 
potential.  In spontaneously hypertensive Wistar-Kyoto male rats, chronic (but not acute) 
administration of the selective melatonin receptor agonist, Ramelteon, in drinking water 
(8mg/kg/day, from 4 to 12 weeks of age) attenuated the age-associated increase of systolic BP 
by 45% (Oxenkrug and Summergrad, 2010), indicating the involvement of melatonin receptors 
in melatonin’s effects in obesity.  
Melatonin administration protected the hearts from rats with MetS (Nduhirabandi et al., 2011; 
Diez et al., 2013). Chronic oral melatonin consumption (4mg/kg/day for 16 weeks) starting 
before the establishment of obesity prevented the increase in the heart weight and protected 
the hearts against obesity-induced increased susceptibility to myocardial IRI (Nduhirabandi et 
al., 2011). As expected, it also prevented the development of obesity-induced metabolic 
alterations (elevated visceral fat, serum insulin, leptin, TG and reduced HDL-c) (Nduhirabandi 
et al., 2011).  This finding was of particular significance since to date there is no effective 
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cardioprotective strategy available in obesity, diabetes as well as ageing conditions (Boengler 
et al., 2009; Downey and Cohen, 2009; Kloner and Schwartz Longacre, 2011).  
How melatonin protects the heart in obesity is still unknown.  From our previous findings 
(Nduhirabandi et al., 2011), we hypothesized that the direct effects of melatonin on the heart 
via its receptor mediated-effects may be involved but this requires further investigation.  A 
recent study by Diez et al. (2013) using hearts isolated from insulin resistant rats fed a high 
fructose diet (model of MetS) with elevated oxidative stress and reduced HDL-c, reported that 
acute melatonin administration initiated at reperfusion (after 15 min of regional ischaemia) 
protected the heart against myocardial IRI as shown by a reduction in duration and amplitude 
of ventricular arrhythmias (Diez et al., 2013). 
Globally, the melatonin-induced improvement of the myocardial structure and function in 
obesity and insulin resistance could be linked to the body weight loss and improvement of 
dyslipidaemia with eventual reduction of oxidative stress, inflammation, insulin resistance and 
hyperglycaemia (Hussein et al., 2007; Oxenkrug and Summergrad, 2010; Nduhirabandi et al., 
2011; Cardinali et al., 2013).  
2.4.3 MELATONIN AND OBESITY: HUMAN STUDIES 
The overall circulating melatonin levels in obese humans are not consistent. For example, the 
mean nocturnal serum melatonin levels were reported to be reduced in patients with severe 
obesity (Shafii et al., 1997) as well as with T2D (Peschke et al., 2006), autonomic neuropathy 
(Tutuncu et al., 2005), retinopathy (Hikichi et al., 2011), and coronary heart disease (Cardinali 
et al., 2011a) as well as obese craniopharyngioma (Lipton et al., 2009). Surprisingly, despite a 
lack of difference in BMI or waist circumference between the obese non-diabetic and T2D 
subjects, nocturnal plasma melatonin levels were significantly higher in obese non-diabetic 
subjects compared to weight-matched T2D subjects (Mantele et al., 2012) who failed to 
produce any detectable melatonin (Mantele et al., 2012).  However, in young male and female 
obese MetS patients (Robeva et al., 2006; Robeva et al., 2008) and in obese girls (Lee et al., 
2012), circulating melatonin or urinary 6-sulfatoxymelatonin levels were not different from 
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control subjects, confirming the early observation that obesity had no effect on melatonin 
secretion and excretion (Rojdmark et al., 1991). Furthermore, it has been noticed that in MetS 
patients, the levels of melatonin per se are not as important as the melatonin/insulin ratio 
which correlates negatively with the lipid profile (Robeva et al., 2008). 
The reasons for these inconsistencies in melatonin secretion in obese subjects remain 
complex and not clear.  It is possible that the increased sympathetic tone in obesity and a 
consecutive alteration in sympathetic innervation of the pineal gland increased melatonin 
concentration in obese non-diabetic subjects (Mantele et al., 2012).  Furthermore, low 
circulating melatonin levels have been linked to many factors including elevated oxidative 
stress and inflammation (Ozguner et al., 2005), but not to low testosterone levels in young men 
with MetS (Robeva et al., 2006).  It appears therefore that circulating melatonin levels could 
vary depending on the age of patients and the severity of obesity (Shafii et al., 1997).   
Few clinical investigations on melatonin or related drugs have considered body weight change 
and adiposity mass in their aims.  However, as discussed above in animal studies, these 
parameters have been affected by the long-term melatonin treatment (Nduhirabandi et al., 
2011).   
2.4.4 MECHANISM OF ACTIONS OF MELATONIN IN OBESITY 
As mentioned previously, the mechanism of action of melatonin in obesity is not well 
understood. Melatonin is a small pleiotropic molecule able to cross each membrane layer and 
enter each cellular compartment to exert its various activities with or without receptor- 
mediated pathways (Hardeland et al., 2011; Venegas et al., 2012). Melatonin receptors as well 
as adipose tissue function and plasticity may be involved. 
2.4.4.1 Role of melatonin receptors 
Involvement of the melatonin receptor in body fat mass regulation has been known for many 
years (LeGouic et al., 1996). Administration of a melatonin receptor agonist or antagonist to 
seasonal animals (before night) affected the body weight and adiposity mass regulation as well 
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as the onset of seasonal obesity: a melatonin agonist and the short day/light exposure had a 
same effect whereas an antagonist and long day/light exposure had similar effects (LeGouic et 
al., 1996).  This involvement of MT receptors in the body weight and fat mass regulation was 
recently demonstrated in spontaneously hypertensive rats, using Ramelteon, a potent selective 
MT1/MT2 receptor agonist (Oxenkrug and Summergrad, 2010) and in obese rats, using the 
melatonin agonist NEU-P11 (She et al., 2009).  
MT receptors have been identified in the major organs involved in metabolism:  liver, pancreas 
and skeletal muscle (Muhlbauer et al., 2009) as well as adipose tissue (Brydon et al., 2001).  
They are involved in the regulation of insulin secretion and may play an active role in the 
regulation of glucose metabolism (Muhlbauer et al., 2009).  It was recently reported that a 
variation in MTNR1B, the gene encoding for MT2, was associated with increased risk of T2D, 
increased fasting plasma glucose and impaired insulin secretion in populations of European 
ancestry (Bouatia-Naji et al., 2009; Prokopenko et al., 2009). Similar observations were also 
made in Chinese (Ling et al., 2011) as well as in Japanese (Tabara et al., 2011) populations.  
Thus, the overall effects of melatonin in obesity appear to be partly mediated through these 
receptors, in addition to the activation of the sympathetic nervous system via hypothalamic 
receptors and subsequent effects on lipolysis and adipose tissue plasticity (Song and 
Bartness, 2001; Bartness et al., 2002).     
2.4.4.2 Role of adipose tissue 
The exact mechanisms whereby melatonin reduces body fat mass are not clear.  In vivo 
melatonin treatment prevents the increase in circulating TG and eventually body fat 
accumulation and weight gain in overweight and obese animals (Nduhirabandi et al., 2011; 
Agil et al., 2012b). In vitro melatonin treatment of adipocytes inhibits differentiation and limits 
adipose tissue hypertrophy (Alonso-Vale et al., 2009)  by inhibiting fatty acid-induced TG 
accumulation in cells exposed to physiological levels of oleic acid (Sanchez-Hidalgo et al., 
2007).  The reduction in body weight gain might be due to a significant decrease in fat content 
as opposed to lean body mass (Wolden-Hanson et al., 2000) and could be related to 
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melatonin-induced improvements in the compromised insulin and leptin signalling associated 
with obesity (Sartori et al., 2009), accompanied by  modulation of plasma levels of insulin, 
glucose, TG, cholesterol, leptin (Ríos-Lugo et al., 2010) .  
The involvement of brown adipose tissue has also been suggested (Tan et al., 2011).  While 
white adipose tissue is specialized in energy storage, brown adipose tissue has a high 
concentration of mitochondria and uniquely expresses uncoupling protein 1(UCP-1), enabling it 
to specialize in energy expenditure and thermogenesis (Townsend and Tseng, 2012).  Brown 
adipose tissue has been suggested to be the factor whereby animals lose weight in response 
to melatonin administration (and gain weight when there is a deficiency of melatonin), 
independently of food intake (Tan et al., 2011). Importantly, for the first time, oral melatonin 
supplementation has recently been shown to induce browning of the inguinal white adipose 
tissue in ZDF rats without affecting their locomotor activity (Jiménez-Aranda et al., 2013). 
Thus, the exploitation of the functional role of brown adipose tissue could be of great interest in 
obesity management.  
2.4.4.3 Leptin resistance 
Leptin resistance is an essential feature of human obesity and refers to the inability of elevated 
circulating leptin levels to reduce common obesity (Scarpace and Zhang, 2009).  The 
adipokine leptin plays a central role in the regulation of food intake, body weight and energy 
expenditure (Benoit et al., 2004). Resistance to leptin action is associated with insulin 
resistance and an increased pro-inflammatory state (Lago et al., 2008). The effects of 
melatonin on leptin resistance have recently been reviewed (Nduhirabandi et al., 2012). At 
molecular levels, it has been found that melatonin, leptin and insulin activated the same 
intracellular signalling pathways namely PI3-K and STAT-3 (Carvalheira et al., 2001; Anhe et 
al., 2004; Picinato et al., 2008). Therefore, melatonin may affect obesity by mimicking the 
actions of insulin and leptin signalling via cross-talk between these pathways. In this regard, 
insulin has been shown to modulate leptin-induced STAT-3 activation in rat hypothalamus 
(Carvalheira et al., 2001). Thus, melatonin may act initially on the hypothalamic insulin and 
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leptin receptor sensitivity (as these hormones do under normal conditions) and eventually relay 
information about peripheral fat stores to central effectors in the hypothalamus to modify food 
intake and energy expenditure (Song and Bartness, 2001; Benoit et al., 2004).    
2.5 MELATONIN AND INSULIN RESISTANCE 
Resistance to insulin action results in increased postprandial and fasting circulating insulin 
levels in order to normalize glycaemia in pre-diabetic subjects and is closely associated with 
dyslipidaemia and other metabolic abnormalities (Benito, 2011; Tesauro and Cardillo, 2011).  
This section focuses on the effect of melatonin on insulin sensitivity and resistance, glucose 
uptake and tolerance and insulin secretion.  
2.5.1 EVIDENCE FOR THE ROLE OF MELATONIN IN INSULIN RESISTANCE 
Endogenous melatonin has been shown to play a role in the regulation of insulin secretion and 
glucose/lipid metabolism (Nishida, 2005; Peschke, 2008; Peschke and Muhlbauer, 2010).  In 
normal rats, pinealectomy induced insulin resistance, glucose intolerance (Lima et al., 1998; 
Zanquetta et al., 2003) and increased serum cholesterol (Mizrak et al., 2004).  To demonstrate 
the role of endogenous melatonin on insulin secretion, Nishida et al. (Nishida et al., 2003) 
using T2D rats, showed that after 21 weeks of pinealectomy, a significant increase in plasma 
insulin and accumulation of TG occurred. The same study found also that when the post-
pinalectomy period was extended to 35 weeks, circulating insulin levels were significantly 
decreased.  This decrease is a clear indicator of impairment of insulin release from pancreatic 
β-cells as seen in patients at an advanced stage of T2D (Kuzuya et al., 2002).  Additionally, it 
was found that pineal gland melatonin synthesis is decreased in T2D Goto-Kakizaki rats 
(Frese et al., 2009).  
In view of insulin resistance preceding the establishment of T2D, the question whether 
melatonin replacement could be beneficial in reversing insulin resistance has been a subject of 
numerous investigations in the field. In this regard, it was found that long term melatonin 
consumption (2.5 mg/kg/day for 9 weeks) increased plasma melatonin levels with a 
concomitant reduction in insulin levels in type 2 diabetic Goto-Kakizaki rats (Peschke et al., 
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2010).  In mice fed a high-fat diet, 8 weeks oral melatonin (100mg/kg/day) markedly improved 
insulin sensitivity and glucose tolerance (Sartori et al., 2009).  In the same model of high-fat 
diet-induced diabetic mice, following 2 weeks of melatonin administration (10mg/kg/day, i.p), 
amelioration of insulin resistance and glucose intolerance were associated with an increase in 
hepatic glycogen and improvement in liver steatosis (Shieh et al., 2009).  Consistently, in high 
fat/high sucrose-fed rats, 8 weeks treatment with melatonin or its agonist NEU-P11 increased 
insulin sensitivity (She et al., 2009).  In rats with T2D, 30 weeks of melatonin treatment (1.1 
mg/kg/day, subcutaneously via implanted melatonin-releasing pellets) reduced circulating 
insulin, leptin and TG levels (Nishida et al., 2002).  These findings were also confirmed by 
additional studies in young Zucker diabetic fatty rats (Agil et al., 2011; Agil et al., 2012b) and 
fructose-fed rats (Kitagawa et al., 2012; Cardinali et al., 2013).  In the latter model 
administration of melatonin (1 or 10mg/kg/day for 2 weeks) improved the abnormal serum 
insulin response curve in oral glucose tolerance tests (Kitagawa et al., 2012), indicating 
potential insulin sensitizing effects of melatonin.  
Interestingly, in a recent study of more than 1000 young women without hypertension, obesity 
and T2D, elevated nocturnal melatonin secretion was independently associated with greater 
insulin sensitivity and a lower prevalence of insulin resistance (McMullan et al., 2013). In adults 
with T2D daily melatonin treatment diminished oxidative stress and enhanced glycemic control 
(Grieco et al., 2013). 
2.5.2 MECHANISM OF ACTIONS OF MELATONIN IN INSULIN RESISTANCE 
The melatonin-induced reduction in circulating insulin levels in obese animals may be linked to 
a reduced body weight and improved lipid metabolism as was recently demonstrated in young 
ZDF rats (Agil et al., 2011) or rats drinking 10% fructose solution (Cardinali et al., 2013). In 
these rat models, the amelioration of insulin resistance was also characterized by improvement 
in glucose tolerance (Agil et al., 2012b; Cardinali et al., 2013).  In addition, in young ZDF, 
melatonin treatment reduced fasting blood glucose, plasma insulin, haemoglobin A1c (HbA1c), 
HOMA-IR, FFA levels and increased index of beta-cell function (Agil et al., 2012b). 
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In the insulin resistant state, the improvement of lipid and glucose regulation could be also 
linked to amelioration of the pro-inflammatory state and oxidative stress (Agil et al., 2012a). It 
is well established that oxidative stress and pro-inflammatory states are important pathological 
features that underlie the development of insulin resistance, MetS, diabetes, and CVD. 
Therefore, in insulin resistant conditions, the reduction in oxidative stress and the pro-
inflammatory state may lead to lowering of lipid peroxidation resulting from free radicals 
generation, due to the continuous hyperglycaemia and hyperlipidaemia.  Consistently, 
melatonin administration for 2 or 6 weeks (1 or 10mg/kg per day) attenuated the levels of 
circulating IL-6 and TNF-α (Agil et al., 2012a; Kitagawa et al., 2012). This amelioration of the 
pro-inflammatory state was also accompanied by a reduction in serum and hepatic lipid 
peroxidation and an increase in hepatic GSH concentration (Kitagawa et al., 2012).  
Interestingly, melatonin treatment was associated with increase in serum adiponectin levels 
and reduction in leptin levels with (Agil et al., 2012b) or without (Kitagawa et al., 2012) effects 
on body weight.  Adiponectin (which is reduced in obese subjects) has been shown to have 
insulin sensitizing actions in the liver and peripheral tissues and other beneficial properties 
associated with cardiovascular protection (anti-apoptotic, anti-inflammatory and anti-
atherogenic properties) (Hui et al., 2012).  Therefore, increased circulating adiponectin levels 
may play an important role in melatonin’s effects. 
On a molecular level, insulin resistance is associated with an abnormal or compromised 
intracellular insulin signalling cascade in peripheral tissues/organs involved in the regulation of 
glucose metabolism (skeletal muscle, liver and adipose tissue).  As mentioned above (see also 
section 2.1.2.2), this cascade principally includes binding of insulin to insulin receptor (IR), Tyr 
phosphorylation of IRS proteins and activation of phosphatidylinositol-3-kinase (PI3-K), 
PKB/Akt and PKC ζ or λ [for details see (Benito, 2011)].  Melatonin (1nM) treatment has been 
shown to stimulate glucose transport in skeletal muscle via the phosphorylation and activation 
of IRS-I and PI3-K respectively (Ha et al., 2006).  It was further demonstrated that melatonin 
improves glucose homeostasis by restoring the vascular actions of insulin which were 
characterized by increased phosphorylation of PKB/Akt and eNOS in aortic tissue (Sartori et 
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al., 2009).  In addition to the phosphorylation of PKB/Akt and PKC-ζ, melatonin (1nM) 
stimulated glycogen synthesis and increased the phosphorylation of glycogen synthase kinase 
3 ß (GSK3-ß) in hepatic cells (Shieh et al., 2009).  More interestingly, these effects of 
melatonin could be blocked by the non-selective MT1/MT2 antagonist, luzindole, or the MT2 
selective antagonist, 4-phenyl-2-propionamido tetraline (4P-PDOT) (Ha et al., 2006; Shieh et 
al., 2009), suggesting possible MT receptor involvement. However, it is not clear how 
activation of the high affinity MT receptors, which are G-protein linked, leads to stimulation of 
the IRS-1/PI3-K pathway and the role of PKC-ζ in this regard. 
Using adipose tissue from female fruit bat, Cynopterus sphinx (seasonal animal), it was shown 
that melatonin treatment (100ng/mL and 500pg/mL) enhanced the insulin-stimulated glucose 
uptake compared to untreated cells (Banerjee et al., 2011). There was however no correlation 
between glucose uptake and the expression of GLUT-4 in these cells (Banerjee et al., 2011). 
Pinealectomy was shown to reduce the expression of GLUT-4 translocation (to the plasma 
membrane) in adipose tissue (Lima et al., 1998; Zanquetta et al., 2003).  Although a decrease 
in  GLUT-4 gene expression was reported following melatonin treatment (1µM for 14 days) in 
human brown adipocyte cells lines (PAZ6) (Brydon et al., 2001), Zanquetta et al. (2003) found 
that 30 days of calorie restriction or melatonin replacement (50µg/100g/day, i.p.) to 
pinealectomized rats was accompanied by an improvement in insulin resistance and increased 
plasma membrane GLUT-4 protein content in adipose tissue.  Importantly, in the hyperthyroid 
rat heart, melatonin administration was able to protect the heart against oxidative damage and 
restored expression of GLUT-4 gene, establishing the ability of antioxidants to reverse 
oxidative stress-mediated metabolic alterations (Ghosh et al., 2007). However, whether 
melatonin affects glucose metabolism in the normal or obese heart is still not yet explored. 
Melatonin receptors may play an important role in the regulation of glucose metabolism.   
Removal of the MT1 receptor significantly impairs the ability of mice to metabolize glucose and 
probably induces insulin resistance in these animals (Contreras-Alcantara et al., 2010).  
Epidemiological studies have also revealed that variants near/in the MTNR1B (or MT2) 
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receptor are associated with impaired pancreatic beta-cell function as shown by impaired 
insulin secretion and concomitant elevated plasma fasting glucose levels (Kan et al., 2010; 
Tam et al., 2010).  Indeed, MT1/MT2 receptors are expressed in pancreatic islets (Peschke et 
al., 2000) and since insulin levels exhibit a nocturnal drop, its production has been suggested 
to be controlled, at least in part, by melatonin (Mulder et al., 2009). Melatonin reduced the 
fasting insulin levels (Puchalski et al., 2003a; She et al., 2009) probably via its inhibitory effects 
on insulin secretion in rat pancreatic islets (Picinato et al., 2002; Peschke, 2008). On other 
hand, melatonin has been shown to act through MT1/MT2 receptors to activate hypothalamic 
PKB/Akt and suppress hepatic gluconeogenesis (Faria et al., 2013) while increasing peripheral 
glucose ultilization (Sartori et al., 2009; Shieh et al., 2009). 
2.5.3 INTERACTION OF CATECHOLAMINES, GLUCAGON, INSULIN AND MELATONIN 
IN GLUCOSE REGULATION 
The interaction between catecholamines, glucagon, insulin and melatonin in glucose regulation 
has recently been reviewed by Peschke et al. (2013).  Although the mechanism underlying the 
interactions between these hormones is complex and not yet clear, catecholamines have been 
indicated as a key feature to understand the biological relevance of insulin-melatonin 
antagonism in T2D as well as T1D (Peschke et al., 2012).  It was found that catecholamines 
(noradrenaline and adrenaline) and melatonin levels were reduced in T2D GK rats 
(characterized by high insulin levels) and elevated in T1D rats (associated with reduced insulin 
levels) (Peschke et al., 2012), assuming that elevated catecholamines decrease insulin 
secretion via stimulation of melatonin synthesis (Peschke et al., 2012).   
Glucagon is the hormone secreted from pancreatic α-cells under hypoglycaemic conditions. It 
plays an important role in blood glucose homeostasis in vivo: it acts as an antagonistic 
hormone to insulin and stimulates hepatic glucose output (Peschke et al., 2013).  Melatonin 
stimulates glucagon secretion in pancreatic α-cells and its action in the liver (Peschke et al., 
2013).  It has been shown that oral melatonin treatment of T2D GK rats for nine weeks, 
increased hepatic expression of glucagon receptor mRNA, while this was reduced in healthy 
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wistar rats (Bahr et al., 2011), indicating the regulatory effects of melatonin on hepatic glucose 
and disturbances of these effects in T2D. 
2.6 CONCLUDING REMARKS  
Convincing experimental evidence supports the potential use of melatonin in cardioprotection. 
Considering that it is cheaper and sold over the counter, extensive clinical trials are required to 
establish the clinical potential of melatonin treatment in a number of pathologies. Currently only 
one prospective trial (Melatonin Adjunct in the acute myocaRdial Infarction treated with 
Angioplasty [MARIA]) is underway investigating whether pharmacological doses of melatonin 
in patients with ST-segment elevation MI will confer cardioprotection (Dominguez-Rodriguez et 
al., 2007). The outcome of this trial is very important as to date there is no effective strategy to 
save lives of people dying from MI, the top leading killer in the world. In the context of obesity 
and insulin resistance, the effect of melatonin is also still lacking clinical evidence. In this 
regard, the few clinical studies that used melatonin did not consider its potential actions in 
obesity and insulin resistance. Fortunately, a randomized controlled trial (no 01038921) of 
melatonin supplementation in men and women with the MetS has recently been designed 
(Terry et al., 2013). Collectively, current literature suggests that melatonin treatment may 
influence and improve metabolic abnormalities present in obese patients and prevent the 
development of CVD. Besides its strong antioxidant properties, the overall metabolic actions of 
melatonin in obesity and insulin resistant conditions appear to be a combined result from its 
various pleiotropic activities associated with multiple signalling in areas of the central nervous 
system and in peripheral organs (Hardeland et al., 2011).  
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Table 2.4 Potential effect of melatonin treatment on obesity and insulin resistance 
 
 
Parameters/organ Before treatment 
Treatment 
effects References 
Body weight ↑ ↓ (Rasmussen et al., 1999; Wolden-Hanson et al., 2000; Prunet-Marcassus et al., 2003; Puchalski et al., 2003a; Hussein et al., 2007) 
Visceral fat ↑ ↓ (Rasmussen et al., 1999; Prunet-Marcassus et al., 2003; Puchalski et al., 2003a; She et 
al., 2009) 
Blood 
Fasting glucose ↑ ↓ Prunet-Marcassus et al., 2003; Shieh et al., 2009; Peschke et al., 2010; Rios-Lugo et al., 2010)  
Insulin ↑ ↓ (Nishida et al., 2002; Puchalski et al., 2003a; Sartori et al., 2009; Shieh et al., 2009; Peschke et al., 2010) 
HDL-C ↓ ↑ (Hussain, 2007; Hussein et al., 2007; She et al., 2009; Agil et al., 2011) 
LDL-C ↑ ↓ (Hussein et al., 2007; Agil et al., 2011; Kozirog et al., 2011) 
TG ↑ ↓ (Nishida et al., 2002; Hussain, 2007; Rios-Lugo et al., 2010; Agil et al., 2011; Kozirog et 
al., 2011) 
VLDL ↑ ↓ (Hoyos et al., 2000) 
Leptin ↑ ↓  or  ↑ ↓ (Wolden-Hanson et al., 2000; Nishida et al., 2002; Prunet-Marcassus et al., 2003; Puchalski et al., 2003a) or ↑ (Baltaci and Mogulkoc, 2007; Song and Chen, 2009) 
Adiponectin ↓ or ↑ (?) ↑ or ↓ (?) ↑ (Agil et al. 2011b, Kitagawa et al. 2011) or ↓ (Rios-Lugo et al., 2010) (?)   
TNF-α ↑ ↓ (Nishida, 2005; Oztekin et al., 2006) 
Muscle 
Insulin sensitivity  
(glucose uptake) ↓ ↑ (Sartori et al., 2009; Srivastava and Krishna, 2010) 
FFA /TG uptake ↑ ↓ (Dauchy et al., 2003) 
Glycogen 
content ↓ ↑ (Mazepa et al., 2000) 
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Table 2.4 Potential effect of melatonin   in obesity and insulin resistance (continued) 
 
Table 2.4 Only some references have been indicated in this table as evidence of the potential effects of melatonin in obesity and insulin resistance. 
↓: decreases or attenuates; ↑: increases or elevates; (?): needs more studies/unusual model of obesity; FFA: free fatty acids; TNF-α: tumor necrosis 
factor-alpha; VLDL: very low density lipoprotein; HDL-C: high density lipoprotein-cholesterol; LDL-C: Low density lipoprotein-cholesterol; TG: 
triglyceride (Nduhirabandi et al., 2012). 
Parameters/organ Before treatment 
Treatment 
effects References 
Liver 
Fibrinogen secretion ↑ ↓ (Bekyarova et al., 2010) 
TG & VLDL release ↑ ↓ (Hussain, 2007) 
Glucose release ↑ ↓ (Kaya et al., 2010) 
C-reactive protein ↑ ↓ (Bekyarova et al., 2010) 
Glycogen content ↓ ↑ (Shieh et al., 2009) 
Liver weight ↑ ↓ (Pan et al., 2006) 
Heart & 
Vessels 
Blood pressure ↑ ↓ (Paulis and Simko, 2007; Kozirog et al., 2011) 
Heart rate ↑ ↓ (Hussein et al., 2007) 
Endothelial dysfunction ↑ ↓ (Sartori et al., 2009) 
Cardiomyopathy 
/Hypertrophy ↑ ↓ (Bertuglia and Reiter, 2007; Ghosh et al., 2007) 
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2.7. MOTIVATION FOR THE INVESTIGATION 
2.7.1. PROBLEM STATEMENT 
As reviewed above, current literature considers obesity as the driving force behind the rising 
prevalence of various metabolic disorders including amongst others T2D and CVD (Cornier et al., 
2008). Insulin resistance is suggested to be important mechanism linking obesity to its 
cardiovascular disorders such as heart failure, coronary heart diseases, atherosclerosis as well as 
hypertension (Reaven et al., 2004; Poirier et al., 2006; Reaven, 2011).  Importantly, impairment of 
myocardial glucose uptake and  metabolism may contribute to the mechanical dysfunction 
observed in T2D and obese patients (Chess and Stanley, 2008) and  increases their susceptibility 
to ischaemic heart disease (Cubbon et al., 2013), the worldwide leading cause of death (Lozano 
et al., 2013). 
In view of the multiple abnormalities associated with obesity and insulin resistant states, the 
question has arisen whether anti-oxidant supplementation would attenuate or prevent their 
detrimental actions. Experimental studies provided a compelling evidence for melatonin as 
potential tool for  effective therapy in obesity and related metabolic abnormalities (for review, see 
(Cardinali et al., 2011a; Nduhirabandi et al., 2012).  Additionally, melatonin administration has a 
strong cardioprotective effect in normal healthy and hypertensive animals (Reiter et al., 2010a).  A 
previous study from our laboratory showed that chronic melatonin treatment starting before the 
establishment of obesity prevented the harmful effects of diet-induced obesity and protected the 
hearts against IRI (Nduhirabandi et al., 2011). However, the exact mechanism whereby melatonin 
exerts its beneficial effects on the ischaemic heart in obesity and insulin resistant states remains 
to be established. In addition, it is not known whether short-term melatonin treatment in 
established obesity is able to confer cardioprotection.  
Obesity and insulin resistance are associated with changes in cardiac mitochondrial function 
including reduced oxidative activity as well as depressed ATP synthesis (Boudina and Abel, 2006; 
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Boudina and Abel, 2007; Essop et al., 2009).  Melatonin has been shown to protect against 
mitochondrial dysfunction [for review, (Acuna-Castroviejo et al., 2007; Srinivasan et al., 2011)].  
Additionally, its cardioprotective action has recently been associated with inhibition of the opening 
of the MPTP (Petrosillo et al., 2009).  However, the effect of melatonin on the mitochondria has 
not yet been studied in obesity. 
Recent findings support the role of melatonin in glucose homeostasis. Melatonin stimulated 
glucose transport in skeletal muscle cells via the IRS-I/PI3-K pathway (Ha et al., 2006; Sartori et 
al., 2009). However, nothing is known about the effects of melatonin on myocardial glucose 
metabolism in healthy controls or in obese animals. In view of the significant role of anaerobic 
glycolysis in the survival of the ischaemic myocardium (Opie, 2004), it is possible that some of the 
beneficial actions of melatonin may be attributed to its actions on myocardial glucose uptake and 
metabolism.   
In addition to the above, one of the features of obesity and insulin resistance is the development 
of a pro-inflammatory state (Furukawa et al., 2004; Martins et al., 2012). This is characterized by 
elevated pro-inflammatory cytokine levels including, amongst others, TNF-α and has been linked 
to endothelial dysfunction (Hotamisligil, 1999; Picchi et al., 2006).  Melatonin treatment has been 
shown to ameliorate inflammation (Nishida, 2005; Agil et al., 2012a) and to improve endothelial 
dysfunction (Sartori et al., 2009; Hu et al., 2013; Rodella et al., 2013) in obesity and insulin 
resistance. However, the effect of melatonin on endothelial function has not yet been investigated 
in the context of the heart. Endothelial dysfunction plays an important role in MI (Libby, 2013).  
However, most of the studies done on the effect of melatonin on endothelial cells have been using 
cells from other vascular beds than the heart (Silva et al., 2007). In particular, the effect of 
melatonin on cardiac microvascular endothelial cells has not yet been investigated. 
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2.7.2. GENERAL AIM 
In view of the above, we aimed to further investigate the manner in which and the mechanism 
whereby melatonin exerts its cardioprotective effects with particular emphasis on its effects on 
myocardial glucose homeostasis, mitochondrial function and cardiac microvascular endothelial 
function in normal and insulin resistant states. In this regard, signalling pathways associated with 
cardioprotection were also investigated. 
2.7.3. HYPOTHESES 
 We hypothesized that obesity and insulin resistance as well as other related metabolic 
abnormalities would contribute to increased myocardial susceptibility to IRI and exacerbate infarct 
size via oxidative stress. By virtue of its pleiotropic actions and its antioxidant activity in particular, 
administration of melatonin would:  
(i) reverse the  metabolic abnormalities associated with obesity and insulin resistance; 
(ii) protect  cardiac mitochondrial function against adverse effects of obesity and insulin 
resistance; 
(iii) protect the heart against myocardial ischaemia-reperfusion damage; 
(iv) stimulate glucose uptake and metabolism in normal and insulin resistant cardiomyocytes; 
(v) prevent or reverse TNF-α-induced endothelial dysfunction  
2.7.4. SPECIFIC AIMS AND OBJECTIVES (fig.2.10) 
1. Investigation of the effects of melatonin treatment in a rat model of diet-induced obesity 
and insulin resistance by determining the effects of varying periods of melatonin 
administration (3 weeks and 6 weeks) on biometric and metabolic parameters, lipid 
peroxidation, myocardial IRI and myocardial signalling including activation of PKB/Akt, 
ERK42/44, GSK-3β, PI3-K, STAT-3 and GLUT-4 expression (see chapter 4, Study I ) 
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2. Investigation of the effects of melatonin treatment (6 weeks) on myocardial mitochondrial 
function in a rat model of diet-induced obesity and insulin resistance by determining basal 
and post-anoxic mitochondrial oxidative phosphorylation capacity (see chapter 5, Study II)  
3. Investigation of the effects of melatonin treatment on myocardial glucose homeostasis (see 
chapter 6, Study III) with regard to: 
(i) Acute effects of melatonin treatment on glucose uptake by cardiomyocytes isolated from 
young untreated rats 
(ii) Acute effects of melatonin on glucose uptake by cardiomyocytes isolated from untreated 
control and obese rats  
(iii) Effects of long-term (6 weeks) melatonin treatment on glucose uptake by cardiomyocytes 
isolated from control and obese rats 
4. Investigation of the effects of acute melatonin treatment on cardiac microvascular 
endothelial cells  (see chapter 7, Study IV) with regard to:  
(i) Melatonin’s effects on cell viability and nitric oxide production  
(ii) Effects of melatonin on TNF-α-induced endothelial dysfunction by determining expression 
and phosphorylation of eNOS, PKB/Akt, ERK42/44, STAT-3 and AMPK, expression of iNOS 
and Iκβ-α and the levels of nitrotyrosine. 
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Figure 2.10 Synthetic diagram of the investigation with specific aims. IRI: ischaemia-reperfusion injury. Studies I, II and III used normal 
and insulin resistant rats; study IV used cultured cardiac microvascular endothelial cells.
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CHAPTER THREE 
MATERIALS AND METHODS: GENERAL 
 
3.1. STUDY DESIGN 
The present investigation was divided in four sub-studies according to their specific aim (fig. 2.10). 
Only general materials and methods including animals, feeding, treatment, western blotting 
technique and statistical analysis or any method used in more than two sub-studies will be 
described. Additional materials and methods are described along with the specific aims within their 
respective sub-study.  
3.2. ANIMALS 
All animals used in the present investigation were obtained from the University of Stellenbosch 
Central Research Facility. They were housed with free access to water and food, a 12-h dark/light 
cycle (light from 6:00 a.m. to 6:00 p.m.) with temperature and humidity kept constant at 22ºC and 
40%, respectively. The experimental procedure was assessed and approved by the Committee for 
Ethical Animal Research of the Faculty of Health Sciences, University of Stellenbosch (Ethical 
clearance no P08/05/008). Animals were treated according to the revised South African National 
Standard for the Care and Use of Animals for Scientific Purposes (South African Bureau of 
Standards, SANS 10386, 2008).  
3.2.1. GROUPING AND FEEDING  
To determine the effects of melatonin on the impact of obesity and insulin resistance on the heart, 
the feeding regime of our existing model of diet-induced obesity (Du Toit et al., 2005) was 
extended from 16 to 20 weeks to exacerbate the effects of obesity. This was first tested in our 
preliminary study on isolated cardiomyocytes from rats fed for 16 to 19 weeks and 20 to 23 weeks. 
Figure 3.1 represents how animals were grouped and their respective feeding and treatment 
programmes. Briefly, at the age of four weeks, male Wistar rats weighing 200± 20 g were 
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randomly allocated to the following groups:, control rats receiving a standard commercial rat chow 
(SRC) and drinking water (group C); diet-induced obesity rats, receiving a high calorie diet (HCD) 
and drinking water (group D).  After 14 weeks of feeding, melatonin was added to drinking water 
of a number of rats from group C or D for 6 weeks (groups CM6 and DM6).  After 17 weeks of 
feeding, melatonin was added to the drinking water of a number of rats from group C or D for 3 
weeks (groups CM3 and DM3). The rats remaining in groups C and D continued their respective 
diets with water without melatonin. For all animals, the duration of feeding was 20 weeks. The 
food was replaced daily.  
   
Figure 3.1 Simplified diagram for animal grouping, feeding and treatment, SRC: standard rat 
chow, Mel: melatonin, wk: week, IRI: ischaemia-reperfusion injury.  Only the number of animals 
used for IRI and western blots (study I) (240) are indicated for each group. The numbers of 
animals used for mitochondrial function (study II) (48) and glucose uptake (study III) (60) are not 
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included in the diagram. Diagrams for these two studies are presented in chapters 5 and 6, 
respectively. 
Diet-induced obesity groups (D, DM6 and DM3) were fed a high calorie diet consisting of 65% 
carbohydrates, 19% protein and 16% fat. Control groups (C, CM6 and CM3) were fed a SRC 
consisting of 60% carbohydrate, 30% protein and 10% fat. The high calorie diet was prepared 
containing 33% SRC and 33 % sweetened full cream condensed milk (Clover®), 7% sucrose and 
27% water. Rats receiving a standard rat chow and a high calorie diet consumed approximately 
371±18 and 570±23 kJ of energy per day, respectively (Du Toit et al., 2008). 
3.2.2. MELATONIN TREATMENT 
Melatonin (Sigma Aldrich, St Louis, MO, USA) was orally administered as previously reported 
(Nduhirabandi et al., 2011). It was first dissolved in a small amount of absolute ethanol and then 
added to the drinking water at a final concentration of 0.05% (v/v) ethanol with melatonin 
(60µg/mL or 40µg/mL). Bottles containing melatonin solution were covered with aluminium foil as 
melatonin is light sensitive. Animals drank water and melatonin (4mg/kg/day) ad libitum. Drinking 
water with or without melatonin was replaced every day one hour before light off as previously 
indicated (Wolden-Hanson et al., 2000; Prunet-Marcassus et al., 2003). The melatonin solution 
was prepared every second day and stored at -4ºC until used. The dosage of 4mg/kg/day was 
regularly adjusted according to the body weight gain and water consumption for the entire period 
of treatment.  
Procedures employed in the studies on acute effects of melatonin on cardiomyocytes and 
endothelial cells are described in chapters 6 and 7, respectively.   
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3.2.3. WESTERN BLOT TECHNIQUE 
3.2.3.1. Heart tissue collection 
Heart tissues were collected either at baseline or at 10 and 30 min of reperfusion after ischaemia 
(see experimental procedure in chapter 4. To obtain baseline values, the hearts were rapidly 
rinsed in ice-cold buffer and the surrounding tissues removed before freeze-clamping. These 
“baseline hearts”  are also referred to as “non-perfused hearts”.  In all conditions, the hearts were 
freeze-clamped with pre-cooled Wollenberger tongs and plunged into liquid nitrogen for 
subsequent biochemical analyses.   
3.2.3.2. Preparation of lysates 
Lysates were prepared differently depending on the type of the sample: heart tissues, 
cardiomyocytes or endothelial cells.  Only the preparation of lysates from the heart tissue  will be 
summarized here. Where applicable, modified lysate preparations are described in their specific 
sub-study. Lysates were prepared from whole heart tissue, cytosolic or nuclear fraction where 
applicable. The tissue extract was performed as follows: the frozen tissue was pulverized and 
homogenized in 600 to 900µL of lysis buffer by a Polytron PT10 homogenizer. The lysis buffer 
contained (in mM) Tris-HCl 20, p-nitrophenyl phosphate 20, EGTA 1.0, EDTA 1.0, NaCl 150, tetra-
sodium-pyrophosphate 2.5, ß-glycerophosphate1.0, sodium orthovanadate 1.0, phenyl methyl 
sulphonyl fluoride (PMSF) 1.0, aprotinin 10 µg/mL and leupeptin 10 µg/mL, Triton-X100 1%, pH 
7.4. Samples were then centrifuged at 1000xg for 10 min to obtain the supernatant, which was 
subsequently used for western blotting. Preparation of lysates from the cytosolic and nuclear 
fractions procedure are described in chapter 4. 
To obtain equal loading during the separation process, the protein content of each sample was 
determined using the Bradford technique (Bradford, 1976). Thereafter, the lysates were adjusted 
accordingly by dilution in Laemmli sample buffer and boiled for 5min. The Bradford reagent 
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composition includes: (0.01% (w/v) Coomassie Brilliant Blue G-250, 4.7% (v/v) ethanol, and 8.5% 
(v/v) phosphoric acid. 
3.2.3.3. Protein separation and transfer  
Before separation, each sample was boiled for 5 min. Depending on the type of protein and 
available volume (lysates), 30 to 60 µg of protein was loaded and separated by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using the standard BIO-RAD Mini-
Protean III system. The gel was made up of a 10 or 12% polyacrylamide gel (resolving gel) and 
4% stacking gel on the top of resolving  gel (see table 3.1). 
The running buffer contained (in mM) Tris 250, glycine 192 and 1% sodium dodecyl sulphate 
(SDS). The electrophoresis separation technique is based on the mobility of proteins in an electric 
field.  Samples, including the commercial molecular weights marker, were loaded into wells in the 
gel. The marker helped to localize exactly the level of each protein separated, according to its 
molecular weight. After separation, the proteins were transferred to a PVDF membrane 
(ImmobilonTM P, Millipore) using a wet electrotransfer set up. The transfer buffer contained (in mM) 
Tris-HCl 25, glycine 192, and methanol (20% v/v). These membranes were routinely stained with 
Ponceau red reversible stain for visualization of proteins and to confirm an adequate transfer.  
3.2.3.4. Blocking of membrane and incubation with antibodies 
Depending on the protein, non-specific binding sites on the membranes were blocked with 5% fat-
free milk in TBST (Tris-buffered saline + 0.1% Tween 20) for 1 to 2h at room temperature. It was 
then washed with TBST (5x5 min) and incubated overnight at 4ºC with the primary antibodies that 
recognize total or phospho-specific proteins.  After overnight incubation, membranes were washed 
with TBST (5x5 min) and then incubated for 1h at room temperature, with a diluted horseradish 
peroxidase-labelled secondary antibody (Cell Signalling Technology®). The secondary antibody 
was either diluted in TBST or in TBST containing 5% fat free milk. 
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Table 3.1. Content of SDS-polyacrylamide gel 
Reagent Stock 7% gel 10% gel 12% gel 4% stack gel 
dH2O distilled 4.65mL 4.9 mL 3.35 mL 3.05 mL 
Tris-HCl (pH 8.8) 1.5 M 2.50mL 2.50 mL 2.50 mL  _____ 
Tris-HCl (pH 8.8) 0.5 M _____ _____ _____ 1.25 mL 
SDS 10% 90µL 100 µL 100 µL 50 µL 
Acrylamide 40% 1.7mL 2.50 mL 3.0 mL 0.5 mL 
APS 10% 50µL 50 µL 50 µL 50 µL 
TEMED 99% 20µL 20 µL 20 µL 10 µL 
 
Primary antibodies used: total STAT-3 and phospho-STAT-3 (Ser-727), phospho-STAT-3 (Tyr- 
705), total eNOS and phospho-eNOS (Ser-1177), total ERK p42/p44 and phospho-ERK p42/p44 
(Thr-202/Tyr- 204); total PKB/Akt and phospho-PKB/Akt (Ser-473); total GSK-3β and phospho-
GSK-3 β (Ser 9), total p38 MAPK and dual phospho-p38 MAPK (Thr-180/Tyr-182); total AMPKα 
and phospho-AMPK (Thr-172), Glut-4, IκB-α, iNOS (NOS2) and nitrotyrosine. Except iNOS and 
Nitrotyrosine which were purchased from Santa Cruz Biotechnology, Inc, all other antibodies were 
from Cell Signalling Technology®. The primary antibodies were diluted in TBST solution or in 5% 
milk solution.  
3.2.3.5. Immunodetection or  visualisation  
After thorough washing with TBST, membranes were covered with ECL (enhanced 
chemiluminescence) detection reagents (Amersham, LIFE SCIENCE) and quickly exposed to an 
autoradiography film (Hyperfilm ECL, RPN 2103-Amersham, LIFE SCIENCE) to detect light 
emission through a non-radioactive method (ECL western blotting). Films were densitometrically 
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analysed (UN-SCAN-IT, Silk Scientific Inc., Orem, Utah, USA) and protein activation was 
expressed as a ratio of phospho- to total protein while protein expression or phosphorylation was 
expressed as arbitrary densitometric units. 
3.3. DATA ANALYSIS 
Unless stated otherwise, all data were expressed as mean ± standard error of the mean (SEM).  
For comparative studies, Student’s t-test (unpaired), one- or two-way ANOVA analyses (with 
Bonferroni post-test, if p< 0.05) where applicable were used for statistical analyses.  A p-value of 
<0.05 was considered as significant. 
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STUDY I 
THE EFFECTS OF SHORT- AND LONG-TERM MELATONIN TREATMENT ON 
MYOCARDIAL ISCHAEMIA-REPERFUSION INJURY IN A RAT MODEL OF OBESITY 
AND INSULIN RESISTANCE 
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CHAPTER FOUR 
4. STUDY I 
 
THE EFFECTS OF SHORT- AND LONG-TERM MELATONIN TREATMENT ON MYOCARDIAL 
ISCHAEMIA-REPERFUSION INJURY IN A RAT MODEL OF OBESITY AND INSULIN 
RESISTANCE 
4.1. INTRODUCTION 
Recent evidence supports the role of melatonin in obesity and the potential beneficial effect of 
melatonin treatment in obesity-related disorders (Nduhirabandi et al., 2012; Reiter et al., 2012).  In 
this regard, chronic melatonin treatment starting before the establishment of obesity prevented the 
development of obesity-related abnormalities and protected the hearts against myocardial 
ischaemia-reperfusion damage (Nduhirabandi et al., 2011). However, the effect of melatonin 
treatment on the heart in established obesity remains unknown. Additionally, the mechanism of 
cardioprotection by melatonin in obesity is not yet established.  Previous studies have consistently 
reported that that PI3-K/Akt and STAT-3 pro-survival signalling pathways were associated with 
cardioprotection (Suleman et al., 2008; Lecour, 2009; Tamareille et al., 2011; Yin et al., 2012).  
Interestingly, Genade et al. (2008) and Lamont et al. (2011) showed that PI3-K/Akt and STAT-3 
signalling were associated with melatonin’s cardioprotective properties in non-obese animals.  
Importantly, these signalling pathways have recently been shown to closely interact to promote 
maximal cardioprotection (Suleman et al., 2008; Tamareille et al., 2011). However, this has not yet 
been investigated focusing on melatonin’s effect in obesity and insulin resistance. 
In order to expand our knowledge of some of these outstanding issues, we investigated the effects 
of melatonin (administered after establishment of obesity) in a rat model of diet-induced obesity 
and insulin resistance.  The specific objectives were to determine the effect of varying periods of 
oral melatonin treatment (3 and 6 weeks) on: (i) biometric and metabolic parameters: food and 
water consumption, body weight, heart weight, visceral fat, fasting blood glucose and glucose 
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tolerance, serum lipid profile, insulin and adiponectin levels; (ii) serum lipid peroxidation; (iii) post-
ischaemic myocardial function and infarct size;  (iv) basal and post-ischaemic activation of 
myocardial PKB/Akt, ERK42/44, GSK-3β, STAT-3, PI3-K and GLUT-4 expression. 
4.2. MATERIALS AND METHODS 
4.2.1. STUDY DESIGN 
Experimental groups, feeding and treatment have been previously described in the general 
methodology (see chapter 3). Here, only specific methods are included.   
4.2.2. EXPERIMENTAL PROCEDURE 
Major phases of this study included animal feeding, treatment and the experimental procedure (at 
the end of feeding).  The treatment was continuously evaluated during the study by determining 
the daily food and water consumption and weekly body weight change. At the end of the treatment 
period or at the end of 20 weeks of feeding, non-fasting or overnight fasting animals were 
sacrificed. As previously described (Nduhirabandi et al., 2011), the animals were anaesthetized by 
intraperitoneal injection of sodium pentobarbitone (160mg/kg), and body weights as well as blood 
glucose levels were determined. The hearts were rapidly removed and blood collected 
immediately from the thoracic cavity of the rat and the visceral fat (intraperitoneal and gonadal fat) 
collected and weighed.  
The heart weights (HW) were determined at baseline (immediately after isolation without 
perfusion, “non-perfused hearts”) or at the end of the reperfusion period of the isolated hearts. As 
it is described further below (section 4.2.2.1-4), in the case of infarct size studies, the hearts were 
subsequently frozen at -20oC while in the case of biochemical analyses experiments, the hearts 
were stored in liquid nitrogen.  The weight of the infused suspension (i.e., Evans blue solution for 
infarct size determination) was subtracted from the measured HW to obtain the final HW.  In 
separate experiments we found that the weights of non-perfused and perfused hearts (after 2h 
reperfusion) were not significantly different. The HW to BW ratios were calculated and expressed 
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in mg/g. The tibial length (TL) was measured and the HW to TL ratio calculated and expressed in 
mg/mm.  
4.2.2.1. Heart perfusion  
Hearts were perfused with the modified Krebs-Henseleit bicarbonate buffer (KHB) containing (in 
mM): NaCl 119, NaHCO3 24.9, KCl 4.7, KH2PO4 1.2, MgSO4.7H2O 0.59, Na2SO4 0.59, CaCl2H2O 
1.25 and glucose 10. KHB was oxygenated and kept at pH 7.4 by gassing with 95% O2 and 5% 
CO2 at 37° C.  
4.2.2.1.1. Perfusion technique 
 The heart was rapidly excised from the anaesthetized rat and arrested in ice-cold (4ºC) KHB. 
Thereafter, it was mounted via the aorta onto the aortic cannula. The left atrium was also 
cannulated via the pulmonary vein. 
After cannulation, hearts were first retrogradely perfused (Langendorff mode), in a non-
recirculating manner at constant hydrostatic pressure (100cmH2O) for 10min. This allows the 
washout of blood and stabilises the heart. After 10min of the retrograde perfusion, the perfusion 
mode was switched to the working heart mode (see figures 4.1 and 4.2) maintaining a preload of 
15cmH2O and afterload of 100cmH2O) for 20min. The hearts were not electrically paced. 
Myocardial temperature was thermostatically controlled and monitored at regular intervals 
(constant at 37ºC during reperfusion and 36º5C during ischaemia). In our laboratory, maintenance 
of temperature at 36º5C during ischaemia was found to be easier than 37ºC. For this, a 
temperature probe was inserted into the pulmonary artery and the water bath adjusted 
accordingly.   
4.2.2.1.2. Perfusion protocol  
Two perfusion protocols were used: regional ischaemia (to determine myocardial infarct size) and 
global ischaemia (to evaluate biochemical changes).  
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• Regional ischaemia protocol  
The regional ischaemia protocol was used for the evaluation of myocardial function and infarct 
size (see figure 4.1). Briefly, at the end of the stabilisation period, after measuring the coronary 
flow (CF), ischaemia was induced by ligating the left anterior descending (LAD) coronary artery, 
approximately 3mm from the coronary sinus, with a Ethicon silk suture (3/0, 26mm ½C Taper, 
Johnson & Johnson Medical (PTY) LTD, South Africa). The LAD was occluded for 35 min at 
36.5ºC.  Adequate regional ischaemia was indicated by a 33% reduction in CF compared to the 
pre-ischaemic CF. Regional ischaemia was also confirmed by cyanosis of the myocardial surface. 
After the ischaemic period, the silk suture was released, and the heart reperfused for 120 min (see 
figure 4.1). Myocardial mechanical function was documented before induction of ischaemia and 
during reperfusion. 
 
Figure 4.1 Diagram showing the perfusion protocol for determination of infarct size; LD: 
Langendorff, WH: working heart, RI: regional ischaemia, CAL: Coronary artery ligation, IFS: infarct 
size.  
• Global ischaemia protocol  
The global ischaemia protocol was used to evaluate post-ischaemic biochemical changes. Briefly, 
after stabilisation, the aortic and atrial cannulas were occluded resulting in a total cessation of 
coronary perfusion to the heart (no-flow ischaemia). During the ischaemia, myocardial 
temperature was maintained at 36.5ºC, and after 15 min, the aortic cannula was opened for 
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reperfusion of the heart for 10 or 30 min (see figure 4.2). At the end of reperfusion, hearts were 
freeze-clamped and stored in liquid nitrogen for further analyses. 
 
Figure 4.2 Diagram showing the perfusion protocol for biochemical analyses; GI: global 
ischaemia, LD: Langendorff, WH: working heart. 
4.2.2.1.3. Determination of myocardial function  
The coronary and aortic flow rates were measured manually. Cardiac output (CO) was calculated 
as the sum of aortic output (AO) and coronary flow (CF). The aortic systolic and diastolic pressure 
(mmHg) and heart rate (HR) [beats per minute (bpm)] were monitored and recorded on a 
computerized system through a side-arm of the aortic cannula connected to a Viggo-Spectramed 
pressure transducer coupled to the computer system. Total work performance (pressure power + 
kinetic power) developed by the heart was determined according to the formula described by 
(Kannengiesser et al., 1979). To determine functional recovery, the post-ischaemic value was 
expressed as the percentage of the pre-ischaemic value.  All data were collected and analysed 
using a PhysiTutor® data acquisition system. 
4.2.2.1.4. Determination of myocardial infarct size and area at risk 
Myocardial infarct size was determined as previously described (Nduhirabandi et al., 2011). At the 
end of 2 h reperfusion, the silk suture around the coronary artery was securely tied and 1mL of 
Evans blue suspension (0.5%) was slowly injected via the aorta cannula. The heart was then 
frozen overnight before being cut into 2 mm thick slices.  After defrosting, the slices were stained 
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with 1% w/v triphenyl tetrazolium chloride (TTC) in phosphate buffer (pH 7.4 at 37ºC) for 15 min. 
To enhance the contrast between stained viable tissue and unstained necrotic tissue slices were 
fixed in 10% v/v formaldehyde solution (at room temperature). At this stage, the damage in each 
slice was visible, the blue area indicating viable tissue, the white or unstained area indicating the 
infarcted area which was surrounded by a red area. These two areas constituted the area at risk 
(AR). All slices were drawn and scanned.  For each slice, the AR and the area of infarcted tissue 
were determined using computerized planimetry (UTHCSA Image Tool Programme, University of 
Texas Health Science Center at San Antonio, TX, USA). For each heart, the areas of the tissue 
slices were summated. The infarct size was expressed as the percentage of the area at risk (I/AR 
%). 
4.2.2.2. Blood analysis 
4.2.2.2.1. Blood collection 
Blood samples were collected as previously described (Du Toit et al., 2008). Following the 
removal of the heart, blood was immediately collected from the thoracic cavity using serum 
separation tubes (BD Vacutainer, Lasec SA, Cape Town, South Africa). These tubes were 
centrifuged at 3000 rpm at 4°C for 10 min, within 30 min of collection. Separated serum was 
transferred to eppendorf tubes and stored at -80ºC for further analyses. 
4.2.2.2.2. Blood glucose determination 
Fasting blood glucose was measured using the glucose meter (Gluco PlusTM, distributed by 
CIPLA DIBCARE, Bellville, South Africa). A small drop of fresh blood, obtained by pricking the 
distal tail with a lancet was placed on a disposable test strip and after 5 seconds, the meter 
displayed the blood glucose level expressed in mmol/L. 
4.2.2.2.3. Intraperitoneal glucose tolerance test (IPGTT) 
This test reflects the efficiency of the body to dispose of glucose after an intraperitoneal injection 
of glucose (Muniyappa et al., 2008). Animals were fasted 18 h but with access to drinking water.  
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The animals were anaesthetized by intraperitoneal injection of sodium pentobarbitone (15 mg/kg), 
body weights were determined and blood glucose measured as described above. These glucose 
levels were considered as basal. A solution of glucose (50%) was then injected intraperitoneally at 
1g/kg and blood glucose levels monitored using a drop of blood collected by tail prick and the 
glucose meter at various time intervals (5, 10, 15, 20, 25, 30, 45, 60, 90 and 120). Following the 
IPGTT, the animals were allowed to recover for a period of 1 week before other experiments.  
4.2.2.2.4. Insulin assay 
 Serum insulin levels were determined using a competitive radioimmunoassay (RIA) (Coat-A-
Count® Insulin, Siemens Healthcare Diagnostic Products Inc., LA, USA) according to the 
manufacturer’s instructions. The homeostasis model assessment for insulin resistance (HOMA-IR) 
index was calculated as the product of fasting glucose concentration (mmol/L) multiplied by the 
insulin concentration (µIU/mL) divided by 22.5.   
4.2.2.2.5. Adiponectin assay 
Fasting serum was collected as mentioned above. Serum adiponectin levels were determined 
using an enzyme linked-immunosorbent assay (ELISA) kit (AdipoGenTM Inc., Incheon, Korea) 
according to the manufacturer’s instructions.  
• Assay procedure 
For quantitative determination of adiponectin in rat serum samples, a polyclonal antibody is 
precoated onto the 96 wells microtiter plate. After appropriate dilution, at room temperature, 
samples and standards (100µl) were added into their respective wells (in duplicate) in order to 
bind to the precoated antibody. Following 1h incubation at 37oC and extensive washing to stop 
competition and separate the free and bound antibodies, a specific monoclonal antibody 
(detection antibody) was added and incubated at 37oC for 1h.  Excess of adiponectin detector 
antibody was washed out and HRP conjugated anti-mouse IgG added and incubated at 37oC for 
1h again. After a final washing, peroxidase activity was quantified using the substrate 3, 3’, 5, 5’-
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tetramethylbenzidine (TMB). Within 30 min following incubation at room temperature in the dark 
for 20 min, the intensity of the resultant colour reaction was read at 450 nm using a microtiter plate 
reader. A standard curve was generated and adiponectin concentration calculated accordingly. 
4.2.2.2.6. Lipid assay 
Fasting and non-fasting serum samples were assayed for lipid peroxidation, total cholesterol (TC), 
triglycerides (TG) and phospholipids (PL) as previously described (Nduhirabandi et al., 2011). 
Serum TC, PL and TG concentrations were determined using enzymatic colorimetric kits (KAT 
Medicals, Calicom Trading (PTY), South Africa) and PL (WAKO Chemicals, Germany) by a 
Labsystems Multiskan MS analyzer (AEC Amersham Co., South Africa).  
Serum levels of conjugate dienes (CD), lipid hydroperoxide (LOOH) and thiobarbituric acid 
reactive substances (TBARS) were measured spectrophotometrically as follows:   
(1)  CDs were measured at 234 nm by a GBC UV/VIS analyser (Wirsam Scientific and Precision 
Equipment, South Africa) after mixing the serum samples with cyclohexane (Spectrosol) (Pryor 
and Castle, 1984; Esterbauer et al., 1989). Separation was enhanced by centrifugation (14,000 × 
g for 10 min at 10°C). 
(2)  To determine LOOH, serum was assayed in the presence of xylenol orange (3,3′-bis[N,N-
di(carboxymethyl)-aminomethyl]-o-cresolsulfonephthalein) (sodium salt) (Sigma Chemical Co., St 
Louis, MI, USA) and Fe2+ in the ferrous oxidation/xylenol orange (FOX) assay that was adapted to 
enhance the solubility of non-polar compounds by including chloroform. Absorbance of the 
resulting Fe3+-xylenol orange complex was measured at 560 nm (Jiang et al., 1991; Jiang et al., 
1992) using Labsystems Multiskan MS Analyser (AEC Amersham Co., South Africa).  
(3)  TBARS were measured according to the method of Jentzsch et al. (1996).  The samples (200 
µL) were mixed with 25 µL butylated hydroxytoluene (BHT) (Fluka Chemie, Switzerland) in ethanol 
(Merck Chemicals, South Africa) and orthophosphoric acid (Sigma) buffer at pH 3.6 and vortexed 
for 10 seconds. 25 µL thiobarbituric acid (TBA) (Sigma) reagent was added and vortexed again. 
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After incubation at 90ºC for 45 min in water bath, the reaction was stopped by putting tubes on ice. 
TBARS were extracted with n-butanol. Saturated NaCl was added and the mixture was then 
centrifuged at 12,000 rpm for 1min.  Absorbance was read at 532 nm using Labsystems Multiskan 
MS Analyser (AEC Amersham Co., South Africa).  
The final concentrations were calculated using the appropriate molar extinction coefficients and 
standards. 
4.2.2.3. Western blotting  
Total PKB/Akt, phospho-PKB/Akt (Ser-473), total GSK-3β, phospho-GSK-3 β (Ser-9), total STAT-
3, phospho-STAT-3 (Ser-727), phospho-STAT-3 (Tyr-705), total ERK p42/p44, phospho-ERK 
p42/p44 (Thr-202/Tyr-204), total PI3-K (p85), phospho-PI3-K (p85) and β-tubulin were assessed 
in the isolated hearts at baseline (before perfusion)  referred to as “ non-perfused hearts” and after 
10 or 30 min of reperfusion using western blotting techniques as described above (see chapter 3). 
The specific protocol for each protein used in the present study is summarized in the table 4.1. 
Membrane was overnight incubated with primary antibody and exposed to the secondary antibody 
for 1h (see chapter 3).  β-tubulin expression was used to assess equal loading.  To determine 
activation, phospho-/total ratios were also calculated. 
For all proteins except for STAT-3 where we used cytosolic and nuclear fractions, the whole-cell-
extract was used as described in chapter 3. To obtain a cytosolic fraction, we used the lysis buffer 
described above but without 1% Triton-X100. The homogenates were centrifuged at 2500rpm for 
10 min at 40C to obtain the cytosolic fraction. The lysis buffer containing 1% triton was added to 
the resultant pellet and homogenized.  The resultant homogeneous solution was then transferred 
into ultracentrifuge tubes and kept on ice for 10 min, before centrifugation at 13000rpm. The 
resultant supernatant was considered as the nuclear fraction. The protein content of cytosolic and 
nuclear fractions was determined using the Bradford method (chapter 3) and the rest of the 
lysates were kept frozen until analyses.  
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Table 4.1  Specificity of the protein  
Protein MW Quantity  SDS-PAGE 
Antibody dilution 
Primary  Secondary  
PKB/Akt 60kDa 50µg 12% 1:1000 TBST  1:4000 TBST(5% milk)  
ERK 42/44 42/44kDa 30µg 12%  1:1000 TBST 1:4000 TBST 
STAT-3 79/86 kDa 50µg 10% 1:500TBST 1:4000 TBST 
PI3-K(p85) 85kDa 50µg 12% 1:1000 TBST 1:4000 TBST 
GSK-3β 46kDa 50µg 10% 1:1000TBST 1:4000 TBST 
GLUT-4 45kDa 40 µg 10% 1:1000 TBST 1:4000 TBST 
β-tubulin 55kDa 30-50µg 10-12% 1:1000 TBST 1:4000 TBST 
 
4.2.3. DATA ANALYSIS 
All data were expressed as mean ± SEM. Infarct size was expressed as a percentage of the area 
at risk. Post-ischaemic functional recovery (aortic output and work total) was expressed as a 
percentage of the pre-ischaemic value. When comparisons between two groups (e.g., treated and 
untreated groups) were made, an unpaired Student t-test was performed. For multiple 
comparisons, the ANOVA (two-way when appropriate) followed by the Bonferroni correction was 
applied. Statistical significance was considered for a p-value of <0.05.  
4.3. RESULTS 
4.3.1. BIOMETRIC AND METABOLIC PARAMETERS 
4.3.1.1. Animal model 
Table 4.2 summarizes the characteristics of the animal model of high calorie diet-induced obesity 
and insulin resistance.  After 20 weeks of feeding, the body weight of control (C) rats averaged 
470±8g. The high calorie diet (D) increased the body weight by 14.4 % (p< 0.001) (fig.4.3A). It 
also increased the visceral fat content by 70.3 % (p<0.001) (fig.4.3B). 
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Fasting blood glucose levels were also increased by 20.4% (p<0.01) (fig.4.3C). Fasted serum 
insulin and TG levels were elevated by 55.8% (p<0.01) and 82.4 % (p<0.05) respectively in the 
diet fed (D) rats (fig.4.3E; 4.3D). The HOMA-IR index was also increased in rats fed a high calorie 
diet (92.3%, p<0.001). Compared to control rats, the high calorie diet caused a significant 
decrease in adiponectin levels (16.0 ± 0.9 vs 3.7 ± 1.4µg/mL, p<0.001) (fig.4.5F). 
The heart weight of control rats averaged 1.14 ± 0.03 mg. The high calorie diet increased the 
heart weight by 12.3 % (p<0.05).  While the heart weight to body weight (HW/BW) ratio was not 
affected by the diet [2.44 ± 0.05 (C) vs 2.43 ± 0.05 (D)], the heart weight to tibial length (HW/TL) 
ratio was increased in high calorie diet groups compared to control (13.3%, p<0.05). 
Table 4.2 Characteristics of animal model of obesity and insulin resistance  
Parameters C D n/group 
Body weight (g) 470±8 538±15  (***) 14 
Visceral fat (g) 19.71 ± 1.1 33.57 ± 1.5 (***) 14 
Fasting blood glucose (mmol/L) 5.29 ± 0.1 6.37 ± 0.4 (**) 8-10 
Serum insulin (µIU/mL) 37.6 ± 3.9 58.6 ± 6.4 (**) 8-10 
Serum adiponectin (µg/mL) 16.0 ± 0.9 3.8 ± 1.4 (***) 6-7 
Serum TG (mmol/L) 0.57 ± 0.07 1.04 ± 0.17(**) 7 
HOMA-IR index 8.87 ± 0.9  17.06 ± 2.8 (**)  8-10 
Heart weight (g) 1.14 ± 0.03 1.28 ± 0.04 (**) 7-10 
HW/BW (mg/g) 2.44 ± 0.05 2.43 ± 0.05 7-10 
HW/TL(mg/mm) 26.8 ± 0.8 30.38 ± 1.0 (*) 7-10 
Blood and serum values were obtained from overnight fasting animals, C: control; D: High calorie 
diet; TG: triglycerides; HW: heart weight; BW: body weight; TL: tibial length; *p<0.05, **p<0.01, 
***p<0.001 (D vs C). 
Stellenbosch University  http://scholar.sun.ac.za
 118 
 
C D
400
450
500
550
600
***
Bo
dy
 
w
ei
gh
t (g
)
C D
0
10
20
30
40
***
Vi
sc
er
a
l f
at
 
(g)
A B
C D
0
2
4
6
8
*
 
 
 
 
 
 
 
Bl
o
o
d 
gl
u
co
se
 
(m
m
o
l/L
)
C D
0.5
1.0
1.5
**
Se
ru
m
 
TG
 
(m
m
o
l/L
)
C D
C D
0
20
40
60
80
**
 
 
 
 
Se
ru
m
 
in
su
lin
 
( µ
IU
/m
L)
C D
0
5
10
15
20
***
 
Se
ru
m
 
ad
ip
on
e
ct
in
 
(µg
/m
L)
E F
Figure 4.3 Characteristics of animal model after overnight fasting, body weights (A, n=14), 
visceral fat (B, n=14), blood glucose (C, n=8-10), serum triglycerides (TG) (D, n=6-7), serum 
insulin (E, n=8-10), serum adiponectin (F, n= 6-7), *p<0.05, **p<0.01, ***p<0.001 (D vs C).  
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4.3.1.2. Effects of melatonin treatment on biometric parameters 
4.3.1.2.1. Body weight  
To investigate the effect of melatonin on body weight during the treatment, for each group, body 
weight was determined before and at end of the treatment and the percentage body weigth gain 
calculated (table 4.3).    
Before the treatment (at the end of 14 and 17 weeks of feeding), the body weight of rats fed a high 
calorie diet had increased significantly compared to control (p<0.05) (table 4.3). A similar  increase 
was also observed after 20 weeks of feeding (538 ± 15 vs 470 ± 8g, p<0.001) (table 4.3).    
After 6 weeks treatment, although melatonin did not prevent the weight gain, it lowered 
significantly the  percentage weight gain from 13.8±0.9%  to 7.5±2.1%  in the C group,  and from 
18.1 ± 1.5% to 8.9 ± 2.1% in the diet group (table 4.3 and fig.4.4).  
At the end of 3 weeks treatment, melatonin significantly reduced the body weight in the control  
group  by 12.2% (p<0.05) but not in the D group (538±15 vs 505±9g, p=0.07) (fig.4.6). The 
percentage body weight gain was also reduced in the C (5.6±0.7% vs 0 ± 0.7%, p<0.05)  but not in 
the D group (fig.4.4). 
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Table 4.3 Effects of melatonin treatment on body weight variation 
Treatment period Group BW    (before) BW (after) % Gain  N/group 
 6 weeks 
(after 14 weeks) 
C 413± 8 470± 8 13.8 ± 0.9 10 
CM6 (a) 407±10 436± 8* 7.1 ± 2.1(*)  14 
D 455 ± 15(*) 538 ± 15(***)   18.1 ± 1.5 14 
DM6 (a) 460±15(*) 500 ± 13(#) 8.7 ± 2.1(*) 14 
3 weeks  
(after 17 weeks) 
C (b) 445±8.7 470±8 5.6±0.7 10 
CM3 (a) 420±15 419±15(*) -0.2 ± 0.7(**) 14 
D (b) 508±15(*) 538 ± 15(***) 5.9 ± 0.8 14 
DM3(a) 481± 10(*) 505 ± 9(##)  4.9 ± 0.9 14 
 
BW: body weight (g), (a): rats receiving melatonin during the treatment; (b): same rats as in 6 
weeks treatment but their body weights were determined  after 17 weeks of feeding, *p<0.05 (vs 
C), **p<0.01 (vs C), ***p<0.001(vs C), #p=0.06 (DM6 vs D), ##p=0.07 (DM3 vs D), n=10-14/group.  
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Figure 4.4 Body weight gain (percentage), BW: body weight; C6, D6 and C3, D3: weight gain of C 
and D rats during 6 and 3 weeks treatment, respectively. CM6, DM6 and CM3, DM3: weight gain 
of rats receiving melatonin for 6 and 3 weeks, respectively, *p<0.05 (CM6 vs C6), **p<0.05 (DM6 
vs D6), ***p<0.05 (CM3 vs C3), α p<0.01 (C6 vs D6), n=10-14/group. 
4.3.1.2.2. Other biometric parameters 
The high calorie diet significantly increased visceral adiposity, absolute heart weight and the heart 
weight to tibial length ratio, but not  the heart  weight  to body weight ratio (table 4.4 and fig.4.7-9).  
Melatonin treatment for 6 weeks did not affect any of these parameters in either control or D 
groups. 3 weeks melatonin treatment significantly reduced  the visceral fat in control (18.1%, 
p<0.01), but not in D group (fig.4.8). In addition, it increased the heart weight to body weight ratio 
in control (15.9%, p<0.05), but not in D group probably due to their reduced body weight (419.9 ± 
15.3 g). 
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Table 4.4 Effects of melatonin on other biometric parameters 
Groups Visceral fat 
 (g) 
HW 
 (g) 
TL 
(mm) 
HW/BW ratio 
(mg/g) 
HW/TL ratio 
(mg/mm) 
C 19.71 ± 1.1 1.14 ± 0.03 42.4±0.03 2.44 ± 0.05 26.8 ± 0.8  
CM6 18.1± 1.1 1.13 ± 0.12 42.1±0.03 2.52±  0.26 27.03 ± 2.5 
CM3 16.14 ± 0.7(*) 1.14 ± 0.04 42.2±0.04 2.83 ± 0.08(*) 27.8 ± 0.9 
D 33.57 ± 1.5(**)  1.28 ± 0.04(*)  42.3±0.05 2.43 ± 0.05 30.38 ± 1.0(*)  
DM6 31.47±  2.1 1.25 ± 0.03 42.5±0.04 2.49 ± 0.07 29.8± 0.5 
DM3 32.1±  1.6 1.19 ±  0.03   41.1±0.03 2.46 ± 0.05 28.2± 0.8 
n/group 14 7-10 10 7-10 7-10 
 
HW: heart weight, BW: body weight, TL: tibial length, *p<0.05 (vs C), **p<0.01 (vs C) 
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Figure 4.5 Visceral fat,* p<0.05 (C vs CM3), **p<0.001(C vs D), n=14/group 
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Figure 4.6   Absolute heart weight, *p<0.05 (C vs D), n=7-10/group 
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Figure 4.7 Heart weight to tibial length (HW/TL) ratios; *p<0.05 (C vs D), n= 7-10/group. 
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Figure 4.8 Heart weight to body weight (HW/BW) ratios, *p<0.05 (CM3 vs C), n=7-10/group. 
4.3.1.3. Effect of melatonin treatment on food and water consumption 
 In order to investigate the mechanism involved in body weight variation, water and food intake 
were determined. Before melatonin treatment, measurements of food and water consumption 
were recorded for 15 days. Animals were divided in two C and D groups. Each group was housed 
in two cages of which one received melatonin and the other received drinking water only (table 
4.5). During the treatment, daily measurements were conducted for both water and food 
consumption. Results are presented in figures 4.9-10 and summarized in the table 4.5. 
Rats fed a high calorie diet consumed more food than the control rats receiving the standard rat 
chow (30.9±1.4 vs 21.07±0.2 or 30.2±1.3 vs 21.03±0.2 g, p<0.001), with a reduced intake of 
drinking water compared to the control group (17.63±0.4 vs 30.6±0.6; 18.1±0.3 vs 32.7±0.9 
mL/day) (table 4.5; fig.4.9-10). Administration of melatonin did not affect the daily water and food 
consumption in either C or D groups (table 4.5; fig. 4.9-10).  
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Table 4.5 Water and food consumption before and during melatonin treatment  
Parameters and treatment C1 C 2 D1 D2 
Water 
A.  Before (mL/rat/day)                                                                                                                    30.6±0.6 32.7±0.9 17.63±0.4* 18.1±0.3* 
B. Treatment   melatonin                        
(mL/rat/day) 
(-) (+) (-)  (+)  
32.4±0.9 34.7±1.03 18.10±0.7* 19.57±1.2* 
Food  
 A. Before  (g/rat/day)                                                                                     21.07±0.2 21.03±0.2 30.9±1.4* 30.2±1.3* 
B. Treatment   melatonin               
(g/rat/day) 
(-)  (+) (-)  (+)  
22.6±0.7 21.6±0.9 35.8±1.2* 34.7±0.9* 
A: before treatment, B: during treatment, (-): no treatment (C 1 and D1), (+): treatment (C2 and 
D2), *p<0.001(D vs C), n=6/group. 
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Figure 4.9 Water consumption before (A) and during (B) treatment, *p<0.001 (D vs C or DM vs 
CM); n=6/group. 
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Figure 4.10 Food consumption, before treatment (A) and during treatment (B) *p <0.001 (D vs C 
or CM vs DM); n=6/group. 
4.3.1.4. Effects of melatonin on metabolic  parameters  
Only the effects on fasting blood glucose, serum insulin and adiponectin levels and HOMA-IR 
index are presented in this section (fig.4.13-15; table 4.6). The effect on glucose tolerance is 
described separately in section 4.3.1.5 (fig.4.15-16). The effects on serum lipids are included in 
the section on lipid peroxidation (section 4.3.2) (tables 4.7-8).  
Fasting blood glucose levels of diet (D) rats were increased compared to controls (6.37 ± 0.4 vs 
5.29 ± 0.1mmol/L, p<0.05). Six and 3 weeks melatonin treatments had no significant effects on 
fasting blood glucose levels in either control or D groups (fig.4.11).  
Following 6 weeks treatment, fasting serum insulin levels were significantly reduced in the treated 
D rats (58.6±6.41 vs 36.12±4.75µIU/mL, p<0.01) (fig.4.12).  A similar reduction was also found 
after three weeks treatment in the D group but not in the control group (fig.4.12; table 4.6).  
Accordingly, HOMA-IR index was reduced by 49.9% (p<0.01) and 47.2 % in the D group, after 
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both 6 and 3 weeks treatments, respectively (fig.4.13). There was, however, no significant 
difference between the HOMA index of treated and untreated control rats (fig.4.13).   
The high calorie diet reduced the levels of serum adiponectin (16.0±0.9 vs 3.8±1.4 µg/mL, 
p<0.001). In this group, 6 and 3 weeks melatonin treatment increased adiponectin by 184.8 % and 
115.7%, respectively (fig.4.14).  Melatonin treatment had no effect on adiponectin levels in the 
control group (fig.4.14). 
Table 4.6 Effects of melatonin on metabolic parameters  
Groups 
Serum insulin 
(µIU/mL) 
Fasting blood 
glucose (mmol/L) 
HOMA-IR 
index 
Serum adiponectin 
(µg/mL) 
C 37.66± 3.9 5.29 ± 0.1 8.87±0.9 16.0± 0.9 
CM6 27.3±4.11## 5.3±0.09 6.62± 0.06 10.5± 2.8 
CM3 31.72±3.406 5.18±0.13 7.5± 0.85 10.4 ±2.1 
D 58.6±6.41** 6.37 ± 0.4* 17.06± 2.8*** 3.8± 1.4***  
DM6 36.12±4.75** 6.01±0.13 10.09± 1.3** 10.7± 2.7* 
DM3 35.95±4.42** 5.79±0.11# 9.01± 1.2** 8.1± 2.1 
n/group 8-10 8-10 8-10 6-7 
 
Triglycerides (TG), total cholesterol (TC), and phospholipid (PL) are presented in the section 4.3.2 
(behind lipid peroxidation). *p<0.05 (DM6 or DM3 vs D) or (D vs C); **p<0.01(D vs C); ***p<0.001 
(D vs C), #p=0.07(DM6 vs D), ##p=0.08 (CM6 vs C). 
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Figure 4.11 Fasting blood glucose, *p<0.05 (D vs C), #p=0.07 (DM3 vs D), n=8-10/group. 
 
C CM6 CM3 D DM6 DM3
0
20
40
60
80
**
#
Se
ru
m
 
in
su
lin
 
( µI
U/
m
L)
 
Figure 4.12 Fasting serum insulin, **p<0.01 (D vs C, DM6, DM3), #p=0.08 (CM6 vs C), n=8-
10/group. 
Stellenbosch University  http://scholar.sun.ac.za
 129 
 
C CM6 CM3 D DM6 DM3
0
5
10
15
20
25
**
*
HO
M
A-
IR
 
in
de
x
  
Figure 4.13 Homeostasis model assessment for insulin resistance (HOMA-IR) index; *p<0.05 (D 
vs DM6 or DM3), **p<0.01 (D vs C), n=8-10/group. 
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Figure 4.14 Fasting serum adiponectin, *p<0.05 (D vs DM6), ***p<0.001(C vs D), n=6-7/group. 
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4.3.1.5. Intraperitoneal glucose tolerance test (IPGTT)  
Following overnight fasting (18h), rats fed a high calorie diet had elevated basal blood glucose 
levels compared to the controls (5.2±0.28 vs 6.4 ± 0.17 mmol/L, p<0.05). Similarly, at the end of 
the test, these rats continued to have elevated glucose levels (4.5±0.2 vs 5.2±0.1momol/L, 
p<0.05) compared to the control (fig.4.15). Melatonin treatment had no significant effect on the 
basal glucose levels in both groups (fig.4.16).   
Rats fed a high calorie diet had an elevated area under curve (AUC) compared to the control 
(870.7±25.6 vs 761.8±27.7, p<0.05) (fig.4.15). Six week melatonin administration did not affect the 
AUC in either group (fig 4.16 A, B). Three weeks melatonin treatment significantly reduced the 
AUC in D but not in control rats (D: 870.7±25.6 vs 756.9±23.7, p<0.05; C: 761.8±27.7, vs 
734.85±41.3, p>0) (fig.4.16 A and B).  In D group, blood glucose levels of 3 weeks melatonin 
treated rats were significantly reduced compared to untreated rats (p<0.05) at 60 min, (fig.4.60 B). 
However at the end of the test there was no difference on blood glucose levels of treated and 
untreated rats. 
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Figure 4.15 Intraperitoneal glucose tolerance test, C: control, D: high calorie diet, *p<0.05 (C vs 
D), n=6/group. 
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Figure 4.16 Intraperitoneal glucose tolerance test in control (A) and diet (B) groups, C; control, CM3 or CM6: control with melatonin 
for 3 or 6 weeks, D: high calorie diet, DM3 or DM6: diet with melatonin for 3 or 6 weeks treatment, *p<0.05 (D vs DM3),**p<0.05 (D 
vs DM6), n=6 group. 
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4.3.2. EFFECT OF MELATONIN TREATMENT ON LIPID PEROXIDATION 
A separate series of experiments was included to investigate the effects of six or three weeks 
melatonin treatment on systemic lipid peroxidation as indicated by the levels of serum conjugated 
dienes (CD), lipid hydroperoxide (LOOH), and thiobarbituric acid reactive substances (TBARS). 
Serum lipids including total cholesterol (TC), triacylglycerol or triglycerides (TG), phospholipids 
(PL) were also measured. The CD, TBARS and LOOH values were additionally normalized by 
dividing their absolute concentrations by the sum of TG and PL. To explore all possible effects, we 
used sera from both fasting and non-fasting control and diet fed rats (collected during the day, 
from 10:00-12:00 A.M.). The period of fasting was 18h (overnight). The results are presented in 
tables 4.8-9 and figures 4.17-18. 
In the non-fasting condition, rats fed a high calorie diet had increased absolute concentrations of 
CD with no effect on absolute values of TBARS and LOOH levels (fig.4.17; table 4.7). This was 
associated with an increase in TG while PL and TC concentrations were unchanged (table 4.7).  
In the fasting state, the increase in serum TG levels in the rats fed a high calorie diet was 
associated with an increase in PL and TBARS levels (table 4.8; fig.4.18) while TC, CD and LOOH 
levels remained at control levels (table 4.8). 
Three or six melatonin treatment had no effect on serum TG, TC and PL in non-fasting condition 
(table 4.7). In fasting state, although the high calorie diet caused a significant increase TG and PL 
levels, these were not affected by melatonin after either 3 or 6 weeks treatment (fig. 4.17 and 
table 4. 8-9). Additionally, TC levels remained unchanged. However, three weeks treatment 
significantly reduced TC levels in D rats but not in controls (table 4.8). 
In both control and diet groups, six weeks melatonin treatment had no effect on TBARS 
regardless of the feeding state (fig. 4.18B; fig.4.18B). However, it reduced the non-fasting serum 
CD and LOOH levels in the control but not in the diet groups (fig.4.17C, D). In fasting condition, 6 
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weeks melatonin treatment had no effect on absolute value of LOOH (fig.4.18C) while it 
significantly reduced  CD levels in the diet but not in the control rats (p<0.05) (fig.4.18D).  
In non-fasting rats, three weeks melatonin treatment had no effect on TBARS, LOOH levels 
(fig.4.17). Interestingly, it increased CD levels in the controls but not in the diet rats (fig.4.17D). In 
fasting rats, 3 weeks treatment increased TBARS levels in the control group only (fig 4.18B) while 
having no effect  on LOOH and  CD levels in both groups (fig.4.18C, D).  
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Figure 4.17 Non-fasting serum triglycerides (TG) (A), thiobarbituric acid reactive substances 
(TBARS) (B), lipid hydroperoxides (LOOH) (C) and conjugated dienes (D),  A: **p<0.01 (C vs 
CM6), C: *p<0.05 (CM6 vs C), D: *p<0.05 (CM6 vs C), ***p<0.001(C vs CM3 or D), n=6/group. 
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Figure 4.18 Fasting serum triglycerides (TG) (A), thiobarbituric acid reactive substances (TBARS) 
(B), lipid hydroperoxides (LOOH) (C) and conjugated dienes (D). A: **p<0.01 (D vs C), B: *p<0.05 
(CM3 vs C), **p<0.01 (D vs C), C: #p=0.06 (DM6 vs D), D: *p<0.05 (DM6 vs D), #p=0.06 (DM3 vs 
D), ##p=0.1 (CM3 vs C), n=6-7/group.
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Table 4.7 Serum lipid peroxidation from non-fasting rats 
 
Parameters 
CONTROL GROUP DIET GROUP 
C CM6 CM3 D DM6 DM3 
TBARS 5.16±0.36 4.13±0.45 4.8±0.13 4.38±0.19 4.5±0.24 4.69±0.13 
CD 26.04±1.62 21.49±1.36* 57.11±3.35*** 56.33±4.2*** 64.27±7.73 46.24±4.59 
LOOH 68.24±3.55 54.53±4.47* 57.48±3.63 65.50±4.66 54.23±6.64 67.33±4.23 
TBARS (n) 1.78±0.12 1.73±0.20 1.66±0.08 0.93±0.07* 1.03±0.10 0.92±0.07 
CD (n) 9.03±0.61 9.24±1.00 19.82±1.46* 11.73±0.42** 14.25±1.65 8.96±0.83# 
LOOH (n) 24.12±2.71 22.83±1.70* 20.32±2.53 13.85±1.19* 12.50±1.81 13.55±1.74 
TG+PL 2.92±0.20 2.42±0.20 2.92±0.17 4.85±0.48* 4.49±0.35 5.21±0.41 
PL 1.77±0.07 1.62±0.06 1.24±0.13 2.05±0.13 2.10±0.08 2.08±0.03 
TG 1.15±0.1 0.80±0.15 1.2±0.13 2.80±0.3** 2.39±0.3 3.13±0.4 
T C 2.96±0.13 2.79±0.08 2.83±0.05 3.06±0.19 3.43±0.33 2.92±0.07 
n/group 6 6 6 6 6 6 
 
CD: conjugated dienes, LOOH: lipid hydroperoxides, TBARS: thiobarbituric acid reactive 
substances, TC: total cholesterol, TG: triglycerides, PL: phospholipid; TBARS, LOOH and CD 
(µmol/L), (n): normalized value (absolute concentration divided by TG+PL) (µmol/mmol);  TC, TG 
and PL (mmol/L), *p<0.05 vs C, **p<0.01 vs C, ***p<0.001 vs C, #p<0.05 vs D, n=6/group.  
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Table 4.8 Serum lipid peroxidation from fasting rats 
Parameters 
CONTROL GROUP DIET GROUP 
C CM6 CM3 D DM6 DM3 
TBARS 12.35±0.34 13.15±0.40 14.42±0.9* 14.52±0.42* 14.55±1.86 14.11±0.26 
CD 94.27±4.08 95.42±2.16 86.50±1.71 96.44±2.39 91.07±1.27# 91.38±1.73@ 
LOOH 151.3 ±7.5 135.6 ±5.3 139.3 ±4.6 176.4 ±17.1 140.3 ±6.1@ 148.7 ±8.2 
TBARS(n) 6.54±0.26 6.79±0.36 7.49±0.30* 5.76±0.44 6.49±0.64 6.19±0.17 
CD(n) 50.08±2.80 49.24±2.33 45.48±2.39 38.58±3.39 41.38±2.49 40.06±0.79 
LOOH(n) 79.47±1.74 69.42±1.39* 73.09±4.01 67.34±2.25** 64.09±5.31 65.15±3.58 
TG+PL  1.90±0.07 1.95±0.09 1.92±0.08 2.64±0.27* 2.24±0.13 2.28±0.05 
TG 0.57± 0.07 0.58± 0.06 0.56± 0.05 1.05± 0.17** 0.79 ±0.12 0.83 ±0.09 
PL 1.33± 0.03 1.37± 0.05 1.35± 0.03 1.59± 0.10* 1.45± 0.02 1.44± 0.04 
TC 1.47± 0.08 1.49± 0.07 1.42± 0.03 1.54± 0.07 1.33± 0.06@ 1.30 ±0.06# 
n/group 7 6 6 7 6 6 
 
CD: conjugated diene, LOOH: lipid hydroperoxide, TBARS: thiobarbituric acid reactive substance; 
TC: total cholesterol, TG: triglycerides; PL: phospholipid; TBARS, LOOH and  CD (µmol/L); TC, 
TG and PL (mmol/L), (n): normalized value (absolute concentration divided by TG+PL) 
(µmol/mmol), *p<0.05 vs C; ** p<0.01 vs. C; #p<0.05 vs D, @:p=0.06-0.07 vs D, n=6-7/group.   
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4.3.3. EFFECTS OF  MELATONIN ON MYOCARDIAL FUNCTION 
The diet had no effect on basal (pre-ischaemic) myocardial function (table 4.9).  Melatonin 
administered for six or three weeks had no significant effect on pre-ischaemic functional 
parameters (coronary flow, aortic output, work total, systolic pressure) of the isolated rat hearts 
from the control as well as the diet animals (table 4.9).  During 30 min of reperfusion following 35 
min of regional ischaemia, the hearts from D had reduced aortic output percentage recovery 
compared to C group. Six weeks melatonin treated rats increased aortic output and cardiac output 
percentage recovery in D rats (p<0.05) while the coronary flow and systolic pressure percentage 
recovery remained unaffected  (fig.4.19-23).  
The aortic output, cardiac output and work total  percentage recovery were  increased significantly  
in the hearts isolated from D rats treated with melatonin for 3 weeks (fig.4.20-22). The systolic 
pressure and coronary flow was not affected by 3 and 6 weeks melatonin treatment (fig.4.19,23)  
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Figure 4.19 Percentage coronary flow recovery after 30 min reperfusion (n=6/group) 
Stellenbosch University  http://scholar.sun.ac.za
 138 
 
Table 4.9 Averaged values of pre-and post-ischaemic myocardial function  
 
CF: coronary flow (mL/min); AO: aortic output (mL/min); CO: cardiac output (mL/min); SP: systolic pressure (mmHg); Wtot: work total 
(mWatts); *p<0.05 (vs D), #p=0.06 (vs D), n=6/group. 
Time Parameters C CM6 CM3 D DM6 DM3 
Stabilization 
After 30 min 
 
Before ischaemia 
 
(Working heart) 
 
 
CF 16.20±0.56 16.83±0.52 15.00±1.0 16.32±0.88 15.33±0.62 14.83±0.61 
AO 36.20±1.4 39.63±2.14 38.33±3.65 29.43±2.18 30.83±2.15 35.33±2.61 
CO 52.40±1.41 56.46±1.65 53.30±6.62 45.76±2.73 46.17±2.71 50.17±3.08 
SP 90.33±1.49 90.57±0.92 90.50±2.07 88.14±2.65 89.17±2.77 90.83±1.85 
Wtot 9.39±0.60 11.37±0.39 10.73±1.23 8.70±1.12 9.22±0.84 10.38±0.91 
Reperfusion 
After 30 min 
 
Post-ischaemia 
 
(Working heart) 
 
 
 
CF 13.41±1.31 14.35±1.29 14.20±2.33 12.0±1.11 14.50±1.16 14.4±1.25 
AO 9.22±3.61(*) 11.35±3.04 12.20±4.43 4.14±1.42 8.04±1.02(*) 11.42±2.36(*) 
CO 22.63±4.78(#)  26.6±3.43 26.40±6.98 16.14±1.9 22.54±1.63(*) 25.67±2.88(*) 
SP 79.25±4.64 80.83±3.68 85.34±2.35 72.14±3.64 77.50±2.97 82.17±3.01 
Wtot 3.19±0.81 3.38±0.39 5.41±1.42 2.640±0.36 3.02±0.65 5.13±0.80(*) 
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Figure 4.20 Aortic output percentage recovery after 30 min reperfusion, *p<0.05 (DM3 vs D); 
#p<0.05 (DM6 vs D), &p<0.05 (C vs D), n=6/group 
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Figure 4.21 Cardiac output percentage recovery after 30 min reperfusion, *p<0.05 (D vs DM3); 
#p=0.08 (D vs DM6), n=6 /group 
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Figure 4.22 Work total percentage recovery after 30 min reperfusion, *p<0.05 (DM3 vs D), 
n=6/group. 
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Figure 4.23 Systolic pressure percentage recovery after 30 min reperfusion, n=6/group 
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4.3.4. EFFECT OF MELATONIN TREATMENT ON MYOCARDIAL INFARCT SIZE 
Figure 4.24 represents the effect of high calorie diet and melatonin administration on 
myocardial infarct size after exposure of the hearts to 35 min coronary ligation.  Hearts from 
the untreated high calorie diet (D) group had larger myocardial infarct sizes compared to 
control hearts (59.35±4.63% (D) vs. 42.03 ±6.27% (C), p<0.05).   
Myocardial infarct size was significantly reduced in six or three weeks treated rats compared to 
untreated (23.04 ±3.30 % for CM6 or 24.19±4.56% for CM3 vs 42.03 ±6.27% for C, p < 0.01), 
and 30.31±2.97% for DM6 or 22.74±2.87% for DM3 vs 59.35±4.63%  for D, p<0.001). 
Six weeks treatment reduced infarct size by 45.6% and 48.9% in C and D groups, respectively. 
In the three weeks melatonin treated C and D groups the reduction in infarct size averaged 
42.4% and 61.6%, respectively. 
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Figure 4.24 Effect of 3 and 6 weeks melatonin treatment on myocardial infarct size, *p<0.05 (C 
vs D); **p<0.01 (CM3 or CM6 vs C);***p<0.001 (DM3 or DM6 vs D), n=7-9/group. 
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4.3.5. EFFECT OF MELATONIN TREATMENT ON MYOCARDIAL SIGNALLING 
To determine by which signalling mechanism melatonin confers cardioprotection  in our animal 
model, we investigated the effect of melatonin on the reperfusion injury salvage kinases (RISK) 
(PKB/Akt, ERK (p42/p44)), glycogen synthase kinase-3 beta (GSK-3β) and signal transducer 
and activator of transcription 3 (STAT-3) (a member of the survivor activating factor 
enhancement (SAFE) pathway) using western blotting. To avoid contamination of ischaemic 
and non-ischaemic tissues which may occur with regional ischaemia we preferred to use a 
model of global ischaemia.  
We assessed baseline (non-perfused hearts) and post- ischaemic (after 10 and 30 min 
reperfusion) phosphorylation of the kinases.  Phosphorylation of STAT-3 was also evaluated in 
cytosolic and nuclear fractions at baseline and after 10 min reperfusion. PI3-K (p85) and 
GLUT-4 were also studied at baseline (non-perfused heart tissues). Results are presented in 
figures 4.25-54 and summarized in tables 4.10-11. Blots shown are representative. Each graph 
is accompanied by representative blots of total and phospho-proteins.  In the case of GLUT-4 
expression, a represantative blot of β-tubulin is included. 
4.3.5.1. PKB/Akt, ERK 42/44  and GSK3-β 
4.3.5.1.1. Baseline tissues 
• PKB/Akt  
In non-perfused tissues, the high calorie diet did not affect total PKB expression and 
phosphorylation in both groups (fig. 4.25-26).   
Melatonin administration for six and three weeks did not affect the total expression of PKB (fig. 
4.25-26). Hearts from 6 weeks melatonin treated groups exhibited a significant increase in 
PKB phosphorylation (Ser-473) (p<0.05) in both control and D groups. Three weeks treatment 
increased PKB phosphorylation in control but not in D group (fig.4.25). 
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Figure 4.25 Effect of six weeks melatonin treatment on baseline PKB phosphorylation,    
*p<0.05 (C vs CM3), #p<0.05 (D vs DM6), n= 6 hearts/group. 
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Figure 4.26 Effect of 3 weeks treatment on baseline PKB/Akt (Ser-473) phosphorylation, 
*p<0.05 (C vs CM3), representative of blots n=3hearts/group. 
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• ERK 42/44 
Feeding a high calorie diet did not affect the baseline phosphorylation pattern of ERK 42/44 
(fig.4.27).  Administration of melatonin had no significant effect on ERK 42/44 phosphorylation 
in either control or D groups (fig.4.27). 
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Figure 4.27 Effect of 6 weeks melatonin treatment on baseline ERK 42/44 phosphorylation, 
#p=0.06 (C vs CM6), n=6 hearts/group. 
• GSK-3β 
The high calorie diet had no effect on the expression and phosphorylation of GSK-3β when 
compared to those of controls. Administration of melatonin for six weeks increased GSK-3β 
phosphorylation in D but not in control groups (fig.4.28), while three weeks treatment increased 
GSK-3β phosphorylation in control group only (fig.4.29). 
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Figure 4.28 Effect of 6 weeks melatonin treatment on baseline GSK-3β phosphorylation, 
*p<0.05 (D vs DM6), n=6 hearts/group.  
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Figure 4.29 Effect of 3 weeks melatonin administration on baseline GSK3-β phosphorylation, 
*p<0.05 (C vs CM3), n=3 hearts/group. 
 
 
Stellenbosch University  http://scholar.sun.ac.za
 146 
 
4.3.5.1.2. The effects of ischaemia-reperfusion on kinases  
4.3.5.1.2.1. After 10 min reperfusion 
• Effects of six weeks treatment 
Similar to baseline, the high calorie diet did not affect the post-ischaemic PKB and ERK42/44 
expression and phosphorylation. Melatonin increased PKB and ERK42/44 activation in both 
control and D group (fig.4.30-31).  Hearts from the six weeks treated group had increased 
phosphorylation and activation of GSK-3β after 10 min reperfusion (fig.4.32) 
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Figure 4.30 Effect of 6 weeks melatonin treatment on PKB phosphorylation (10 min 
reperfusion), *p<0.05 (C vs CM6), #p<0.05 (D vs DM6), n=6 hearts/group. 
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o ERK 42/44 
 
Figure 4.31 Effect of 6 weeks melatonin treatment on ERK42/44 phosphorylation (10 min reperfusion), *p<0.05 (C vs CM6), 
#p<0.05 (D vs DM6), n=6 hearts/group. 
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Figure 4.32 Effect of 6 weeks melatonin treatment on GSK-3β phosphorylation (10 min 
reperfusion), *p<0.05 (C vs CM6), #p<0.05 (D vs DM6), n=6hearts/group. 
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• Effect of three weeks treatment 
Following 15 min global ischaemia, hearts from three weeks melatonin treated group had 
increased the phosphorylation of PKB and GSK3-β  (p<0.05) in both control and D groups 
(fig.4.33, 35). ERK42 was also activated in both groups while ERK44 was activated in control 
group only (fig.4.34). 
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Figure 4.33 Effect of 3 weeks melatonin treatment on PKB phosphorylation (10 min 
reperfusion), *p<0.05 (C vs CM3), #p<0.05 (D vs DM3), n=3-4 hearts/group 
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o ERK 42/44
 
 Figure 4.34 Effect of 3 weeks melatonin treatment on ERK42/44 phosphorylation (10 min reperfusion), *p<0.05 (C vs CM3), 
#p<0.05 (D vs DM3), n=6 hearts/group. 
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Figure 4.35 Effect of 6 weeks melatonin treatment on GSK-3β phosphorylation (10 min 
reperfusion), *p<0.05 (C vs CM3), **p<0.05 (D vs DM3), n=6 hearts/group. 
 
4.3.5.1.2.2. After 30 min reperfusion 
In this series, only the effects of six weeks treatment were evaluated. Hearts from the 
melatonin treated group showed increased PKB phosphorylation (Ser-473) in both groups 
(p<0.05) (fig. 4.36) without any effect on ERK 42/44 activation (fig.4.35). GSK3-β was 
phosphorylated in treated D group only (fig.4.36). 
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Figure 4.36 Effect of 6 weeks melatonin treatment on PKB phosphorylation (30 min 
reperfusion), *p<0.05 (C vs CM6), #p<0.05 (D vs DM6), n=3 hearts/group. 
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Figure 4.37 Effect of 6 weeks melatonin treatment on ERK42/44 phosphorylation (30 min 
reperfusion), n=3 hearts/group. 
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Figure 4.38 Effect of 6 weeks melatonin treatment on GSK-3β phosphorylation (30 min 
reperfusion), *p<0.05 (D vs DM6), n=3 hearts/group. 
4.3.5.2. Baseline PI3-K (p85) 
 Oral administration of melatonin for six or three weeks had no effect on baseline PI3-K 
phosphorylation and activation in both control and D groups (fig.4.39).   
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 Figure 4.39 Effect of 3 and 6 weeks melatonin on baseline PI3-K (p85) phosphorylation, n=4 
hearts/group. 
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4.3.5.3. Baseline GLUT-4 expression 
High calorie diet had no significant effect on GLUT-4 expression. However, 6 weeks but not 3 
weeks melatonin treatment increased the levels of expression in both diet and control (fig.4. 
40). 
 
Figure 4.40 Effect of melatonin on baseline GLUT-4 expression, *p<0.05 (D vs DM6 or C vs 
CM6), n=4 hearts/group.  
4.3.5.4. STAT-3 
4.3.5.4.1. Baseline tissues 
4.3.5.4.1.1. Effect of six weeks treatment 
The high calorie diet did not affect nuclear phosphorylated STAT-3 (Tyr-705 and Ser-727). 
However hearts from the D group had a decreased cytosolic STAT-3 phosphorylation (Tyr-
705) compared to control (not shown).  
Six weeks melatonin did not affect baseline cytosolic STAT-3 (Tyr-705) in any of the groups, 
Ser-727 was however increased (p<0.05) in control but not D group (fig.4.41-42).  While 
cardiac nuclear fractions from melatonin treated groups had increased phosphorylation at Tyr-
705, Ser-727 was not affected (fig.4.43-44). Six weeks treatment did not affect cytosolic or 
nuclear expression of total STAT-3. 
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Figure 4.41 Baseline STAT-3 phosphorylation (Tyr-705), cytosolic fraction, n=4hearts /group. 
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 Figure 4.42 Baseline STAT-3 phosphorylation (Ser -727), cytosolic fraction,*p<0.05 (C vs 
CM6), n=3 hearts/group. 
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Figure 4.43 Baseline STAT-3 phosphorylation (Ser-727), nuclear fraction, n=4hearts/group. 
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Figure 4.44 Baseline STAT-3 phosphorylation (Tyr-705), nuclear fraction, *p<0.05 (C vs CM6 
or D vs DM6), n=4 hearts/group. 
4.3.5.4.1.2. Effect of three weeks treatment 
Three weeks melatonin treatment did not affect the expression of STAT-3 in any of the groups.  
It, however, did increase cytosolic STAT-3 phosphorylation at Ser-727 (p<0.05) in D but not in 
control group (fig.4.45). There was no effect of melatonin treatment on cytosolic Tyr-705 in 
both control and D groups (not shown). However, it increased the nuclear phosphorylated 
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STAT-3 (Tyr-705) in D group only (fig.4.46). Nuclear Ser-727 was not affected in both groups 
(fig.4.47).  
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Figure 4.45 Baseline STAT-3 phosphorylation (Ser -727), cytosolic fraction, *p<0.05 (D vs 
DM3), n=3 hearts /group. 
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Figure 4.46 Baseline STAT-3 phosphorylation (Tyr-705), nuclear fraction, *p<0.05 (D vs DM3), 
n=4 hearts/group. 
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4.3.5.4.2. Effect of ischaemia-reperfusion on STAT-3 
4.3.5.4.2.1. Effect of six weeks treatment 
The diet had no effect on post-ischaemic STAT-3 expression and phosphorylation at 10 min 
reperfusion. Six weeks melatonin treatment increased post-ischaemic nuclear and cytosolic 
fractions of phosphorylated STAT-3 (Tyr-705) in both control and diet groups (p<0.05) 
(fig.4.47, 50).  However, nuclear fraction of phosphorylated STAT-3 Ser-727 was not affected 
by the treatment (fig.4.48) while the cytosolic fraction of STAT-3 Ser-727 showed increased 
phosphorylation in the control but not in diet group (fig.4.49). 
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Figure 4.47 STAT-3 phosphorylation (Tyr-705), nuclear fraction (10 min reperfusion), *p<0.05 
(C vs CM6), #p<0.05 (D vs DM6), n=3 hearts/group 
Stellenbosch University  http://scholar.sun.ac.za
 159 
 
C CM6 D DM6
0.0
0.1
0.2
0.3
0.4
0.5
p-STAT-3 (Ser-727)
Total STAT-3
NC
p-
/to
ta
l S
TA
T-
3(S
er
-
72
7)
 
ra
tio
 
(ar
bi
tra
ry
 
u
n
its
)
 
Figure 4.48 STAT-3 phosphorylation (Ser-727), nuclear fraction (10 min reperfusion), n=3 
hearts/group. 
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Figure 4.49 STAT-3 phosphorylation (Ser-727), cytosolic fraction (10 min reperfusion), 
#p=0.06 (C vs CM6), n=3 hearts/group 
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Figure 4.50 STAT-3 phosphorylation (Tyr 705), cytosolic fraction (10 min reperfusion), *p<0.05 
(C vs CM6), #p<0.05 (D vs DM6), n=3 hearts/group. 
4.3.5.4.2.2. Effects of three weeks treatment 
Three weeks melatonin treatment increased cytosolic STAT-3 (Ser-727) phosphorylation in the 
control but not in the diet group (p<0.05) while the nuclear STAT-3 (Ser-727) was not affected 
in any of the groups (fig.4.51, 53). Nuclear phosphorylated STAT-3 (Tyr-705) was increased by 
melatonin treatment in control but not in D groups (fig.4.53). Cytosolic STAT-3 (Tyr- 705) was 
not affected by three weeks melatonin treatment (fig.4.52). 
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Figure 4.51 STAT-3 phosphorylation (Ser-727), cytosolic fraction (10 min reperfusion), 
*p<0.05 (C vs CM3), n=3 hearts/group. 
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Figure 4.52 STAT-3 phosphorylation (Tyr-705), cytosolic fraction (10 min reperfusion), n=3 
hearts/group. 
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Figure 4.53 STAT-3 phosphorylation (Ser-727), nuclear fraction (10 min reperfusion), n=3 
hearts/group. 
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Figure 4.54 STAT-3 phosphorylation (Tyr-705), nuclear fraction (10 min reperfusion), *p<0.05 
(C vs M3), n=3 hearts/group. 
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Table 4.10 Summary of melatonin’s effect on PKB/Akt, ERK42/44, GSK-3β, PI3-K and GLUT-4 
 
Activity or expression: ↔: no significant effect, ↑: increase, ↗: a trend increase (melatonin vs drinking water), (ND): not determined, p: phospho-,       
WK: week, C: control, D: diet. Total expression of PKB/Akt, ERK42/44, GSK-3β and PI3-K were not affected by the treatment.   
               
 
Proteins 
Baseline 10 min reperfusion 30 min  reperfusion 
Control group Diet group Control group Diet group Control group Diet group 
6WK 3WK 6WK 3WK 6WK 3WK 6WK 3WK 6WK 3WK 6WK 3WK 
PKB/Akt p (Ser-473) ↑ ↑ ↑ ↔ ↑ ↑ ↑ ↑ ↑ ND ↑ ND 
ERK42/44 
p42 ↔ ND ↔ ND ↑ ↑ ↑ ↑ ↔ ND ↔ ND 
p44 ↗ ND ↔ ND ↑ ↑ ↑ ↔ ↔ ND ↔ ND 
GSK3-β p (Ser-9) ↔ ↑ ↑ ↔ ↑ ↑ ↑ ↑ ↔ ND ↑ ND 
PI3-K p (p85) ↔ ↔ ↔ ↔ ND ND ND ND ND ND ND ND 
GLUT-4 Expression ↑ ↔ ↑ ↔ ND ND ND ND ND ND ND ND 
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Table 4.11 Summary of melatonin’s effect on STAT-3 activation 
 
Tyr: tyrosine, Ser: serine, act: activation (phospho-/total ratio), ↔: no significant effect,                     
↑: increase, ↗: (p=0.06) a trend increase (melatonin vs drinking water). 
  
Samples /collection Group STAT-3 Nuclear fraction 
Cytososlic 
fraction 
 
Baseline (non-
perfused hearts) 
6 weeks 
Control 
Tyr- 705 act ↑ ↔ 
Ser-727 ↔ act ↑ 
Diet 
Tyr -705 act ↑ ↔ 
Ser- 727 ↔ ↔ 
3 weeks 
Control 
Tyr- 705 ↔ ↔ 
Ser-727 ↔ ↔ 
Diet 
Tyr -705 act ↑ 
 
Ser-727 ↔ act ↑ 
Post-ischaemic 
hearts (at 10 min 
reperfusion) 
6 weeks 
Control 
Tyr- 705 act ↑ act ↑ 
Ser-727 ↔ a trend↗ 
Diet 
Tyr- 705 act ↑ act ↑ 
Ser-727 ↔ ↔ 
3 weeks 
Control 
Tyr- 705 act ↑ ↔ 
Ser -727 ↔ act ↑ 
Diet 
Tyr -705 ↔ ↔ 
Ser -727 ↔ ↔ 
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4.4. DISCUSSION 
In the present study we investigated the effects of 3 and 6 weeks melatonin treatment on 
myocardial IRI in a rat model of diet-induced obesity and insulin resistance.   
The key findings are as follows:  
1. The high-calorie diet caused significant increases in body weight gain, visceral 
adiposity, fasting blood glucose, serum insulin, triglycerides, HOMA-IR index and a 
concomitant reduction in serum adiponectin levels. These changes were associated 
with increases in serum TBARS levels, cardiac hypertrophy as well as larger 
myocardial infarct size after exposure to IRI.  
2. Three weeks melatonin administration to obese and insulin resistant rats reduced 
insulin resistance and protected the heart against ex vivo myocardial IRI independently 
of body weight gain and visceral adiposity. These effects were associated with 
increased activation of baseline myocardial STAT-3 and the RISK pathway during 
reperfusion.   
3. Six weeks melatonin treatment also protected the heart against IRI with similar 
signalling effects as those of 3 weeks treatment but with additional phosphorylation of 
PKB/Akt and GSK-3β at baseline and STAT-3 during reperfusion. The baseline 
expression of myocardial GLUT-4 was also increased while PI3-K (p85) 
phosphorylation was not affected. 
4.4.1 DIET-INDUCED OBESITY AND INSULIN RESISTANCE  
Long-term imbalance between energy consumption and expenditure induces obesity 
(Swinburn et al., 2009).  Consistently, rats fed a high calorie diet consumed more food than 
their age matched controls (fig.4.10) and became obese due to hyperphagia (du Toit et al., 
2008; Nduhirabandi et al., 2011; Flepisi et al., 2013; Huisamen et al., 2013).  Increased body 
weight gain was associated with excess visceral fat accumulation and a concomitant increase 
in circulating TG as well as systemic insulin resistance as indicated by increases in the 
Stellenbosch University  http://scholar.sun.ac.za
  
166 
 
HOMA-IR index, fasting blood glucose and serum insulin levels (fig.4.3) as previously reported 
(Flepisi et al., 2013; Huisamen et al., 2013). Because the obesity-inducing diet was essentially 
liquid compared to the standard rat chow, water consumption of obese rats was consequently 
reduced compared to control animals (fig.4.9).  
Diet-induced visceral fat accumulation is an important factor in the development of insulin 
resistance and MetS (Grundy, 2012). In genetically and environmentally susceptible 
individuals, chronic overnutrition with an excessive energy intake and low energy expenditure 
results in adipocyte hypertrophy and visceral fat accumulation, due to saturation of the 
expansion capacity or inability of subcutaneous adipose tissue to expand (Lionetti et al., 2009; 
Bluher et al., 2013).  An increase in adipose tissue causes elevation of circulating free fatty 
acids (FFA), altered adipose tissue derived factors and eventual ectopic fat accumulation 
which contribute to a proinflammatory (elevated TNF-α, IL-6) and a prothrombotic state 
(Grundy, 2012), the hallmarks of insulin resistance. In this regard, an increase in FFA may 
contribute to elevated glucose levels as follows: induction of insulin resistance (inhibition of 
insulin-mediated glucose uptake pathways) in skeletal muscle, impairment of beta-cell function 
(lipotoxicity) as well as an increase in hepatic glucose output (Grundy, 2012). In addition to 
lipotoxicity, hyperglycaemia may, over time, contribute to oxidative stress (Furukawa et al., 
2004; Vincent and Taylor, 2006; Galili et al., 2007; Chess and Stanley, 2008; Singh et al., 
2011). 
In addition to the above, diet-induced obesity and insulin resistance are associated with 
alterations in adipose-tissue derived hormones (adipokines dysregulation) including, amongst 
others, reduced levels of circulating adiponectin (hypoadiponectinaemia) (Piya et al., 2013).  
Adiponectin is one of the most abundant adipose tissue-secreted hormones and has been 
shown to have many physiological effects including enhancing insulin sensitivity in various 
tissues, vasodilator, anti-apoptotic, anti-inflammatory and anti-oxidative activities in both 
cardiac and vascular cells [for review, see (Hui et al., 2012)].  Additionally, adiponectin may 
act directly or indirectly on the brain (via potentiation of the central actions of leptin) and 
mediate weight loss by increasing energy expenditure via thermogenesis without altering food 
Stellenbosch University  http://scholar.sun.ac.za
  
167 
 
intake (Qi et al., 2004). A decrease in serum adiponectin levels (fig.4.3) was also observed in 
the diet animals in the present study, as consistently reported in obese animals and humans 
(Arita et al., 1999; Weyer et al., 2001; Kadowaki et al., 2008)  
 Furthermore, diet-induced obesity was associated with glucose intolerance (fig.4.15). The 
development of glucose intolerance is a complex and multifactorial process involving central 
and peripheral regulation (e.g., hypothalamus, liver, adipose tissue, pancreas, muscles) [for 
review, see (Norris and Rich, 2012)]. The present study showed that reduced glucose 
tolerance is associated with insulin resistance and low circulating levels of adiponectin (fig.4.3) 
as repeatedly indicated in humans and animal studies [for reviews, see (Kadowaki et al., 
2008; Ye and Scherer, 2013)].  
Indeed, as it will be further discussed below, improvement in circulating adiponectin may be 
beneficial in obesity and in cardiovascular health (Agil et al., 2012b; Hui et al., 2012). In view 
of its pleiotropic actions, although further research is required, circulating adiponectin levels is 
suggested as a potential clinical marker of metabolic diseases in general (Mather and 
Goldberg, 2013) and myocardial infarction in particular (Persson et al., 2010). 
4.4.2 MELATONIN’S EFFECTS ON OBESITY AND INSULIN RESISTANCE 
4.4.2.1 Effects of six weeks treatment 
• Obesity 
Convincing evidence exists for a role of melatonin in body weight regulation (Korkmaz et al., 
2009b; Tan et al., 2011; Reiter et al., 2012). In the present study, melatonin administered for 
six weeks reduced body weight gain in both control and diet rats with no effect on food or 
water consumption (fig.4.9-10). This is in agreement with previous studies in obese [for 
review, see (Nduhirabandi et al., 2012)] and non-obese (Bojkova et al., 2006; Kassayova et 
al., 2006) animals. However, melatonin treatment has also been shown to affect the food 
intake in obese rabbits (Hussein et al., 2007) and a rat model of ovariectomized-induced 
obesity (Sanchez-Mateos et al., 2007; Baxi et al., 2012). These controversies may be due to 
differences in animal models (Nduhirabandi et al., 2012). 
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The reduction of body weight gain following long-term melatonin treatment is associated with a 
decrease in visceral fat mass and concomitant improvement in lipid profile (Nduhirabandi et 
al., 2011; Cardinali et al., 2013). Surprisingly, in the present study, body weight reduction by 
six weeks melatonin treatment was not associated with significant changes in visceral fat 
mass and lipid profile as indicated by circulating TG and total cholesterol levels (fig.4.4; table 
4.7). It is well established that elevated circulating TG correlates with visceral adiposity 
(Tchernof and Despres, 2013). The dissociation between body weight gain and visceral 
adiposity could be due to the dosage and duration of the treatment as previously 
demonstrated (Rasmussen et al., 2001). For example, a reduction in body weight gain and 
visceral fat mass following six weeks melatonin treatment has been observed in studies using 
a higher concentration of 10mk/kg/day (Agil et al., 2011; Agil et al., 2012b), 2.5 times the 
dosage used in the present study.  Other examples include studies where melatonin  was 
administered for longer periods than 6 weeks such as 12 weeks (0.4µg/mL, oral) (Wolden-
Hanson et al., 2000), 12 weeks  (0.5 mg/kg, oral) (Zanuto et al., 2013), 16 weeks (4mg/kg/day, 
oral) (Nduhirabandi et al., 2011) and  24 weeks (4µg/mL, oral) (Kassayova et al., 2006). In a 
number of studies, melatonin was administered by injection for 4 weeks (1mg/kg/day, 
subcutaneous) in obese rabbits (Hussein et al., 2007), 8 weeks (10mg/kg/day, intraperitoneal) 
(She et al., 2009) or 10 weeks (5mg/kg/day, intraperitoneal) (Wan et al., 2013) in obese rats. 
Collectively, in these studies, weight gain reduction was associated with visceral adiposity 
reduction. 
However, in agreement with the present study, 8 weeks oral melatonin administration to obese 
rats at 0.5mg/kg/day (Zanuto et al., 2013) or 5% fructose-fed rats at 20µg/mL (Cardinali et al., 
2013) or obese mice (100mg/kg/day)(Sartori et al., 2009) had no effect on body weight gain, 
visceral adiposity and TG levels. Furthermore, although three weeks melatonin treatment was 
able to reduce the body weight gain at the high dose of 30mg/kg/day (twice per day, gavage), 
it had no significant effect on visceral adiposity (Prunet-Marcassus et al., 2003), supporting the 
dissociation of body weight gain and visceral adiposity as observed in the present study. 
Thus, it appears that the effects of melatonin may vary depending on dosage, duration of 
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treatment and type of animal model used as well as the mode of administration (Nduhirabandi 
et al., 2012).   
The mechanism of body weight reduction by melatonin is complex and still not clear. Several 
studies have indicated that melatonin-induced body weight reduction may result from the 
lowering of circulating TG and subsequent decrease in body fat content (Nduhirabandi et al., 
2011; Agil et al., 2012b). This is supported by in vitro studies where melatonin treatment of 
adipocytes inhibited their differentiation, TG accumulation and hypertrophy (Sanchez-Hidalgo 
et al., 2007; Alonso-Vale et al., 2009)(Alonso-Vale et al., 2009). The effect of melatonin on 
lipids is discussed below in the section on lipid peroxidation.  Other mechanisms of weight 
loss would include the melatonin-induced loss of skeletal muscle since visceral fat mass 
remained unchanged.  However, as far as we know, there is no available report on this topic.  
Furthermore, the observed body weight loss could be related to melatonin-induced 
improvements in the compromised insulin and leptin signalling associated with obesity 
(Nishida et al., 2003; Sartori et al., 2009), accompanied by modulation of plasma levels of 
insulin, glucose, TG, cholesterol, leptin and adiponectin (Ríos-Lugo et al., 2010; Agil et al., 
2011). It has been reported that melatonin, leptin and insulin activated the same intracellular 
signalling pathways namely PI3-K and STAT-3 (Carvalheira et al., 2001; Anhe et al., 2004; 
Picinato et al., 2008). Thus, melatonin may reduce body weight gain by mimicking the actions 
of insulin and leptin signalling via cross-talk between these pathways.    
• Insulin resistance  
Insulin resistance refers to the condition associated with an impaired or decreased cellular 
sensitivity to insulin actions. In the present study, the body weight gain reduction by melatonin 
was associated with lowering insulin resistance as shown by the reduction in fasting insulin 
levels and HOMA-IR index (fig.4.6; fig.4.12-13). This is in agreement with previous 
observations in our laboratory (Nduhirabandi et al., 2011) and elsewhere (Wolden-Hanson et 
al., 2000; She et al., 2009; Wan et al., 2013).  
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However, how melatonin improves insulin sensitivity or reduced insulin levels in obesity is also 
not clear. Although the causal role between visceral adiposity and insulin resistance is 
uncertain (Knudsen et al., 2012), it is widely accepted that weight loss decreases visceral fat 
and improves insulin sensitivity (Tchernof and Despres, 2013). Since the observed body 
weight reduction and improved insulin sensitivity were not associated with visceral fat 
reduction and improvement in lipid profile (fig.4.6-7; fig.4.13) in the present study, the 
possibility exists that other mechanisms may be involved, for example, increased plasma 
levels of adiponectin (Yang et al., 2001). Interestingly, the improvement in insulin sensitivity 
associated with increased adiponectin levels (fig.4.12-14) has also been reported by others 
(Agil et al., 2012b; Kitagawa et al., 2012).  As indicated above, adiponectin plays an important 
role in glucose homeostasis (Ye and Scherer, 2013).  Apart from its insulin sensitizing actions 
in the liver and peripheral tissues, adiponectin has other beneficial effects associated with 
cardiovascular protection [for reviews, see (Kadowaki et al., 2008; Hui et al., 2012)].   
Melatonin has also been shown to restore insulin-induced vasodilation to skeletal muscle, a 
major site of glucose utilization (Sartori et al., 2009). 
Melatonin has also been shown to inhibit insulin secretion, thereby contributing to the reduced 
circulating insulin levels (Picinato et al., 2002; Peschke, 2008; Peschke et al., 2012). In these 
events MT1/MT2 receptors are highly involved.  These receptors are expressed in pancreatic 
islets (Peschke et al., 2000) and since insulin levels exhibit a nocturnal drop, its production 
has been suggested to be controlled, at least in part, by melatonin (Mulder et al., 2009).  
Other contributing hormonal interactions include catecholamines as well as glucagon [for 
review, see (Peschke et al., 2013)].  While catecholamines regulate the interaction between 
melatonin and insulin levels, melatonin also stimulates glucagon secretion by the pancreatic 
α-cells and its actions in the liver (Bahr et al., 2011; Peschke et al., 2013).  
In addition to the improvement of insulin sensitivity, the brown adipose tissue has recently 
emerged as important role player in the effects of melatonin on body weight gain [for review 
see (Tan et al., 2011)].   In this regard, oral melatonin supplementation induced browning of 
the inguinal white adipose tissue in ZDF rats (Jiménez-Aranda et al., 2013).  Melatonin-
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induced brown adipose tissue activation is thought to reduce body weight through increased 
thermogenesis (Tan et al., 2011) without affecting locomotor activity (Jiménez-Aranda et al., 
2013). Concerning the latter, other reports have indicated that body weight reduction by 
melatonin treatment was associated with an increase in physical activity (Wolden- Hanson et 
al., 2000; Terron et al., 2013).  
Furthermore, there is strong evidence for the involvement of MT receptors in melatonin’s 
effects. Indeed, MT receptors have been identified in the central and peripheral organs 
involved in body metabolism including brain, liver, pancreas, skeletal muscle and adipose 
tissue (Brydon et al., 2001; Muhlbauer et al., 2009). Importantly, removal of the MT1 receptor 
significantly impairs the ability of mice to metabolize glucose and probably induces insulin 
resistance in these animals (Contreras-Alcantara et al., 2010).  It is suggested that the overall 
effects of melatonin on obesity and insulin resistance may be partly mediated through MT 
receptors, in addition to the activation of the sympathetic nervous system via hypothalamic 
receptors and subsequent effects on lipolysis and adipose tissue plasticity (Song and 
Bartness, 2001; Bartness et al., 2002; Nduhirabandi et al., 2012).  
Moreover, as noticed by others (Karamitri et al., 2013), melatonin's potential weight-lowering 
effects and the positive impact of melatonin in ameliorating metabolic-associated 
complications have never been tested in humans.  
4.4.2.2  Effect of three weeks melatonin treatment 
As discussed above, long-term melatonin treatment has been widely shown to reduce body 
weight and improve metabolic abnormalities associated with obesity (reviewed by 
Nduhirabandi et al., 2012). In control rats, three weeks melatonin treatment was able to 
reduce the body weight and visceral fat (fig.4.6) in contrast to six weeks treatment which had 
no effect on visceral fat. In this context, the starting point of treatment may be crucial. For 
example, administration of  melatonin (oral, 0.2 µg /mL, drinking water) for 10 weeks, starting 
at 3 months of age, in contrast to 6 months, failed to suppress intra-abdominal fat deposition 
as well as insulin levels (Rasmussen et al., 2001), indicating age-dependent effects of 
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melatonin. Interestingly, body weight loss was associated with visceral fat mass reduction 
(fig.4.6). 
However, in obese rats, the body weight gain and visceral fat mass were not affected by 3 
weeks treatment (fig.4.4; fig.4.5). Since melatonin effects are dose and time-dependent, this 
may be due to the short period of treatment as previously indicated. In this regard, we found 
that 6 weeks reduced body weight gain (fig.4.4).  Previous studies have also indicated that 
body weight loss was only observed from the third week of melatonin treatment in control rats 
(20µg/mL, oral) (Terrón et al., 2013) and rats fed a high fat diet (25µg/mL, oral) (Rios-Lugo et 
al., 2010). Furthermore, 3 weeks melatonin administration at high dose (30mg/kg/day, 
gavage) has been shown to reduce body weight gain but not visceral adiposity of rats fed a 
high-fat diet (Prunet-Marcassus et al., 2003).  Importantly, even at high dose (100mg/kg/day), 
oral melatonin treatment for 8 weeks was not able to reduce the body weight of obese mice 
(Sartori et al., 2009). 
Following melatonin treatment, enhancement of insulin sensitivity, as shown by decreased 
insulin levels and HOMA-IR index, was not associated with body weight and visceral fat loss in 
obese animals (fig.4.5,12-13) as previously reported in obese mice (Sartori et al., 2009) and 
rats (Zanuto et al., 2013). This may also indicate that amelioration of insulin actions preceded 
the significant reduction in body weight gain or visceral adiposity (Sartori et al., 2009; Zanuto 
et al., 2013). In this regard, various mechanisms such as the inhibitory actions of melatonin on 
insulin secretion (Peschke et al., 2013) as well as its insulin-mimicking/sensitizing activities 
(Carvalheira et al., 2001; Anhe et al., 2004; Picinato et al., 2008; Zanuto et al., 2013) may 
have been involved as discussed above. 
4.4.3 MELATONIN AND GLUCOSE TOLERANCE 
 To further characterize the effect of melatonin on insulin sensitivity, we performed an 
intraperitoneal glucose tolerance test. This reflects the efficiency of the body to dispose of 
glucose after a glucose load or meal and is closely associated with insulin sensitivity and 
secretion (Norris and Rich, 2012). Experimental evidence in pinealectomized, obese, insulin 
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resistant, diabetic animals has supported the role of melatonin in glucose homeostasis (for 
review, see (Peschke and Muhlbauer, 2010; Nduhirabandi et al., 2012; Karamitri et al., 2013; 
Peschke et al., 2013). This has also been confirmed in epidemiological studies (Bouatia-Naji 
et al., 2009; Liu et al., 2010; Mussig et al., 2010; Tam et al., 2010; Dietrich et al., 2011; 
Reinehr et al., 2011; Song et al., 2011; Nagorny and Lyssenko, 2012).  
The effects of melatonin on glucose homeostasis are further discussed in chapter 6.  Only 
blood glucose levels will be discussed here. 
As discussed above, consistent with previous studies, melatonin treatment  reduced the levels 
of insulin and HOMA-IR index  in the insulin resistant rats to control (Bertuglia and Reiter, 
2009; Sartori et al., 2009; Baxi et al., 2012; Kitagawa et al., 2012; Cardinali et al., 2013) 
without affecting blood glucose levels (Sartori et al., 2009; Nduhirabandi et al., 2011; Zanuto 
et al., 2013).  Accordingly, six week melatonin administration did not affect the glucose 
tolerance (fig.4.16A, B) while three weeks improved glucose tolerance in the diet group 
(fig.4.16A, B). This difference is difficult to explain without further investigation. However, 
when comparing three weeks to 6 weeks treatment there was no significant difference 
between these two treatments. This may also reflect the fasting blood glucose levels where a 
slight diminution of blood glucose was observed after 3 weeks treatment (fig.4.11).  At high 
dose (10 mg/kg/day), intraperitoneal injection of melatonin for 2 weeks ameliorated glucose 
tolerance and insulin sensitivity in obese diabetic mice with an increase in hepatic glycogen 
(Shieh et al., 2009).  In control animals, 6 or 3 weeks melatonin treatment did not affect the 
blood glucose levels as well as glucose tolerance as previously reported (Sartori et al., 2009; 
Kitagawa et al., 2012; Cardinali et al., 2013).  
4.4.4 MELATONIN AND LIPID PEROXIDATION 
Increased body fat accumulation and related dyslipidaemia are associated with increased 
systemic and tissue oxidative stress (Furukawa et al., 2004; Vincent and Taylor, 2006; Galili et 
al., 2007; Singh et al., 2011) and it is generally accepted that obesity may be a state of chronic 
oxidative stress (Vincent et al., 2007; Codoner-Franch et al., 2009; Wu et al., 2009).  Lipid 
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peroxidation is an important marker of oxidative stress, a condition where cell damage occurs 
as result of accumulation of reactive oxygen/nitrogen species (ROS/RNS) due to an imbalance 
between their production and their removal by antioxidants (Singal et al., 1998; Hansel et al., 
2004; Grattagliano et al., 2008). In the present study, we evaluated serum lipid peroxidation 
parameters including conjugated dienes (CD), lipid hydroperoxide (LOOH), and thiobarbituric 
acid reactive substances (TBARS) as well as serum lipids including total cholesterol (TC), 
triacylglycerol or triglycerides (TG), and phospholipids (PL). Although fasting lipids are strongly 
recommended to assess the cardiovascular risks, (NCEP, 2002; Nigam, 2011), non-fasting 
measurements appear to be clinically more convenient than fasting and may also be used 
(Nigam, 2011). 
4.4.4.1 Effect on blood lipids 
Regardless of the feeding state of the animals, the high calorie diet elevated TG levels while 
having no effect on TC levels (tables 4.8-9). Melatonin treatment had no significant effect on 
these parameters except a reduction in TC levels observed in the fasting diet rats after 3 
weeks treatment. The absence of effects on TG levels may be due to the duration of treatment 
as indicated above. Previous long-term studies have consistently demonstrated that melatonin 
reversed or attenuated alterations in circulating lipids in non-obese hypercholesterolemic rats 
(Hoyos et al., 2000; Hussain, 2007) and this was confirmed in various rat models of obesity 
(Prunet-Marcassus et al., 2003; Agil et al., 2011; Nduhirabandi et al., 2011; Nduhirabandi et 
al., 2012; Zhang et al., 2012). This has also been demonstrated in obese rabbits (Hussein et 
al., 2007) and has been associated with a reduction in TG and increased high-density-
lipoprotein (HDL-c) as well as lowering of low-density-lipoprotein (LDL-c) cholesterol, with 
(Hussein et al., 2007; She et al., 2009) or without (Ríos-Lugo et al., 2010; Agil et al., 2011) 
effect on total cholesterol levels. Collectively, these studies strongly supported the potential 
beneficial effect of melatonin supplement in improving lipid metabolism. 
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4.4.4.2 Effect on lipid peroxidation parameters 
The results obtained highlight the differences between serum samples from fasting and non-
fasting animals, which  in turn, could have a profound effect on the interpretaion of the data.  
We will limit our discussion to the absolute (and not normalized) values obtained.  
• Fasting state 
In the fasting condition, the high calorie diet  increased  the serum TBARS compared to 
control while other lipid peroxidation parameters (CD and LOOH) were not affected (fig 4.18). 
This was associated with increases in TG levels and, because of short term period, six weeks 
melatonin treatment had no effect on serum TBARS (fig.4.18B). However, it reduced the CD in 
the diet but not in the control rats (fig.4.18D). This CD reduction may be indicative of the 
antioxidant activity of melatonin, or due to an effect of melatonin on unsaturated fatty acid 
metabolism (Hoyos et al., 2000; Nishida et al., 2002).  
Although three weeks melatonin treatment had no effect on CD and LOOH (fig.4.18C,D), 
surprisingly, it increased TBARS in control but not in diet rats (fig.4.18.B). This increase is 
difficult to explain and needs further investigation. Whether it is a feature of transient effects as 
previously reported during the first weeks of melatonin treatment and considered as 
stabilization time (Puchalski et al., 2003a), will need to be elucidated.  
Results reported in the literature regarding the effect of melatonin on lipid peroxidation are 
controversial and should be interpreted with care due to multiple activities of melatonin.  In this 
regard, melatonin has been shown to elicit pro-free radical effects on a set of normal or tumor 
leukocytes but with no effect on oxidative stress, as shown by absence of protein 
carbonylation, preservation of viability and regular proliferation rate (Radogna et al., 2009).  
Additionally, melatonin treatment was recently shown to decrease and increase H2O2 levels of 
the liver in the aged  and young rats, respectively (Güney et al., 2013). These controversial 
effects were further supported by other studies in which it was shown that prolonged melatonin 
administration for 3 but not 6 months increased lipid peroxidation (malondialdehyde) levels in 
the liver of male and female young (fasted) rats (Kasayova et al., 2006). 
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• Non-fasting state 
In fed conditions, a high calorie diet was associated with a marked increase in CD levels 
(fig.4.17D) while six weeks melatonin treatment had no effect on serum TBARS (fig.4.17B). 
However, this was associatied with reduction in CD and LOOH levels in control rats 
(fig.4.17.C, D).  As mentioned above, these decreases in lipid peroxidation products could be 
indication of antioxidant activities of melatonin or due to its effect on lipid metabolism (Nishida 
et al., 2002). For example, melatonin has been shown to  delay the onset of the propagation 
phase for conjugated dienes (Bonnefont-Rousselot et al., 2003).  
Three weeks melatonin treatment did not affect TBARS and LOOH levels (fig.4.17A, fig.4.17C) 
but, interestingly, caused a marked increase in CD in control animals (fig.4.17D). These 
observations are difficult to explain and further investigation is warranted. Importantly, 3 weeks 
melatonin treatment increased CD in the non-fasting state while increasing TBARS in the 
fasting state in controls. This may be indicative of the pro-oxidant activity of melatonin as 
previous indicated (Osseni et al., 2000; Guney et al., 2013). 
Collectively, as shown by the reduction in CD and LOOH levels, melatonin manifested some 
features of its antioxidant activities (Korkmaz et al., 2009a; Bonnefont-Rousselot and Collin, 
2010). Probably due to the short-term treatment, TG levels were not affected. However,  it 
appears that the cardioprotective effects observed in the present study are unlikely to be 
related to melatonin’s effects on systemic lipid peroxidation. Therefore, an evaluation of lipid 
peroxidation at tissue level is further needed. Similar results were also reported in non-fasted 
serum following chronic melatonin treatment (16 weeks) which had no effect on myocardial 
and serum glutathione (Nduhirabandi et al., 2011). 
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4.4.5 MELATONIN, THE HEART AND OBESITY  
This section includes the effects of melatonin on cardiac morphology and function (in normoxic 
conditions) and myocardial IRI. 
4.4.5.1 Melatonin and cardiac morphology in obesity 
Obesity and insulin resistance are associated with cardiac remodelling and hypertrophy [for 
review, see (Abel et al., 2008; Ashrafian et al., 2011)].  Cardiac hypertrophy refers to an 
increase in the size of the entire heart, but more commonly, alterations occur in specific 
cardiac chambers relative to body size (Rider et al., 2011). It is traditionally evaluated by the 
determination of absolute heart weight (HW), relative heart weight [i.e., heart weight to body 
weight (HW/BW) ratio] or heart weight to tibial length (HW/TL) ratio.  HW/TL ratio appears to 
be a more sensitive indicator of cardiac hypertrophy compared to HW/BW which did not show 
any difference between control and obese groups (fig.4.6-8). Consistently with a previous 
study (Flepisi et al., 2013), in the present study, hearts from rats fed a high calorie diet 
exhibited increases  in the absolute HW and HW/TL ratio compared to their age matched 
controls (fig.4.7).   
The development of cardiac hypertrophy in obesity and insulin resistance involves numerous 
factors including hemodynamic changes as well as metabolic (fuel availability) and humoral 
(such as oxidative stress, adipokines and inflammation) factors (Abel et al., 2008).  In this 
regard, it has been demonstrated that cardiac hypertrophy was associated with increased 
oxidative stress in hyperthyroidism (Ghosh et al., 2007) and leptin resistance in obesity 
(Majane et al., 2009; Rider et al., 2012). In addition to increased serum TBARS (in the fasting 
condition), low circulating adiponectin and elevated fasting blood glucose levels as well as 
insulin resistance observed in the present study may have contributed to development of 
cardiac hypertrophy (Sundström et al., 2000; Velagaleti et al., 2010).  However, since cardiac 
hypertrophy is caused by multiple factors including the observed metabolic abnormalities, 
three or six weeks of melatonin treatment was seemingly not sufficient to confer a significant 
effect via the improvement of these metabolic factors. Conversely, 16 weeks melatonin 
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treatment prevented obesity related metabolic abnormalities and reduced the absolute HW as 
well as HW/BW ratio in both control and diet groups (Nduhirabandi et al., 2011).  
Despite the absence of melatonin’s effects on other hypertrophic parameters in both groups 
(fig.4.6-8), three weeks treatment increased the HW/BW ratio (fig.4.8) in agreement with a 
previous study (Bojkova et al., 2006). However, this increase could be due to the reduction in 
body weight. In agreement with our findings, 4 days of melatonin treatment (4mg/kg/day, 
intraperitoneal injection) to pinealectomized rats did not affect their heart weights due to the 
short period of treatment (Mizrak et al., 2004).  
4.4.5.2 Melatonin and myocardial function in obesity   
 Several epidemiological studies have consistently indicated that obesity and insulin 
resistance negatively affect cardiac function in various degrees from subclinical to clinical 
dysfunction (Gray and Kim, 2011; Abel et al., 2012; Narumi et al., 2012).  Globally, the extent 
of impairment of heart function paralleled the degree of obesity (de Divitiis et al., 1981; 
Sokmen et al., 2013). This has been demonstrated in animal models of diet-induced obesity in 
vivo, in  isolated hearts as well as in cardiomyocytes (Abel et al., 2008).  However, 
controversial results have also been obtained in this regard.   This can possibly be due to the 
differences in animal models.  Our laboratory has previously reported  that rats fed a high 
calorie diet had a depressed ex vivo basal function compared to their age-matched controls 
(du Toit et al., 2008; Nduhirabandi et al., 2011). However, data obtained in this study indicate 
that a high calorie diet had no effect  on  ex vivo myocardial function in agreement with other 
previous findings in obese rats (Wensley et al., 2013) and mice (Calligaris et al., 2013). An 
explanation for these variable responses is not readly available.  
Both six and three weeks melatonin treatments had no significant effects on ex vivo basal 
myocardial function of hearts from both control and obese rats (table 4.9). This is in 
agreement with previous studies ex vivo (Lochner et al., 2006; Nduhirabandi et al., 2011, 
Lamont et al., 2011) and in vivo (Sahna et al., 2005) in non-obese rats. The lack of effect of 
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melatonin treatment  (compared with basal function  after 16 weeks melatonin treatment 
(Nduhirabandi et al., 2011), is probably due to the short administration period.    
4.4.5.3 Melatonin and myocardial IRI in obesity  
Reperfusion injury is characterized by (i) myocardial dysfunction, (ii) arrhythmias and (iii) cell 
death or myocardial infarction [for review, see (Opie, 2004)].  Here, only myocardial functional 
recovery and infarct size are discussed. 
4.4.5.3.1 Myocardial IRI , obesity and insulin resistance 
As discussed before, convincing evidence exists for the association between obesity and 
ischaemic heart disease (Ranjith et al., 2007; Fedorowski et al., 2009; Prasad et al., 2010). In 
addition, the human diabetic  heart is highly susceptible to myocardial IRI (Cubbon et al., 
2013). However, experimental data on the impact of obesity and insulin resistance on 
myocardial IRI are controversial, reporting larger, smaller or similar myocardial infarct sizes in 
animal models of obesity and insulin resistance when compared to their age matched controls 
[for review, see (Miki et al., 2012; Whittington et al., 2012)]. Thus, the contribution of obesity 
and insulin resistance to IRI appears complex and subject to many confounding factors. It may 
reflect  the clinical complexity of obesity (Diercks et al., 2006; Romero-Corral et al., 2006).  
Hearts from rats fed a high calorie diet showed a significant increase in  myocardial infarct 
size  after coronary artery ligation ex vivo (fig 4.24) confirming previous  in vivo (Clark et al., 
2011; Wensley et al., 2013) and  ex vivo (du Toit et al., 2008; Essop et al., 2009; Huisamen et 
al., 2011; Nduhirabandi et al., 2011) data. Similar observations were made in mice fed a high-
fat diet (Thakker et al., 2008), ob/ob mice (in vivo) (Bouhidel et al., 2008), db/db mice (in vivo) 
(Jones et al., 1999; Lefer et al., 2001), Zucker obese (ZO) rats (ex vivo) (Katakam et al., 
2007), Zucker diabetic fatty (ZDF) rats (Sidell et al., 2002) as well as type 2 diabetic BBZ rats 
(in vivo) (Li et al., 2008).  The exacerbation of  myocardial IRI in obesity and insulin resistance 
may be due to (amongst others): (1) increased inflammation (Thakker et al., 2008), (2) 
increased oxidative stress (Katakam et al., 2007; Ansley and Wang, 2013) and (3) a cascade 
of maladaptative metabolic changes in FFA metabolism (Harmancey et al., 2013) [for review, 
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see (Miki et al., 2012; Whittington et al., 2012)]. Adipokine dysregulation such as leptin 
resistance and hypoadiponectinaemia may also  contribute to these observations (Lopaschuk 
et al., 2007).  
In contrast to the exacerbation of infarct size observed in the present study, a part from a 
reduction in aortic output recovery, the high calorie diet had no significant effect on functional 
recovery compared to control (fig. 4.19-23). The dissociation between reduction in infarct size 
and myocardial function has been also reported by previous studies in control rats  in vivo  
(Lee et al., 2002; Sahna et al., 2005) and ex vivo  (Lochner et al., 2006; Genade et al., 2008; 
Lamont et al., 2011) confirming that a reduction in infarct size is not always accompanied by 
an improvement in functional recovery during reperfusion, due to concomitant stunning 
(Lochner et al., 2003). 
4.4.5.3.2 Effect of melatonin on myocardial IRI 
 It is well established that melatonin treatment before the onset of ischaemia or during 
reperfusion confers cardioprotection in non-obese animals (for review, Reiter et al., 2003; 
Lochner et al., 2013). Recent investigations in insulin resistant animal models have confirmed 
melatonin’s cardioprotective actions (Nduhirabandi et al., 2011; Diez et al., 2013). Consistent 
with the previous study on chronic melatonin treatment (16 weeks) in obese rats 
(Nduhirabandi et al., 2011), hearts isolated from rats treated with melatonin for three or six 
weeks also showed a significant reduction in myocardial infarct size after coronary artery 
ligation (fig.4.24). This was associated with an improvement in myocardial function in the diet 
but not in the control group (fig.4.19-23 and table 4.9), confirming previous findings obtained 
after chronic melatonin treatment (Nduhirabandi et al., 2011). The dissociation of reduced 
infarct size and myocardial function observed in the the latter groups was also reported in the 
previous studies (Lochner et al 2006; Nduhirabandi et al., 2011, Lamont et al., 2011) and 
suggest that the beneficial effects of melatonin have overridden the effect of stunning in the 
diet group. 
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How melatonin treatment confers cardioprotection in obesity is not yet established.  Melatonin 
has been shown to protect the heart against IRI via its direct and indirect antioxidant 
properties involving free radical scavenging and stimulation of other cellular antioxidants 
(Reiter et al.,2003; Tengattini et al., 2008).  In the present investigation, additional 
mechanisms may have also contributed to the observed cardioprotection. For example, in the 
obese group, 6 weeks melatonin treatment was associated with amelioration of insulin 
sensitivity and increased serum adiponectin levels. These factors could play a crucial role in 
the observed cardioprotection (Hui et al., 2012). Another factor to be considered is the 
attenuation of leptin resistance in obesity (Nduhirabandi et al., 2011, Prunet-Marcassus et al., 
2003).  
Additionally, for all melatonin-treated hearts, the anti-adrenergic, anti-inflammatory and anti-
excitatory effects of melatonin may also have contributed to the observed cardioprotection 
(Genade et al., 2008; Dominguez-Rodriguez et al., 2009; Patel et al., 2010). In this regard, the 
significance of the MT receptors has been consistently demonstrated (Lochner et al., 2006; 
Sallinen et al., 2007; Genade et al., 2008). On other hand, melatonin is a small molecule able 
to enter in the cardiomyocyte and exert direct or indirect nuclear transcriptional activities of 
cardioprotective genes (Carlberg, 2000; Korkmaz et al., 2012). The following section 
discusses melatonin’s effect on intracellular signalling which may also play an important role in 
the cardioprotection of the hearts isolated from  melatonin-treated control and diet groups.   
4.4.5.4 Melatonin and myocardial intracellular signalling 
In addition to its non-receptor mediated actions (i.e., free radicals scavenging), melatonin has 
been shown to exert its effects via receptor- mediated activities.  Melatonin membrane 
receptors 1 and 2 (MT1/2) and nuclear receptors have been identified in the heart 
(Ekmekcioglu et al., 2003).  Melatonin has been shown to act via various signalling pathways 
(Lochner et al., 2013).  To determine by which signalling pathways melatonin confers 
cardioprotection, we investigated the effects of 3 and 6 weeks melatonin treatment on the 
proteins implicated in two survival pathways namely PKB/Akt-ERK42/44 and GSK-3β (Ser-9) 
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(reperfusion injury salvage kinases or RISK pathway) and STAT-3 (survivor activating factor 
enhancement or SAFE pathway).  Normoxic hearts after removal from the body (“non-
perfused hearts”) and post-ischaemic hearts at 10 or 30 min reperfusion following global 
ischaemia were used. GLUT-4 and PI3-K were additionally evaluated at baseline as members 
of the insulin signalling pathway. 
4.4.5.4.1 Melatonin, PKB/Akt, ERK42/44 and cardioprotection 
• Baseline 
 Under baseline conditions, isolated hearts from rats fed a high calorie diet did not show any 
signifcant differences in the phosphorylation or activation of PKB/Akt and ERK42/44 
compared to their age-matched controls(fig.4.25-27). In contrast to our findings, elevated 
basal phosphorylation of PKB/Akt was reported as a feature of early myocardial changes in a 
rat model of hyperphagia-induced obesity (Huisamen et al., 2012) while over time, a 
depressed phosphorylation of PKB/Akt was observed in insulin resistant rats indicating 
impaired myocardial insulin signalling (Ouwens et al., 2005; Huisamen et al., 2013). 
In the present study, 3 weeks melatonin treatment increased basal PKB/Akt phosphorylation 
without affecting ERK42/44 in both control and diet rats (fig.4.30-31).  This has been also 
reported by previous studies in a number of tissues, for example, aorta of obese mice (Sartori 
et al., 2009), the hypothalamus, liver, skeletal muscle and peri-epididymal adipose tissue of 
old obese rats (Zanuto et al., 2013) after long-term melatonin treatment. In contrast to our 
findings, PKB/Akt phosphorylation was associated with an increase in the phosphorylation of 
ERK42/44 (Zanuto et al., 2013). Similar effects were also observed in hepatic cells (Shieh et 
al., 2009) and isolated pancreatic islets (Picinato et al., 2008), while ERK42/44 
phosphorylation in C2C12 murine skeletal muscle cells was unchanged (Ha et al., 2006). The 
effect of melatonin on PKB/Akt and ERK42/44 activation is further discussed in chapter 7, 
focusing on endothelial cells. 
The effects of melatonin on the PKB/Akt pathway have recently been reviewed as 
controversial or varying according to the type of cells and actions: inhibition (pro-apoptotic and 
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pro-oxidant effects in cancer cells) or activation (anti-apoptotic or anti-oxidant effects in non-
tumor cells) or simply without effect (Hardeland, 2013). 
• Reperfusion  
After 10 min reperfusion following global ischaemia, six weeks melatonin treatment increased 
PKB/Akt and ERK42/44 phosphorylation in both control and diet groups and PKB/Akt 
phosphorylation remained significantly elevated after 30 min reperfusion (fig.4.33-37). This is 
consistent with previous studies in our laboratory where acute melatonin treatment protected 
the isolated heart by activating the PKB/Akt and ERK42/44 pathway (Genade et al., 2008; 
Lochner et al., 2013). Although this was associated with increased PKB/Akt phosphorylation 
at baseline, this is not a prerequisite for cardioprotection since three weeks treatment 
conferred cardioprotection without having PKB/Akt activation at baseline (fig.4.26). In addition, 
although a depression in PKB/Akt phosphorylation is generally associated with increased 
susceptibility to myocardial IRI (Huisamen, 2003; Huisamen et al., 2013), the role of PKB/Akt, 
particularly in diabetic state, is still under debate as blockade of PKB/Akt may also confer 
cardioprotection (Linares-Palomino et al., 2010).  
Similar to six weeks, three weeks melatonin treatment also increased PKB/Akt and ERK42/44 
activation in the control and the diet groups (fig.4.33-34).  Thus the results obtained in the 
present study suggest that the cardioprotective actions of short-term melatonin-treatment are 
also associated with activation of the RISK pathway. It has been shown by several workers 
that activation of the RISK pathway is associated with anti-apoptotic activities and is closely 
linked to inhibition of mitochondrial permeability transition pore (MPTP)(Hausenloy et al., 
2005).  The effects of melatonin on PKB/Akt are further discussed in chapters 6 and 7 
focusing on glucose homeostasis and endothelial cells, respectively. 
4.4.5.4.2 Melatonin, GSK-3 β and cardioprotection 
• Baseline 
GSK-3β has recently emerged as a multifunctional kinase, widely distributed in many cellular 
compartments including the cytosol, mitochondria, and nucleus (Juhaszova et al., 2009). 
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Originally identified as an enzyme that phosphorylates and down-regulates glycogen synthase 
(the rate-limiting enzyme of glycogen metabolism), GSK-3β is phosphorylated (inhibition) by 
PKB/Akt at Ser-9.  This enzyme has also emerged as an integration point of several survival 
pathways where it plays a central role in transferring protective signals downstream to target 
the MPTP [for review, see (Juhaszova et al., 2009)]. 
The high calorie diet did not affect the expression and phosphorylation of GSK-3β (fig.4.28-29) 
under baseline conditions, in contrast to the study by Wensley et al. (2013). This could be due 
difference in animal models and protocols as they used a feeding period of 30 weeks feeding 
as opposed to 20 weeks in the present study.  Melatonin treatment for 6 weeks increased 
baseline GSK-3β phosphorylation in the diet but not in the control group while 3 weeks 
treatment increased this phosphorylation in the control but not in the diet group (fig.4.28-29). 
The reason for these discrepancies between the effects of 6 and 3 weeks treatment in the 
control and diet groups is not known.  Recent results from our lab showed that long-term GSK-
3β inhibition (i.e., phosphorylation) had detrimental effects in control while promoting insulin 
sensitivity in obese rats (Flepisi et al., 2013).  These opposing effects observed in control and 
obese rats need to be further investigated.  As far we know, this is the first study evaluating 
the effect of melatonin on myocardial GSK-3β. In HepG2 cells, melatonin increased the 
phosphorylation of GSK-3β in a PKB/Akt-dependent pathway (Shieh et al., 2009).  
• Reperfusion 
As discussed above, the high calorie diet did not affect the expression and phosphorylation of 
GSK-3β (fig.4.32, 35). Melatonin treatment for 3 or 6 weeks increased phosphorylation of 
GSK-3β at 10 min reperfusion in both control and diet groups and this phosphorylation was 
observed until 30 min of reperfusion (fig.4.38). However, the exact mechanism whereby 
melatonin increased GSK-3β in the heart remains unknown. Previous studies have shown that 
melatonin improved neurodegenerative disorders via indirect inhibition of the activity of GSK-
3β by activating and/or enhancing the activity of PKC or by inducing PKB/Akt phosphorylation, 
as both inactivate GSK-3β through phosphorylation (Rosales-Corral et al., 2011).  
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A strong possibility is that the enhanced activation of RISK pathway observed during 
reperfusion causes GSK-3β phosphorylation. Furthermore, melatonin has been shown to 
protect the heart by inhibition of MPTP opening (Petrosillo et al., 2009). However, whether 
GSK-3β inactivation was involved in melatonin-induced cardioprotection via MPTP has not 
been investigated. In the present study, it appears that pre-ischaemic inhibition of GSK-3β is 
not a prerequisite for the observed cardioprotection since baseline GSK-3β phosphorylation 
was not affected by melatonin (fig.4.28-26).  However, GSK-3β phosphorylation during 
reperfusion is known to play an important role in cardioprotection (Juhaszova et al., 2009). For 
example, it has been found that level of cardioprotection afforded by pharmacological 
preconditioning (erythropoietin infusion) was closely correlated with the level of GSK-3β (Ser-
9) phosphorylation upon reperfusion in the heart (Nishihara et al., 2006). The results obtained 
in the present study also suggest that melatonin exerts its protective actions during 
reperfusion via this kinase. 
4.4.5.4.3 Melatonin, STAT-3 and cardioprotection 
Signal transducer and activator of transcription 3 (STAT-3) is a family of cytoplasmic proteins 
with roles as signal messengers and transcription factors that participate in normal cellular 
responses to cytokines, growth factors and hormones and also play a crucial role in 
cardioprotection (Zgheib et al., 2012; Zouein et al., 2013). 
• Baseline  
Under baseline conditions, the diet had no significant effect on the localization of 
phosphorylated nuclear STAT-3 (Tyr-705 and Ser-727) (fig.4.41-42). Six weeks melatonin 
treatment increased nuclear localization of phosphorylated STAT-3 t (Tyr-705) in both control 
and diet groups while the cytosolic STAT-3 phosphorylation (Ser-727) was increased in 
control only (fig.4.41-42). The increased nuclear STAT-3 phosphorylated at Tyr-705 may 
reflect translocation of STAT-3 to the nucleus, leading to increased transcriptional activities of 
cardioprotective genes (Zgheib et al., 2012; Zouein et al., 2013). Thus, melatonin treatment 
may have conferred cardioprotection by increasing nuclear phosphorylated STAT-3 (Tyr-705) 
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before the ischaemic insult consistent with a previous study in non-obese animals (Lamont et 
al., 2011). In agreement with a recent study by Yang et al. (2013) in control rats, we found 
increased STAT-3 (Ser-727) phosphorylation in the cytosol which may function as a switch 
favouring the mitochondrial actions of STAT-3 over its canonical nuclear actions (Zgheib et al., 
2012).  
Three weeks melatonin treatment increased baseline cytosolic phosphorylation of STAT-3 
(Ser-727) and nuclear phosphorylated STAT-3 (Tyr-705) in the diet group (fig.4.45-46). Similar 
findings were also reported in non-obese rats (Lamont et al., 2011; Yang et al., 2013). 
However, the baseline phosphorylation of cytosolic or nuclear STAT-3 (Ser 727 or Tyr-705) in 
the control group was not affected (results not shown), indicating specificity of the effect of 
melatonin. 
• Reperfusion 
Similar to baseline, the diet had no effect on STAT-3 expression and phosphorylation at 10 
min reperfusion of control and diet groups (fig.4.47-54). In both groups, six weeks melatonin 
treatment increased the phosphorylation of nuclear and cytosolic STAT-3 (Tyr-705) without 
affecting STAT-3 (Ser-727) (fig.4.47-50). Three weeks melatonin treatment increased 
phosphorylation of cytosolic STAT-3 (Ser-727) and nuclear phosphorylated STAT-3 (Tyr-705) 
in the control with no effect in the diet group (fig.4.51-4.54). This lack of phosphorylation at 
reperfusion in the diet group following 3 weeks treatment is difficult to explain without 
additional investigations but may be due to the short treatment period. 
STAT-3 activation at reperfusion is in agreement with previous studies in non-obese animals 
(Lochner et al., 2013). Indeed, STAT-3 activation has been consistently reported as 
cardioprotective in the setting of early preconditioning as well as postconditioning (Lecour, 
2009; Zgheib et al., 2012).  As the present findings showed, STAT-3 can be phosphorylated at 
both its Ser-727 and Tyr-705 residues.  
Theoretically, it is indicated that following JAK2 stimulation, phosphorylated Tyr-705 leads to 
STAT-3 dimerization and translocation to the nucleus where, with an additional Ser-727 
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phosphorylation, it is involved in gene expression (Lecour and James, 2011; Zgheib et al., 
2012). However, recent evidence suggests that STAT-3 has additional direct non-
transcriptional activities at the level of the mitochondria where it is involved in limiting ROS 
generation (Lecour, 2009; Zgheib et al., 2012; Yang et al., 2013). This was confirmed in a 
recent study where ex vivo melatonin pre-treatment conferred cardioprotection via activation 
of STAT-3 associated with a reduced apoptotic index, diminished lactate dehydrogenase 
release, up-regulation of the anti-apoptotic protein Bcl2 and down-regulation of the pro-
apoptotic protein Bax (Yang et al., 2013). Interestingly, melatonin exposure preserved the 
mitochondrial redox potential and increased mitochondrial superoxide dismutase activity with 
concomitant reduction in hydrogen peroxide and malondialdehyde formation (Yang et al., 
2013). 
Taken together, it appears that STAT-3 is involved in cardioprotection of both control and diet 
groups with 6 weeks melatonin treatment being more effective (particularly at Tyr-705 in both 
nucleus and cytosol). In addition, it has been also demonstrated that STAT-3 phosphorylation 
was maximal between 2 and 5 min of reperfusion, probably preceding the phosphorylation of 
PKB/Akt, ERK42/44 and GSK-3β (Smith et al., 2010) which was maximal at 10 min (Smith et 
al., 2010). Whether this time point may have affected our results in the 3 weeks melatonin 
treated group needs further investigation. The effect of melatonin on STAT-3 is further 
discussed in chapter 7 focusing on endothelial cells.   
4.4.5.4.4 Interaction between STAT-3 and PKB/Akt-ERK42/44 
Concomitant activation of STAT-3 and PKB/Akt-ERK42/44 as observed in the present study at 
reperfusion has been also demonstrated by others (Suleman et al., 2008; Lecour, 2009; 
Tamareille et al., 2011). Briefly, both PI3 K/Akt and STAT-3 pro-survival signalling has been 
shown to closely interact to promote maximal protection and this was confirmed by the fact 
that inhibition of either STAT-3 or PKB/Akt activation abolished the protection induced by pre– 
or post-conditioning (Suleman et al., 2008; Tamareille et al., 2011). In addition, it was found 
that inhibition of phosphorylation of STAT-3 inhibited activation of PKB/Akt and vice versa 
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(Suleman et al., 2008; Lecour, 2009).  On other hand, in the anoxic-reoxygenated embryonic 
heart, STAT-3 was shown to interact with GSK-3β in the nucleus and PKB/ERK42/44 in the 
cytosol (Pedretti and Raddatz, 2011). In addition, it was also shown that both STAT-3 and 
PKB/Akt pathways convey their signals to the mitochondria (where many of the pro-survival 
and death signals appear also to converge), leading to the inhibition of MPTP opening 
(Lecour, 2009; Smith et al., 2010). Hypothetical interaction between PKB/Akt and STAT-3 
pathways as observed in the present study is represented in figure 4.55.  
4.4.5.4.5 Melatonin, GLUT-4 expression and PI3-K (p85) 
Transport of glucose across the cell membrane is the first step of glucose metabolism. It is 
triggered by various stimuli including amongst others increased workload, ischaemia, insulin 
and cathecholamines [for review, see (Montessuit and Lerch, 2013)]. Glucose transporters 
(GLUT) are important integral membrane proteins, which are involved in the regulation of 
glucose transport between extracellular and intracellular compartments, maintaining a 
constant supply of glucose for the organism's metabolism (Montessuit and Lerch, 2013).  
Although the basal glucose transporter in many cell types is GLUT-1, GLUT-4 is the most 
prominently expressed in differentiated cardiomyocytes, adipocytes and skeletal muscle 
(Montessuit and Lerch, 2013; Mueckler and Thorens, 2013). Insulin stimulates glucose 
transport via phosphorylation of PI3-K (p85) which phosphorylates PKB/Akt. This in turn 
increases GLUT-4 expression and translocation to the membrane for eventual glucose uptake. 
In agreement with a previous study, the high calorie diet had no effect on GLUT-expression 
(Huisamen et al., 2013). However, although a depression in GLUT-4 expression may indicate 
impairment in glucose uptake and hence insulin resistance, expression of membrane GLUT-4 
protein is a better indicator for glucose uptake (Huisamen et al., 2001).  
The role of melatonin on glucose transporters has been supported by previous observations 
that pinealectomized animals (without circulating melatonin) had reduced GLUT-4 expression 
in adipose tissue (Lima et al., 1998; Zanquetta et al., 2003) and four weeks melatonin 
administration (after pinealectomy) restored the GLUT-4 protein expression to control values 
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in adipose tissue (Zanquetta et al., 2003). Additionally, melatonin administration was shown to 
restore the expression of the myocardial GLUT-4 protein as well as the GLUT-4 gene which 
were reduced in response to oxidative stress associated with cardiac hypertrophy (Ghosh et 
al., 2007).   Consistently, administration of melatonin for 6 weeks increased the baseline levels 
of GLUT-4 expression in both diet and control hearts (fig.4.40). In other studies, as discussed 
in chapter 6, melatonin has also been shown to affect GLUT4-expression. However, the 
mechanism whereby melatonin increased myocardial GLUT-4 expression in control and obese 
animals remains unknown. In the present study, some factors including lowering of insulin 
resistance, increased adiponectin levels in obese animals and potential indirect effects of 
melatonin mimicking or enhancing insulin action in all melatonin treated animals, could 
contribute to increased GLUT-4 expression. The effect of melatonin on glucose uptake is 
further discussed in chapter 6 focusing on isolated cardiomyocytes. 
Similar to GLUT-4, we showed that the high calorie diet had no effect on expression and 
phosphorylation of PI3-K (p85). Furthermore, in contrast to GLUT-4 and PKB/Akt,  melatonin 
treatment had no effect on expression and phosphorylation of this kinase (fig.39).  An 
association between  PI3-K and increased PKB/Akt phosphorylation has been demonstrated 
in adipose tissue, skeletal muscle, liver and hypothalamus following melatonin treatment in 
obese rats (Zanuto et al., 2013).  The significance of PI3-K in melatonin’s effects was further 
demonstrated using a PI3-K inhibitor. For example, while melatonin administration induced 
PKB/Akt phosphorylation, co-administration of melatonin with a PI3-K inhibitor abolished 
PKB/Akt phosphorylation in  hepatic tissues (Faria et al., 2013) and in primary astrocytes 
(Kong et al., 2008).  
In view of the melatonin-induced PKB/Akt phosphorylation and increased GLUT-4 expression 
in the present study, we expected to observe an increase in PI3-K phosphorylation in the 
context of insulin signalling pathway. However, as indicated above, PKB/Akt activation is not 
always directly correlated with insulin-stimulated glucose uptake (Huisamen, 2003). In 
addition, a reduction in PI3-K with normal PKB/Akt (Nadler et al., 2001) and abnormal 
activation of PKB/Akt (Cook et al., 2010) were reported in T2D. Importantly, an increase in 
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PI3-K expression was recently been shown to be associated with normal PKB/Akt expression 
after melatonin treatment (Mendes et al., 2013), supporting the observed dissociation between 
PKB/Akt and PI3-K. Obviously, further investigation into this phenomenon is warranted. 
In view of the increased GLUT-4 expression by 6, but not 3 weeks melatonin treatment, the 
contribution of improved glucose transport to the observed cardioprotection is still unclear. In 
addition, whether the elevated glucose transporter expression was associated with improved 
glucose metabolism needs to be determined. The role of melatonin in glucose homeostasis is 
further discussed in chapter 6.   
 
 Figure 4.55 Hypothetical representation of the effect of melatonin on myocardial intracellular 
signalling. Melatonin treatment phosphorylated cytosolic STAT-3 at baseline which triggers its 
translocation to the nucleus and subsequent transcriptional activities for cardioprotective 
genes. This is associated with activation of the RISK pathway (PKB/Akt-ERK42/44) and 
inhibition of GSK-3β at reperfusion. Both PKB/Akt and STAT-3 pathways are interconnected 
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and may convey their signals to the mitochondria. Whether these events are associated with 
increased glucose uptake/metabolism activities remains unknown.  : Melatonin 
4.5. STRENGHTS AND LIMITATIONS OF THE STUDY 
The rat model of obesity and insulin resistance was successfully induced. In contrast to 
chronic melatonin treatment or parenteral administration the short-term oral treatment did not 
affect body weight, visceral adiposity, circulating lipids and cardiac morphology.  Althought 
there are inevitable physiological interactions in the in vivo setting, we were able to study the 
potential mechanisms implicated in cardioprotection induced by melatonin in obese and non-
obese rats without indirect effects associated with body weight and visceral fat loss and heart 
weight reduction. Three weeks melatonin treatment appears to be the minimum period where 
metabolic changes become noticeable (Prunet-Marcassus et al., 2003; Rios-Lugo et al., 2010; 
Terrón et al., 2013), for example, body weight and visceral fat loss, increased serum CD and 
TBARS in control animals, improved glucose tolerance in diet animals.  Interestingly, six 
weeks melatonin treatment, where several of its effects are visible (Agil et al., 2011; Agil et al., 
2012b), had no effect on visceral fat.  However, 6 weeks treatment contributed to our insight 
into myocardial signalling, body weight gain, adiponectin levels and lack of effect on glucose 
tolerance.  
The present study did not investigate the cardioprotective effect (functional recovery) of 
melatonin using the global ischaemia protocol. This has previously been demonstrated in 
isolated hearts from non-obese rats (Lochner et al., 2006; Petrosillo et al., 2006; Genade et 
al., 2008). In this regard, additional studies using  specific inhibitors or knockout mice are 
needed to confirm the association between the protein activation as indicated by  the 
intracellular signalling pathways and cardioprotection.  
4.6. CONCLUSION 
 Melatonin is a multifunctional molecule. In the present study, we have demonstrated that, 
independent of body weight and visceral fat loss, short-term (3-6 weeks) melatonin treatment 
was as effective in eliciting cardioprotection as the long term (16 weeks) treatment in obese 
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insulin-resistant animals (Nduhirabandi et al, 2011). This protection was associated with a 
reduction in insulin resistance with no effect on  blood glucose and lipids. On a molecular 
level, melatonin treatment induced baseline activation of STAT-3 and activation of the RISK 
pathway and STAT-3 at reperfusion.  
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STUDY II 
THE EFFECTS OF MELATONIN TREATMENT ON MYOCARDIAL 
MITOCHONDRIAL FUNCTION IN A RAT MODEL OF DIET-INDUCED 
OBESITY AND INSULIN RESISTANCE 
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CHAPTER FIVE 
5. STUDY II 
 
THE EFFECTS OF MELATONIN TREATMENT ON MYOCARDIAL MITOCHONDRIAL 
FUNCTION IN A RAT MODEL OF DIET-INDUCED OBESITY AND INSULIN RESISTANCE 
5.1. INTRODUCTION 
Obesity and insulin resistance are associated with metabolic, structural and functional cardiac 
alterations (Abel, 2008). These are accompanied by changes in mitochondrial function which 
are characterized by a reduction in oxidative activity and ATP synthesis (Boudina et al., 2007; 
Qatanani and Lazar, 2007).  It is well established that mitochondria are the primary cellular 
site for energy supply to the heart and for both FFA oxidation and utilization (Stanley et al., 
2005).  In normal conditions the heart relies more on mitochondrial activity to obtain the 
energy required for contraction (Stanley et al., 2005). Therefore, defects in mitochondrial 
function are likely to have detrimental effects on heart function. 
In the insulin resistant state, cardiac mitochondrial function is overwhelmed by excess free 
fatty acids and eventually subsequent ROS generation which have been shown to exacerbate 
IRI damage (Boudina et al., 2007, 2009). The contribution of mitochondrial dysfunction and 
oxidative stress to cardiomyocyte death in this regard is well established (Opie, 2004), with the 
opening of the MPTP playing an important role (Yellon and Hausenloy, 2007).  Melatonin has 
been shown to protect the mitochondria in several ways; for example by its ability to scavenge 
free radicals and by increasing their antioxidant capacity (e.g., SOD, GSH, and catalase) (for 
review, Srinivasan et al., 2011; Reiter et al., 2008). Melatonin-induced cardioprotection has 
been shown to be associated with inhibition of the opening of the MPTP (Petrosillo et al., 
2009). However, the role of melatonin has not yet been studied in the setting of myocardial 
mitochondrial function in obesity.  
 In view of the above, we aimed to investigate the effects of oral melatonin treatment on 
myocardial mitochondrial function in a rat model of diet-induced obesity. We tested the 
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hypothesis that melatonin treatment protects cardiac mitochondria against the adverse effects 
of obesity and insulin resistance and improves basal and post-anoxic mitochondrial function. 
5.2. MATERIALS AND METHODS  
5.2.2. Study design 
Animals, feeding and treatment are described in chapter 3.  Figure 5.1 represents animal 
grouping and feeding for the present investigation.  Animals were fed for 20 weeks. Four 
groups were used in this study: (i) untreated control (C), (ii) treated control (CM), (iii) untreated 
diet (D) and (iv) treated diet (DM). The treated animals received melatonin in drinking water for 
6 weeks starting after 14 weeks of feeding. Melatonin administration is described chapter 3. 
 
Figure 5.1 Animal grouping, feeding and treatment. SRC: standard rat chow, Mel:  6 weeks 
melatonin treatment, 48 animals were used with 12 animals for each group.  For each group, 6 
rats were used for the baseline studies (isolated hearts without perfusion referred to as “non-
perfused hearts”) (see chapter 4) and 6 for perfusion studies (isolated hearts subjected to 20 
min global ischaemia, further referred to as “perfused or ischaemic hearts”).  
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5.2.3. Mitochondrial isolation  
Mitochondria were isolated from the hearts either at baseline (immediately after removal; 
referred to as “non-perfused hearts”) or after 20 min global ischaemia (referred to as “perfused 
or ischaemic hearts”). Briefly, after removal, hearts were immediately arrested in ice cold 
mitochondrial isolation medium (pH 7.4) containing: KCl (0.18M), EDTA (0.01M). All 
procedures for mitochondrial isolation were carried out on ice.  Arrested hearts were rapidly 
cut into small pieces and washed repeatedly with the same isolation medium in order to 
remove all traces of blood. The tissue was then homogenized with a Polytron (PT10) 
homogenizer for 2 cycles of 4 seconds each (at setting 4) before centrifugation at 2500rpm 
(755xg) for 10min at 4°C. After centrifugation, the pellet was discarded and the supernatant 
re-centrifuged at 12500rpm (18800xg) to obtain a mitochondrial pellet. This was resuspended 
and homogenized in 0.5mLisolation medium using a Potter Elvehjem homogenizer and kept 
on ice until further use.  50µLof the mitochondrial suspension was used for determination of 
protein content using the Lowry method (Lowry et al. 1951). 
5.2.4. Determination of mitochondrial function 
Mitochondrial respiration was measured polarographically at 26°C using an oxygraph 
(Hansatech Instruments Bannan, UK) containing a Clarke-type electrode as previously 
described (Boudina et al., 2005)  
Figure 5.2 represents the steps followed. After calibration, the mitochondrial incubation 
medium (250mM sucrose, 10mM Tris-HCl, 8.5mM K2HPO4.2H2O, pH 7.4) containing 2mM 
malate and either 5mM glutamate or 0.45mM palmitoyl-L-carnitine as respiratory substrates 
was added to the oxygraph chamber (equilibrated with ambient oxygen). When the chamber 
temperature reached 26ºC, the recording was started and 50µL of mitochondrial suspension 
added to the incubation buffer in the chamber.  At this point, the baseline respiration (State 2), 
which is substrate-dependent, was measured. Thereafter, 50µL of 7.5mM adenosine 
diphosphate (ADP) solution was added and the chamber sealed. The addition of ADP caused 
rapid oxygen consumption by the mitochondria to produce ATP (State 3 respiration). After 
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phosphorylation of all added ADP, state 4 respiration ensued (see figure 5.2). After this 
period, the seal of the chamber was removed and an additional amount of ADP (100µL of 
75mM ADP) was added to the mitochondrial suspension and the chamber resealed. This 
event caused the mitochondria to utilize all available oxygen in the chamber and thereby 
inducing anoxia. Following 20 min of anoxia, using a plastic Pasteur pipette for reoxygenation, 
the oxygen concentration was restored to approximately half of that present in the chamber 
prior to the addition of the mitochondrial suspension. This re-oxygenation in the presence of 
excess ADP induced another cycle of State 3 respiration.  All these steps were repeated for 
each substrate (glutamate or palmitoyl-L-Carnitine).  
• Parameters investigated: 
Figure 5.2 represents a typical graph generated by an oxygraph. From this figure the following 
parameters were calculated: 1) State 2 respiration (slope A): mitochondrial respiration in the 
presence of the specific substrates in the incubation solution before addition of ADP.  2) State 
3 respiration (slope B): mitochondrial respiration in the presence of ADP (at this stage 
substrates were oxidized in the presence of ADP, and as oxidative phosphorylation takes 
place, ADP was converted to ATP).  3) State 4 respiration (Slope C): mitochondrial respiration 
after all ADP was converted to ATP. 
Mitochondrial respiratory rates (states 2, 3 and 4) were expressed as nAtoms oxygen uptake 
/mg mitochondrial protein/min. The respiratory control index (RCI), which is a good index of 
the coupling of oxidation and phosphorylation, was obtained according to the following 
formula: state 3 respiration/state 4 respiration. The amount of ADP added to the incubation 
system was obtained spectrophotometrically (the molar extinction coefficient of ADP: 15.4 at 
259nm).  The ADP/O ratio is calculated as follows: nmoles ADP phosphorylated/nAtoms 
oxygen uptake during state 3. The percentage recovery of the state 3 following reoxygenation 
was also determined to indicate the mitochondrial susceptibility to anoxia/reoxygenation.  
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Figure 5.2 Diagram for a typical respiration graph generated by oxygraph, A: state 2 
respiration, B:  state 3 respiration, C: state 4 respiration. 
5.2.5. DATA ANALYSIS 
All statistical analyses were performed as indicated in chapter 3. 
5.3. RESULTS 
5.3.1. Biometric parameters 
As in previous experiments, the high calorie diet caused a significant increase in body weight 
gain and administration of melatonin for 6 weeks reduced the body weight gain in both control 
and diet groups (table 5.1). 
Table 5.1 Body weight  
Groups C CM6 D DM6 
Body weight (g) 488±12 457±9 575±10*** 509±11** 
n/group 13 12 12 11 
 
C: control, CM6: control receiving melatonin treatment, D: high calorie diet, DM: high calorie 
diet with melatonin treatment; *p<0.05 (C vs CM6), **p<0.01(D vs DM6), ***p<0.001(C vs D) 
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5.3.2. Mitochondrial function 
To investigate the effect of melatonin and the high calorie diet as well as anoxia/reoxygenation 
on mitochondrial function, mitochondria were isolated from the hearts of treated and untreated 
rats at either baseline (i.e., without perfusion) or after 20min global ischaemia (referred to as 
perfused or ischaemic hearts).  After polarographic evaluation of mitochondrial respiration and 
phosphorylation the mitochondria were subjected to 20min of anoxia followed by reoxy 
genation to elicit state 3 respiration, to assess the susceptibility of isolated mitochondria to 
anoxia/reoxygenation injury. This was expressed as the percentage recovery of state 3 
respiration rate. Glutamate and palmitoyl-L-carnitine were used as respiratory substrates. 
Results are presented in tables 5.2-3. 
• Non-perfused hearts (baseline) 
Table 5.2 represents the results of the respiratory function of mitochondria isolated from non-
perfused hearts.  The rate of state 3 reoxygenation was significantly elevated in the diet group 
(compared to the control) with palmitoyl-L-carnitine as substrate. However, there was no 
significant difference between the respiratory function of mitochondria isolated from non-
perfused control and diet hearts.   
In the control group, melatonin treatment for 6 weeks reduced  the rate of state 4 respiration 
with palmitoyl-L-carnitine as substrate (22.19±0.72 vs 15.91±2.69 nAtoms oxygen/min/mg, 
p<0.05) while the other parameters of mitochondrial respiratory function were not affected 
regardless of substrate used (fig.5.3A,B; table 5.2).  
In the diet group, melatonin treatment reduced the oxygen consumption rate (state 3) 
(121.1±3.94 vs 87.48±4.24 nAtoms oxygen/min/mg, p<0.05) with glutamate as substrate, 
while the reduction seen with palmitoyl-L-carnitine was not significant.  When palmitoyl-L-
carnitine was used as respiratory substrate, melatonin also significantly reduced the rate of 
state 3 reoxygenation after exposure to anoxia (99.75±6.62 vs 73.95±3.46 nAtoms 
oxygen/min/mg, p<0.05) with no effect on state 3 percentage recovery, due to the differences 
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in state 3 respiratory rates before induction of anoxia (table 5.2; fig.5.3B). Other parameters 
were not affected by melatonin treatment (fig. 5.3A, B; table 5.2). 
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Figure 5.3 Non-perfused hearts, basal respiratory control index (RCI) (A), state 3 
respiration rate (B), state 4 respiration rate (C), Glut; glutamate, Palm: palmitoyl-L-
carnitine, *p<0.05 (D vs DM or C vs CM), n=5-6/group 
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Table 5.2   Respiratory function of mitochondria isolated from non-perfused hearts (baseline) 
Groups C (n=6) CM (n=6) D (n=6) DM (n=5) 
Substrates Glut Palm Glut Palm Glut Palm Glut Palm 
State 2   22.07±2.03 24.64±1.79 20.70 ± 3.61 18.63±3.32 19.50±1.13 23.52±2.65 22.96±2.28 25.97±2.39 
State 3 115.2±14.06 121.3±10.9 87.87±19.57 107.7±24.35 121.1±3.94 119.4±9.38 87.48±4.24 (*) 94.20±7.64  
State 4 19.55±1.39 22.19±0.72 17.43 ±3.92 15.91±2.69 (#) 17.28± 1.26 19.52±2.41 15.90 ±1.10 16.84±1.10 
State 3 reox 91.21±8.51 75.68±5.42 71.93±14.15 66.86±8.93 97.99±7.44 99.75±6.62 (#) 
74.79±2.79 
(p=0.06) 
73.95±3.46 
(*) 
RCI 
(State3/state4) 6.01±0.72 5.53±0.61 4.73±1.08 6.13±0.62 7.15±0.54 6.27±0.42 
5.52±0.21 
(p=0.07)  5.61±0.36 
ADP/O 2.52±0.25 2.28±0.15 2.60±0.13 2.55±0.17 2.38±0.22 2.14±0.22 2.24±0.10 2.18±0.13 
Oxphos rate 285.4±36.57 277.9±34.9 187.3±37.24 230.5±57.8 289.1±31.43 289.6±26.8 197.0±15.1 (p=0.07) 208.5±27.8 
State 3 (%) 
recovery 80.72±3.19 63.95 ±5.40 84.39 ±6.03 67.95 ±7.17 81.14 ±6.44 66.53 ±11.69 85.59 ±1.14 79.21 ±3.07 
 
Glut: glutamate, Palm: palmitoyl-L-carnitine, States 2, 3, 4 (nAtoms oxygen/min/mg), State 3 reox: state 3 after anoxia-reoxygenation (nAtoms 
oxygen/min/mg), Oxphos: oxidative phosphorylation rate (nmolADP/min/ mg), ADP/O: adenosine diphosphate /oxygen uptake (nmol ADP/ 
nAtoms oxygen), #p<0.05 vs C, *p<0.05 vs D, n=5-6/group.
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• Perfused hearts ( after ischaemia) 
Table 5.3 represents results of respiratory function of mitochondria isolated from perfused 
hearts (after 20min of global ischaemia). The high calorie diet did not significantly affect the 
respiratory function with both substrates. In the control group, melatonin treatment did not 
affect the respiratory function regardless of substrate used. In the diet group, isolated 
mitochondria from melatonin treated rats had significantly increased the rates of state 2 
respiration (both substrates) (table 5.3) and oxidative phosphorylation (149.8 ±21.6 vs 255.4 
±19.1 nmolADP/min/ mg, p<0.05) (glutamate as substrate) (fig.5.4B). However, ADP/O and 
RCI were not significantly affected by melatonin treatment with both glutamate and palmitoyl-
L-carnitine as substrates (fig.5.4A; table 5.3).  
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Figure 5.4 Perfused hearts, ADP/O ratio (A) and oxidative phosphorylation rate (Oxphos) 
(B), Glut: glutamate, Palm: palmitoyl-L-carnitine, *p<0.05 (D vs DM), n=6/group. 
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Table 5.3 Respiratory function of mitochondria isolated from the hearts subjed to 20min global ischaemia  
Groups C (n=6) CM (n=6) D (n=6) DM (n=6) 
Substrates Glut Palm Glut Palm Glut Palm Glut Palm 
State 2 19.14±1.37 20.10± 1.73 17.11±1.63 21.61 ±2.04 15.71±1.61 19.45±1.42 24.03±3.35  (*) 
27.44±3.62 
(*) 
State 3 84.97 ±8.10 102.1±14.2 94.30 ±6.11 91.79±12.6 72.18± 10.5 98.70±11.75 97.69 ±10.38 113.7±24.29 
State 4 14.65± 1.06 19.05 ±1.09 14.61 ±0.49 21.59± 2.63 14.87±0.95 17.77± .94 19.08± 1.94 (p=0.07) 22.24 ±3.08 
State 3 reox 71.38 ±8.51 65.51±8.78 79.72 ±10.86 59.45±16.84 66.42 ±8.21 77.88±9.71 66.42 ±8.21 68.14±4.90 
RCI 
(State3/state4) 5.40±0.37 5.24± 0.42 6.44±0.32  4.52± 0.76 4.76±0.48 5.32±0.40 5.52 ±0.22 5.08 ±0.64 
ADP/O 2.28±0.05 2.30±0.05 2.431±0.079 2.52 ±0.16 2.48±0.23 2.5±0.09  2.68 ±0.21 3.03 ±0.32 (p=0.09)  
Oxphos  194.4±19.9 206.0±19.36 229.8 ±19.2 233.3 ±35.8 149.8 ±21.6 250.6±35.2 255.4 ±19.1 (**) 274.0±15.5 
State 3 
recovery (%) 84.07±8.45 63.61 ±11.2 84.04±7.67 64.36 ±17.05 91.41±4.70 78.98 ±4.02 68.66±18.77 59.90±18.61 
 
Glut: glutamate, Palm: palmitoyl-L-carnitine, States 2, 3 and 4 (nAtoms oxygen/min/mg), State 3 reox: state 3 after reoxygenation (nAtoms 
oxygen/min/mg), Oxphos: oxidative phosphorylation rate (nmolADP/min/mg), ADP/O: adenosine diphosphate /oxygen uptake (nmol ADP/ 
nAtoms oxygen), * p<0.05 vs D, **p<0.01 vs D. 
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• The effect of ischaemia  on mitochondrial function 
To determine the effect of ischaemia per se on mitochondrial function, we compared the 
data obtained from mitochondria isolated from non-perfused hearts (baseline) with those 
obtained from mitochondria isolated from perfused hearts (from both untreated control and 
diet groups) subjected to 20 min global ischaemia.  Results are presented in table 5.4   
Global ischaemia had a depressing effect on mitochondrial function: the oxygen uptake rate 
was lower (with both substrates), but significance was obtained only in a few instances. For 
example, state 4 respiration rate (both substrates) was reduced in the control (p<0.05) but 
not in the diet group (table 5.4). State 3 respiration rate, RCI and state 3 reoxygenation rate 
were reduced in the diet group only, with glutamate as substrate (table 5.4).  
Importantly, the oxidative phosphorylation rate was decreased in both control and D groups, 
with glutamate as substrate (p<0.05) (table 5.4). Other parameters including the ADP/O ratio 
and state 3 percentage recovery were not affected by ischaemia in both groups. 
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Table 5.4 Comparison of mitochondrial oxidative phosphorylation in perfused (ischaemic) and non-perfused hearts 
 
Glut: glutamate, Palm: palmitoyl-L-carnitine, States 2, 3 and 4 (nAtoms oxygen/min/mg), State 3 reox: state 3 after reoxygenation (nAtoms 
oxygen/min/mg), Oxphos: oxidative phosphorylation rate (nmolADP/min/mg), ADP/O: adenosine diphosphate /oxygen uptake (nmol ADP/ 
nAtoms oxygen), RCI: respiratory control index, #p<0.05 vs C (perfused vs non-perfused hearts), *p<0.05 vs D (perfused vs non-perfused 
hearts), n=6/group. 
Groups C (non- perfused) (n=6) C (perfused)(n=6) D (non-perfused) (n=6) D (perfused) (n=6) 
Substrate Glut Palm Glut Palm Glut Palm Glut Palm 
State 2   22.07±2.03 24.64±1.79 19.14±1.37 20.10± 1.73 19.50±1.13 23.52±2.65 15.71±1.61 19.45±1.42 
State 3 115.2±14.06 121.3±10.9 84.97 ±8.10 102.1±14.2 121.1±3.94 119.4±9.38 72.18± 10.5* 98.70±11.75 
State 4 19.55±1.39 22.19±0.72 14.65± 1.06# 19.05 ±1.09# 17.28± 1.26 19.52±2.41 14.87±0.95 17.77± .94 
State 3 reox 91.21±8.51 75.68±5.42 71.38 ±8.51 65.51±8.78 97.99±7.44  99.75±6.62  66.42 ±8.21* 77.88±9.71 
RCI (State3/state4) 6.01±0.72 5.53±0.61 5.40±0.37 5.24± 0.42 7.15±0.54 6.27±0.42 4.76±0.48* 5.32±0.40 
ADP/O 2.52±0.25 2.28±0.15 2.28±0.05 2.30±0.05 2.38±0.22 2.14±0.22 2.48±0.23 2.5±0.09  
Oxphos rate 285.4±36.57 277.9±34.9 194.4±19.9# 206.0±19.36 289.1±31.43 289.6±26.8 149.8 ±21.6* 250.6±35.2 
State 3 (%) recovery 80.72±3.19 63.95 ±5.40 84.07±8.45 63.61 ±11.2 81.14 ±6.44 66.53±11.69 91.41±4.70 78.98 ±4.02 
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5.4. DISCUSSION 
 In the present study the effects of six weeks melatonin treatment were evaluated on 
myocardial mitochondrial function in obesity and insulin resistance.  
 The main findings were as follows: (i) the high calorie diet caused a significant increase in 
body weight and insulin resistance without having any effect on the oxidative phosphorylation 
capacity of the mitochondria isolated from non-perfused (baseline) hearts; (ii) when respiratory 
function of mitochondria isolated from non-perfused hearts was compared to that of 
mitochondria isolated from perfused hearts subjected to global ischaemia, the function of the 
diet group showed a greater reduction than that of the controls, depending on the substrates;  
(iii) in mitochondria isolated from non-perfused hearts, melatonin administration for 6 weeks 
induced a reduction in oxygen consumption (state 3 respiration rate), particularly in the diet 
group, while other parameters were unchanged; (iv) in mitochondria isolated from perfused 
hearts (after global ischaemia), melatonin induced an increase in state 2 respiration and 
oxidative phosphorylation rate of mitochondria isolated from the diet group, while having no 
significant effect on the control group.  
5.4.1. Non-perfused hearts (baseline) 
Under normal conditions the heart relies mainly on mitochondrial activity for its energy 
requirements (Stanley et al., 2005). Results on the effects of obesity and insulin resistance on 
mitochondrial function are controversial: a reduction in oxidative activity and ATP synthesis 
has been reported (Boudina et al., 2005; Boudina and Abel, 2006). However, it has also been 
shown that despite peripheral insulin resistance, obesity is not always associated with defects 
in myocardial mitochondrial function (Ussher et al., 2009; Samocha-Bonet et al., 2012; Gupte 
et al., 2013). The latter may occur in the setting of pre-diabetes and diabetes due to 
hyperinsulinaemia which over time may cause a progressive loss of insulin actions and 
mitochondrial dysfunction as previously reported (Boudina and Abel, 2007; Boudina et al., 
2009; Liu and Lloyd, 2013).  
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Interestingly, in the present study, mitochondria isolated from non-perfused hearts (baseline 
study) from rats fed a high calorie diet, despite an increase in body weight, exhibited no 
significant change in their respiratory parameters (RCI, ADP/O) and state 3 percentage 
recovery  after anoxia/reoxygenation when compared to controls (fig.5.3A,B). Therefore, since 
the mitochondrial respiratory function was not significantly affected in the obese group, it was 
unlikely that melatonin would have any significant effects in this regard.  It is known that 
mitochondria take up melatonin in vitro in a concentration-dependent manner (Lopez et al., 
2009) while in vivo administration of melatonin also results in its accumulation in mitochondria 
(Reyes-Toso et al., 2006). Thus, long-term melatonin treatment in the present study is 
expected to affect the mitochondrial function.   
Consistent with a previous study on isolated rat liver mitochondria following 40 days of 
melatonin treatment (Reyes-Toso et al., 2006), we observed that melatonin reduced the rate of 
state 4 respiration in control and state 3 reoxygenation in diet group respectively, with 
palmitoyl-L-carnitine as substrate (table 5.2). The inhibitory effect of melatonin on 
mitochondrial oxygen uptake was also previously observed in rat liver mitochondria and 
occurred in the presence of excess substrates and subsequent overstimulation of oxygen 
uptake (Reyes-Toso et al., 2006; Srinivasan et al., 2011).  This could also be the case in 
mitochondria isolated from the hearts of diet rats during the reoxygenation phase when ADP 
and substrates are present in excess. 
Furthermore, melatonin treatment also induced a reduction in the rate of oxygen consumption 
(state 3 respiration) in the diet group when glutamate was used as substrate (table 5.2). 
Similar findings were also previously reported in an in vitro study where melatonin 
administered to isolated rat liver mitochondria induced, in a dose–dependent manner, a 
reduction in oxygen consumption and membrane potential and inhibited the production of 
superoxide and H2O2 while maintaining the efficiency of oxidative phosphorylation (Lopez et 
al., 2009).   
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However, further research is needed to determine the mechanism whereby six weeks 
melatonin exhibited these effects in both control and diet groups. Long-term melatonin 
treatment has been suggested to prevent damage to the respiratory chain by induction of 
antioxidant enzymes such as SOD and GSH (Leon et al., 2005; Reyes-Toso et al., 2006). This 
is supported by a number of in vitro studies as indicated above and additionally, may involve 
the induction of antioxidant enzyme gene expression [for review, see (Rodriguez et al., 2004; 
Leon et al., 2005; Hardeland, 2009; Korkmaz et al., 2012)]. As stated above, recent 
observations indicate that melatonin is highly concentrated in the mitochondria upon melatonin 
treatment (Venegas et al., 2012). Hence, melatonin accumulated in the mitochondria during 
the treatment could also contribute directly to the observed effects in the present study.  
On other hand, other studies have reported melatonin–induced increases in respiratory 
function [for details, see (Leon et al., 2005; Acuna Castroviejo et al., 2011; Srinivasan et al., 
2011)]. However, this is not regarded as controversial because it reflects the multiple 
regulatory activities of melatonin: being able to increase or decrease or maintain mitochondrial 
function depending on the type of malfunction or experimental protocol (Hardeland, 2009; 
Paradies et al., 2010). This view was recently supported by a study using liver mitochondria 
from diabetic rats where melatonin administration (10mg/kg/day, 30 days, intraperitoneal) 
showed a considerable protective effect by reversing the decreased state 3 respiration rate 
and the diminished RCI to the control values (Cheshchevik et al., 2011).  
5.4.2. Perfused hearts (after global ischaemia) 
 In addition to baseline data, we further investigated whether hearts from obese rats are more 
susceptible to ischaemic injury and to what extent long-term melatonin treatment affected 
these hearts. Hearts isolated from both control and diet groups were subjected to 20 min 
global ischaemia and mitochondria subsequently isolated. After polarographic evaluation of 
respiration and phosphorylation, the mitochondria were subjected to 20 min of anoxia followed 
by reoxygenation to elicit state 3 respiration, to assess the susceptibility of isolated 
mitochondria to anoxia-reoxygenation injury.  Several studies have shown that myocardial 
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ischaemia leads to progressive injury to the mitochondrial function affecting the electron 
transport chain, oxidative phosphorylation, Krebs cycle enzymes and ATP production (Veitch 
et al., 1992; Lesnefsky et al., 2004; Kurian et al., 2012). Several of these studies have 
investigated the effects of reperfusion on mitochondrial function but the extent of mitochondrial 
injury that occurs during reperfusion compared to the effects of ischaemia alone remains 
unclear (Lesnefsky et al., 2004; Kurian et al., 2012) as reperfusion does  not cause additional 
defects in the distal electron transport chain of intact subsarcolemmal mitochondria (Veitch et 
al., 1992; Lesnefsky et al., 2004). 
Two subpopulations of mitochondria have been identified namely subsarcolemmal 
mitochondria which are located beneath the plasma membrane and interfibrillar mitochondria 
which are located between the myofibrils, the former being more susceptible to ischaemic 
injury than the latter (Lesnefsky et al., 2004; Kurian et al., 2012). In the present study the 
subsarcolemmal mitochondrial fraction was studied. 
Interestingly, mitochondria isolated from hearts from untreated diet rats had similar 
mitochondrial respiratory function parameters to those isolated from the control rats regardless 
of respiratory substrates used (table 5.3). This is in contrast to previous studies where age-
dependent defects in mitochondrial oxygen consumption and ATP synthesis were observed in 
mice with impaired insulin signalling (Boudina and Abel,  2006) and reduced ADP 
phosphorylation rates in obese rats (Boudina and Abel, 2006; Essop et al., 2009). 
However, although there was no significant difference between the respiratory function of 
untreated control and diet groups, melatonin treatment exhibited different actions on the 
respiratory function of the mitochondria isolated from these hearts exposed to 20 min global 
ischaemia. Indeed, while it maintained the respiratory function of the mitochondria isolated 
from the control hearts, it caused a significant increase in a number of parameters of 
mitochondrial respiratory function in the diet group including the rate of state 2 respiration (with 
both substrates) and oxidative phosphorylation rate (glutamate as substrate) (fig.5.4B). This 
may be indicative of increased coupling efficiency (ATP production) as previously reported 
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(Petrosillo et al., 2006). Why this coupling efficiency was increased only in the diet group and 
not in the control group is not clear because the parameters of mitochondrial function in both 
untreated diet and control groups were similar (fig.5.4B). Additionally, the increase in state 2 
respiration may be related to high endogenous mitochondrial ADP induced by melatonin 
treatment as previously demonstrated (Martin et al., 2002). The increased mitochondrial 
oxidative phosphorylation rate observed with glutamate as substrate is in agreement with the 
reduction in infarct size observed in hearts from melatonin-treated obese rats after coronary 
artery ligation (see chapter 4). 
As far as we know, this is the first investigation on the effect of relatively long-term melatonin 
treatment on myocardial mitochondrial function in obesity and insulin resistance. In this regard, 
relatively few investigations have focussed on the effect of melatonin on cardiac mitochondrial 
function.  Using normal rats, a study by Petrosillo et al. (2006) has shown that, while the rate of 
state 3 respiration in vitro was markedly decreased in mitochondria isolated from reperfused 
hearts after ischaemia, melatonin treatment significantly reversed these effects. Additionally, 
these effects were accompanied by a reduction in the degree of the mitochondrial lipid 
peroxidation (Petrosillo et al., 2006; Petrosillo et al., 2009b), inhibition of the MPTP opening 
(Petrosillo et al., 2009a) as well as mitochondrial STAT-3 phosphorylation (Yang et al., 2013). 
5.4.3. Effect of ischaemia on mitochondrial function  
As indicated above, a pivotal feature of ischaemia is that the supply of oxygen and nutrients to 
the mitochondria is inadequate to support oxidative phosphorylation (Solaini and Harris, 2005). 
Previously, it was shown that compared to baseline, mitochondria isolated from ischaemic 
hearts (Veitch et al., 1992) and rat liver (Okatani et al., 2003) were more prone to severe 
morphological and functional defects 
To determine whether mitochondria isolated from hearts from obese rats were more 
susceptible to ischaemic damage than those from the control group, a comparison  was made 
of the data obtained from mitochondria isolated from non-perfused hearts (baseline) and those 
obtained from mitochondria isolated from perfused hearts and exposed to 20 min global 
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ischaemia.  Interestingly, we found that ischaemia reduced the state 3 respiration rate, RCI 
and the rate of oxidative phosphorylation and reoxygenation in the diet group with glutamate 
as substrate (table 5.4), suggesting that mitochondria isolated from obese hearts are indeed 
more prone to ischaemic injury.  Although this was not observed with palmitoyl-L-carnitine as 
substrate, it may be indicative of a reduction in coupling efficiency in the diet group and may be 
associated with potential depletion of ATP synthesis (Leon et al., 2005).  
The absence of any effect with palmitoyl-L-carnitine as substrate in mitochondria from hearts 
isolated from the diet group may be due to the metabolic changes occurring in the hearts in 
obesity.  The increased supply of FFA to the heart is associated with increases in FFA uptake, 
malonyl-CoA levels and FFA oxidation [for review, see (Lopaschuk et al., 2010)]. Thus, it may 
be that mitochondria isolated from hearts from the diet animals are geared towards fatty acid 
metabolism and less susceptible to anoxia/reoxygenation damage than mitochondria when 
incubated with glutamate as substrate (table 5.4). Interestingly, as previously indicated, 
melatonin treatment was able to prevent the reduction in oxidative phosphorylation occurring in 
the diet group (fig.5.4B).   
5.5. CONCLUDING REMARKS 
 “To understand melatonin’s mitochondrial role, it is necessary to interpret the results in a 
contextual and non-simplistic way” (Hardeland, 2009). To our knowledge, this is the first study 
on the effect of melatonin on myocardial mitochondrial function in obesity.  We have shown 
that compared to control, obesity did not affect the respiratory function of mitochondria isolated 
from non-perfused hearts (baseline).  
On the other hand, we also demonstrated that when the respiratory function of mitochondria 
isolated from non-perfused hearts is compared to that of mitochondria isolated from perfused 
hearts which were subjected to global ischaemia, the diet group was more susceptible to 
ischaemic damage. Additionally, the effects of six weeks melatonin treatment depended on 
whether mitochondria were isolated from non-perfused hearts or hearts previously exposed to 
ischaemia.   
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However, the present study is a preliminary investigation which does not allow definite 
conclusions regarding the effects of either obesity or ischaemia on mitochondrial behaviour. 
This will require additional parameters such as evaluation of ATPase activity, antioxidant 
activities, mitochondrial membrane potential and MPTP opening as well as morphological 
changes are warranted. However, the results obtained could form the basis for further studies 
to better understand the effects of melatonin treatment on myocardial mitochondrial function in 
obesity.   
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STUDY III  
EFFECTS OF MELATONIN TREATMENT ON GLUCOSE 
HOMEOSTASIS IN NORMAL AND INSULIN RESISTANT 
STATES 
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      CHAPTER SIX 
6. STUDY III 
 
EFFECTS OF MELATONIN TREATMENT ON GLUCOSE HOMEOSTASIS IN NORMAL AND 
INSULIN RESISTANT STATES 
6.1. INTRODUCTION 
Obesity is frequently associated with insulin resistance and defects in glucose homeostasis 
(Grundy, 2012). Glucose homeostasis encompasses various and complex physiological 
mechanisms for the maintenance of blood glucose concentrations within very narrow 
physiological limits (Norris and Rich, 2012). The normal glucose homeostasis in the fed and 
fasted states has recently been reviewed (Nolan et al., 2011). It is well established that the 
fasting blood glucose concentration is the net result of the balance between endogenous 
glucose production (mainly through hepatic glycogenolysis and gluconeogenesis) and 
utilization by insulin-independent tissues, such as the brain (Nolan et al., 2011). Additionally, in 
the non-fasting condition, insulin (produced by pancreatic β-cells) plays a crucial role in the 
regulation of blood glucose levels (following absorption of carbohydrates in the gut) by 
inhibiting endogenous glucose production and stimulating glucose uptake into peripheral 
tissues, including the heart, skeletal muscle and adipose tissue (Nolan et al., 2011). By 
definition, insulin resistance refers to the condition in which the body produces insulin but does 
not use it properly due to decreased cellular sensitivity to its effects on glucose uptake, 
metabolism and storage (Benito, 2011; Hardy et al., 2012; Rask-Madsen and Kahn, 2012). As 
a consequence, normal circulating insulin concentrations become inadequate to produce a 
normal insulin response in target tissues (Cefalu, 2001; Hardy et al., 2012).  
In obesity, defects in glucose homeostasis lead to compensatory hyperinsulinaemia which, in 
the case of β−cell failure, leads to hyperglycaemia and eventually T2D (Reaven, 2004; Grundy, 
2012).  Recent animal and epidemiological studies support the involvement of melatonin in the 
regulation of glucose metabolism (Ha et al., 2006; Sartori et al., 2009; Xia et al., 2012). 
Removal of the MT1 receptor significantly impaired the ability of mice to metabolize glucose 
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and induced insulin resistance in these animals (Contreras-Alcantara et al., 2010). 
Interestingly, melatonin treatment has been shown to improve glucose homeostasis (insulin 
sensitivity and glucose tolerance) in obesity and insulin resistance (Sartori et al., 2009; Agil et 
al., 2012b; Wan et al., 2013). However, the mechanism underlying the improvement of glucose 
homeostasis is complex and not well understood (Peschke, 2008; Peschke et al., 2012). 
In the evolution of insulin resistance, impairment of insulin-stimulated glucose transport has 
been considered as the most consistent change that develops early, in the hearts of animal 
models (Wright et al., 2009).  As recently demonstrated by Cook et al. (2010), this change 
occurs as a consequence of both reduced GLUT-4 protein expression and impaired 
translocation (Cook et al., 2010; Abel et al., 2012).  Melatonin replacement in pinealectomized 
rats improved pinealectomy-induced insulin resistance and increased plasma membrane 
GLUT-4 protein content in adipose tissue (Zanquetta et al., 2003). Importantly, in hyperthyroid 
rats melatonin treatment was able to protect the heart against oxidative damage and restore 
the expression of the cardiac GLUT-4 gene, supporting the ability of melatonin to improve 
alterations in glucose uptake (Ghosh et al., 2007). However, its effect on myocardial glucose 
uptake and metabolism has not yet been investigated. 
In the present study, we aimed to investigate the effects of melatonin treatment on glucose 
homeostasis focusing on glucose uptake by isolated cardiomyocytes in normal and insulin 
resistant conditions. We tested the hypothesis that acute or long-term (6 weeks) melatonin 
treatment stimulates glucose uptake of normal and insulin resistant cardiomyocytes via 
melatonin receptors. 
Our specific objectives were to determine: 
1. The acute effects of melatonin on glucose uptake by cardiomyocytes isolated from 
young untreated rats. 
2. The acute effects of melatonin on cardiomyocytes isolated from age-matched untreated 
control and obese rats by determining the glucose uptake, insulin sensitivity, effect of 
Stellenbosch University  http://scholar.sun.ac.za
 216 
 
the melatonin receptor antagonist (luzindole) and associated signalling events 
(PKB/Akt, AMPK and GLUT-4 expression). 
3. The effects of long-term (6 weeks) melatonin on glucose uptake by cardiomyocytes 
isolated from control and obese rats. 
6.2. MATERIALS AND METHODS 
6.2.1. Animals  
All animals used were obtained from the University of Stellenbosch Central Research Facility. 
They were housed in the same facility and kept under the same conditions as previously 
indicated in chapter 3. 
6.2.2. Study design: grouping, feeding and treatment 
Animal feeding and treatment are presented in figure 6.1. Animals were divided in five groups: 
normal young rats plus four groups of diet and control rats: untreated (C) and melatonin 
treated (CM) control rats, untreated (D) and melatonin treated (DM) obese rats.  
Normal young rats (225−250g) fed a normal rat chow were used to determine the acute effects 
of melatonin on insulin-stimulated glucose uptake by isolated cardiomyocytes 
Control (C) and diet (D) rats were fed as previously in chapter 3. To evaluate the progressive 
changes in insulin sensitivity, the feeding period was varied from 16 to 19 and 20 to 23 weeks. 
Similar to normal young rats, cardiomyocytes prepared from these rats, were used for the 
determination of the acute effect of melatonin treatment on insulin-stimulated glucose uptake. 
In addition to glucose uptake, these cardiomyocytes were also used for western blot analysis.   
To evaluate the effect of six weeks melatonin treatment on glucose uptake, a number of rats 
were fed for 20 weeks. Four groups were used: (i) untreated control (C), (ii) treated control 
(CM), (iii) untreated diet (D) and (iv) treated diet (DM). The treated animals received melatonin 
in drinking water for 6 weeks (starting after 14 or 17 weeks after initiation of the diet) as 
described in chapter 3.  
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Figure 6.1.Simplified protocol for animal feeding and treatment.  An additional group of normal 
young rats (12) was added to four groups of rats including untreated (18) and melatonin 
treated (6) control, untreated (18) and melatonin treated (6) obese rats. Mel: melatonin, SRC; 
standard rat chow. 
 For the administration of melatonin to isolated cardiomyocytes, the compound was first 
dissolved in ethanol and then in medium buffer (see below “solution E” without substrate) to 
yield a final concentration of 1nM, 10nM, 100nM, 1µM or 10µM. Luzindole and phloretin 
(Sigma-Aldrich , St Louis, MO) were dissolved in dimethyl sulfoxide (DMSO), stored at −80◦C 
as stocks and diluted with medium “solution E” immediately before use.  
6.2.3. Experimental procedure 
6.2.3.1. Cardiomyocytes preparation 
Cardiomyocytes from the different animal groups (fig.6.1) were prepared as previously 
reported (Huisamen et al., 2001; Strijdom et al., 2004).  Briefly, after removal, the heart was 
retrogradely perfused with a calcium free medium or “solution A” (HEPES buffer: 6mM KC1, 
1mM Na2HPO4, 0.2mM NaH2PO4, 1.4mM MgSO4, 128mM NaCl, 10mM HEPES (Sigma-
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Aldrich, St Louis, MO), 5.5mM glucose, 2mM pyruvate, pH 7.4, 37◦C, equilibrated with oxygen) 
for 5 min to remove all blood present in the heart.  Thereafter, the perfusion was switched to 
the second medium or “solution B” [50 mL; “Solution A” containing 0.7% bovine serum albumin 
(BSA) (fraction V, fatty acid free) (Roche, Cape Town), 1.1mg/mL collagenase (Worthington 
Type 2 Biochemical Corporation, Lakewood, NJ) and 15mM 2,3-butanedione monoxime 
(BDM) (Sigma-Aldrich , St Louis, MO)] for 15 min (fig. 6.2). At this stage, for adequate enzyme 
activity, the calcium concentration was gradually increased to 200µM over an additional 5min 
(2X50µL of 100mM CaCl2) and the perfusion continued to a total time of 35 min.  
After perfusion, the ventricles were carefully separated, minced with tweezers and suspended 
in the medium buffer “solution C” (50mL; 25mL of “solution B” and 25mL of “solution A” 
containing 1% BSA and 200µΜ CaCl2). The suspension was placed in a flat-bottomed flask in 
a shaking water bath (37oC, 180 strokes/min) and digested for a further 15min, whereafter the 
calcium concentration was gradually raised to 1.25mM over an additional 5min (4 x 100µL 
followed by 1x125µL of 100mM CaCl2 at intervals of 1min)  (fig. 6.2). 
The isolated cells were filtered through a nylon mesh (pore-size 200×200µm) and gently 
centrifuged (3min at 100rpm). The pellet obtained was re-suspended in HEPES buffer 
containing 1.25mM CaCl2, 2% BSA (fraction V, fatty acid free) or solution “D” and the cells 
allowed to settle for 3 to 4min. The supernatant was carefully aspirated and cells resuspended 
in the same buffer and allowed to recover from the trauma of isolation for 90min before the 
glucose uptake assay. After recovery, the viability of the isolated cardiomyocytes was 
evaluated by trypan blue exclusion. Viability of > 80% was a prerequisite. 
 
Figure 6.2 Simplified protocol for cardiomyocyte isolation: heart perfusion and digestion.  
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6.2.3.2. Determination of 2-deoxy-D-glucose uptake  
• Assay procedure 
2-deoxy-D-glucose (2DG) uptake was measured as previously reported (Huisamen et al., 
2001). In brief, 500µL of suspension of cardiomyocytes (approximately 0.5 mg protein)  were  
assayed in a total volume of 750 µL of oxygenated medium buffer “solution E” containing (in 
mmol/L): KCl 6; Na2HPO4 1; NaH2PO4 0.2; MgSO4 1.4; NaCl 128; HEPES 10; CaCl2 1.25 plus 
2% BSA (fraction V, fatty acid free); pH 7.4.  Samples were assayed in duplicate. 
Figure 6.3 represents the protocol followed for the determination of glucose uptake with 
different treatments. For insulin-stimulated glucose uptake experiments, the cells were pre-
incubated for 15min in a shaking water bath (37◦C, 180 strokes/min) with or without 50µL of 
phloretin (final concentration: 400 µM) for measurement of non-carrier mediated glucose 
uptake (such as GLUT-4, GLUT-1). Each experimental group was then incubated with or 
without 75µL of insulin (final concentration: 1nM, 10nM, 100nM) or 75µL melatonin (final 
concentration: 1nM, 10nM, 100nM, 1µM and 10µM) under the same conditions for 30min 
before glucose uptake was initiated. When both hormones were added to the same cell 
population, melatonin was administered 30 min before addition of insulin (fig.6.3B). In another 
series of experiments, 7.5µL of luzindole (final concentration: 5µM) and/or melatonin were 
administered separately after 15min of stabilization. When both were added to the same cell 
population, luzindole was administered 30min before melatonin was added (fig 6.3B).  
Glucose uptake was initiated by addition of 25µL of 2-deoxy-D- [3H] glucose (2DG) (1.5 
µCi/mL; final concentration: 1.8µM) (Perkin Elmer, Boston). Glucose uptake was allowed to 
progress for 30 min before stopping the reaction by adding 50 µL phloretin (final concentration: 
400 µM).   
After this step, the cells were centrifuged at 2500 rpm for 1 min and the supernatant containing 
radio-labeled 2DG aspirated. Thereafter, the pellet was washed twice with HEPES buffer and 
then dissolved in 0.5mL 1N NaOH at 70 °C in a water bath for 30 to 40min. The final volume of 
the solution was brought to 1mL by adding 0.5mL of dH2O.  50µL of this solution was used for 
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the determination of the protein content by the method of Lowry et al. (1951) while the 
remainder was counted for radioactivity.   
 
Figure 6.3 Simplified protocol for glucose uptake assay. A: When insulin, melatonin (Mel) or 
luzindole (Luz) are used separately, B: when melatonin (1) and insulin (2) or luzindole (1) and 
melatonin (2) are combined, Stab: stabilisation period.  WB: Western blotting  
• Glucose uptake quantification 
Glucose uptake quantification was done in duplicate using 20mL-scintillation vials. Scintillation 
liquid (2mL) was added to 450µL of each sample and mixed before incubation. Additionally, 
two vials containing the scintillation liquid only or the scintillation liquid plus radio-labeled 2DG 
were included for determination of the blank and the total counts, respectively.  
Counting of the radioactivity was done using a scintillation counter (Beckman) after overnight 
stabilization of the samples in the dark at room temperature.  Glucose uptake was determined 
using the following formula:  “Counts-Blank /Specific activity of 2DG x protein content” 
Glucose uptake was expressed as pmol 2DG/mg protein/30min. The glucose uptake value of 
phloretin was subtracted from each sample to get the final glucose uptake value and the fold 
stimulation calculated. 
• Western blotting 
Cell lysates were made after 30min incubation with or without insulin or melatonin before the 
addition of 2-deoxy- D-[3H] glucose (see figure 6.3).  At the end of the incubation period, cells 
were put on ice, transferred to eppendorf tubes, quickly centrifuged and washed 3 times with 
ice-cold HEPES buffer without BSA.  The cells were then lysed in 100 µL of lysis buffer 
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(described in chapter 3). In this regard, cells were sonicated on ice 3 times (intervals of 3 
seconds pulse and 1 second break). Thereafter, they were centrifuged for 20min and the 
subsequent supernatant used for western blotting (as described in chapter 3).  We investigated 
the effect of melatonin on expression and phosphorylation of PKB/Akt (Ser-473); AMPK and 
GLUT-4 expression in cardiomyocytes after incubation with or without insulin or melatonin. 
6.2.4. Data  analysis 
All statistical analyses were done as indicated in chapter 3. 
6.3. RESULTS 
6.3.1. Acute effect of melatonin on glucose uptake by cardiomyocytes  
6.3.1.1.  Normal young rats 
 The effect of melatonin administration on glucose uptake by cardiomyocytes isolated from 
normal young rats is represented in figures 6.4-5. Melatonin at 10 nM (Mel1), 100nM (Mel2), 
10µM (Mel3) and 50 µM (Mel4) had no significant effect on glucose uptake, compared to the 
basal levels (fig.6.4).  
 Insulin, on the other hand caused a 2.3 fold increase in glucose uptake, compared to the 
basal levels. Insulin (1nM) added to cells pre-treated with melatonin (100nM) caused a further 
stimulation of glucose uptake (3.36±0.48 vs 2.48±0.20 fold increase, p<0.05) (fig.6.5). 
However, melatonin at other concentrations did not influence the levels of insulin stimulated 
glucose uptake (fig.6.5). 
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Figure 6.4 Effect of melatonin on glucose uptake of adult cardiomyocytes, Ins: insulin, Mel: 
melatonin, Mel1:10nM, Mel2:100nM, Mel3:10µM, Mel4: 50µM, *p<0.01 (Insulin vs basal), n= 
individual preparations: 12 (basal), 12 (Ins), 3 (Mel1), 8 (Mel2), 4 (Mel3), 3 (Mel4).   
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Figure 6.5 Effect of melatonin on insulin stimulated glucose uptake (fold stimulation), Ins: 
insulin, Mel: melatonin, Ins: 1nM; Mel1:100nM, Mel2:10nM, Mel3:10mM; *p<0.05 (Ins vs 
Ins+Mel1); **p<0.05 (basal vs Ins or Ins +Mel); n=5-10 individual preparations /group  
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6.3.1.2. Rats fed a high calorie diet for 16 to 19 weeks 
Results obtained from the acute effect of melatonin treatment on insulin-stimulated glucose 
uptake are presented in figures 6.6-8 and summarized in table 6.2. Basal glucose uptake did 
not differ significantly between cardiomyocytes isolated from C and D groups (table 6.2).  
In the control group, melatonin or/and luzindole alone did not affect the basal glucose uptake. 
However, melatonin (100nM) enhanced the insulin (1nM) stimulated glucose uptake as a trend 
(73.9± 4.1 vs 49.3±5.6 pmol/mg protein, p=0.05) (fig.6.6).  
Insulin-stimulated glucose uptake was similar in cardiomyocytes isolated from the C and D 
group (fig.6.8; table 6.2). Melatonin pre-treatment (100nM) caused an increase in insulin-
stimulated glucose uptake as a trend in control (p=0.053) (fig 6.6-7). This was significantly 
elevated when compared to D group (fig.6.8B).  
Table 6.2 Glucose uptake by cardiomyocytes from rats fed for 16 to 19 weeks of feeding 
A: absolute values 
Group  Basal Insulin Ins+Mel Mel Mel+Luz BW(g) Vfat (g) 
C 25.6±2.8* 49.3±5.6@ 73.9± 4.1 ** Ŧ 25.5±4.4 19.5±3.5 435±21 17.0±1.4 
D 20.8±3.1* 40.8±3.8 47.5±4.9 20.0±3.4 14.3±3.05 517±11# 33.3±1.3& 
B: Fold stimulation   
C 1 1.92±0.12 2.8±0.16 ** Ŧ 0.99±0.2 0.76±0.07 - - 
D 1 1.96±0.22 2.3±0.07 0.96±0.1 0.68±0.06 - - 
n 6 6 4 6 5 6 6 
 
C: control group, D: diet group, BW: body weight, Vfat: visceral fat, Mel: melatonin, Luz: 
luzindole, *p<0.01 vs Ins, **p<0.001 vs basal, @p=0.05 vs Ins+Mel, Ŧp<0.05 vs D, n=4-6 
individual preparations /group; #p<0.001 vs C, &p<0.001 vs C, n=6/group. Glucose uptake was 
expressed as pmol 2DG/mg protein/30 min (A) or as fold stimulation (B). 
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Figure 6.6 Effect of melatonin and luzindole on glucose uptake by cardiomyocytes isolated 
from control groups, Ins: insulin (1nM), Mel: melatonin (100nM), Luz: luzindole (5µM), *p<0.01 
(basal vs Ins), **p<0.001 (basal vs Ins+Mel), @p=0.053 (Ins vs Ins+Mel), n=4-6 individual 
preparation/group.  
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Figure 6.7 Effect of melatonin and luzindole on glucose uptake by cardiomyocytes isolated 
from diet  groups, after 16-19 weeks, Ins: insulin (1nM), Mel: melatonin (100nM),  Luz: 
luzindole (5µM), *p<0.01 ( basal vs Ins or Ins+Mel), @p=0.3 (Ins vs Ins+Mel), n=4-6 individual 
preparations /group.  
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 Figure 6.8 Insulin-stimulated glucose uptake in control (C) and diet (D) groups, after 16-19 
weeks, A: Insulin alone, B: Insulin with melatonin (Ins+Mel), Ins: insulin (1nM), Mel: 100nM, 
*p<0.01(basal vs Ins or Ins+Mel), **p<0.05 (C vs D), n= 4-6 individual preparations/group. 
6.3.1.3. Rats fed a high calorie diet for 20 to 23 weeks of feeding 
Results for the acute effect of melatonin treatment and insulin-stimulated glucose uptake are 
presented in figures 6.9-11 and summarized in the table 6.3. 
The high calorie diet fed for 20-23 weeks had no effect on basal glucose uptake by 
cardiomyocytes (table 6.3).  While insulin-stimulated glucose uptake was low in the D group, 
compared with the control group (fig.6.11), insulin-stimulated glucose uptake with melatonin 
pre-treatment was similar in both groups (fig.6.11).  
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Table 6.3 Glucose uptake by cardiomyocytes isolated from rats fed for 20 to 23 weeks 
A: Absolute values 
Group Basal Ins Ins+ Mel Mel Mel+Luz BW Vfat 
C 19.9±2.6*** 35.3±6.3 Ŧ 33.5±5.9 19.2±1.7 12.5±2.1* 457±14 18.4±10.9 
D 18.1±1.6 ** 25.9±1.6 27.8±1.1 18.4±2.3 12.1±0.4* 575±61# 38.7±2.6& 
B: Fold stimulation   
C 1 1.75±0.09Ŧ 1.68±0.07 0.96±0.03 0.62±0.13* - - 
D 1 1.41±0.10 1.55±0.13 1.02±0.06 0.66±0.05* - - 
n 6 6 5 6 4 6 6 
 
C: control, D: diet, BW: body weight, Vfat: visceral fat, ND: not determined, Ins: insulin (1nM), 
Mel: melatonin (100nM), Luz: luzindole (5µM), *p<0.05 (Mel vs Mel+Luz), **p<0.01 vs Ins or 
Ins+Mel, ***p<0.01 vs Ins or Ins+Mel, Ŧp<0.05 vs D, n=4-6 individual preparations/group, 
#p<0.001 vs C, &p<0.001 vs C, n=6/group. Glucose uptake was expressed as 2DG pmol/mg 
protein/30min (A), and fold stimulation (B). 
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Figure 6.9 Glucose uptake by cardiomyocytes isolated from control rats after 20-23 weeks of 
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feeding. Ins: 1nM; Mel: 100nM, Luz: luzindole (5µM), *p<0.05 (Basal vs Ins or Ins +Mel); 
**p<0.05 (Mel vs Mel+Luz), n=4-6 individual preparations/group 
Diet group 
Basal Ins Ins+ Mel Mel Mel+Luz
0
10
20
30
*
**
2D
G
(pm
ol
/m
g 
pr
ot
ei
n
/3
0m
in
)
 
Figure 6.10 Glucose uptake by cardiomyocytes isolated from diet rats after 20-23 weeks of 
feeding, Ins (1nM); Mel (100nM), Luz: luzindole (5µM), **p<0.05 (Mel vs Mel+Luz), *p<0.01 
(Basal vs Ins or Ins+Mel), n=4-6 individual preparations/group. 
Comparison between C and D group (20 to 23 weeks) 
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Figure 6.11 Insulin-stimulated glucose uptake by cardiomyocytes from control (C) and diet (D) 
groups.  Ins: insulin (1nM); Mel: melatonin (100nM), *p<0.05 [Ins (C) vs Ins (D) or Ins (D) vs 
basal], **p<0.01 [Ins +Mel (C) or Ins+Mel (D) vs basal or Ins (C) vs basal], n=5-6 individual 
preparations/group. 
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6.3.2. Effect of oral melatonin treatment on glucose uptake by cardiomyocytes 
isolated from rats fed a high-calorie diet. 
• Biometric parameters 
Similar to previous experiments, the high calorie diet significantly increased the body weight 
and visceral fat mass of the rats (table 6.4). Melatonin treatment attenuated body weight and 
the visceral fat mass in the D group (table 6.4). 
Table 6.4 Body weight and visceral fat mass 
Parameters C CM D DM n 
Body weight (g) 433±25 411± 17 538±43** 488±21# 6 
Visceral  fat (g) 17.7±1.8 14.33±1.9* 37.50±7.5** 28.0±4.0# 6 
 
C: control, D: diet, CM and DM: control and diet receiving melatonin for 6 weeks, *p<0.05 vs C, 
#p<0.05 vs D, **p<0.001 vs C, n=6 /group. 
• Glucose uptake 
A high calorie diet alone did not affect the basal glucose uptake by cardiomyocytes isolated 
from control and diet groups.  It reduced however insulin-stimulated glucose uptake with 
100nM insulin (fig.6.12).   
In the control group, melatonin treatment did not affect the basal glucose uptake (22.6±3.7 vs 
21.1±3.5 pmol/mg protein/30min, p>0.05) (fig.6.12). However, administration of 1nM or 100nM 
insulin to cardiomyocytes isolated from the control treated group (CM) resulted in  elevated 
insulin-stimulated glucose uptake compared to their respective untreated groups (p<0.05).  
In the D group, the basal glucose uptake by cardiomyocytes isolated from melatonin treated 
rats was higher than that of untreated rats (26.4±2.1 vs 19.8±3.4 pmol/mg protein/30min, 
p<0.05) (fig.6.12). With administration of 100nM insulin, cardiomyocytes from the treated group 
(DM) had elevated stimulated glucose uptake when compared to their respective untreated 
group (50.1±1.7 vs 32.1±5.1 pmol/mg protein, p<0.01) (fig.6.12). 
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Figure 6.12 Insulin-stimulated glucose uptake by cardiomyocytes isolated from rats fed a high 
calorie diet with or without melatonin treatment, Ins: insulin, C: control, C M: control with 
melatonin, D: diet, DM: diet with melatonin, *p<0.05 (DM vs D), **p<0.05 (CM vs C), &p< 0.05 
(D vs C), #p<0.01(DM vs D), n=4-6 individual preparations/group analysed in duplicate. 
6.3.3. Effect of acute melatonin and insulin treatment on cardiomyocyte signalling 
To investigate which mechanism is implicated in enhancing glucose uptake, cardiomyocytes 
were isolated from control and diet rats fed for 20 weeks. Isolated cardiomyocytes were treated 
with or without melatonin for 30 min and insulin was added for an additional 30 min. Luzindole 
was administered for 30 min before melatonin treatment when they were administered to the 
same cell population.   
 Insulin alone or with melatonin increased the activation of PKB/Akt in control and in D groups 
with a more than 2.2 and 1.5 fold increase respectively (fig.6.13). In control but not in diet 
group, melatonin treatment significantly increased the phosphorylation of PKB/Akt (Ser-473) 
compared to basal levels (p<0.05) (fig.6.13). Interestingly, luzindole attenuated melatonin-
induced PKB/Akt phosphorylation while insulin with or without melatonin had higher PKB/Akt 
phosphorylation in control than in D group (fig.6.13).  
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AMPK and GLUT-4 expression were not affected in all groups of treatment (fig.6.14-15). 
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Figure 6.13 PKB/Akt phosphorylation and activation, C: control, D: diet (high calorie diet), 
Basal (1), Ins: insulin (2), Insulin+melatonin (3), Mel: melatonin (4), luzindole+melatonin (5), 
Luz: luzindole, C: *p<0.05 (Ins or Ins+Mel vs basal), **p<0.05 (Mel vs basal or luzindole), D: 
*p<0.05 (Ins or Ins+Mel vs basal),  #p<0.05 (D vs C), n=3 individual preparations/group. Blot 
presented is representative. C and D performed on the same blot.  
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Figure 6.14 GLUT-4 expression, C: control (A), D: high calorie diet (B), basal (1), Ins: insulin 
(2), insulin+melatonin (3), Luz: Luzindole, Mel: melatonin (4), Luzindole + melatonin (5), n=3 
individual preparations/group.  Blot presented is representative. C and D performed on the 
same blot.  
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Figure 6.15 AMPK expression and phosphorylation, C: control (A), D: high calorie diet (B), 
basal (1), Ins: insulin (2), insulin +melatonin (3), Mel: melatonin (4), luzindole + melatonin (5), 
Luz: luzindole, n=3 individual preparations/group. Blot presented is representative. C and D 
performed on the same blot. 
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6.4. DISCUSSION  
As mentioned in the introduction to this chapter, glucose homeostasis involves various and 
complex mechanisms associated with glucose availability and utilization (Norris and Rich, 
2012). The first step of glucose metabolism is glucose transport across the cell membrane. In 
chapter 4 we focused on melatonin’s effects on insulin resistance focussing on fasting blood 
glucose and serum insulin levels as well as glucose tolerance. It is well established that in the 
non-fasting condition, insulin plays a crucial role in the regulation of blood glucose levels by 
inhibiting endogenous glucose production and stimulating glucose uptake into peripheral 
tissues, including the heart, skeletal muscle and adipose tissue (Nolan et al., 2011). To gain 
more information regarding myocardial glucose metabolism in obesity, we studied the effects 
of melatonin treatment on glucose uptake by cardiomyocytes isolated from hearts from normal 
and insulin resistant rats.  
The main findings  are as follows:  (i) acute melatonin treatment alone had no effect on 
glucose uptake by cardiomyocytes isolated from hearts from young, old or insulin resistant 
rats; (ii) acute melatonin treatment enhanced, in a concentration-dependent manner, the 
insulin-stimulated glucose uptake by cardiomyocytes isolated from the hearts of normal young 
rats; (iii) acute melatonin treatment did not affect insulin-stimulated glucose uptake by 
cardiomyocytes isolated from old control or insulin resistant animals; (iv) acute melatonin 
administration to cardiomyocytes isolated from hearts from control but not insulin resistant rats 
was associated with increased basal PKB/Akt phosphorylation with no effect on AMPK 
phosphorylation and GLUT-4 expression, (v) long-term (6 weeks) melatonin treatment 
increased basal glucose uptake by cardiomyocytes isolated from the hearts of obese rats and 
enhanced insulin-stimulated glucose uptake in both groups. 
6.4.1. Effects of acute melatonin treatment on cardiomyocyte glucose uptake 
The role of melatonin in glucose metabolism has recently attracted many investigators 
(Peschke, 2008; Agil et al., 2012b; de Oliveira et al., 2012; Faria et al., 2013; Karamitri et al., 
2013; Zanuto et al., 2013). The implication of melatonin in glucose regulation in general and in 
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glucose uptake in particular has been supported by the observation that pinealectomized 
animals developed insulin resistance (Lima et al., 1998; Alonso-Vale et al., 2004). In this 
regard, pinealectomy was associated with a decrease in glucose uptake by adipose tissue 
(Lima et al., 1998; Alonso-Vale et al., 2004). Accordingly, administration of melatonin reversed 
pinealectomy-induced insulin resistance and improved glucose uptake of isolated adipose 
tissue (Lima et al., 1998; Alonso-Vale et al., 2004). On other hand, as expected, due to its anti-
lipogenic activities, a decrease in glucose uptake was reported in PAZ6 adipocyte cells after 
14 days incubation with melatonin (Brydon et al., 2001).  Additionally, melatonin was shown to 
increase glucose uptake in C2C12 myotubules (Ha et al., 2006). However, controversially, in the 
present study, melatonin had no significant effect on glucose uptake by isolated 
cardiomyocytes from hearts from young rats (fig.6.4).  Similar findings have also been reported 
in chick brain (Cantwell and Cassone, 2002) as well as in adipose tissue isolated from a 
female fruit bat (Banerjee et al., 2011). Interestingly, when insulin (1nM) was added to cells 
pre-treated with melatonin (100nM), it caused a further stimulation of glucose uptake (fig.6.5). 
This synergistic interaction between melatonin and insulin-stimulated glucose uptake is 
consistent with previous studies (Banerjee et al., 2011; de Oliveira et al., 2012; Wang et al., 
2013) and supports the potential insulin-sensitizing effect as previously suggested (see 
chapter 4, section 4.4.2).   
We expanded our investigation by additionally studying the effect of obesity and insulin 
resistance on glucose uptake, using cardiomyocytes isolated from hearts from control and diet 
rats fed for 16 to 19 weeks.  Despite increased body weight and visceral fat mass, the diet had 
no effect on basal glucose uptake (table 6.2) as previously reported (Huisamen et al., 2011). In 
addition, as it was observed in cardiomyocytes isolated from hearts from young rats, melatonin 
alone was without effect.  However, it enhanced the insulin stimulated glucose uptake as a 
trend (fig.6.6) in cardiomyocytes from control hearts, but this disappeared in the diet group 
(fig.6.7).  This could be merely due to ageing coupled to the progression of insulin resistance 
as previously demonstrated in control and obese mice (Carroll et al., 2005). 
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In addition to above, we furthered our investigation by using cardiomyocytes isolated from 
hearts from control and diet rats fed for a longer period, namely 20 to 23 weeks. As it was 
observed in 16 to 19 weeks study, the diet and/or melatonin had no effect on basal glucose 
uptake (table 6.3). Additionally, insulin-stimulated glucose uptake was significantly lower in the 
diet group, compared with the control group (fig.6.11) which may be indicative of an 
impairment of insulin actions and myocardial insulin resistance.  As observed in 16 to 19 
weeks study, melatonin pre-treatment had no effect on insulin-stimulated glucose uptake in 
both groups, in contrast to what was observed in the younger animals (fig.6.11).  The loss of 
the synergistic interaction between melatonin and insulin action is difficult to explain.  It may be 
a result of ageing in the control group which is coupled to insulin resistance in obese (D) group 
as previously demonstrated in control and obese mice (Carroll et al., 2005).  However, 
additional investigation is needed to explain this phenomenon. 
To explore whether melatonin receptors are involved in glucose uptake, we used the melatonin 
receptor antagonist luzindole. Luzindole alone had no effect on cardiomyocyte glucose uptake 
(fig.6.19-10). Surprisingly, in the presence of melatonin, luzindole significantly attenuated 
glucose uptake (fig.6.19-10), an effect difficult to explain since melatonin had no effect on 
basal glucose uptake by isolated cardiomyocytes.  However Luzindole has been shown to 
attenuate the melatonin-stimulated glucose uptake in C2C12 in myotubules (Ha et al., 2006) 
and this was recently confirmed in insulin resistant 3T3-L1adipocytes (Wang et al., 2013).  
Although the basal levels were not shown, not only did the melatonin receptor agonist, 
piromelatine (Neu-P11), enhance insulin-stimulated glucose uptake as was observed with 
melatonin, but luzindole was also able to reverse these effects (Wang et al., 2013), supporting 
the involvement of the melatonin receptor in the synergistic interaction between melatonin and 
insulin-stimulated glucose uptake.  
6.4.2. Effects of long-term melatonin treatment on cardiomyocyte glucose uptake  
 Long-term melatonin treatment has been shown to improve glucose homeostasis and to 
reduce insulin resistance (Sartori et al., 2009; Agil et al., 2012b; Wan et al., 2013; Zanuto et 
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al., 2013). Although the high calorie diet caused a significant increase in body weight and 
visceral fat mass (table 6.4), obesity had no effect on basal cardiomyocyte glucose uptake 
consistent with a previous study (Huisamen et al., 2011). It reduced however insulin-stimulated 
glucose uptake as previous reported (Huisamen et al., 2011; Flepisi et al., 2013).  
As expected, melatonin treatment induced a significant weight gain inhibition in the diet group 
(table 6.4) with a concomitant increase in basal glucose uptake by isolated cardiomyocytes 
(fig.6.12).  In view of the increase in basal glucose uptake, although we did not measure 
GLUT-1 expression, this is responsible for the basal glucose transporter in many cell types and 
its expression would give more insight [for review, see (Mueckler and Thorens, 2013)]. 
Importantly, when stimulated by insulin, cardiomyocytes isolated from both treated groups 
exhibited increased glucose uptake (fig.6.12). Collectively, these findings support the 
involvement of  melatonin in glucose homeostasis at cellular levels as previously demonstrated 
(Sartori et al., 2009; Shieh et al., 2009; Faria et al., 2013; Wan et al., 2013).  However, how 
melatonin affected glucose homeostasis and enhanced insulin sensitivity is complex and 
unclear (this has largely been discussed in chapter 4). In obesity, long-term melatonin 
treatment may indirectly increase insulin sensitivity through changes in the metabolic profile 
such as increasing adiponectin levels and reducing leptin resistance (Agil et al., 2011, 
Kitagawa et al., 2012). In the following section we will further discuss the potential intracellular 
signalling associated with the synergistic interaction between melatonin and insulin. 
6.4.3. Melatonin and cardiomyocyte signalling 
As discussed above, melatonin receptors may play an important role in the regulation of 
glucose metabolism. Melatonin receptors have been identified in cardiomyocytes (Peliciari-
Garcia et al., 2011). Importantly, removal of the MT1 receptor significantly impairs the ability of 
mice to metabolize glucose and probably induces insulin resistance in these animals 
(Contreras-Alcantara et al., 2010). In view of the synergistic interaction between insulin and 
melatonin on glucose uptake, we aimed to explore the intracellular signalling processes that 
may be involved in this effect. For this particular study, we preferred to use cardiomyocytes 
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isolated from control and diet groups for 20 weeks as in chapters 4 and 5. To avoid the 
complexity of the multiple physiological factors of in vivo treatment, we used an in vitro 
approach to evaluate the direct effect of melatonin treatment. Isolated cardiomyocytes were 
treated with or without melatonin for 30 min and insulin was added for an additional 30 min, 
followed by evaluation of the expression and phosphorylation of PKB/Akt and AMPK as well as 
GLUT-4 expression. The following section will focus on their role in glucose uptake. 
6.4.3.1. PKB/Akt, AMPK, GLUT-4 and glucose uptake 
PKB/Akt and AMPK play important roles in insulin mediated and non-insulin mediated glucose 
uptake, respectively [for review, see (Montessuit and Lerch, 2013)].  As discussed in chapter 4 
(section 4.4.4.4), GLUT-4 is the most prominent glucose transporter in differentiated 
cardiomyocytes (Montessuit and Lerch, 2013). Apart from its involvement in insulin- stimulated 
actions, PKB/Akt has multiple other actions, including cell survival activities where it can be 
activated independently of insulin actions [for review, see (Manning and Cantley, 2007)].  
Our results showed that the high calorie diet reduced basal PKB/Akt phosphorylation (fig.6.13) 
confirming previous findings in isolated cardiomyocytes from obese animals (Huisamen et al., 
2001). This could be, however, increased by melatonin alone as well as insulin with or without 
melatonin pre-treatment, all showing a higher increase in the control than in the diet group. 
The involvement of PKB/Akt phosphorylation in glucose homeostasis upon melatonin 
treatment has been consistently reported by several researchers using various tissues/organs 
(Sartori et al., 2009; Shieh et al., 2009; Faria et al., 2013; Wan et al., 2013). Our results 
showed that PKB/Akt phosphorylation was closely associated with glucose uptake stimulated 
by insulin alone or with melatonin pre-treatment (fig.6.13), confirming involvement of PKB/Akt 
in insulin-stimulated glucose uptake  (fig.6.11).   
On other hand, however, an increase in PKB/Akt phosphorylation in cells treated with 
melatonin alone in the absence of insulin) was also observed. This is unlikely to play a role in 
glucose uptake since in vitro melatonin treatment alone had no significant effect on basal 
glucose uptake (fig.6.9-10),  highlighting that PKB/Akt  phosphorylation does not necessarily 
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translate into glucose uptake.   In this regard, Ha and co-workers (2006) have also shown that 
melatonin induced glucose uptake in C2C12 mouse skeletal muscle cells independently of 
PKB/Akt phosphorylation, suggesting a tissue-dependent effect. Interestingly, luzindole 
abolished PKB/Akt phosphorylation induced by melatonin treatment alone (fig.6.13), 
suggesting involvement of the melatonin receptor in melatonin-induced PKB/Akt 
phosphorylation. The involvement of PKB/Akt in melatonin’s effects is further discussed in 
chapters 4 and 7 focusing on heart tissues and endothelial cells, respectively. 
Supporting the observation made by Ha et al. (2006), AMPK expression and phosphorylation 
were not affected, suggesting that the effects of melatonin are not AMPK dependent (fig.6.15). 
The lack of effect of insulin on AMPK was also reported in cardiomyoctes isolated from hearts 
from control and obese mice (Carroll et al., 2005). The effects of melatonin on AMPK are 
further discussed in chapter 7 focusing on endothelial cell function.  
GLUT-4 expression was not affected by either the diet or melatonin treatment (fig.6.14). This is 
in agreement with an in vivo study where melatonin did not affect basal GLUT-4 expression in 
skeletal muscles after 16 weeks of treatment (Mendes et al., 2013). However, although a 
defect in GLUT-4 expression may indicate an impaired insulin action, its translocation to the 
membrane is a better indicator of glucose uptake (Montessuit and Lerch, 2013). One month of 
calorie restriction or melatonin replacement (50µg/100g/day, i.p.) to pinealectomized rats 
improved insulin sensitivity and increased plasma membrane GLUT-4 protein content in 
adipose tissue (Zanquetta et al. 2003).  However, as previously indicated, melatonin’s effect 
may vary depending on the cell type of as well as the experimental protocol. For example, a 
decrease in glucose uptake and corresponding GLUT-4 gene expression was previously 
reported following melatonin treatment in human brown adipocyte cells lines (PAZ6) (Brydon et 
al., 2001).  
The effect of melatonin treatment on GLUT-4 expression is further discussed in chapter 4. 
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6.5. CONCLUSION 
Convincing evidence exists for the involvement of melatonin in glucose homeostasis (Peschke, 
2008; Sartori et al., 2009; Agil et al., 2012b; Peschke et al., 2013; Zanuto et al., 2013). 
However, the role of melatonin in glucose metabolism is not yet clear. In the present study, we 
have demonstrated that acute melatonin treatment of isolated cardiomyocytes had no effect on 
basal glucose uptake regardless of the age of the animal or insulin sensitivity. We have also 
demonstrated that long-term melatonin treatment increased basal glucose uptake by 
cardiomyocytes isolated from the hearts of obese insulin resistant rats. Additionally, we 
showed that melatonin enhanced insulin-stimulated glucose uptake by cardiomyocytes when 
administered in vivo or in vitro. Interestingly, the increase in PKB/Akt phosphorylation induced 
by acute melatonin treatment in vitro was not associated with increased glucose uptake and 
further investigation into the intracellular signalling processes involved is warranted.  
6.6. STUDY LIMITATION 
The present investigation focused on glucose uptake by isolated cardiomyocytes under 
normoxic conditions. Therefore, additional investigations using isolated cardiomyocytes 
exposed to stimulated ischaemia or anoxia are needed to elucidate the effects of melatonin on 
glucose uptake/metabolism and its role in cardioprotection. In addition, since the heart is 
comprised of a number of different cell types in which the effects of  melatonin  on glucose 
uptake/metabolism may differ, further investigation using isolated perfused hearts (under 
normoxic or ischaemic conditions) is warranted to get more insight into the role of melatonin in 
myocardial glucose uptake. 
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STUDY IV 
THE EFFECTS OF ACUTE MELATONIN TREATMENT ON CARDIAC 
MICROVASCULAR ENDOTHELIAL CELLS 
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CHAPTER SEVEN 
7. STUDY IV 
 
THE EFFECTS OF ACUTE MELATONIN TREATMENT ON CARDIAC MICROVASCULAR 
ENDOTHELIAL CELLS 
7.1. INTRODUCTION 
Obesity and insulin resistance have been associated with a low grade inflammatory state 
(Furukawa et al., 2004; de Luca and Olefsky, 2008; Lionetti et al., 2009) which is identified by 
elevated circulating cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin (IL)-
1β, IL-6 and IL-8 (Picchi et al., 2006; Qatanani and Lazar, 2007; Agil et al., 2012a). TNF-α has 
been shown to induce vascular endothelial dysfunction in MetS and diabetes (Hotamisligil, 
1999; Picchi et al., 2006). In these conditions, melatonin administration reversed the levels of 
inflammatory markers including TNF-α (Nishida, 2005; Agil et al., 2012a) which is known as the 
first pro-inflammatory cytokine to be released by an inflammatory response (Carvalho-Sousa et 
al., 2011). Additionally, it has recently been demonstrated that TNF-α interferes with melatonin 
synthesis (Carvalho-Sousa et al., 2011), supplying an explanation for the reduced levels of 
melatonin observed in inflammatory states (Tamura et al., 2010).   
Previous studies on the effects of melatonin using endothelial cells have indicated that 
melatonin has beneficial effects in preventing/protecting against endothelial dysfunction 
(Rodella et al., 2013). Indeed, melatonin is a pleiotropic molecule able to enter all cells, 
including circulating platelets, and is transported everywhere in the body (Di Bella and 
Gualano, 2006; Hardeland et al., 2006).  In the case of the vascular endothelium, it can 
regulate blood-tissue exchanges (Di Bella and Gualano, 2006).  In this regard, melatonin has 
been suggested to interact with endothelial cells by regulating the release of both relaxing-
factors (e.g., nitric oxide) and contracting-factors (e.g., endothelin) (Di Bella and Gualano, 
2006). Importantly, compared to cells from animals with normal nocturnal levels of melatonin, 
endothelial cells obtained from animals  with lower nocturnal melatonin levels  expressed  
higher levels of adhesion molecules and inducible nitric oxide synthase (iNOS) (Tamura et al., 
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2010). This was also associated with an increased translocation of the transcription factor 
nuclear factor kappa B (NF-kB) to the nuclei (Tamura et al., 2010), indicating endothelial 
protection by endogenous melatonin. These melatonin-induced endothelium protective 
properties have been shown to be accomplished via diverse mechanisms including free radical 
scavenging activities, stimulation of antioxidant defence enzymes, normalization of lipid and 
blood pressure profiles and an eventual increase in nitric oxide (NO) bioavailability (Anwar et 
al., 2001; Grossini et al., 2011; Rodella et al., 2013). 
The cardiac and coronary vascular endothelium plays an important role in cardiac function in 
normal and pathological conditions (Brutsaert, 2003; Strijdom and Lochner, 2009). Cardiac 
endothelium comprises myocardial capillary endothelial cells (cardiac microvascular 
endothelial cells or CMECs) and endocardial endothelial cells (Strijdom and Lochner, 2009). 
While the coronary endothelial cells affect the cardiomyocytes indirectly, CMECs directly 
influence the physiology of cardiomyocytes (Strijdom and Lochner, 2009). In addition, not only 
do CMECs outnumber cardiomyocytes by a ratio of 3:1 (Brutsaert, 2003), but also produce 
more NO than cardiomyocytes (Strijdom et al., 2006).  NO, in turn, plays an important role in 
the regulation of the myocardial contractile performance, heart rate, metabolism and 
modulation of growth (Massion et al., 2003).  It is also implicated in the cardioprotective 
response of the heart to ischaemia-reperfusion damage (Schulz et al., 2004).  In the setting of 
IRI, endothelial cell damage leads to microvascular dysfunction [for review, see Opie (2004)]. 
Therefore, as CMECs represent about 90% of the total endothelial cells in the heart (Piper et 
al., 1990), their dysfunction may be even more detrimental in ischaemia.  Surprisingly, the role 
of CMECs dysfunction has been overlooked or simply not explored in myocardial IRI. In this 
regard, few studies have been done on CMECs (Zhang et al., 2011; Qi et al., 2013).  In 
addition, whether insulin resistance affects CMECs function has not yet been studied. 
 In view of this unexploited area of research, more investigations on CMECs are required. In 
the context of the role of melatonin in cardioprotection, considering the direct impact of CMECs 
on cardiomyoyte physiology (especially NO production) (Strijdom and Lochner, 2009), 
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investigation into the acute and long- term effects of melatonin on the CMECs NO production 
in normal as well as pathological conditions is warranted. Furthermore, whether the 
cardioprotective effects of melatonin are associated with cardiac endothelial protection remains 
unexplored. Thus, in this study, we investigated the effects of acute melatonin treatment on 
cardiac microvascular endothelial cells.  
Our objectives were to determine: i) the effect of melatonin on endothelial cells focusing on NO 
production and cell viability, ii) the effect of melatonin on TNF-α-induced endothelial 
dysfunction, focusing on eNOS activation and expression and intracellular signalling as 
indicated by activation of ERK1/2, PKB/Akt, STAT-3, AMPK and expression of iNOS, Iκβ-α and 
nitrotyrosine levels. 
7.2. MATERIAL AND METHODS 
Similar to the previous parts of our investigation, chemicals and other materials used are 
described in chapter 3. In this section, the cell culture technique and experimental procedure 
are described.  
7.2.1. CARDIAC MICROVASCULAR ENDOTHELIAL CELL (CMEC) CULTURE 
Adult rat CMECs were commercially purchased from VEC technologies (Rensselaer, New 
York, USA). Upon arrival, CMECs in 25 or 75 mL fibronectin coated tissue culture flasks were 
immediately cultured as previously described (Strijdom et al., 2009).  A standard tissue culture 
incubator with an atmosphere of 21 % oxygen, 5 % carbon dioxide, 40-60 % humidity and 
temperature at 37 ºC was used during the entire cell culture procedure.  Briefly, CMEC cultures 
were maintained in a microvascular endothelial cell growth medium (EGM) (Clonetics EGM-2 
MV; Lonza, Walkersville, MD, USA), supplemented with 10% foetal bovine serum (FBS) 
(Highveld Biological, RSA) and other standard endothelial cell culture supplements such as 
growth factors and antibiotics. Cells were grown until they were fully confluent.  At this stage, 
passaging of primary cultures was performed with 500 BAEE units trypsin/180 µg EDTA • 4Na 
per mL in Dulbecco’s phosphate buffered saline (PBS) (Sigma Chemical Co, St Louis, Mo, 
USA).  Subcultures became confluent in about 5 days.  After the 4th to 7th passage, cells were 
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finally plated in fibronectin-coated 35mm dishes at a density of ~1 × 106 cells/dish.  Purity of 
CMEC cultures was verified by microscopic identification of typical “cobblestone” monolayer 
morphology (Strijdom et al., 2006; Strijdom et al., 2009b). Functional characterization was 
determined by measuring the uptake of fluorescently labelled Dil-ac-LDL, a marker specific for 
endothelial cells (Piper, 1990) by flow activated cell sorter (FACS) analysis, with demonstration 
of a positive staining rate throughout. No experiments were conducted on CMEC subcultures 
with < 80 % purity. 
Prior to experimentation, the existing 10% FBS-containing EGM was removed and substituted 
with EGM in which the FBS was reduced to 5%. 
7.2.2. DRUG ADMINISTRATION 
Melatonin was first dissolved in DMSO and thereafter in growth medium to yield a final 
concentration of 1nM, 1µM or 10µM. These concentrations have been used in previous studies 
on microvascular endothelial cells (Silva et al., 2007; Tamura et al., 2009).   
After determination of the effect of melatonin on NO production and cell viability, we opted to 
use 1nM in further experiments including the TNF-α-induced endothelial dysfunction study. 
This dosage is near the physiological melatonin concentration (Arendt, 2006). All tubes 
containing melatonin were covered by aluminium foil to protect against the light.  Compared to 
the control (fresh growth medium), DMSO alone had no effect on cell viability and other 
parameters. 
7.2.3. EXPERIMENTAL PROCEDURE 
Figure 7.1 shows the main steps in the experimental procedure. We have divided our 
investigation into three parts: 1) Cell viability assessment, 2) NO production determination and 
3) TNF-α-induced endothelial dysfunction.  
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Figure 7.1 Simplified schematic representation of the experimental procedure. PI: propidium 
iodide, DAF-2/DA: 4, 5-diaminofluorescein-2/diacetate, FACS: flow activated cell sorter, NO: 
nitric oxide 
7.2.3.1. Cell viability  
Cell viability was assessed as previously described (Strijdom et al., 2009b).  To investigate the 
effect of melatonin on endothelial cell viability, 5µM of propidium iodide (PI) (Sigma Chemical 
Co, St Louis, Mo, USA) and 5µM annexin V (conjugated with Alexa Fluor® 647) (Calbiochem 
San Diego, CA, USA) were administered  to melatonin-pre-treated cells (at 1nM, 1µM and 10 
µM for 1h, 6h and 24h incubation).  After the treatment period, cells were trypsinised and 
washed sequentially in staining and binding buffer (BioLegend, San Diego, CA, USA) before 
administration of PI or Annexin V and incubation at room temperature in the dark for 15 min. 
This was followed by FACS analysis.   
PI and Annexin V were used to determine cell viability. PI uptake identified the non-viable 
(necrotic) cell population. Due to loss of membrane integrity, the cell membrane becomes 
permeable and the PI probe enters into the cell and subsequently stains the nucleus.  Annexin 
V staining was used as a marker for apoptotic cells. It binds to phosphatidylserine protein 
which is an intracellular membrane protein that translocates to the external surface of the 
plasma membrane in apoptotic events. 
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7.2.3.2. NO production determination  
NO production was measured directly using the NO-specific 4, 5-diaminofluorescein-
2/diacetate (DAF-2/DA) fluorescent probe as previously described by Strijdom et al. (2006). 
Cells were incubated with varying concentrations of melatonin (1nM, 1µM and 10 µM) and 
different times of incubation: 1h, 6h and 24 h. At the end of the incubation, cells were washed 
with PBS and incubated with 10 µM DAF-2/DA at 37ºC for 2 h. Thereafter DAF-2/DA was 
washed out, cells trypsinised and resuspended in probe-free PBS for FACS analysis. 
7.2.3.3. Flow cytometry 
FACS analysis of CMECs treated with PI and Annexin V or DAF-2/DA was performed as 
previously described (Strijdom et al., 2009b).  A FACS analyser (Becton-Dickinson 
FACSCalibur, Franklin Lakes, NJ) was used to quantify fluorescence in the FL1-H channel at 
the single-cell level, and data was analysed using Cellquest® version 3.3 (Becton, Dickinson 
and Co, San Jose, CA, USA) software.  Briefly, selected cell populations (5,000–15,000 cells) 
were gated from initial acquisition populations containing 30,000–50,000 events. Selection was 
done by gating control samples according to their forward scatter (cell length) and side scatter 
(cell granularity) signals, thereby excluding non-cellular particles and debris. In order to 
standardize selection of the analysed cell populations between different samples, gating 
coordinates of control samples were used for all subsequent samples in a particular FACS 
session. Caution was taken to ensure that selected samples contain equal cell numbers for 
comparison purposes.  
Fluorescence signals were recorded on a frequency histogram by logarithmic amplifiers.  A 
probe-free absolute control sample (to determine autofluorescence) and probe-containing 
control samples were included in all experiments. Fluorescence data were expressed as mean 
fluorescence intensity (% of control, control adjusted to 100%). 
7.2.3.4. TNF-α-induced endothelial dysfunction 
To investigate the effect of melatonin on TNF-α-induced endothelial dysfunction, four different 
groups of treatments were studied: (i) untreated cells (or control), (ii) cells treated with 
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melatonin (1nM) for 1h or for 24 h, (iii) cells treated with TNF-α (20ng/mL) for 24h and (iv)  cells 
pre-treated with melatonin (1nM) for 1h and thereafter treated with melatonin combined with 
TNF-α (20ng/mL) (Sigma Chemical Co, St Louis, Mo, USA) for 24h. All samples were 
incubated in fresh growth medium. After incubation (1h or 24h), samples were prepared for 
western blotting.  
7.2.3.4.1. Western blot analysis  
After trypsinization, at least four plates of cells (submitted to the same treatment protocol) were 
pooled to make one lysate. The proteins studied are summarized in table 7.1. Protein 
expression and activation were assessed using western blot analysis as indicated in chapter 3. 
Lysates were made using a lysis buffer containing (in mM): Tris-HCl (pH 7.5) 20, EGTA 1, 
EDTA 1, NaCl 150, β-glycerophosphate 1,  sodium orthovanadate 1,  tetra-sodium diphosphate 
2.5, NaF 50,  PMSF 1,  0.1% Sodium dodecylsulfate (SDS),  aprotinin 10 µg/mL; leupeptin 10 
µg/mL and 1% Triton-X100. After sonication, the protein content of each lysate was determined 
using the Bradford technique (Bradford, 1976).  
For each cell lysate, equal amounts of protein were loaded on 7.5 and 10% SDS-
polyacrylamide gels and transferred onto PVDF membranes (see table 7.1) and proteins 
separated as described in chapter 3.  
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Table 7.1 Protocol for detection of proteins 
Protein MW Quantity Gel 
Antibody dilution 
Primary Secondary 
PKB/Akt 60kDa 50µg 12% 1:1000 TBST 1:4000 TBST(5% milk) 
ERK 42/44 42/44kDa 30µg 12% 1:1000 TBST 1:4000 TBST 
STAT-3 79/86 kDa 50µg 10% 1:1000TBST 1:4000 TBST 
iNOS 130 kDa 60µg 7% 1:2000TBST 1:4000TBST(5%Milk) 
eNOS 140kDa 60µg 7% 1:1000 TBST 1:4000TBST(2.5%Milk) 
IκB-α 39kDa 50µg 12% 1:1000 TBS 1:4000TBST 
p38 MAPK 43kDa 30µg 12% 1:1000 TBST 1:4000 TBST 
AMPK 62kDa 60 µg 10% 1:1000 TBST 1:4000 TBST(5% milk) 
Nitrotyrosine 60kDa 50µg 10% 1:1000 TBST 1:5000TBST 
β-tubulin 55kDa ------* 10-12% 1:1000 TBST 1:4000 TBST 
 
MW: Molecular weight, *β-tubulin was used to check the equal loading (performed after striping 
the membrane).  
7.2.4. DATA ANALYSIS 
All statistical analyses were performed as indicated in chapter 3. For cell viability and NO 
production experiments, fluorescence data were expressed as percentage of control, control 
adjusted to 100%. 
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7.3. RESULTS 
7.3.1. CELL VIABILITY 
To test the effect of melatonin administration on endothelial cell viability, melatonin (1nM, 1µM 
or 10 µM) was administrated to CMECs for 1h, 6h and 24 h. After 1h, melatonin treatment 
caused a significant reduction in necrosis (PI) (1nM: 49.3±21%; 1µM: 24.0±1.1%; 10µM: 
21.8±2.6%) and apoptosis (Annexin V) (1nM: 48.3±16.8%; 1µM: 30.1±2.8%; 10µM: 23.3±3%) 
compared to untreated cells (p<0.05) (fig.7.2).  
However, after 6h, melatonin caused a dose-dependent increase in percentage of necrotic 
cells, becoming significant at 10µM (177.2±10.4%, p<0.05) (fig.7.3B). As similar observation 
was also made after 24h treatment, becoming significant at 1µM and 10µM (1µM: 125.0±9.2%; 
10µM: 129.2±8.8%) (fig.7.4B). Melatonin, however, had no effect on the number of apoptotic 
cells, regardless of the concentration after 6h and 24h (fig.7.3-4).  
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Figure 7.2 Effect of melatonin on cell viability after 1h treatment, expressed as percentage of 
control, control=100%, A: AnnexinV, B: propidium iodide (PI), *p<0.05 vs control, n=6-8/group.  
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Figure 7.3 Effect of melatonin on cell viability after 6h of treatment, expressed as percentage 
of control, control=100%, A: AnnexinV, B: propidium iodide (PI), *p<0.05 vs control, #p=0.07 vs 
control, n=6-8/group. 
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Figure 7.4 Effect of melatonin on cell viability after 24h of treatment, expressed as percentage 
of control, control=100%, A: AnnexinV, B: propidium iodide (PI), *p<0.05 vs control, n=6-
8/group. 
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7.3.2. NO PRODUCTION 
To test the effect of melatonin administration on NO production, melatonin at the dosages of 
1nM, 1µM and 10µM was administered to CMECs for 1h, 6h and 24h. After 1h, melatonin 
(1nM) treatment caused a significant reduction in NO levels (91.9±2.7% vs control, p<0.05). 
After 6h, melatonin at all concentrations attenuated the levels of NO (1nM: 85.3±5.1%; 1µM: 
69.2±6.6%; 10µM: 81.4±5.6%) compared to control (p<0.05) (fig.7.6).  When the treatment was 
extended to 24h, melatonin at 10µM reduced significantly the level of NO (93.4±2.1%) 
compared to control while other dosages did not affect the level of NO (fig.7.7). 
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Figure 7.5 Effect of melatonin on NO production (mean DAF fluorescence) after 1h (A) and 6h 
(B) treatment, expressed as percentage of control, control=100%, *p<0.05 vs control, n=4-
6/group. 
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Figure 7.6 Effect of melatonin on NO production (mean DAF fluorescence) after 24h treatment, 
expressed as percentage of control, control=100%, *p<0.05 vs control, n=4-6/group. 
7.3.3. TNF-α-INDUCED ENDOTHELIAL DYSFUNCTION 
7.3.3.1. NO production 
To test the effect of TNF-α on endothelial cell dysfunction, TNF-α was administered at the 
dosages of 0.5, 5 and 20ng/mL to CMECs for 24h. The following data are from Amanda Genis 
(Division of Medical Physiology, SU) who performed the experiment. TNF-α administered at the 
dosages of 0.5ng/mL and 20ng/mL significantly reduced NO production compared to the 
control (fig.7.7A). However, it had no effect on NO production when administered at 5ng/mL.  
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Figure 7.7A  Effect of TNF-α on CMECs NO production, 24h incubation, fluorescence values 
expressed as percentage of the control (control =100%), C: control, PC: positive control, T1: 
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TNF-α (0.5ng/mL), T2: TNF-α (5ng/mL), T3: TNF-α (20ng/mL), *p<0.05 vs Control, n=4/group, 
experiment performed 3 times.  
7.3.3.2. PKB/Akt-eNOS pathway 
In view of the above results on NO production, we further studied the effect of TNF-α on the 
PKB/Akt-eNOS pathway. Cells were incubated with TNF-α (0.5, 5 and 20ng/mL) for 24 h after 
which lysates were prepared for western blot analysis.  Results are presented in figure 7.7B.  
When TNF-α was administered at 5ng/mL, it had no effect on PKB/Akt expression and 
phosphorylation. This was associated with reduction in eNOS phosphorylation while its 
expression was increased, causing a decrease in activation. A similar trend in eNOS 
expression and phosphorylation was also observed when TNF-α was administered at the low 
dosage of 0.5ng/mL.  Here, PKB/Akt expression and phosphorylation both were reduced but 
the phospho-/total ratio remained unchanged.   
When the TNF-α dosage was increased to 20ng/mL, PKB/Akt expression and phosphorylation 
were also reduced but to such extent that the phospho-/total ratio was significantly lower than 
the control. Importantly, this was associated with a marked increase in eNOS expression and 
significant reduction in phosphorylation leading to a phospho-/total ratio of 18.5% of the control 
levels (fig.7.7B).  
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Figure 7.7B Effects of TNF-α on CMECs , 24h incubation, expression and phosphorylation of  PKB /Akt (A) and eNOS (B), Representative 
graph, values expressed as phospho-/total ratios normalized to the control values, 1: control, 2: TNF-α (0.5ng/mL)(n=4), 3: TNF-α (5ng/mL), 4: 
TNF-α (20ng/mL), *p<0.05 vs control, n=4/group, blots presented are representative, experiment was performed  twice (Amanda Genis). 
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7.3.4. EFFECT OF MELATONIN ON TNF-α-INDUCED ENDOTHELIAL DYSFUNCTION 
To test the effect of melatonin administration on endothelial cell dysfunction, melatonin at the 
dose of 1nM was administered to CMECs for 1h before the administration of TNF-α (20ng/mL).  
This melatonin concentration was chosen because the other dosages had increased the levels 
of necrotic cells after 24h treatment (fig.7.4). The TNF-α dosage was chosen due to its 
pronounced effects on PKB/Akt and eNOS activation as well as NO production compared to 
other dosages (fig.7.7A; B). After 24h incubation, lysates were prepared for western blot 
analysis. Results are presented in figures 7.8-16 and summarized in the table 7.4. β-Tubulin 
was used to check equal loading of proteins. Its representative blot is only added on the graph 
where proteins are downregulated (e.g., PKB/Akt, eNOS) or if only the total protein expression 
was evaluated (e.g., iNOS, IκB-α).  
For all figures, C: control, M1: melatonin treatment for 1h, M: melatonin treatment for 24h, T: 
TNF-α treatment for 24h, TM: co-administration of melatonin with TNF-α for 24h following 1h 
melatonin pre-treatment.    
• PKB/Akt  
Figure 7.8 represents the effect of melatonin and TNF-α treatment on PKB/Akt phosphorylation 
in CMECs.  Compared to the control, melatonin administration for 1h and 24h increased the 
phosphorylation of PKB/Akt significantly (1.5 and 1.2 fold increased phosphorylation, 
respectively), the phosphorylation of PKB/Akt being higher after 1h than after 24h treatment.  
When compared to TNF-α treatment alone, the effect of melatonin  administration on PKB/Akt 
phosphorylation after 1h and 24 h was 1.9 and 1.5 folds higher than that of TNF-α, 
respectively.   
TNF-α reduced significantly the phosphorylation of PKB/Akt (Ser-473) compared to control or 
other treatments with melatonin alone or combined with TNF-α (p<0.05).   
When TNF-α was co-administered with melatonin for 24h, PKB/Akt phosphorylation was 
significantly reduced compared to 1h and  24h melatonin and similar to the control but 
significantly higher than that of TNF-α alone for 24h. 
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Cells pre-treated with melatonin for 1h followed by 24h co-administration of TNF-α and 
melatonin had a significant reduction in expression of total PKB/Akt and β-tubulin when 
compared to the control and other treatments (p<0.05). β-Tubulin blot was performed to check 
the equal loading on phosho-PKB/Akt membrane. 
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Figure 7.8 Effect of melatonin and TNF-α on the expression and phosphorylation of PKB/Akt, 
*p<0.05 (C vs M1, T and M), **p<0.05(M vs M1, T and TM), ***p<0.05 (TM vs T), n=3/group 
(M1=2).  
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• eNOS  
Compared to control, 1h melatonin treatment reduced eNOS phosphorylation (p<0.05). 
However, when the treatment was extended to 24h, this reduction disappeared and the eNOS 
phosphorylation was similar to the control (fig.7.9).  
TNF-α alone for 24h reduced eNOS phosphorylation compared to the control. However, when 
combined with melatonin this reduction disappeared.  β-Tubulin blot was performed to check 
the equal loading on phosho-eNOS membrane.  
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Figure 7.9 Effect of melatonin and TNF-α on eNOS expression and phosphorylation, 
Figure 7.9, *p<0.05 (C vs M1, T), **p<0.05 (M vs M1, T, TM), n=3/group (M1=2). 
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• iNOS expression  
Figure 7.10 represents the effects of melatonin and TNF-α treatment. Melatonin administered 
for 1 h increased iNOS expression, while 24 h treatment was without effect.  Compared to the 
control and 24h melatonin treatment, TNF-α treatment induced increased iNOS expression 
(p<0.05). 
Pre-treatment with melatonin for 1h followed by 24h TNF-α plus melatonin treatment caused a 
significant reduction in the expression of iNOS compared to control and TNF-α (p<0.05). 
However, there was no difference between the effect of melatonin administered alone for 1h 
and that of TNF-α treatment after 24h (p>0.05). 
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Figure 7.10 Effect of melatonin and TNF-α on iNOS expression, *p<0.05 (C vs M1, T and TM), 
**p<0.05 (T vs M, and TM), ***p<0.01 (M1 vs M, TM), n=3/group (M1=2). 
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• Nitrotyrosine  levels 
After 1h, melatonin reduced the levels of nitrotyrosine compared to control (p<0.05). When the 
treatment was extended to 24h, nitrotyrosine levels were similar to that of the control cells.    
When TNF-α was co-administered with melatonin in 1h melatonin pre-treated cells, after 24 h, 
nitrotyrosine levels were significantly reduced compared to 1h and  24 h melatonin as well as  
24h TNF-α treatments.   
Similar to eNOS and PKB/Akt (fig.7.9 and 10), nitrotyrosine levels and β-tubulin expression 
were reduced when melatonin was co-administered with TNF-α for 24 h.  
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Figure 7.11 Effect of melatonin and TNF-α on nitrotyrosine levels, *p<0.05 (M1 vs C, M and 
TM), **p<0.05 (T vs C, M, TM),***p<0.01(TM vs C, M,  n=3/group (M1=2). 
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• IκB-α expression 
Melatonin treatment for 1h did not affect the expression of IκB-α compared to control. When 
the treatment was prolonged to 24h, the expression remained unchanged.  TNF-α treatment 
for 24h reduced significantly IκB-α expression compared to control, 1h and 24h melatonin 
treatments.  
When TNF-α was co-administered with melatonin in 1h melatonin pre-treated cells, after 24h, 
IκB-α expression was significantly reduced compared to control, 1h and 24h melatonin but not  
24h TNF-α treatments. 
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Figure 7.12 Effect of melatonin and TNF-α on expression of IκB-α, *p<0.05 (T vs C, M1 and 
M), **p<0.05 (TM vs C, M1 and M), (M vs C, p>0.05), n= 3/group (M1=2) 
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• ERK 42/44  
Figure 7.13 represents the effects of melatonin and TNF-α treatment on ERK44/42.  Melatonin 
alone or combined with TNF-α did not affect the expression and phosphorylation of ERK44/42 
compared to the control.  TNF- α treatment for 24h reduced only the p/total ratio of ERK42 
(p<0.05) compared to control.  
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Figure 7.13 Effect of melatonin and TNF-α on expression and phosphorylation of ERK42 (A) 
and ERK 44 (B).  A: *p<0.05 (T vs C, M1), #p<0.05 (TM vs T), n=3/group (M1=2). 
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• AMPK  
Melatonin administered for 1h caused a significant increase in the phosphorylation of AMPK 
(Thr-172). After 24h treatment, this effect disappeared (fig.7.14).   
Compared to the control, TNF-α treatment also induced an increase in phosphorylation of 
AMPK (Thr-172) (p<0.05). Pre-treatment with melatonin followed by co-administration of 
melatonin with TNF-α for 24 h reduced significantly the phosphorylation of AMPK (Thr-172) 
compared to control, 1h melatonin and  TNF-α treatments (p<0.05). β-Tubulin blot was 
performed to check the equal loading on phosho-AMPK (Thr-172) membrane. 
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Figure 7.14 Effect of melatonin and TNF-α on expression and phosphorylation of AMPK (Thr-
172), *p<0.05 (C vs M1 and T), **p<0.05 (T vs M and TM), ***p<0.05 (M vs M1), n=3/group 
(M1=2). 
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• p38 MAPK  
Figure 7.15 represents the effect of melatonin and TNF-α treatment on p38MAPK.  After 1h, 
melatonin increased the phosphorylation of p38MAPK compared to control. When the 
treatment was extended to 24h, the phosphorylation of p38 MAPK remained high.  
TNF-α treatment for 24h caused a significant reduction in the phosphorylation of p38MAPK 
compared to control, 1h and 24 h melatonin treatments.  
When TNF-α was co-administered with melatonin to 1h melatonin pre-treated cells, after 24 h, 
p38MAPK phosphorylation was significantly increased compared to  control  and 24h TNF-α 
but not  1h and 24 h melatonin treatments. 
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Figure 7.15 Effect of melatonin and TNF-α on expression and phosphorylation of p38MAPK, 
*p<0.05 (C vs M1, T, M and TM), **p<0.05(M vs T), ***p<0.05 (TM vs M1and T), n=3/group 
(M1=2)  
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• STAT-3  
Figure 7.16 represents the effect of melatonin and TNF-α treatment on STAT-3. In this study 
Cell lysates without fractionation were used. Melatonin treatment after 1h and 24h did not 
affect the phosphorylation of STAT-3 (Ser-727) compared to control.  Although 24h TNF-α 
treatment also had no significant effect on STAT-3 phosphorylation compared to control, its 
associated phosphorylation was higher than that seen after 24h melatonin treatment.  
When TNF-α was co-administered with melatonin in 1h melatonin pre-treated cells, after 24 h, 
STAT-3 phosphorylation was significantly reduced compared to  control, 1h and 24h melatonin 
as well as 24h TNF-α  treatments. 
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Figure 7.16 Effect of melatonin and TNF-α on expression and phosphorylation of STAT-3, 
*p<0.05 (TM vs C, M, T and M1), **p<0.05 (M vs T), n=3/group (M1=2). 
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Table 7.4 Summary of western blots results 
A 
vs Control 
Phosphorylation/activation Expression 
eNOS PKB/Akt ERK42 ERK44 p38MAPK AMPK 
STAT-3 
(Ser-727) iNOs IκB-α Nitrotyrosine 
M1 (1h) ↓ ↑ ↔ ↔ ↑ ↑ ↔ ↑ ↔ ↓ 
M (24h) ↔ ↑ ↔ ↔ ↑ ↔ ↔ ↔ ↔  ↔ 
T (24) ↓ ↓ ↓ ↔ ↓ ↑ ↔ ↑ ↓ ↓ 
T+M (24h) ↔ ↔ ↑ ↔ ↑ ↔ ↓ ↓ ↓ ↓ 
B 
vs TNF-α 
Phosphorylation/activation Expression 
eNOS PKB/Akt ERK42 ERK44 p38MAPK AMPK 
STAT-3 
(Ser-727) iNOs IκB-α Nitrotyrosine 
M1 (1h) ↔ ↑ ↔ ↔ ↑ ↑ ↔ ↔ ↑ ↔ 
M (24h) ↑ ↑ ↔ ↔ ↑ ↓ ↓ ↓ ↑ ↑ 
T+M (24h) ↔ ↑ ↑ ↔ ↑ ↓ ↓ ↓ ↔ ↓ 
 
A: compared to control, B: compared to TNF-α treatment, ↑: significant increase, ↓: significant decrease, ↔: no significant difference,  M1 (1h): 
melatonin treatment for 1h, M (24h): melatonin treatment for 24 h, T (24): TNF-α treatment  for 24h, T+M (24h): Co-administration of melatonin 
and TNF-α  for 24 h following 1h melatonin pre-treatment; melatonin (1nM), TNF-α (20ng/mL)
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Table 7.5 Summary of results of cell viability and NO production 
A: Cell viability 
 
      vs. control 
Melatonin (dosages)                      
1nM 1µM 10µM 
1h 
Apoptosis (Annexin V) ↓ ↓ ↓ 
Necrosis (Propidium iodide) ↓ ↓ ↓ 
6h 
Apoptosis (Annexin V) ↔ ↔ ↔ 
Necrosis (Propidium iodide) ↔ ↔ ↑ 
24h 
Apoptosis (Annexin V) ↔ ↔ ↔ 
Necrosis (Propidium iodide) ↔ ↑ ↑ 
 
B: Nitric oxide production  
    
      vs. control 
Melatonin (dosages) 
1nM 1µM 10µM 
1h DAF ↓ ↔ ↔ 
6h DAF ↓ ↓ ↓ 
24h DAF ↔ ↔ ↓ 
 
A: Cell viability vs control; B: Nitric oxide (NO) production vs control, ↑: significant increase, ↓: 
significant decrease, ↔: no significant difference. 
7.4. DISCUSSION 
 In the present study we investigated the effects of melatonin treatment on CMECs evaluating 
cell viability, NO production and TNF-α-induced endothelial dysfunction as well as intracellular 
signalling associated with the treatment of melatonin and TNF-α administered separately or in 
combination. Findings are summarized in tables 7.4-5. 
7.4.1. EFFECT OF MELATONIN ON CELL VIABILITY  
Cell viability was evaluated by Annexin V and PI staining as markers for apoptotic and necrotic 
cells, respectively. Apoptosis and necrosis are two different processes of cell death that can 
coexist in the same tissue [for review, see (Fadeel and Orrenius, 2005)].   Necrosis refers to 
the pathological or accidental mode of cell death involving irreversible swelling of the 
cytoplasm and distortion of organelles including mitochondria followed by rupture of the cell 
membrane and inflammation that damage the cells and its surrounding tissues (Fadeel and 
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Orrenius, 2005).  Apoptosis is a sequential process where the dying cell undergoes nuclear 
and cytoplasmic condensation with blebbing of the plasma membrane leading to formation of 
apoptotic bodies which are recognized and removed via phagocytosis by macrophages without 
damaging the surrounding tissues (Fadeel and Orrenius, 2005). After 1h, melatonin (1nM, 1µM 
and 10Μm) increased the cell viability by reducing the percentage of necrotic and apoptotic 
cells compared to the control (fig.7.2). This is in agreement with previous studies where 
melatonin has been shown to increase cell viability of a resting human liver cell line (HepG2) 
(0.1–10µM/24h) (Osseni et al., 2000), sperm cells (2mM/30min) (Du Plessis et al., 2010) or 
bovine oviduct epithelial cells (bOECs) (1-1mM/24h) (Kim et al., 2011) and to inhibit NO-
induced apoptosis in PGT-β immortalized pineal cells (0.1mM/10h) (Yoo et al., 2002).  In 
addition, melatonin increased cell viability and protected Chinese hamster ovary (CHO) cells 
(300µM-3mM/30min-24h) (Celik and Naziroglu, 2012) and human umbilical vein endothelial 
cells (HUVECs) (125-500µM/2-8h) (Duan et al., 2013) against H2O2-induced injury.  The 
hormone also protected hepatocytes against necrosis and apoptosis induced by IRI (Kim and 
Lee, 2008). This was also demonstrated in the hearts of senescence-accelerated mice 
(SAMP8) treated with melatonin (Forman et al., 2010).  
When melatonin treatment was prolonged to 6h and 24h, apoptosis was no longer reduced.    
(fig.7.3-4). However, surprisingly, the percentage of necrotic cells was increased after 6 h 
(10µM) and 24h (1,10µM) (fig.7.3-4), which  may reflect a dose- and time-dependent effect of 
melatonin as previously described in human liver cell line (HepG2) (Osseni et al., 2000). 
Consistent with the present study, a low concentration (0.1–10µM) administered for a short 
period increased cell viability and a high concentration (1–10,000µM) for a long period 
decreased cell viability of human liver cell line HepG2 (Osseni et al., 2000).  
7.4.2. MELATONIN AND NO PRODUCTION 
Nitric oxide (NO) is an important protective molecule in the cardiovascular system (Heusch et 
al., 2008; Strijdom et al., 2009a). It is primarily produced by the NO synthases (NOS) namely 
neuronal NOS (nNOS or NOS-1), inducible NOS (iNOS or NOS-2), and endothelial NOS 
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(eNOS or NOS-3) present in the heart (Balligand and Cannon, 1997).  Viewed as an 
endothelial cell survival factor (Dimmeler and Zeiher, 1999), a reduction in NO bioavailability is 
considered as a marker for endothelial dysfunction (Muniyappa and Sowers, 2013).  However, 
besides its important beneficial activities, in pathophysiological conditions excessive NO 
production may contribute to oxidative stress and an associated inflammatory state with 
eventual tissue damage (Pacher et al., 2007).  
To investigate how melatonin affects endothelial function in addition to improved cell viability, 
we evaluated NO production of resting CMECs (non-stimulated). Similar to cell viability, 
melatonin treatment affected NO production in a dose-and time-dependent manner. After 1h, 
melatonin (1nM) reduced NO production while other concentrations (1µM and 10µM) were 
without effect on NO production (fig.7.5). However, when the treatment is extended to 6h, 
melatonin at all concentrations (1nM, 1µM and 10µM) decreased NO production (fig.7.6). After 
24h, only cells treated with 10µM melatonin had reduced NO production compared to control 
(fig.7.7).  As far as we know, there are no other reports on the effect of melatonin on CMECs. 
In contrast to our study, microvascular endothelial cells from cremaster muscle treated with 
0.1nM and 1nM melatonin, had no effect on the basal NO production [probably due to the short 
period of incubation (1min)](Tamura et al., 2006). However, similar to the present findings, 
melatonin (1nM) reduced bradykinin-induced NO production in microvascular endothelial cells 
(Tamura et al., 2006; Silva et al., 2007).  As was also observed in our study, the reduction in 
NO production by melatonin was dose-and time-dependent and was linked to its anti-oxidative 
activities (Tamura et al., 2009).  Indeed, an excessive amount of NO (free radical) is known to 
cause cytotoxic changes and melatonin protects the cells through its free radical scavenging 
activities (Aydogan et al., 2006; Korkmaz et al., 2009).  Interestingly, when the percentage of 
necrotic cells (PI levels) in CMECs reached its highest peak after 6h (compared to 1h and 24) 
(fig.7.2-4), the reduction in NO production appeared to be the highest (fig.7.5-7). Thus, the 
observed reduction in NO production after 6h melatonin treatment may be a causal factor in 
the reduction in cell viability seen at this time-point. However this remains to be established. 
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7.4.3. MELATONIN AND INTRACELLULAR SIGNALLING 
To investigate the signalling associated with the effect of melatonin on cell viability and NO 
production, cells were treated with melatonin (1nM) and incubated for 1h and 24h. The survival 
pathways including PKB/Akt, eNOS and iNOS (involving NO production), MAPK including 
p38MAPK, ERK42/44 as well as other proteins implicated in cellular stress events such as 
nitrotyrosine, IκB-α, STAT-3 and AMPK were evaluated using western blots.  
7.4.3.1. NO production pathways: PKB/Akt-eNOS and iNOS 
PKB/Akt is a serine/threonine kinase that has been shown to play a crucial role in cellular 
activities including, amongst others, cell survival, growth, proliferation, metabolism and 
angiogenesis (Manning and Cantley, 2007; Sussman et al., 2011). It constitutes the central 
node of cell signalling downstream of growth factors, cytokines, and other cellular stimuli 
(Manning and Cantley, 2007). After 1h, melatonin treatment at 1nM reduced the percentage 
apoptotic and necrotic cells in resting CMECs (fig.7.2) and this reduction was associated with 
an increase in PKB/Akt phosphorylation (fig.7.8), as a survival factor (Manning and Cantley, 
2007). These findings are consistent with previous studies where melatonin treatment 
increased PKB/Akt phosphorylation in the rat hypothalamus (Anhe et al., 2004), hepatic 
HepG2 cells (Shieh et al., 2009), Müller cells (Jiang et al., 2012) and human neuronal cell line 
SK-N-MC (Choi et al., 2008).  
Interestingly, melatonin inhibited NO-induced apoptosis by increasing PKB/Akt phosphorylation 
and Bcl-2 expression and reducing Bax expression (Choi et al., 2008; Kim et al., 2011).  Since 
excess NO production can induce apoptosis (Choi et al., 2008; Kim et al., 2011), the anti-
apoptotic effect observed in the present study may also be related to the reduction in basal NO 
production (fig.7.4) and eNOS phosphorylation (fig.7.10). However, the respective 
contributions of a reduction in eNOS phosphorylation (fig.7.9) and increased iNOS expression 
(fig.7.10) to the reduction in NO production induced by 1h melatonin treatment, is difficult to 
interpret. On the other hand, the reduction in NO production is also difficult to interpret in view 
of the activation of PKB/Akt and AMPK which are upstream of eNOS. However, it appears in 
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this context that melatonin reduced NO availability via its direct free radical scavenging 
activities (which are receptor independent) (Aydogan et al., 2006). Elevated iNOS expression 
is associated with an inflammatory state where eNOS expression, which is a protective 
enzyme, is reduced (Rodella et al., 2010; Kireev et al., 2012). In contrast to our finding, 
melatonin treatment in nicotine-treated rats has been shown to increase eNOS expression with 
a concomitant reduction in iNOS expression (Rodella et al., 2010).   
When the treatment was extended to 24h, PKB/Akt phosphorylation remained significantly 
increased while eNOS phosphorylation and iNOS expression returned to control levels (fig.7.8-
9), indicating that signalling events are also time-dependent and that PKB/Akt phosphorylation, 
independent of eNOS phosphorylation, was involved in the effects of melatonin on CMECs. 
7.4.3.2. Melatonin and cellular stress: oxidative stress and inflammation  
To investigate the effect of melatonin on basal cellular stress we evaluated the expression or 
phosphorylation of IκB-α, p38MAPK, ERK42/44, STAT-3, AMPK and nitrotyrosine levels after 
1h and 24h melatonin treatment. A nitrotyrosine level is an index of formation of peroxynitrite 
(ONOO−) and hence considered as a marker of oxidative stress (Pacher et al., 2007).  After 
1h, melatonin treatment reduced basal nitrotyrosine levels (fig.7.11), supporting melatonin’s 
antioxidant activities (Korkmaz et al., 2009).   
In addition, p38MAPK phosphorylation was increased (fig.7.15). This is the first study to 
evaluate the effect of melatonin treatment on p38 MAPK in CMECs. The role of p38MAPK in 
cell viability is controversial (Rose et al., 2010). Our laboratory has previously found that 
melatonin-induced cardioprotection was associated with a reduction in post-ischemic 
phosphorylation of p38MAPK (Genade et al., 2008; Nduhirabandi et al., 2011), indicating the 
pro-apoptotic effects of p38MAPK (Li et al., 2005; Luchetti et al., 2009). On other hand, 
p38MAPK has also been suggested to be a pro-survival kinase in LPS-induced activation of 
BV-2 cells (Svensson et al., 2011) and in cardioprotection (Engelbrecht et al., 2006). 
Furthermore, a survival role for p38MAPK has been recently reported associated with 
PKB/Akt, AMPK and ERK42/44 phosphorylation in neutrophils (Rossi and Lord, 2013). On the 
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other hand, melatonin treatment had no effect on the phosphorylation of PKB/Akt and 
p38MAPK in C2C12 myotubes (Ha et al., 2006) as well as AMPK in HepG2 cells (Shieh et al., 
2009). 
In our model of CMECs, activation of p38MAPK was found to be associated with increased cell 
viability (tables 7.4-5). However, the effects of p38MAPK on cell survival remain controversial 
and may depend on the cell type and the isoform activated. 
The role of activation of AMPK in endothelial cells is complex. Viewed as a metabolic-sensing 
kinase, AMPK is also known as a stress-activated protein kinase (Fisslthaler and Fleming, 
2009), being activated by cellular stresses associated with reduced cellular ATP levels in 
endothelial cells (Nagata et al., 2003; Fisslthaler and Fleming, 2009).  Apart from its well-
known anti-apoptotic effects and activation of eNOS (Liu et al., 2010), it exhibits its anti-
inflammatory actions by inhibiting NF-κB signalling and thus prevents the appearance of a pro-
inflammatory phenotype [for review, see (Fisslthaler and Fleming, 2009; Salminen et al., 
2011)]. However, whether AMPK phosphorylation plays an important role in the anti-apoptotic 
effect seen in our study needs further investigation.   
ERK42/44 phosphorylation, IκB-α expression and STAT-3 phosphorylation after 1h melatonin 
treatment were similar to the control and thus probably not involved in the improvement in cell 
viability observed at this time point. Increased ERK42/44 phosphorylation was recently 
reported to be involved in the anti-apoptotic effects of melatonin treatment in UVB-stressed 
U937 cells (Luchetti et al., 2009). STAT-3 is an important transcription factor which is the 
signalling target of pro-inflammatory cytokines and is activated by hypoxia/reoxygenation in 
human umbilical vein endothelial cells (HUVEC) (Mattagajasingh et al., 2012). Although its 
inhibition has been associated with PKB/Akt phosphorylation and protection of bovine aortic 
endothelial cells (bAEC) and human umbilical vein endothelial cells (HUVEC) (Neria et al., 
2007), it was found to be unaffected by melatonin in CMECs and thus probably not important 
in the results obtained in the present study. 
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7.4.4. MELATONIN AND TNF-α-INDUCED ENDOTHELIAL DYSFUNCTION   
Several studies have shown that vascular endothelial dysfunction results from reduced NO 
bioavailability, increased oxidative stress, elevated expression of pro-inflammatory and pro-
thrombotic factors which lead to abnormal vasoreactivity (Muniyappa and Sowers, 2013).  
TNF-α has been shown to induce endothelial dysfunction in MetS and diabetes (Hotamisligil, 
1999; Picchi et al., 2006).  
To investigate the effect of TNF-α on endothelial function, cells were incubated with TNF-α for 
24h. Interestingly, TNF-α treatment caused increased  iNOS expression and AMPK 
phosphorylation (fig.7.10, 14) associated with a reduction in PKB/Akt and eNOS 
phosphorylation as well as IκB-α expression, supporting its pro-inflammatory actions coupled 
to the reduced NO availability [for reviews, see (Fisslthaler and Fleming, 2009; Salminen et al., 
2011)].  
In agreement with the present study, a reduction in PKB/Akt and eNOS activation was also 
previously reported in bovine aortic endothelial cells treated with TNF-α (5ng/mL/6h) (Li et al., 
2007). Interestingly, this was additionally associated with increased AMPK phosphorylation (Li 
et al., 2007). However, in contrast to our study, TNF-α (5ng/mL) induced increases in 
p38MAPK and ERK42/44 phosphorylation (Li et al., 2007). Apart from difference in TNF-α 
dosage, this controversial response may be linked to endothelial cell heterogeneinity as 
recently demonstrated (Woth et al., 2013).  
IκB-α is the regulatory protein of the nuclear transcription factor NF-κB with which it is 
associated in the cytoplasm of resting endothelial cells (Beg and Baldwin, 1993). TNF-α 
induces phosphorylation of IκB-α leading to its degradation and subsequent translocation of 
NF-κB to the nucleus, where by its transcriptional activities initiates a pro-inflammatory 
response such as an increase in iNOS expression (Anderson et al., 2004). Consistent with a 
previous study in bAECs (Anderson et al., 2004), IκB-α expression was reduced following 
TNF-α treatment (fig.7.12). Interestingly, it was associated with increased iNOS expression 
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(fig.7.10) which may result from increased pro-inflammatory transcription following degradation 
of the complex NF-κB and IκB-α (Beg and Baldwin, 1993; Cruz et al., 2001).  
To evaluate the effect of melatonin treatment on TNF-α-induced endothelial dysfunction, cells 
were first pre-treated with melatonin for 1h before co-administration of TNF-α and melatonin for 
24h. The overall results (table 7.4A) show that melatonin treatment was able to prevent the 
TNF-α-induced reduction in eNOS and PKB/Akt phosphorylation (fig.7.8-9) and reversed the 
TNF-α-induced AMPK phosphorylation (returning it to the control levels) and iNOS expression 
(reduced compared to control) (fig.7.10;14), indicating potential beneficial effects of melatonin 
in this regard (Korkmaz et al., 2009).  
The reduction in the expression of eNOS, PKB/Akt, nitrotyrosine as revealed by β-tubulin 
expression (fig.7.9-12) in cells where melatonin was co-administered with TNF-α for 24h is 
surprising. Whether co-administration of TNF-α and melatonin affects the morphological 
changes on β-actin and other cytoskeleton proteins as did TNF-α treatment (Kohno et al., 
1993), requires further attention. The observed increased degradation of IκB-α leading to 
activation of NF-κB and its nuclear translocation may be implicated (Beg and Baldwin, 1993; 
Cruz et al., 2001). 
Compared to the effect of TNF-α  (table 7.4B), co-administration of TNF-α and melatonin was 
able to retain/preserve the effects observed after 1h melatonin pre-treatment (increased 
PKB/Akt and p38 MAPK phosphorylation); it also maintained the effect of 24h melatonin 
treatment compared to TNF-α (reduced phosphorylation of AMPK and STAT-3 and iNOS 
expression). The failure to reduce IκB-α could be linked to the low concentration used 1nM 
(Sasaki et al., 2002). However, except for IκB-α expression, the TNF-α signalling effects were 
lost or even reversed by melatonin treatment (table 7.4B). 
7.5.  CONCLUSION  
We investigated the effect of acute melatonin treatment on CMECs with or without TNF-α-
induced endothelial dysfunction. Our main findings showed that melatonin treatment increased 
cell viability of CMECs and reduced NO production in a dose-and time-dependent manner. 
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These effects were associated with changes in intracellular signalling which also reflected a 
time-dependence aspect. While TNF-α treatment affected the intracellular signalling of 
CMECs, co-administration with melatonin was able to reverse the signalling due to TNF-α 
treatment. Except for IκB-α expression, the effects of TNF-α treatment on CMECs including 
PKB/Akt, eNOS, p38MAPK, AMPK phosphorylation were lost or even reversed by melatonin 
co-treatment. These observations could be of paramount importance in the beneficial effects of 
melatonin on the ischaemic/reperfused heart, taking into account the significant role of the 
endothelial cell in this regard.  
 In view of these preliminary findings, further investigation on the effect of melatonin on 
CMECs (in normoxic, hypoxic or anoxic condition) using specific inhibitors is needed. In this 
regard, the role of PKB/Akt and p38MAPK as well as the anti-apoptotic activities of melatonin 
need further exploration in TNF-α-induced endothelial dysfunction by determining cell viability 
and NO production. In addition, whether melatonin affects CMECs function via receptor- 
mediated activities also needs to be investigated. 
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CHAPTER VIII 
8. CONCLUDING REMARKS  
 
8.1. CONCLUSIONS 
The present dissertation is a continuation of our previous studies on the role of melatonin in 
cardioprotection. Melatonin has been shown to have strong cardioprotectives actions in lean 
animals but its effects in obesity and insulin resistance are not well established. Although our 
previous studies were designed and performed with particular emphasis on myocardial 
ischaemia-reperfusion injury, the present study additionally focussed on myocardial glucose 
homeostasis, mitochondrial function and microvascular endothelial function in normal or/and 
insulin resistant states.   
We considered cardioprotection as a multifactorial process involving all the cell types in the 
heart in general, and cardiomyocytes and cardiac endothelial cells in particular. Thus, the 
present investigation comprised the effects of melatonin on the heart at baseline level or when 
exposed to IRI in insulin resistant rats and their age-matched controls.  
The present dissertation demonstrated the effects of relatively short-term in vivo treatment with 
melatonin on the heart by evaluating its ex vivo basal function and intracellular signalling. 
Additionally, the effect of melatonin was studied in the context of glucose uptake by 
cardiomyocytes isolated from the hearts of healthy young and old as well as insulin resistant 
rats.  Furthermore, the effects of melatonin on mitochondria (isolated from hearts from insulin 
resistant rats and their age-matched controls), which are the primary cellular sites for energy 
supply to the heart, were evaluated focussing on their oxidative phosphorylation capacity, 
respiratory function and response to exposure to anoxia. Since the cardiac endothelium may 
play an important role in exacerbating myocardial damage in ischaemia, the effects of 
melatonin on resting endothelial cells were investigated. To mimic the events in obesity and 
insulin resistance where circulating TNF-α levels are elevated, the effects of melatonin on 
TNF-α-induced endothelial dysfunction were also evaluated. 
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Apart from the above-mentioned baseline investigations, we studied the effects of in vivo 
melatonin treatment on the heart exposed to regional or global ischaemia, followed by 
reperfusion and determination of infarct size and myocardial function. In a number of hearts, 
mitochondria were isolated after exposure to ischaemia and their respiratory function 
evaluated. Additionally, effects of melatonin on myocardial signalling during reperfusion were 
determined.  The main findings of the present investigation are presented in the figure 8.1 
Using obese, insulin-resistant rats as an experimental model, the present dissertation showed 
for the first time that melatonin:  
When administered in vivo for 3 or 6 weeks (in drinking water)  
• protected the heart against myocardial ischaemia-reperfusion damage independent 
of changes in body weight, visceral fat, blood lipid and glucose levels while 
baseline activation of STAT-3 and the RISK pathway during reperfusion were 
involved in this cardioprotection 
• regulated respiratory function of mitochondria isolated from non-perfused or 
perfused hearts exposed to ischaemic injury 
• improved cardiac glucose homeostasis by increasing basal glucose uptake and  
enhancing insulin actions   
When administered in vitro (acute treatment):  
•  had no effect on cardiomyocyte glucose uptake per se, but enhanced insulin–      
stimulated glucose uptake in normal, but not insulin resistant cardiomyocytes 
• increased cell viability and reduced NO production in cardiac microvascular  
endothelial cells and was able to reverse the signalling induced by TNF-α 
treatment by increasing PKB/Akt activation independent of eNOS activation  
The present dissertation also confirmed previous studies done on obese and non-insulin 
resistant by showing that short-term melatonin treatment  
• was also cardioprotective in normal and insulin resistant rats  
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• reduced insulin resistance independent of body weight gain 
• reduced body weight gain independent of visceral fat mass, blood  lipid and glucose 
levels 
Finally, this dissertation demonstrated that melatonin is a pleiotropic hormone, having multiple 
effects depending, amongst others, on the duration and dosage of the treatment as well as the 
type of experiment (in vivo or ex vivo setting).  Unfortunately the broad scope of the studies 
undertaken, hampered in depth investigation of several of the interesting observations made 
and it is obvious that there are still many unanswered questions which need to be addressed. 
8.2. PERSPECTIVES FOR THE FUTURE 
In contrast to other cardioprotective strategies, the present investigation confirms the powerful 
cardioprotective potential of melatonin, even when administered at a late stage in the 
development of obesity and insulin resistance. Its marked effects on weight (not visceral fat) 
loss are intriguing and needs further investigation.  Clinical trials are certainly warranted in this 
regard.  
The present investigation also draws the attention to the potential beneficial effects of 
melatonin on mitochondrial function in insulin resistance and on cardiac microvascular 
endothelial cell function. Further studies are needed to shed more light on the interesting 
preliminary findings obtained. 
Indications are that the hormone has also a profound effect on glucose homeostasis in obesity 
and insulin resistance. Again the need for clinical studies is evident: most, if not all, the current 
knowledge on this topic is derived from rodent studies, which are, in contrast to humans, active 
and non-fasting during the night. 
Finally, melatonin is a hormone with fascinating actions. Based on current knowledge, daily 
intake of melatonin may have many beneficial actions in the human. Melatonin is a cheap drug 
and already sold over the counter. However, clinical trials are required to confirm its 
therapeutic use in humans. 
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Figure 8.1 Diagram showing the main findings of the investigation. Studies I, II and III used normal and insulin resistant rats;                              
study IV used cultured cardiac microvascular endothelial cells (CMECs). 
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